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Summary
cAMP participates in cell signal transduction and influences biological 
responses such as muscle contraction, learning and memory, inflammatory 
cytokine production, and cell growth, differentiation and apoptosis. The sole 
means of cAMP degradation is by PDE enzymes. The PDE4 family 
represents the major cAMP-hydrolysing activity in many cells. Four genes 
encode the PDE4 isoforms and over twenty have now been characterised. 
Each isoform differs by virtue of a unique N-terminal intra-cellular targeting 
region, and by differential inclusion of regulatory UCR domains via 5’ mRNA 
splicing. The plethora of PDE4 isoforms underpins compartmentalisation of 
cAMP signalling, facilitating the generation of cAMP domains or gradients.
couples p-arrestin and is the second PDE4 isoform to interact with XAP2.
Ill
Work in this thesis characterises a novel PDE4A long isoform, namely 
PDE4A11. It is expressed with a species-conserved, unique 81 amino acid N- 
terminal region encoded by a single 5’ exon. Transcript analysis of human 
cells and tissues alludes to tissue-specific and developmental changes in
expression. PDE4A11 is targeted to the perinuclear region and membrane 
ruffles of COST cells. Sequence analysis identifies putative PIP3-mediated 
membrane targeting. PDE4A11 is kinetically comparable to the other PDE4A 
long isoforms and is inhibited by conventional PDE4 inhibitors. It is 
insensitive to conformational changes detected by altered rolipram inhibition, 
a likely consequence of reduced LR2 and/or enhanced N-terminal interactions 
with Lyn-SHS. Soluble and particulate forms exhibit distinct rates of thermal 
inactivation. PDE4A11 is activated by PKA phosphorylation at Ser-119 within 
UCR1. N-terminal phosphorylation by ERK1/2 should be pursued. PDE4A11
Phosphorylation of PDE4 isoforms confers activity and protein 
interaction regulation. All PDE4 long isoforms are activated by PKA 
phosphorylation within UCR1. Phosphorylation of the catalytic unit by ERK1/2 
occurs in all PDE4 isoforms, except PDE4A, and activates short form PDE4s
Summary
and inhibits long forms. Activation of the PI-3K pathway also facilitates PDE4 
activation. The identification of PDE4A5 as an authentic substrate for 
MAPKAPK2 is described, and the functional effects are investigated. This 
novel phosphorylation occurs at a serine residue, distinct from the PKA site, 
within UCR1. The kinase and target residue is identified in C0S1 cells 
expressing PDE4A5, following treatment with anisomycin, the p38 MAPK 
inhibitor, SB203580, and siRNA-mediated knockdown of MAPKAPK2, 
together with N-terminal truncation of PDE4A5 and Ser-147-Ala mutation. 
Phosphorylation of PDE4A5 by MAPKAPK2 has no effect on catalytic activity 
but delays the onset and amplitude of PKA-mediated activation. The 
interaction of PDE4A5 with XAP2, but not p-arrestin, is attenuated by 
MAPKAPK2 phosphorylation. Phosphorylation does not affect PDE4A5 intra­
cellular targeting or its susceptibility to caspase-3 cleavage. Enzyme 
conformational change with a Ser-147-Asp phospho-mimetic is not observed.
PDE4 inhibition reduces the production of ROS in many immune and 
inflammatory cells, consequential of the immuno-suppressive and anti­
inflammatory effects of cAMP. Oxidative stress is Implicated in the 4::'pathogenesis of disease states such as COPD and cardiac hypertrophy. The 
final chapter of this thesis strives to unravel the role of PDE4 inhibition in the 
attenuation of ROS production in cardiac myocytes. Angiotensin II promotes 
the delivery of p47-phox, an integral component of the active NADPH oxidase 
enzyme, to the membrane. Elevation of intra-cellular cAMP concentrations 
using forskolin and rolipram prevents p47-phox translocation, an effect that is 
partially rescued with the PKA inhibitor, H89. PKA directly phosphorylates 
p47-phox and six putative sites are identified within the C-terminal region. 
PDE4A4B is able to interact directly with p47-phox and p67-p/?ox, whereas 
PDE4A10 only interacts with p47~phox, indicating specificity in the PDE4 
control of the PKA phosphorylation state of phox proteins.
In summary, the work in this thesis contributes further to our 
understanding of the PDE4 regulation of intra-cellular cAMP concentrations in 
cells, and the specific response mediated through the multitude of isoforms 
and modification of function by both phosphorylation and protein interactions.
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Chapter 1 Introduction
Chapter 1 Introduction
1.1 General Signal Transduction
The concept of the second messenger was formulated from studies on
The majority of endogenous biological mediators or first messengers, 
such as peptide hormones, neurotransmitters, cytokines and growth factors 
cannot penetrate the cell membrane. Therefore, they must elicit their specific ■ibiological action through a signal transduction cascade emanating from the 
cell surface plasma membrane. Such signal transduction is defined as the 
process of converting a biological signal, represented by the activation of a 
cell-surface receptor, to an intra-cellular response. Initiation of this response 
can occur through receptors that contain intrinsic enzymatic activity, receptors 
that function as ion channels and receptors linked to G-proteins. In many 
instances the activation of such receptors generates second messenger 
molecules that are responsible for translating the extra-cellular biological 
signal to the desired intra-cellular response.
:
.. t
■'4'1.2 cAMP as a Second Messenger
'■:-4
the 3’, 5’ cyclic adenosine mono-phosphate (cAMP) signalling system [Beavo :3f.and Brunton, 2002]. cAMP is an intra-cellular second messenger molecule
that connects, and ultimately regulates, events emanating from the cell 
surface plasma membrane to nuclear events, such as gene transcription 
[Montminy, 1997 and Daniel et al., 1998]. cAMP has fundamental roles in 
metabolic processes, muscle contraction, secretion events, learning and 
memory, ion channel conductance, pro-inflammatory cytokine production, and 
cell growth, differentiation and apoptosis [Houslay and Milligan, 1997, Beavo 
and Brunton, 2002 and Taskén and Aandahl, 2004].
I
,Chapter 1 Introduction
I
1.3 G-Protein Coupled Receptors
G-protein coupled receptors (GPCRs) are membrane-bound receptors 
that are coupled to intra-cellular signalling systems via various G-proteins.
The binding of ligands, e.g. biogenic amines or peptides, to these receptors 
induces a conformational change that allows the coupling and activation of G- 
proteins and the subsequent regulation of intra-cellular cell signalling events 
through the modulation of enzyme activity, leading to alterations in protein if
kinases, ion channel conductance and gene expression [Rashid et al., 2004,
Strock and Diversé-Pierluissi, 2004 and Hollmann et al., 2005]. The 
importance of GPCRs in mammalian cell signalling is acknowledged by the 
fact that approximately 2-5% of the mammalian genome codes for these types 
of receptors [Yin et al., 2004 and Hollmann et al., 2005]. Examples of GPCRs 
include the a- and p-adrenergic receptors, the muscarinic acetylcholine ..ifreceptor, the dopamine receptors, the 5-hydroxytryptamine (5-HT) receptors 
and the opiate receptors [Rashid et al., 2004].
GPCRs are composed of seven trans-membrane a-helices and are 
sometimes referred to as 7-transmembrane-spanning receptors (7-TMs). A 
schematic of the GPCR and G-protein interactions are shown in Figure 1.1. 
The N-terminal region of the GPCR is located in the extra-cellular space and
*
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Is hyper-variable. It can vary in length from four to fifty amino acid residues 
and can be subject to N-linked glycosylation [Yin et al., 2004, Milligan, 2004 
and Hollmann et al., 2005]. Seven transmembrane-spanning regions, of 
approximately twenty to twenty-seven amino acids, cross the lipid bi-layer of 
the plasma membrane and are linked by alternate intra- and extra-cellular 
loops. The third transmembrane region contains a critical amino acid residue
..athat confers ligand specificity [Yin et al., 2004 and Hollmann et al., 2005].This residue is located immediately after a conserved cysteine and if basic the 
ligand is liable to be a peptide, e.g. vasopressin, and if acidic then it is more 
probable that the ligand is a biogenic amine, e.g. adrenaline or 5-HT. The C- 
terminal region is approximately fifty amino acids in length and is relatively 
conserved throughout all GPCRs. Together with the second and third
2 ■ g.
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cytoplasmic loop, the C-terminal region confers G-protein specificity of binding 
[Yin et al., 2004 and Hollmann et al., 2005]. GPCRs are now accepted to 
exist as dimers or even oligomers and this state is a functional requirement 
[Mercier et al., 2002, Breitwleser, 2004, Milligan, 2004 and Javitch, 2004]. 
Indeed, without the formation of dimers the promotion and insertion of the 
GPCR to the plasma membrane appears to be attenuated [Milligan, 2004].
Continuous exposure of a GPCR to a ligand, in many instances, results 
in profound and rapid attenuation of the intra-cellular signalling processes 
[Kohout and Lefkowitz, 2003]. This rapid desensitisation process occurs as a 
result of phosphorylation of the C-terminal domain of the GPCR by G-protein 
receptor kinase (GRK), the activity of which is regulated by both protein 
kinase A (PKA) and extra-cellular signal-regulated kinase (ERK) 
phosphorylation [Lefkowitz et al., 2002, Rapacciuolo et al., 2003, Li et al., '"ï2006 and Vaughan et al., 2006]. Additional desensitisation through A-kinase 
anchoring protein (AKAP)-recruited PKA phosphorylation of the GPCR may 
also occur [Tao et al., 2003]. GRK phosphorylation events disrupt GPCR 
coupling interactions because they allow for the recruitment of cytosolic p- 
arrestins that bind to the GPCR and physically interdict its coupling to the G- 
protein [Kohout and Lefkowitz, 2003]. Long-term desensitisation can also 
arise upon loss of cell surface receptors by receptor internalisation as a 
consequence of these phosphorylation events. Indeed, GRK phosphorylation
;of the receptor in recruiting p-arrestin allows transfer to clathrin-coated 
vesicles, through p-arrestin interactions with clathrin and AP-2, and results in 
receptor endocytosis [Lefkowitz and Shenoy, 2005 and Vaughan et al.. 2006].
Similarly, PKA phosphorylation can also result in receptor endocytosis via 
caveolae [Rapacciuolo et al., 2003]. Following desensitisation and 
internalisation the receptors are de-phosphorylated, through protein
:phosphatase 2 (PP2), in the early endosomes and subsequently recycled and 
returned to the plasma membrane to participate in further cell signalling 
events [Oakley et al., 1999, Tao et al., 2003 and Simaan et al., 2005].
The C-terminal region of the GPCR is also the site for other post- 
translational modifications such as palmitoylation, which can cause insertion
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of part of the C-terminal region into the lipid bi-layer thereby forming a fourth 
intra-cellular loop, ubiquitination, and the interaction with other scaffold protein 
targets [Yin et al., 2004, Milligan, 2004 and Hollmann et al., 2005]. 
Ubiquitination of GPCRs prevents receptor recycling and targets it for 
proteasomal degradation [Penela et al., 2003].
G-proteins are a class of guanine nucleotide binding proteins that 
interact with the second and third intra-cellular loops and the C-terminal 
region of the GPCR. There are four major classes of G-proteins, Gs, Gj/o, 
Gq/11 and G12/13. Each class of G-protein demonstrates a particular affinity for 
any given GPCR. However, the other classes of G-proteins are able to bind 
with reduced affinity, or gain increased affinity, through post-translational 
modifications, such as phosphorylation or palmitoylation. For example, 
phosphorylation of the P2-adrenoceptor by PKA reduces the GPCRs affinity 
for Gg and increases its affinity for Gj/o, known as Gg to G\/o switching [Baillie et 
al., 2003].
g ": I
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Each G-protein is a heterotrimeric protein complex composed of three 
subunits, a (40-46kDa), p (35kDa), and y (8kDa) [Hollmann et al., 2005]. In 
its inactive state the G-protein a-subunit is bound to guanosine di-phosphate 
(GDP) and this facilitates the interaction between the a-subunit and the py- 
subunits. The py-subunits are responsible for the interaction of the inactive 
heterotrimeric complex with the plasma membrane [Hollmann et al., 2005]. 
Activation of the GPCR is accompanied by a conformational change within the 
intra-cellular looped structures. This facilitates the activation of the G-protein 
heterotrimeric complex via a guanine nucleotide exchange factor (GEF), 
which slowly substitutes the GDP for guanosine tri-phosphate (GTP) in the a- 
subunit. This induces both dissociation of the unstable GTP-bound a-subunit 
with the py-subunits and consequently dissociation of all three subunits from 
the GPCR. This dissociation results in a reduction of agonist binding to the 
extra-cellular sites of the GPCR. Both the GTP-bound a-subunit and the Py- 
subunits can initiate a plethora of intra-cellular downstream cell signalling 
events, such as the modulation of enzyme activities or ion channels [Cooper, 
2003, Strock and Diversé-Pierluissi, 2004, and Li et al., 2006]. An example of
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G-protein regulation of enzymes is the adenylyl cyclase isoforms and these
are described in Table 1.1. The termination of the signalling occurs through a
GTPase activating factor (GAP), whereby GTP is hydrolysed to GDP and the 
GDP-bound a-subunit and the py-subunits re-associate. The heterotrimeric 
complex returns to its membrane-bound state and is now ready to regulate 
further intra-cellular signalling processes. I
f
t
:
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Ligand, e.g. biogenic amine or peptide
N-terminal
Extra-cellular
Plasma
Membrane
Intra-cellular
PKA phosphorylation 
/
Receptor desensitisation & 
internalisation
GRK phosphorylation
C-terminal
Intra-cellular signalling (e.g. inhibition of adenylyl cyclases, 
activation of ERK1/2, plasma membrane recruitment of GRK2)
Intra-cellular signalling (e.g. activation of adenylyl cyclases)
Figure 1.1 -  Schematic representation of the G-protein coupled receptor.
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1.4 Adenylyl Cyclase
Adenylyl cyclases (ACs) (EC 4.6.1.1) are membrane-associated 
glycoprotein enzymes that convert adenosine tri-phosphate (ATP) into cAMP, 
as shown in Figure 1.2 [Taskén and Aandahl, 2004]. AC isoforms show 
distinct structural homology to DNA polymerase [Cooper, 2003]. There are 
currently ten known isoforms of ACs, nine of which are membrane associated 
and the other is a Mn^^-dependent soluble form located within the cytosolic 
compartment of the cell [Bundey and Insel, 2004]. These isoforms are 
summarised in Table 1.1, which describes their individual tissue distribution 
and their specific means of regulation. The membrane-bound isoforms of AC, 
located at the plasma membrane in lipid rafts [Bundey and Insel, 2004], have
two trans-membrane helical regions that facilitate membrane targeting, and
.two cytosolic domains, known as cyclase homology domains, which are 
critical for the assembly and function of the catalytic machinery. The intra- 
molecular interactions of the two cytosolic domains must be in the correct 
orientation to form an active AC module. Modulation of this interaction may
■result in an AC conformation that has enhanced or attenuated catalytic 
activity. The binding of Mg^^ ions to two metal ion-binding sites, co-ordinated 
by two aspartic acid residues, also plays a significant role in regulating AC 
isoform activity [Cooper, 2003]. Regulation of activity occurs through the 
binding of free metal ions, through the interaction with various G-protein sub- 
types and by direct phosphorylation, as discussed in more detail below 
[Hurley, 1999 and Sunahara and Taussig, 2002].
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Figure 1.2 -  Catalysis of cAMP from ATP by adenylyl cyclase.
through displacement of the bound ions. Interestingly, released I
from intra-cellular locations, e.g. the sarcoplasmic reticulum, has no effect on
Ca^^ sensitive AC isoforms, whereas the flux of Ca^^ ions through L-type Ga^^
channels is able to bind and significantly modulate activity [Sunahara and
Taussig, 2002]. This is indicative of compartmentalisation of AC isoforms,
and their localisation in caveolae or lipid rafts may underlie this effect [Bundey
and Insel, 2004]. Intra-cellular Ca^^ concentrations between 10-25pM inhibit
2006]. Indeed, Ca^^/calmodulin can stimulate AC1 and AC8 isoforms as well 
as cAMP-specific phosphodiesterases to generate rapid and dynamic 
changes in cAMP concentrations [Willoughby and Cooper, 2005]. Soluble AC 
is uniquely activated by bicarbonate ions {HCO3 ) [Sun et al., 2002] and it has ■I'been recently demonstrated in neutrophils that it can also be activated by 
TNF-induced increases in intra-cellular Ca^^ concentrations [Han et al., 2005].
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The effect of Ca^  ^ binding is isoform-specific and is likely to occur
all AC isoforms, but concentrations in the range of 0.2-0.6pM inhibit AC5 and 
AC6 but stimulate AC1, ACS and AC8 [Cooper, 2003 and Beazely and Watts,
Forskolin is a synthetic activator of all membrane-bound AC isoforms, 
except AC9, by augmenting the interaction between the two cytosolic domains 
that make up the core catalytic unit [Hurley, 1999]. Forskolin acts co­
operatively with the G-protein subunit Gos. The activation of ACs by GTP- 
bound Gqs proteins occurs through a similar mechanism to that of forskolin, 
and it is postulated that this occurs concomitantly with an activating 
conformational change in the catalytic unit. Conversely, the GTP-bound G-
Iprotein Goi results in an inhibition of ACS and AC6 isoforms through direct 
interaction with the catalytic regions, and a conformational change of equal 
magnitude but opposite orientation. The binding of Goi does not occur at the 
same site as Gos but at a site on the opposite side, hence the inverse 
conformational shift. The binding of Gpy subunits also causes an isoform- 
specific activation or inhibition respectively. The consensus motif required for 
G(3y subunit binding is GIn-Xaa-Xaa-Glu-Arg [Sunahara and Taussig, 2002].
Indeed G|3y subunits have been shown to regulate ion channel function 
[Strock and Diversé-Pierluissi, 2004], GPCR kinases [Li et al., 2006] and 
mitogen-activated protein kinases (MAPKs) [Pearson et al., 2001]. Re-
9 I
10
Chapter 1 Introduction
association of the GDP-bound Ga subunit with the Gpy subunits terminates 
the AC signalling event. Whether there is a functional role for Goq remains to 
be elucidated [Sunahara and Taussig, 2002].
Post-translational modifications such as phosphorylation, glycosylation 
and S-nitrosylation can also regulate AC activity [Beazely and Watts, 2006]. 
Protein kinase C (PKC) is the major protein kinase to regulate AC activity. 
AC1, AC2, ACS, ACS and ACT stimulated activity is enhanced by PKC 
phosphorylation, whereas AC4 and AC6 phosphorylation by PKC results in 
down-regulation of stimulated activity. Protein kinase A (PKA) initiates an 
inhibitory effect on ACS and AC6, and similarly Ca^^-calmodulin-dependent 
kinase (CaMK) II and IV phosphorylation of ACS and AC1 respectively. 
Furthermore, direct interaction and phosphorylation of the AC2, ACS and AC6 
by c-Raf kinase can also regulate the activity of these isoforms [Ding et al., 
2004 and Beazely and Watts, 2006]. N-linked glycosylation has also been 
established as important for both AC activity and intra-cellular membrane 
targeting.
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Isoform Distribution RegulationG-protein Calcium Protein Kinases
1 Brain
Gqs stimulation 
Gpy inhibition 
Gqo inhibition
Ca^VCaM
stimulation
PKC weak stimulation 
CaMK IV inhibition
2 Brain, skeletal muscle, lung & heart
Gos stimulation 
Gpy stimulation No effect
PKC stimulation 
c-Raf activation
3
Brain, olfactory 
epithelium & 
pancreas
Gqs stimulation Ca^VCaMstimulation
PKC weak stimulation 
CaMK II inhibition
4
Brain, heart, kidney, 
liver, lung, adipose 
tissue & uterus
Gos stimulation 
Gpy stimulation No effect PKC inhibition
5
Brain, heart, kidney, 
liver, lung, adipose 
tissue & uterus
Gos stimulation 
Gpy inhibition 
Goi inhibition
Ca^^ inhibition
PKA inhibition 
PKCa/Ç stimulation 
c-Raf activation
6 Ubiquitous (heart & kidney)
Gos stimulation 
Gpy inhibition 
Goi inhibition
Ca^^ inhibition PKA & PKC inhibition c-Raf activation
7 Ubiquitous (brain) Gos stimulation Gpy stimulation No effect PKC stimulation
8 Brain, lung & pancreas
Gqs stimulation 
Gpy inhibition
Ca^'/CaM
stimulation No effect
9 Brain & skeletal muscle GQs stimulation
Ca^^/calcinuerin
inhibition No effect
^Soluble Ubiquitous (testis) No effect Ga^  ^stimulation No effect
î :
s
ï
gî
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'#Table 1.1 -  The mammalian adenylyl cyclase enzyme isoforms and their 
regulatory properties.
The tissue distribution shown in parentheses indicates the most abundant 
tissue expression of the ubiquitously expressed isoforms.
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1.5 cAMP Signalling
15.'/ cAMP
[Sutherland and Rail, 1958 and Beavo and Brunton, 2002]. This influential 
work, undertaken in the late 1950s, was recognised by a Nobel Prize award to
I
Earl W. Sutherland established cAMP as a second messenger '"gmolecule, shaping the intra-cellular response to the hormone adrenaline
Sutherland in 1971. The importance of this cell signalling cascade is reflected -ft
in the awards of further Nobel Prizes, to Alfred Gilman and Martin Rodbell for :their discovery of G-proteins, to Arvid Carlsson, Paul Greengard and Eric 
Kandel for their work on the central nervous system (CNS) and the functional 
role of cAMP and cGMP, and to Richard Axel and Linda Buck for their work :
on odorant GPCRs and the organisation of the olfactory system.
.
cAMP is not uniformly distributed within the cell but compartmentalised 
in functionally distinct pools [Houslay and Milligan, 1997, Zaccolo and Pozzan,
2002, Houslay and Adams, 2003 and Brunton, 2003]. cAMP is produced at a 
basal concentration of approximately IpM. These concentrations are able to 
rise to greater than 10-20pM and fall to basal concentrations in milli-seconds.
Such dynamic modulation of intra-cellular cAMP concentrations occurs as a 
result of alterations in the activation state of adenylyl cyclases and cAMP- 
specific phosphodiesterases [Houslay and Milligan, 1997 and McConnachie et 
al., 2006]. It is likely that an uncontrolled increase in cAMP concentration will 
eventually result in the loss of cAMP compartmentalisation and complete 
uniform distribution. This is likely to cause aberrant signalling pathways to 
occur coupled with an inappropriate cell response. Therefore, it is important 
to retain cAMP in the correct spatial orientation and at the appropriate
'ftconcentration. This implies the use of scaffold, anchoring and adapter 
proteins to co-ordinate the assembly and localisation of cAMP signalling 
complexes, providing efficiency and specificity in signal transduction. cAMP •ftbinding proteins include cAMP-specific phosphodiesterases (cAMP-PDEs), 
cAMP-dependent protein kinase or PKA and their associated AKAPs, guanine
12
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nucleotide exchange proteins activated by cAMP (EPAC), and cAMP-gated 
ion channels [Beavo and Brunton, 2002].
15.2  cAMP-dependent Protein Kinase
cAMP-dependent protein kinase, or PKA, is a broad-spectrum protein 
kinase that phosphorylates a plethora of target proteins, including receptors, 
enzymes, ion channels, and the transcription factor CREB. The consensus 
motif for phosphorylation by PKA is Arg-Arg-Xaa-[Ser/Thr]. It is a tetrameric 
protein kinase consisting of two catalytic (C) subunits, the activities of which 
are controlled through the interaction with two regulatory (R) subunits. All 
subunits are differentially expressed on a cell-type specific basis. There are 
three genes encoding the catalytic subunits, Ca, Cp, and Cy. Splice variants 
of the catalytic subunits have been reported. Similarly, there are four genes 
encoding the regulatory subunits, Rio, Rip, Rlla, and Rlip, and their 
associated splice variants. In its tetrameric form PKA is inactive. cAMP co- 
operatively binds to the R subunits, up to two cAMP molecules per subunit, 
and facilitates the dissociation of the activated C subunits, both from each 
other, and the dimeric R subunits [Daniel et al., 1998 and Taskén and 
Aandahl, 2004].
The Rl subunit is generally considered to have a cytosolic sub-cellular 
localisation [McConnachie et al., 2006]. The Rll subunit is thought to be 
responsible for mediating AKAP interactions [Dodge et al., 2001, Taskén et 
al., 2001 and McCahill et al., 2005], allowing it to be localised at distinct sub- 
cellular sites, such as the plasma membrane, and to intra-cellular organelles 
to provide signalling complexes. The differences in the N-terminal regions of 
the Rl and Rll subunits are believed to underlie the disparity for AKAP 
binding.
Three distinct genes produce three catalytic isoforms, a, p, and y, each 
of which is subject to interactions with isoforms of the endogenous inhibitor, I
13
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PKI. The N-terminal regions of all PKI isoforms bind to the catalytic subunits 
and serve as a pseudo-substrate thereby abolishing PKA activity.
1.5.2.1 A-Kinase Anchoring Proteins
AKAPs are expressed on a cell-type specific basis and have distinct 
patterns of intra-cellular localisation [Taskén and Aandahl, 2004, and 
Langeberg and Scott, 2005]. AKAPs sequester PKA to promote the close 
proximity to the wide range of substrates that it phosphorylates [Murphy and 
Scott, 1998]. Over fifty AKAPs have been identified and there is modest 
homology between them. However, most AKAPs do conform to a generalised 
structure, whereby one region facilitates PKA binding, a second region intra­
cellular targeting, and several distinct regions for interactions with other 
signalling molecules [Wong and Scott, 2004]. Some AKAPs promote the 
delivery of PKA to the plasma membrane through direct interaction with a 
basic region, found towards the N-terminal of the AKAP, and the 
phosphatidyl-inositol 4,5 bisphosphate, myristoyl or palmitoyl components of 
the plasma membrane. And conversely, for example, the C-terminal region of 
AKAP6 binds the PKA holo-enzyme. Site-directed mutagenesis of a residue 
in AKAP6 prevents the binding and subsequent recruitment of PKA to the 
desired cellular location [Carlisle Michel et al., 2004]. AKAPs interact with the 
PKA Rll regulatory subunit at the dimérisation interface of the R subunits 
[Newlon et al., 1999, Colledge and Scott, 1999 and Newlon et al., 2001]. 
However, certain AKAPs have also been shown to interact with the PKA Rl 
subunit. Thus, sequestration of PKA Rl and Rll subunits may be dependent 
upon the R subunit availability in a particular cell type and the AKAP 
expression pattern.
AKAP1 interacts with the RIa subunit with a Kq of 185nM whereas the 
Rlla subunit binds with a Kd of 2nM. AKAP interactions with PKA can be 
disrupted using a peptide (Ht31) based upon AKAP 13 [Klussmann et al., 
2001]. Furthermore, AKAPs themselves can be directly phosphorylated by 
PKA [Tao et al., 2003 and Bajpai et al., 2006]. AKAPs can also integrate a 
plethora of cell signalling pathways through their interaction with receptors.
14
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• ' ie.g. p-adrenoceptors and AMPA/NMDA receptors [Fraser et al., 2000, Oiiveria 
et al., 2003], enzymes including phosphodiesterase-4 (PDE4) [Baillie et al.,
2005], other kinases, e.g. PKC, PPs, e.g. PP1 and PP2, and channels, e.g. 
ion channels and aquaporin-2 [Henn et al., 2004, Hoshi et al., 2005, and Chen 
and Kass, 2005]. AKAPs can also influence the structural organisation of the 
cell cytoskeleton through interactions with the actin microfilaments and the 
microtubules. AKAPs are likely to play a fundamental role in regulating cell 
cycle progression through interactions with centrosomes, chromatin 
condensation and de-condensation, and nuclear envelope dis-assembly and ft:re-assembly [Taskén et al., 2001 and Taskén and Aandahl, 2004].
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AKAP
Gene Alternative Nomenclature Protein Interactions
1 S-AKAP84/D-AKAP1/AKAP121/AKAP149 Lamin B, PP1, PDE4A
2 AKAP-KL
3 AKAP110 Gi3 0 , PDE4A
4 AKAP82/FSC1
5 AKAP75/79/150
PKC, PP2B, p-adrenoceptor, SAP97, 
PSD-95, AM PA & NMDA receptors, 
L-type Ca^^ channels, aquaporin-2 
water channel
6 m-AKAP PDE4D3, PP2A, ERK5, EPAC1
7 AKAP15/18(a, p, y, 5) Na^ & L-type Ca^^ channels, aquaporin-2 water channel
8 AKAP95 Eg7/condensing, PDE4A
9 AKAP450/AKAP350/Yotiao/CG-NAP/Hyperion PDE4D3, PP1, PP2A, PKN, PKCe, CK1, NMDA receptor
10 D-AKAP2
11 AKAP220/hAKAP220 PP1
12 AKAP250/Gravin PKC, p-adrenoceptor, actin :
13 AKAP-Lbc/Ht31/Rt31
Table 1.2 -  The A-kinase anchoring proteins and gene nomenclature.
Many other proteins have been assigned AKAP function to date including 
Microtubule-associated protein 2B (MAP2B), Ezri n/AKAP7 8/T -AKAP80, 
Pericentrin, WAVE-1/Scar, Myosin VII A, PBR-associated protein 7 (PAP7), 
Neurobeachin, AKAP28, Myeloid translocation gene (MTG) 8/16b [Asirvatham 
et al., 2004], AKAP140, AKAP85, Brefeldin A-inhibited guanine nucleotide- 
exchange protein 2 (BIG2) [Li et al., 2003], and Rab32 but have yet to be 
given designated gene nomenclature. Table and information adapted from 
Taskén and Aandahl, 2004, Wong and Scott, 2004 and McConnachie et al., 
2006.
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1.5.2.2 Gene Transcription
17
The intra-cellular levels of cAMP have a profound effect at the level of 
gene transcription [Montminy, 1997 and Zambon et al., 2005]. For gene 
expression to be regulated by cAMP the promoter region must contain a 
cAMP response element (CRE), which conforms to the general DNA 
consensus motif 5-TGACGTCA-3' [Daniel et al., 1998 and Shaywitz and 
Greenberg, 1999]. The CRE motif is typically located approximately 100 
nucleotides from a TATA box sequence. Genes containing the CRE motif 
include those encoding certain cAMP-specific PDE4 isoforms [Vicini and iConti, 1997 and Le Jeune et al., 2002], the gluco-corticoid receptor, the aryl 
aromatic hydrocarbon receptor, insulin, tyrosine hydroxylase, inducible nitric
oxide synthase (iNOS) and angiotensinogen, to name but a few [Mayr and 
Montminy, 2001 and Beavo and Brunton, 2002]. As described in Section
1.5.2 above, cAMP binding to the PKA holoenzyme releases the active C 
subunits of PKA from their R subunits. Without such dissociation of the 
holoenzyme, PKA is unable to traverse the nuclear membrane because it is 
simply too large. The active C subunits cross the nuclear membrane through 
passive diffusion and directly phosphorylate and activate a number of 
transcription factors such as cAMP response element binding protein (CREB), 
cAMP response element modulator (CREM), activating transcription factor-1 
(ATF-1) and nuclear factor-xB (NF-kB) [Daniel et al., 1998 and Houslay and 
Kolch, 2000]. The phosphorylation of CREB is widely accepted as a 
measurable read-out of PKA activation [MacKenzie and Houslay, 2000,
'Staples et al., 2001 and Rangarajan et al., 2003]. CREB is phosphorylated by 
PKA at Ser-133 within the consensus sequence Arg-Arg-Pro-Ser-Tyr 
[Montminy, 1997 and Houslay and Kolch, 2000]. CREB can also be 
phosphorylated at additional sites by other kinases including PKC, CaMKs,
ERK1/2 via MAPKAPK1/pp90^ft MAPKAPK2 and casein kinase-2 (CK-2).
Indeed, PKA serves as the priming kinase for glycogen synthase kinase-3 
(GSK-3) phosphorylation at Ser-129, the activity of which is subject to PKA 
regulation [Daniel et al., 1998, Fang et al., 2000 and Doble and Woodgett,
2003]. The interaction of phosphorylated CREB dimers with the CRE motif 
occurs through a basic C-terminal leucine zipper motif (bZIP). The bZIP motif
J iSH
1.5.3 Guanine Nucleotide Exchange Protein Activated by cAMP
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of CREB also contains the nuclear localisation signal. The subsequent 'ftinteraction of CREB binding protein (CBP), or its homologue p300, initiates 
target gene expression through intrinsic histone acetyl-transferase activity and '■'ftthe recruitment of RNA polymerase II [Shaywitz and Greenberg, 1999 and 
Mayr and Montminy, 2001]. Furthermore, the recruitment to the nearby 
TATA box of the TATA-binding protein (TBP) and a multitude of TBP- 
associated factors (TAFs), forming the TFIID multi-protein complex, are 
crucial components of the transcriptional machinery, with TFIIB bridging the 
interaction between TFIID and RNA polymerase II. Termination of cAMP- 
induced gene transcription occurs through the de-phosphorylation of CREB by 
PP1 or PP2B, or through the interaction of PKA with PKI, which drives the 
catalytic units back to the cytoplasm by exposing a nuclear export motif 
[Daniel et al., 1998 and Mayr and Montminy, 2001].
Ras is a monomeric GEF that is activated by receptor tyrosine 
kinases (RTKs) such as the epidermal growth factor (EGF) receptor and the 
insulin receptor [Malarkey et al., 1995]. Activation of these receptors through
• f t -ligand binding results in the conversion of Ras from its inactive GDP-bound 
form to its active-GTP bound form. Rapi and Rap2 are also members of the 
Ras-like family of small GTPases [Zwartkruis and Bos, 1999].
A novel 881-residue protein, guanine nucleotide exchange protein 
activated by cAMP (EPAC), was identified with a distinct region for cAMP 
binding and a second region capable of supporting GEF activity [de Rooij et 
al., 1998 and Kraemer et al., 2001]. Two EPAC proteins, EPAC1 and EPAC2 
(cAMP-GEFI and cAMP-GEFII), so called because of the number of cAMP 
binding sites, have been described [de Rooij et al., 2000, Kraemer et ai., 2001 
and Rehmann et ai., 2003]. EPAC1 is composed of an N-terminal regulatory 
module containing a Dishevelled, Egl-10, Pleckstrin (DEP) domain, the cyclic
f t :nucleotide binding site(s), and the Ras exchange motif (REM), with the GEF 
domain or catalytic machinery towards the C-terminal region [Kraemer et al..
EPACs may also regulate other protein kinase activity, such as protein 
kinase B (PKB) or phospholipase Ce (PLCe). What is certain is that the
19
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2001 and Rehmann et al., 2003]. EPAC2 has the same domains as EPAC1 
but it differs in that it contains a second cAMP-binding site at the extreme N- 
terminus, and a Ras association domain between the REM and GEF domains 
[Bos, 2003 and Rehmann et al., 2006].
ft'
Physiological concentrations of cAMP bind EPAC and directly activate
S'-Rapi and Rap2 through GDP/GTP exchange, a process that is independent ’Iof phosphorylation by PKA [de Rooij et al., 1998 and de Rooij et al., 2000 and :ft:Kraemer et al., 2001]. EPAC thus functions as a GEF for Rapi and Rap2 [de 
Rooij et al., 1998]. Whilst half-maximal activation of PKA requires around 
IpM of cAMP, half-maximal activation of EPAC2 requires approximately 
40pM cAMP [Bos, 2003]. The binding of cAMP induces a conformational 
change in EPAC proteins that relieves the N-terminal inhibitory constraint by 
exposing, and thereby activating, the GEF domain. This is exemplified by 
truncation of the cAMP binding domain, the identification of a related to EPAC 
protein (rEPAC) that lacks the cAMP binding domain and constitutively 
activates both Rapi and Rap2, and the use of N- and C-terminally tagged
ftfluorescence resonance energy transfer (FRET) constructs [de Rooij et al.,
1998, de Rooij et al., 2000, Bos, 2003 and Ponsioen et al., 2004].
EPAC is ubiquitously expressed in human tissues [Zwartkruis and Bos,
1999 and Bos, 2003]. Within the cell EPACs are localised at perinuclear and ''ftmitochondrial locations and may co-localise with soluble forms of AC [Taskén 
and Aandahl, 2004 and Bundey and Insel, 2004]. This localization is subject 
to change during the cell cycle [Bos, 2003]. Localisation is controlled by the 
DEP domain [de Rooij et al., 1998 and Kraemer et al., 2001]. Removal of 
the DEP and cAMP binding domains has no effect on EPAC activity, but it 
does affect its localisation at the plasma membrane [de Rooij et al., 2000 and 
Magiera et al., 2004]. Assessing the role of EPACs in a cellular signalling 
context, it is hardly surprising that EPAC1 also associates with AKAP6 using 
PDE4D3 as a bridge [McConnachie et al., 2006].
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activation of EPAC, possibly augmented by the interaction with microtubule- 
associated protein 1A, light chain 2 (MAP1A-LC2), and Rapi causes a 
significant increase in cell adhesion [Rangarajan et al., 2003, Gupta and 
Yarwood, 2005 and Yanvood, 2006]. The mobilisation of intra-cellular Ca^"' 
stores through EPAC2-mediated regulation of the ryanodine receptor has also 
been described and may play a role in insulin secretion from the pancreatic 13- 
islets [Bos, 2003]. The availability of cAMP analogues, selective for EPAC
1.5.4 cAMP-gated Ion Channels
neurons [Bradley et al., 2005]. CNG ion channels have been exploited to 
investigate cAMP compartmentalisation [Rochais et al., 2004].
î
over PKA, will allow the elucidation of a plethora of cell signalling pathways ft
that are subject to the EPAC regulation [Christensen et al., 2003].
Cyclic nucleotide-gated (CNG) ion channels are members of the 
voltage-gated ion channel super-family [Kaupp and Seifert, 2002]. CNG ion 
channels are activated by both cAMP and cGMP but have ligand specificity 
[Young and Krougliak, 2004]. They have four subunits, each composed of six 
transmembrane-spanning regions with intra-cellular N- and C-terminal
fft.regions. There are six types of subunit, four "A" and two “B” subunits. Homo- 
and hetero-tetrameric channels are formed from combinations of subunits and ;:'ft
these direct their specific means of regulation [Bradley et al., 2005]. Cyclic 
nucleotide binding occurs at the C-terminal of the channel and other sites of 
functional regulation are at sites within the N-terminal. The activation of the 
specific channel requires the co-operative binding of multiple cyclic nucleotide 
molecules and is not subject to any desensitisation mechanism. They are not
./ft
cation-specific and allow the influx of either alkali Na^ ions or divalent Ca^^ ft:ions [Cooper, 2003]. CNG ion channel activity is modulated by both 
Ca^YCaM and phosphorylation. They are expressed in a wide variety of
tissue but are most commonly studied in photoreceptors or olfactory sensory
20
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Figure 1.3 -  Schematic representation of the cAMP signalling system.
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1.6 Cyclic Nucleotide Phosphodiesterases
%
j
Cyclic nucleotide phosphodiesterases (PDEs) (EC 3.1.4.17) are 
enzymes that catalyse the hydrolysis of cyclic nucleotides to the associated 5’ 
mononucleotide. This catalytic reaction is shown structurally in Figure 1.4 
[Lugnier, 2006]. POE activity is detectable at various locations within cells
. 'f tincluding the cytosol, the plasma membrane, the cytoskeleton and the 
nucleus [Houslay and Adams, 2003]. The PDE super-family, shown in Table 
1.1, constitutes eleven PDEs characterised by their substrate specificity, i.e. 
their ability to hydrolyse cAMP and/or cGMP, their specific means of 
regulation, and their specific inhibition by selective inhibitors [Houslay, 2001].
A central theme for all PDEs appears to be the presence of N-terminal, 
tandem regulatory domains that function to control the activity of the core, 
conserved catalytic unit, as depicted in Figure 1.5 [Francis et al., 2001 and 
Houslay and Adams, 2003].
22
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Figure 1.4 -  Cyclic nucieotide hydrolysis by phosphodiesterases.
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PDE Genes Substrates Regulation RegulatoryDomains Selective InhibitioncAMP cGWP
1 A, B and 0 Yes Yes Ca^7CaM PKA and CaMK
Ca^YCaM
Binding
Nicardipine and 
Vinpocetine
2 A Yes Yes
Activated by 
cGMP 
Phosphorylated 
by PKC
GAP EHNA
3 A and B Yes No
Inhibited by 
cGMP 
Phosphorylated 
by PKA, PKB/Akt 
& PI3-K
Cilostimide and 
Milrinone
4 A, B, 0  and D Yes No
Phosphorylated 
by PKA and 
ERK1/2
UCR
Rolipram, Ro 20-1724, 
Cilomilast (Ariflo®), 
Denbufylline and 
Roflumilast
5 A No Yes
Binds cGMP 
Phosphorylated 
by PKA and PKG
GAP Zaprinast and Sildenafil (Viagra®)
6 A, B and C No Yes
Activated by 
Rhodopsin and 
Transducin (GO
Zaprinast and Sildenafil 
(Viagra®)
7 A and B Yes No BRL 50481 and ICI 242
8 A Yes No Unknown,IBMX-insensitive
9 A No Yes Zaprinast, SCH51866, IBMX-insensitive
10 A Yes Yes Inhibited by cAMP Dipyridamole and Zaprinast
11 A Yes Yes Dipyridamole and Zaprinast
m
j
:
1
Ï
Table 1.3 -  Classification of the PDE enzyme super-families.
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1.6.1 Phosphodiesterase-1
There are three genes (A-C) encoding PDE1 and these are expressed 
as multiple splice variants arising from both 5’ and 3' mRNA alternative 
splicing [Snyder et al., 1999]. PDE1 enzymes are dimers and can hydrolyse 
both cAMP and cGMP, with Km values of 1-100pM and 1-5pM respectively 
[Francis et al., 2001]. They are composed of paired Ca^Vcalmodulin (CaM) 
binding domains and the co-operative occupancy of four Ca^^ ions, 
irrespective of intra-cellular origin, of the binding domains serves to activate 
enzymatic activity [Spence et al., 1995 and Lugnier, 2006]. PDE1 enzymes 
exist in an auto-inhibited state and are also inhibited directly, at the active site, 
by nicardipine and vinpocetine, and by the anti-schizophrenic drug tri-fluoro- 
perazine, a CaM antagonist [Houslay, 2001]. Activity can also be down- 
regulated by phosphorylation by both PKA and CaMK, byfattenuating CaM 
binding. PDE1 is ubiquitously expressed and its expression profile can be 
dynamically regulated by 7-oxo-prostacyclin in the heart and phosphatidyl 
inositol signalling in Chinese Hamster Ovary (CHO) cells [Spence et al., 1995 
and Kostic et al., 1997].
1.6.2 Phosphodiesterase-2
One gene (A) encodes three 5' mRNA splice variants of PDE2 [Francis
et al., 2001]. PDE2 enzymes can hydrolyse both cAMP and cGMP, with a Km 
value of 15-30pM. PDE2 enzymes are unique as they are activated through a 
decrease in Km rather than an increase in Vmax, as is observed for other 
PDEs. They contain tandem GAP domains that promote dimérisation and 
directly bind cGMP to activate and co-operatively increase the rate of 
hydrolysis of cAMP; a point of cross talk for the signalling pathways [Lugnier, 
2006]. Activity is also enhanced by phosphorylation by PKC [Houslay, 2001]. 
PDE2 enzymes are inhibited through direct competition for cGMP binding by 
erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA), an adenosine deaminase 
inhibitor [Michie et al., 1995]. PDE2 is widely expressed in many human 
tissues and has a ubiquitous sub-cellular localisation [Lugnier, 2006]. It is
25
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particularly abundant in the CNS and contributes to the compartmentalisation 
of olfactory signal transduction [Juilfs et al., 1997].
1.6.3 Phosphodiesterase~3
■■ft
PDE3 enzyme splice variants are encoded by two genes (A and B), 
which are positioned at chromosome 11p15.1 and 11p15, and are not subject 
to mRNA splicing [Meacci et al., 1992, Lobbert et al., 1996 and Miki et al.,
1996]. PDE3 dimers specifically hydrolyse cAMP and are competitively 
inhibited by cGMP [Lugnier, 2006]. The Km values for PDE3 hydrolysis of
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both cyclic nucleotides are 0.1-0.8pM, but the Vmax for cAMP hydrolysis is
greater [Francis et al., 2001]. Excess cAMP in Jurkat T-cells induces
expression of PDE3 [Erdogen and Houslay, 1996]. PDE3 is targeted to the 
endoplasmic reticulum through two N-terminal domains and as such are 
appropriately positioned to control the phosphorylation status of voltage-gated 
ion channels and Ca^^ release [Shakur et al., 2000]. Together with PDE4,
PDE3 enzymes are responsible for the major cAMP hydrolysing activity in 
heart cells and platelets [Mongillo et al., 2004]. PDE3A has a fundamental 
role in controlling cardiac contractility through the modulation of Ca^^ 
channels, and inhibition of these enzymes in the heart by cilostimide and 
milrinone results in positive inotropy, i.e. increased contractility. Furthermore,
PDE3 inhibition attenuates platelet aggregation [Francis et al., 2001]. PDE3B 
expression is altered and thought to play a role in type 2 diabetes mellitus 
[Matsumoto et al., 2003]. Increasing intra-cellular cAMP concentrations 
increases the rate of lipolysis in adipocytes, via PKA phosphorylation and 
activation of hormone-sensitive lipase, and in pancreatic (3-cells enhances
■iinsulin secretion in response to glucose [Harndahl et al., 2002 and 
McConnachie et al., 2006]. More recently, a role has been identified for 
cAMP and PDE3B in GLUT-4 translocation in adipocytes [Zmuda- 
Trzebiatowska et al., 2006]. PDE3B is phosphorylated and activated by PKA 
and thus functions in a classical negative feedback loop to lower intra-cellular 
cAMP concentrations. PDE3B is also phosphorylated and activated by 
PKB/Akt, a protein kinase involved in the insulin signalling cascade, and is
. 1
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therefore likely to utilise PDE3B activation to reduce further insulin secretion, 
in an autocrine manner [Rondinone et al., 2000 and Onuma et al., 2002].
1.6.6 Phosphodiesterase-6
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1.6.4 Phosphodiesterase~4
PDE4 enzymes are the subject of this thesis and are discussed in 
much greater detail in Section 1.7 below.
1.6.5 Phosphodiesterase-5
PDE5 enzymes are widely known as being the drug target for the 
compound Viagra® (sildenafil) for the treatment of penile erectile dysfunction 
[Corbin and Francis, 1999 and Sung et al., 2003]. Viagra® prevents the 
PDE5 hydrolysis of cGMP promoting smooth muscle relaxation and 
increasing the blood flow to the corpus cavernosum. Zaprinast also inhibits 
the cGMP-hydrolysing activity of PDE5 enzymes [Lugnier, 2006]. One gene 
(A) located on chromosome 4q25-27 encodes three PDE5 isoforms that occur 
through both alternative mRNA splicing and the use of alternate promoters, 
regulated by cyclic nucleotide expression [Francis et al., 2001]. PDE5 
enzymes exist as dimers and have a Km of 5-20pM for cGMP binding at the N- 
terminal GAF domain. PDE5s are subject to activation and conformational 
change initially by cGMP binding and secondly by both PKA and protein 
kinase G (PKG) phosphorylation leading to a further increase in cGMP 
binding affinity [Lugnier, 2006]. PDE5 is expressed in lung, heart and the 
cerebellum and at lower levels in the brain and kidney [Francis et al., 2001 
and Houslay, 2001].
PDE6 enzymes are light activated via rhodopsin and transducin, a G- 
protein, and are found to be expressed exclusively in the rod and cone 
sensory cells of the visual system [Houslay, 2001]. Within the cell PDE6
:enzymes are predominantly membrane bound [Francis et al., 2001]. PDE6
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enzyme subunits are encoded by distinct genes and are specific for cGMP, 
with a Km in the region of 5-20pM. Structurally they are hetero-tetramers
■;'ècomposed of a-catalytic and/or |3-catalytic subunits and two y-regulatory 
subunits with rod PDE6 enzymes composed of a, p and y subunits and cones 
a, a, and y subunits [Lugnier, 2006]. For photo-transduction, rhodopsin 
absorbs a photon of light and activates transducin, which exchanges GDP for 
GTP. GTP-bound transducin then displaces the y-subunits and activates 
PDE6 catalytic activity.
1.6.7 Phosphodiesterase-7
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PDE7 enzymes are encoded by two genes (A and B), which are 
located on chromosome 8q13-q22 and subject to 5’ mRNA splicing [Houslay 
and Milligan, 199% and Lugnier, 2006]. They have very low Km values 
(approximately 0.1 pM) for cAMP hydrolysis [Richter et al., 2002]. BRL 50481 
and ICI 242 have been shown to inhibit PDE7 activity, whereas rolipram has 
no effect. Within the cell PDE7 associates with the golgi apparatus, as shown 
by co-localisation with the golgi marker GM130 [Asirvatham et al., 2004]. In Athe same study PDE7A has been shown to bind AKAP-MTG in T-cells, where 
its expression predominates and thus, may be subject to regulation by PKA.
1.6.8 Phosphodiesterase-8
PDE8 enzymes are encoded by one gene (A) and have similar Km 
values for cAMP hydrolysis as PDE7 [Francis et al., 2001 and Lugnier, 2006].
They are insensitive to current PDE inhibitors, including IBMX. A Per-ARNT- 
Sim (PAS) domain is located at the N-terminal and may regulate intra-cellular 
distribution and activity, through protein-protein interactions [Soderling and
Beavo, 2000]. Expression of PDE8 isoforms is highest in the testis and lower wexpression is detected in a plethora of other tissues including brain, liver and 
kidney.
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1.6.9 Phosphodiesterase-9
Encoded by one gene (A) located on chromosome 21q22.3, PDE9 
enzymes, of which there is four splice variants, are specific for cGMP with a 
Km value of approximately 0.07pM [Soderling and Beavo, 2000]. They contain 
a REC domain, but as yet the precise role of this domain is unknown [Lugnier, 
2006]. Intriguingly, cGMP-specific PDE9 is, like the cAMP-specific PDE8, 
insensitive to inhibition by IBMX but activity is attenuated with zaprinast and 
SCH 51866. PDE9 has broad tissue distribution including, kidney, liver, lung, 
brain, testis, skeletal muscle, heart, thymus and spleen [Soderling and Beavo, 
2000].
1.6.10 Phosphodiesterase-10
Km value of 0.05pM and a Vmax value 5-fold higher for cAMP than cGMP, Km 
3pM. This kinetic profile may underlie the cAMP inhibition of cGMP hydrolysis 
by PDE10. IBMX, dipyridamole and zaprinast inhibit PDE10. PDE10 is 
ubiquitously expressed in human tissue. Unlike PDE10A1, PDE10A2 is 
phosphorylated at its extreme N-terminal by PKA and this phosphorylation 
prompts it redistribution from the membrane of the golgi apparatus to the 
cytosol [Kotera et al., 2004].
1.6.11 Phosphodiesterase-11
Similarly, PDE11 enzymes are encoded by just one gene (A) and also 
do not discriminate between cAMP and cGMP, with a Km value of 
approximately 0.75pM for both cyclic nucleotides [Francis et al., 2001]. 
PDE11 isoforms show differential inclusion of tandem GAF domains, a likely 
result of alternative 5' mRNA splicing similar to that for the ÜCR regulatory
29
Alternative mRNA splice variants of PDE10 enzymes are encoded by 
one gene (A) located on chromosome 6q26-27 and contain GAF domains of 
unknown function [Francis et al., 2001 and Lugnier, 2006]. PDE10 displays a
!
domains of PDE4 isoforms [Houslay, 2001 and Lugnier, 2006]. Inclusion of :
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the extreme N-terminal GAF domain may allow PDE11 to be regulated by 
PKA and PKG phosphorylation, as putative consensus motifs exist [Lugnier,
2006]. IBMX, dipyridamole and zaprinast also inhibit PDE11. PDE11 has 
wide tissue distribution.
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Figure 1.5 -  Modular structures of the PDE enzyme super-family.
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1.7 cAMP-specific Phosphodiesterase-4
1.7.1 Phosphodiesterase-4 Gene and Modular Structure
Phosphodiesterase-4 (PDE4) enzymes, or as they were once known 
“type-iV” or “type-4”, are a family of over 20 proteins encoded by four distinct 
genes, PDE4A -  PDE4D [Conti et al., 2003 and Houslay et al., 2005].
PDE4A1, originally known as RD1 (ratdnc-1), was the first PDE4 to be cloned.
This was achieved using a probe based upon the Drosophila melanogaster 
dunce^ gene, which encodes a PDE4 enzyme [Davis et al., 1989]. This work 
was advanced with the identification of multiple PDE4 isoforms [Swinnen et 
al., 1989] and the classification of these into four related, but distinct, gene %
products [Bolger et al., 1993]. The four genes encoding the PDE4 enzymes 
are located on three different chromosomes in humans. Chromosome 
19p13.2 encodes PDE4A [Milatovich et al., 1994 and Horton et al., 1995] with 
the PDE4C gene located on the same chromosome at 19p13.1 [Sullivan et 
al., 1999]. The other PDE4 genes encoding PDE4B and PDE4D are located Ion chromosomes 1p31 and 5q12 respectively [Milatovich et al., 1994 and 
Szpirer et al., 1995]. The genes are approximately 50,000 base pairs in 
length and consist of eighteen or more coding regions or exons [Szpirer et al.,
1995, Houslay, 2001 and Houslay and Adams, 2003]. PDE4 isoforms occur 
through alternative splicing of 5' mRNA transcripts [Swinnen et al., 1989,
Bolger et al., 1996, Bolger et al., 1997 and Richter et al., 2005]. Such splicing 
supports the remarkable homology of the PDE4 catalytic unit and the 
conserved sub-family specific C-terminal regions. The splice variants are I
.individually characterised by their N-terminal regions, which are encoded by
single, unique 5’ exons. It is likely that the identification of hitherto unknown 
novel 5’ exons, appropriately positioned downstream of promoter regions, will 
augment the current crop of known PDE4 isoforms and significantly contribute 
to the compartmentalisation and regulation of cAMP signalling [Rena et al., 
2001 and Wallace et al., 2005]. However, PDE4 enzymes can also be 
classified by virtue of the differential inclusion of their upstream conserved 
regions 1 and 2 (UCR1 and UCR2) regulatory domains into long, short or
33
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1.7.2 Phosphodiesterase-4 Expression Profiles
PDE4 enzymes provide the major cAMP hydrolysing activity in many 
cell types [Houslay, 2001 and Conti et al., 2003]. PDE4 isoforms are 
ubiquitously expressed on a cell-type specific basis and the abundance of 
isoforms confers distinct intra-cellular targeting [Houslay and Adams, 2003
super-short forms. Long forms are characterised by their unique and specific 
5’ exons that take up the position of exon 1. A common long form region is 
encoded immediately 5' to exon 2. Exons 2-4 encode the UGR1 regulatory 
module, which consists of approximately 60 amino acids. This is connected 
to linker region 1 (LR1). LR1 is 24 amino acids in length and encoded by 
exons 4 and 5. Short forms of PDE4 enzymes result from a splice junction 
located between exons 5 and 6. Thus, the PDE4 short forms contain no 
UCR1 module. LR1 is sub-family specific and connects UCR1 to UCR2. 
UCR2 is encoded by exons 6-8 and produces a second regulatory domain of
approximately 80 amino acids. A splice junction embedded between exons 6 
and 7 results in the truncation of UCR2 producing super-short PDE4 ;
enzymes. The UCR regulatory domains interact with the catalytic unit through 
a 10-28 amino acid sequence known as linker region 2 (LR2), a sub-family 
specific sequence encoded by exons 8 and 9. The catalytic unit itself is 
approximately 320-350 amino acids in length and is encoded by exons 10-15.
It is highly conserved throughout all PDE4 enzymes. The C-terminal region, 
also encoded by exon 15, shows distinct homology within each gene family.
The modular structures of PDE4 enzymes are shown in Figure 1.5.
and Houslay et al., 2005]. Many studies have employed reverse transcriptase
polymerase chain reaction (RT-PCR) to assess PDE4 transcripts within cells 
[Rena et al., 2001, Wallace et al., 2005 and Richter et al., 2005]. However, it 
should be understood that the presence of such RNA transcripts is not always 
representative at the level of protein expression. The expression and turnover 
of long PDE4 forms is considered to be a stable process with low protein 
degradation whereas the short and super-short splice variants typically show 
a greater level of variation in their expression and are more rapidly degraded
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differential brain expression profiles may underlie the role of specific PDE4 
isoform inhibition as potential therapeutics for the treatment of CNS disorders,
xi
a-
[Richter and Conti, 2004]. It is widely appreciated that any change in PDE4 
isoform expression is likely to underpin a fundamental change in cAMP 
signalling in cells [Houslay and Adams, 2003 and Shepherd et al., 2004].
PDE4A isoforms have very prominent expression patterns in the brain 
[Shakur et al., 1994, McPhee et al., 1995, Engels et al., 1995, McPhee et al.,
2001 and D’Sa et al., 2005]. Significant expression of PDE4A isoforms 
occurs in the granular layer of the olfactory bulb, the piriform cortex, the 
dentate gyrus and the CA1 and CA2 pyramidal cells [McPhee et al., 2001].
The long PDE4A isoforms, PDE4A5 and PDE4A10, show distinct expression 
in the striatum, thalamus and hippocampus but not the cerebellum.
Transcripts for PDE4A11 were also detected in brain tissue and in the same 
study developmental changes in brain expression for this isoform were |
proposed [Wallace et al., 2005]. PDE4A1 expression was strongly evident in 
the cerebellum, the glomerular layer of the olfactory bulb and the CA3 
pyramidal cells. Little or no expression of all three isoforms was detected in 
the medial nucleus of the amygdale. Expression of PDE4B isoforms in many
regions of the brain has also been identified [Lobban et al., 1994]. These
such as depression, Alzheimer’s and Parkinson’s disease, and may explain 
the nausea and emetic side effects of PDE4 inhibitors [D’Sa et al., 2005].
PDE4 isoforms have been shown to provide the dominant cAMP 
hydrolysing activity in many inflammatory cells such as neutrophils, 
eosinophils, monocytes, macrophages and T-lymphocytes [Manning et al., 
1999, Le Jeune et al., 2002, Barber et al., 2004, Shepherd et al., 2004, 
Abrahamsen, et al., 2004, Ariga et al., 2004, Wallace et al., 2005 and Jones 
et al., 2005]. Eosinophils and neutrophils are known to express PDE4A, 
PDE4B and PDE4D isoforms with no expression of PDE4C [Pryzwansky and 
Madden, 2003]. PDE4A showed different localisation patterns in each of 
these inflammatory cells with uniform distribution in all intra-cellular granules
myeloperoxidase-containing granules. Indeed, PDE4A appears to play a
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some phosphorylation driven compensatory mechanism [Millen et al., 2006].
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significant role in the regulation of granule exocytosis. The U937 monocytic 
cell line has been shown to express isoforms from three of the four PDE4 sub­
families. These include PDE4A4B, PDE4B2, PDE4D3 and PDE4D5 
[MacKenzie and Houslay, 2000]. The activity of PDE4D and PDE4B isoforms 
predominate over that of PDE4A. No expression of PDE4C was detected. 
This is consistent with other studies that have shown an absence of PDE4C 
expression in inflammatory cells [Hansen et al., 2000]. U937 monocyte to 
macrophage differentiation shows a change in PDE4D to PDE4B isoform 
expression [Shepherd et al., 2004]. Jurkat T-cells express endogenous 
PDE4A and PDE4D isoforms but show no expression of PDE4B or PDE4C 
isoforms [Erdogen and Houslay, 1997].
Studies undertaken with isolated rat hearts have significant PDE4A, 
PDE4B and PDE4D transcript levels together with PDE1C [Kostic et al.,
1997]. No transcripts for PDE4C expression were detected. Exposure to 7- 
oxo-prostacyclin, a known cardio-protective agent, elicits considerable 
alteration of these transcript levels, increasing PDE4B1 and PDE4B3 
transcripts, decreasing PDE4D transcripts, while at the same time retaining 
PDE4A transcript levels at the basal state. Human pulmonary arterial smooth 
muscle cells express PDE4 isoforms, specifically PDE4A10, PDE4A11, 
PDE4B2, PDE4C and PDE4D5 [MacLean et al., 1997 and Millen et al., 2006]. 
In these cells the PDE4 isoform expression profile is altered in the hypoxic 
state, but intriguingly the overall PDE4 activity remains unchanged indicating
Furthermore, in human airway smooth muscle cells cAMP levels 
control the expression of the PDE4D5 isoform, the enzyme responsible for its 
degradation [Le Jeune et al., 2002]. Analysis of the promoter region directly 
up-stream of the initiating ATG start codon identified a crucial CRE, where on 
site-directed mutagenesis ablated any up-regulation of PDE4D5 expression 
on treatment of the cells with cAMP elevating agents such as forskolin or 
isoprenaline. This effect has been shown for PDE4B2, with prostaglandin, as 
well as other PDE4D isoforms in a variety of cell types [Méhats et al., 1999
and Oger et al., 2002]. Similarly, forskolin-induced transcription of PDE4D
■
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isoforms occurred in Jurkat T-cells whereas the presence of transcripts for 
PDE4A isoforms was attenuated [Erdogen and Houslay, 1997]. These data 
indicates highly specific transcriptional control of distinct PDE4 sub-family 
expression through PKA-mediated gene transcription. ■ft.
1.7.3 Phosphodiesterase-4 Catalytic Unit
The catalytic unit of all PDE4 enzymes has a common signature motif 
[Houslay, 2001]. This motif is His-Asp-[Leu/lleA/al/Met/Phe/Tyr]-Xaa-His-Xaa- 
[Ala/Gly]-Xaa-Xaa-Asn-Glu-Xaa-[Leu/lleA/al/Met/Phe/Tyr]. The common 
structures of the PDE4B (amino acids 152-528) and PDE4D (amino acids 
183-510) catalytic unit have been resolved and have approximately 80% 
homology [Xu et al., 2000 and Lee et al., 2002]. Therefore, the catalytic unit 
of all PDE4 enzymes is composed of seventeen a-helices arranged In three 
sub-domains of eight, four and six helices respectively and a short p-hairpin 
[Xu et al., 2000 and Houslay and Adams, 2003]. The cAMP-binding pocket 
has a volume of 440 cubic angstroms and is lined with hydrophobic residues 
and residues with negatively charged side chains [Houslay, 2001]. The metal 
ion binding sites within the catalytic machinery are of extreme functional 
significance. Disruption of this binding could be exploited for selective PDE4 
inhibition. There are two distinct binding sites for divalent cations. A tightly 
bound zinc ion (Zn ) is located in the first pocket with preferential binding for 
the second site given to a magnesium ion (Mg^^), although the presence of 
Zn^^ or manganese (Mn^^) ions in this site has been reported [Xu et al., 2000 
and Xu et al., 2004]. Direct binding of Zn^^ in the first metal ion-binding site is 
mediated by interactions with His-238, His-274, Asp-275 and Asp-392 
[Houslay and Adams, 2003]. Binding of the second metal ion is coordinated 
by five amino acids, His-274, Glu-304, His-307, Thr-345 and Asp-392. It 
should be noted that the annotation of the residue number above corresponds 
to the PDE4B2 isoform. Interestingly all of the residues involved in the 
binding of the metals ions are absolutely conserved across all of the PDE 
families [Houslay and Adams, 2003]. These bound ions are an essential 
feature of the catalytic machinery and their presence allows cAMP binding
37
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and facilitates 5’ AMP release [Percival et al., 1997, Liu et al., 2001 and 
Laliberté et al., 2002]. It was elucidated that Asp-440 in PDE4A1 was the 
critical residue that directs substrate specificity for either cAMP or cGMP 
[Richter et al., 2001]. Site-directed mutagenesis of this conserved residue in 
PDE4 isoforms to either asparagine or alanine rendered the PDE4 unable to 
discriminate between cAMP and cGMP [Herman et al., 2000 and Richter et
al., 2001].
1.7.4 Phosphodiesterase-4 Isoforms
There are now some twenty human isoforms within the PDE4 family, 
as shown in Table 1.4, and a succinct nomenclature for describing these has 
been derived [Houslay, 2001]. PDE4 isoforms are described by indicating the 
species, followed by the PDE family, the gene family and then the isoform or 
splice variant number. For example, HSPDE4A11 describes the human form 
of a PDE4 expressed by gene A and is assigned the number 11 to denote the 
isoform or splice variant [Wallace et al., 2005].
It should be noted here that PDE4 isoforms migrate on SDS-PAGE 
with a higher molecular weight than their predicted amino acid sequence and 
the C-terminal region is fundamental [Johnston et al., 1997]. The molecular 
weights quoted below are determined from their primary amino acid structure.
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PDE4 AccessionNumber
Predicted 
Molecular 
Weight (kDa)
Classification References
PDE4A1 U97584 79 Super-short Sullivan et al., 1998
PDE4A4B L20965 99 Long Huston et al., 1996
PDE4A7 U18088 38 Inactive Horton et al., 1995 Johnston et al., 2004
PDE4A10 A P I10461 93 Long Rena et al., 2001
PDE4A11 AY618547 93 Long Wallace et al., 2005
PDE4B1 CAH70628 83 Long Bolger et al., 1993
PDE4B2 NP_002591 64 Short Bolger et al., 1994 Houslay et al., 1998
PDE4B3 AAB96381 83 Long Huston et al., 1997
PDE4B4 XP 001862 73 Long Shepherd et al., 2003
PDE4C1 NP 000914 80 Long
PDE4C2 AAD47055 68 Long
PDE4C3 AAD47054 76 Long
PDE4D1 AAA97890 66 Short Némoz et al., 1996
PDE4D2 AAA97891 58 Super-short Némoz et al., 1996
PDE4D3 AAA97892 77 Long Némoz et al., 1996
PDE4D4 NP 006194 91 Long _ Bolger et al., 1997
PDE4D5 AAC00069 84 Long Bolger et al., 1997
PDE4D6 AF536975 59 Super-short Wang et al., 2003
PDE4D7 AF536976 84 Long Wang et al., 2003
PDE4D8 AF536977 77 Long Wang et al., 2003 Richter et al., 2005
PDE4D9 AY245867 Long Wang et al., 2003 Richter et al., 2005
i
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Table 1.4 -  The human PDE4 isoforms.
Table adapted from Zhang et al., 2005.
39
î 'ïï
Chapter 1 Introduction
1.7.4.1 Phosphodiesterase-4A
PDE4A1 is expressed in both human and rat as a super-short isoform 
of 79kDa [Sullivan et al., 1998]. Human PDE4A4B and its rat homologue 
PDE4A5 are both long isoforms of 99kDa and 94kDa respectively [Huston et 
al., 1996 and McPhee et al., 1995]. PDE4A10 and PDE4A11 are long
isoforms expressed in both humans and rats with indistinguishable molecular 
weights of approximately 93kDa [Rena et al., 2001 and Wallace et al., 2005]. 
PDE4A8 is a long isoform of 88kDa expressed solely in rats [Bolger et al.,
1996]. No human expression has been identified. PDE4A7 is a catalytically 
inactive isoform that is 38kDa due to 5’ and 3' alternative mRNA splicing 
[Horton et al., 1995 and Johnston et al., 2004]. PDE4A isoforms are unique 
amongst the other PDE4 gene families in that their C-terminal regions are not
conserved across humans and rats. The different human isoforms have 
consistent Km values of 2-4pM for cAMP hydrolysis and similar relative 
cytosolic Vmax values compared to PDE4A4B. Interestingly the rat isoforms 
have significantly lower relative cytosolic Vmax values. Elucidating 
endogenous PDE4A function in many cell types is difficult due to low 
expression levels.
1.7.4.2 Phosphodiesterase-4B
The most recent PDE4B to be cloned and characterised is the long rat 
isoform PDE4B4, which has a molecular weight of 73kDa [Shepherd et al., 
2003]. Human and rat PDE4B1 and PDE4B3 are the other long isoforms of 
this gene family and are indistinguishable in terms of molecular weight at 
83kDa [Bolger et al., 1993 and Huston et al., 1997]. PDE4B2 is a short
isoform of 64kDa expressed in both human and rat [Bolger et al., 1994 and 
Houslay et al., 1998]. The different isoforms have Km values of 2-6pM. The 
relative cytosolic Vmax value of PDE4B2 is 2-fold higher than that of PDE4B1, 
with PDE4B3 and PDE4B4 having relative cytosolic Vmax values 4-fold higher 
compared to PDE4B1 [Shepherd et al., 2003]. Endogenous PDE4B
,'ï-expression is detectable in most cells.
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1.7.4.3 Phosphodiesterase-4C
1.7.4.4 Phosphodiesterase-4 D
The isoforms and splice variants of the PDE4C gene family have not 
been as rigorously investigated. This is in some part due to their very low X
expression levels. Currently there are three known long isoforms expressed
by the PDE4C gene, namely PDE4C1, PDE4G2 and PDE4C3 [Houslay,
2001]. No short or super-short isoforms have been identified and these are 
unlikely to exist due to limited space between the long form exons for 
upstream functional promoter regions [Sullivan et al., 1999].
The PDE4D gene family has been extensively investigated and 
encodes up to nine isoforms or splice variants [Bolger et al.; 1997 and Richter 
et al., 2005]. PDE4D1 is a short isoform with a predicted molecular weight of 
66kDa and PDE4D2 is a super-short isoform of 58kDa [Némoz et al., 1996]. 
PDE4D3 [Némoz et al., 1996], PDE4D4 and PDE4D5 [Bolger et al., 1997] are 
long isoforms of 77kDa, 91 kDa and 84kDa respectively. A further two 5’ 
differentially spliced isoforms were identified, namely PDE4D6 (super-short; 
59kDa) and PDE4D7 (long; 84kDa) [Wang et al., 2003]. This was followed by 
the identification and cloning of two further long isoforms, PDE4D8 (long; 
77kDa) and PDE4D9 (long; 77kDa) [Wang et al., 2003 and Richter et al., 
2005]. Because the many PDE4D isoforms have very similar molecular 
weights the need for unique anti-sera to the N-terminal regions is of prime 
importance in determining the expression of these novel isoforms. PDE4D1 
to PDE4D5 have been kinetically characterised and have Km values of 
approximately IpM and consistent relative cytosolic Vmax values with the 
exception of PDE4D4, which exhibits a 3-fold increase. PDE4D isoforms are 
usually ubiquitously expressed at high levels, in particular PDE4D3 and 
PDE4D5.
J
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1.7.5 Phosphorylation o f Phosphodiesterase-4
1.7.5.1 cAMP-dependent Protein Kinase
The first evidence of PDE4 enzymes being phosphorylated and 
activated by a cAMP-dependent protein kinase was shown in thyroid FRTL-5 
cells on stimulation with thyroid stimulating hormone (TSH) [Sette et al., 
1994]. PKA phosphorylation sites on PDE4D3 were mapped to two serine
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residues (Ser-13 and Ser-54) [Hoffman et al., 1998]. PKA phosphorylation at 
Ser-13, within the unique N-terminal region of the enzyme, has been shown to 
facilitate the recruitment of AKAP6 [Carlisle Michel et al., 2004]. However, 
site-directed mutagenesis of Ser-13 to alanine and aspartate respectively 
exhibits no change in either specific enzymatic activity or in its susceptibility to 
inhibition by rolipram [Hoffman et al., 1998]. Significantly, PKA 
phosphorylation at Ser-54 within PDE4D3 serves to activate the enzyme 
(approximately 2.5-fold activation) and increases its affinity for inhibition by 
rolipram (approximately 7-fold left shift in IC50 concentration response curve) 
[Sette and Conti, 1996, Hoffman et al., 1998 and MacKenzie et al., 2002]. 
The activating serine residue is located within the UCR1 regulatory module 
where the consensus motif Arg-Arg-Glu-Ser-Phe is present. This motif is 
conserved in all PDE4 long isoforms and has been shown to activate long 
isoforms from each PDE4 sub-family [MacKenzie et al., 2002 and 
Manganiello, 2002]. It has been proposed that PKA phosphorylation within 
UCR1 affects the positioning of the Mg^^ ion bound at the second metal ion 
site within the catalytic unit and that this modification serves to enhance the 
catalytic efficiency of PDE4 long isoforms [Houslay and Adams, 2003].
Furthermore, it is now widely appreciated that the UCR1 and UCR2 domains
■electro-statically interact, through the positively charged residues contained 
within UCR1 and the negatively charged residues of UCR2, and thus regulate 
the PDE4 catalytic machinery [Beard et al., 2000]. Phosphorylation of the 
target serine leads to the attenuation of these ionic bonds by introducing a 
significant negative charge, i.e. phospho-serine, and affecting the C-terminal 
region of UCR1 and its subsequent interaction with the N-terminal of UCR2.
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As a consequence, PKA phosphorylation of UCR1 reduces the affinity of the 
UCR1-UCR2 interaction and perhaps this attenuation relieves a down- 
regulation exerted by UCR2 upon the catalytic unit [Lim et al., 1999]. These 
data provide further ramification that the UCR domains of PDE4 enzymes 
provide regulation of catalytic activity.
ft:
1.7.5.2 Extra-cellular Signal-regulated Kinase
•ly
Mitogen-activated protein kinases (MARK) are serine/threonine protein 
kinases whose activities are stimulated by the action of many growth factors 
and cytokines [Pearson et al., 2001]. They are the ultimate components of 
intra-cellular signal transduction cascades and can phosphorylate 
transcription factors that are then able to induce gene expression of many 
other proteins, including protein kinases. The MAPK consensus site for 
phosphorylation, found on many target proteins, is Pro-Xaa-[Ser/Thr]-Pro 
[Hoffman et al., 1999]. Extra-cellular signal-regulated kinases 1/2 (ERK1/2), 
or p44/p42 MAPK, are members of the MAPK family. Authentic cellular 
substrates for ERK1/2 require two kinase-docking motifs [MacKenzie et al., 
2000 and Houslay and Adams, 2003]. A kinase interaction motif (KIM) can be 
found approximately 135 amino acids N-terminal of the MAPK consensus site. 
This has the consensus sequence [Leu/Val]-Xaa-Xaa-[Arg/Lys]-[Arg/Lys]- 
Xaa(3-6)-Leu-Xaa-[Leu/Ser]. A second ERK1/2 docking site is a Phe-Xaa-Phe 
(FQF) motif. This motif is located approximately 16 residues C-terminally to 
the MAPK consensus site and this directs the specificity for ERK1/2 
phosphorylation over c-Jun N-terminal kinase (JNK) [Sharrocks et al., 2000 
and Blondi and Nebreda, 2003]. Site directed mutagenesis of either, or both, 
docking motifs result in the ablation of ERK1/2 interaction with, and 
phosphorylation of, the target protein [MacKenzie et al., 2000].
PDE4B2 was identified as a substrate for ERK1/2 phosphorylation 
through expression in baculovirus and mass spectrometry analysis [Lenhard 
et al., 1996]. This study identified the target residue as Ser-487 within an 
ERK1/2 consensus motif. The ERK phosphorylation signature motif is
43
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present in PDE4B, PDE4C and PDE4D isoforms (Pro-Glu-Ser-Pro) but not in 
isoforms from the PDE4A sub-family (Arg-Glu-Ser-Pro) [Baillie et al., 2000].
The single replacement of a proline residue with an arginine residue in the 
ERK1/2 consensus site within the catalytic unit of PDE4A isoforms is enough 
to prevent ERK1/2 phosphorylation. Nevertheless, it should be noted that 
PDE4A isoforms possess both KIM and FQF docking motifs and could 
function as ERK1/2 scaffold proteins without being phosphorylated. ERK1/2 
phosphorylation of a single serine residue within the catalytic units of PDE4B,
4C and 4D isoforms alters the specific activity of the enzyme [Hoffman et al.,
1999, MacKenzie et al., 2000 and Baillie et al., 2000]. The nature of this ft!functional activity change is dependent on the alternative splicing of the 
specific isoform, i.e. whether the isoform is considered to be a long or a short 
form PDE4. ERK1/2-mediated inhibition of PDE4 long isoforms (activity is 
approximately 60% of native PDE4 activity) is a transient effect that is 
overcome by a PKA-mediated activation through phosphorylation of UCR1, as
44
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discussed in Section 1.7.5.1 [Houslay and Kolch, 2000 and Baillie at al.,
ft!2001]. In contrast, ERK1/2 phosphorylation at the same serine residue within 
the catalytic unit of PDE4 short forms serves to activate these enzymes .ft(activity is approximately 140% of native PDE4 activity) [MacKenzie et al.,
2000 and Baillie et al., 2000]. ERK1/2 phosphorylation of super-short PDE4
isoforms induces a small inhibitory effect [MacKenzie et al., 2000]. The 
mechanism underlying the modulation of catalytic activity has been assigned 
to the positioning of the Mg ion bound at the second metal ion site within the 
catalytic unit and that this modification serves to modulate the catalytic activity 
of PDE4 isoforms subjected to ERK1/2 phosphorylation [Houslay and Adams,
2003].
I
ft1.7.5.3 Phosphatidylinositol-3 Kinase-dependent Phosphorylation
Q
PDE4A5, the rat homologue of human PDE4A4B, is phosphorylated 
and activated (activity is approximately 177% of native PDE4 activity) in 3T3- 
F442A pre-adipocytes by a hitherto unknown kinase that constitutes a crucial 
role in phosphatidylinositol-3 kinase (PI-3K) signalling [MacKenzie et al.,
1998]. This phosphorylation event reduced the intra-cellular cAMP
ftf;
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concentration, an effect rescued by wortmannin, a P1-3K inhibitor, and the 
immuno-suppressant rapamycin, and prevented the differentiation to 
adipocytes. The exact mechanism through which this occurs remains to be 
elucidated. However, it is proposed that the activation of p70S6 kinase, 
downstream of both PI-3K and mTOR, is crucial. However, no consensus 
sequence for p70S6 kinase is present on PDE4A5. One candidate may be 
mTOR itself as it is known to contain intrinsic kinase activity. Subsequent 
work has shown that this differentiation process requires Janus Kinase-2 
(JAK-2) and Signal Transducer and Activator of Transcription-5 (STAT-5) 
signalling and not MAPK or p70S6 kinase although their expression is 
essential [Yarwood et al., 1999]. In U937 monocytic cells, PDE4A4B is 
activated on challenge with lipopolysaccharide (LPS) or interferon-y (IFN-y) 
[MacKenzie and Houslay, 2000]. This activation was also sensitive to 
wortmannin and rapamycin. Consistent with these findings Is the role of 
reducing intra-cellular cAMP concentrations through increased expression of 
PDE4B2 resulting in PI-3K signalling pathway activation, and cell proliferation 
and survival through PKB/Akt activation [Smith et al., 2005 and Song et al., 
2005]. The mechanism through which cAMP achieves this activation is 
currently unknown. Taken together these data imply another important point 
of cross talk with respect to cAMP signalling.
1.7.6 Phosphodiesterase-4 Partner Proteins
Cell signalling pathways require the efficient and specific formation of
specific locations in the cell and as such are appropriately positioned to 
regulate cellular behaviour. Specific protein-protein interaction is not a
.S’­i l
protein complexes. Proteins within these complexes are then targeted to
X
random process. Protein binding motifs have been identified for many
receptors, enzymes, protein kinases, scaffold, anchoring, and adaptor 
proteins. Screening of proteins for putative binding sites will give much 
needed insight into the molecular basis through which these proteins 
modulate cellular signal transduction.
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1.7.6.1 Src Homology 3 Binding Domains
46
Src homology 3 (SH3) binding domains are approximately 60 amino 
acids in length and contain proline-rich sequences or proline recognition
domains [Mayer, 2001, Jia et al., 2005 and Li, 2005]. They are found in a 
variety of proteins including receptors with Intrinsic tyrosine kinase activity 
(GRB2), PDE4 Isoforms (PDE4A4B, PDE4A5 and PDE4D4) PI-3K 
(p85/p110), PLCy and phox proteins of the NADPH oxidase enzyme (p40-, 
p47- and p67-phox). The conventional class 1 and class 2 binding motifs are 
illustrated in Table 1.5 and are based around the core conserved Pro-Xaa- 
Xaa-Pro consensus sequence [Jia et al., 2005]. The affinity of a protein 
containing class 1 or class 2 SH3 binding motifs is moderate at best with Kd 
values no better than 1-200pM [Li, 2005]. A number of other so-called non- 
conventional motifs have been identified [Jia et al., 2005]. Elucidation of new 
motifs may underlie increasing specificity for SH3 binding.
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SH3 Binding Domains Consensus Sequences
Core Pro-Xaa-Xaa-Pro
Class 1 [Arg/Lys]-Xaa-Xaa-Pro-Xaa-Xaa-Pro
Class II Pro-Xaa-Xaa-Pro-Xaa-[Arg/Lys]
Non-conventional
P ro-Xaa-Xaa-Asp-Ty r 
Arg-Lys-Xaa-Xaa-T y r-Xaa-Xaa-Ty r 
Pro-Xaa-[Val/lle]-[Arg/Asn]-Arg-Xaa-Xaa-Lys-Pro 
[Arg/Lys]-Xaa-Xaa-[Lys/Arg] 
Lys-Lys-Pro-Pro 
His-Xaa-Xaa-Lys 
[Lys/Arg]-Xaa-Xaa-Xaa-Xaa-LyS”Xaa-[Lys/Arg]-[Lys/Arg]
Table 1.5 -  Core, classical and non-conventional SH3 binding domains.
Sequences rich In positively charged and/or basic residues can also serve as 
putative SH3 binding domains. The consensus sequences are presented 
using the three-letter amino acid abbreviation and Xaa represents any amino 
acid.
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The cleavage of PDE4A5 by caspase-3 causes intra-cellular 
disruption and redistribution of this isoform [Huston et al., 2000]. Caspase-3 
cleavage requires the consensus motif Asp-Xaa-Xaa-Asp. Tandem caspase- 
3 cleavage sites are found within the unique N-terminal region of PDE4A5 at
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The SH3 domain of the Src tyrosyl protein kinase has been shown to 
interact with the unique N-terminal region of the rat PDE4A5 isoform 
[O’Connell et al., 1996 and Beard et al., 2002]. This interaction is mediated 
through two class 1 8H3 binding domains at Pro-4 (PAAPSER) and Pro-61 
(PHRPIER), with a class 2 SH3 binding domain at Arg-35 (RQPRTP). The 
SH3 domain of the Lyn tyrosyl protein kinase has been shown to interact 
directly with PDE4A4B, the human homologue of rat PDE4A5 [McPhee et al.,
1999]. PDE4A4B contains similar SH3 binding motifs within the unique N- 
terminal region. However, an additional binding site has been identified within 
LR2, a site not present within rat PDE4A isoforms. This is a further class 1 
SH3 binding domain positioned at Arg-315 (RPRPSQP). Membrane-bound or 
particulate forms of PDE4A4B exhibit significantly different sensitivities for 
inhibition by rolipram when compared to the cytosolic form of the same 
enzyme [Huston et al., 1996]. The particulate forms have approximately 60- 
fold higher affinity for inhibition by rolipram. Allowing the SH3 domain of 
recombinant Lyn tyrosyl protein kinase to interact with the cytosolic form of 
PDE4A4B can mimic this high affinity rolipram binding state (HARBS). 
Consequently, the cytosolic form of PDE4A4B exists as a low affinity rolipram 
binding state (LARBS). Thus, the formation of PDE4A4B protein complexes 
with SH3 domain-containing proteins promotes a change in the catalytic 
conformation of the PDE4A4B isoform. Sequential deletion of the unique N- 
terminal SH3 domain binding sites contained within PDE4A5 has been shown 
to disrupt its intra-cellular distribution [Huston et al., 2000 and Beard et al., 
2002]. Furthermore, proteins containing SH3 domains also bind PDE4D4 
through specific N-terminal interactions and might also play a role in defining 
its intra-cellular localisation without necessarily affecting the catalytic 
conformation [Beard et al., 1999]. Like PDE4A5, SH3 domain binding is 
mediated through two distinct proline-rich regions within the unique N- 
terminal. These commence at Pro-58 and Pro-75 respectively.
48
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Asp-69 and Asp-72 respectively. Caspase-3 cleavage can also occur in the 
human homologue PDE4A4B but not in the other long isoforms PDE4A10 or 
PDE4A11 [Wallace et al., 2005]. The interaction of PDE4A5 with the SH3 
domain of Src tyrosyl protein kinases is ablated following caspase-3 cleavage 
and this promotes the dynamic redistribution of the enzymes intra-cellular 
localisation [Huston et al., 2000]. Over-expression and confocal immuno­
fluorescence of PDE4A5 in COS cells confirms the localisation to the 
perinuclear region and to the cortical regions of the plasma membrane. On 
caspase-3 cleavage this highly organised distribution was attenuated 
rendering the cleaved species to exhibit a more even intra-cellular distribution. 
It is proposed that the correct intra-cellular localisation of PDE4A5 is 
prominent to cell survival and concomitant to the activation of PDE4A5 
through the PI-3K cell survival signalling pathway [MacKenzie et al., 1998], as 
discussed in Section 1.7.5.3. i
1.7.6.2 Phosphatidic Acid
Growth factors, cytokines and hormones can activate phospholipase D. 
Phospholipase D is an enzyme that catalyses the hydrolysis of 
phosphatidylcholine, the principal phospholipid in most membranes, to 
phosphatidic acid (PA). PA can also be formed by the phosphorylation of 
diacylglycerol by diacylglycerol kinase. PDE4 enzymes have been shown to 
interact with PA [Némoz et al., 1997, Grange et al., 2000 and Baillie et al.,
2002]. Interestingly, PA interaction has been shown to occur in PDE4 
isoforms from PDE4A, PDE4B and PDE4D sub-families respectively [Némoz 
et al., 1997]. In the case of the PDE4A1 super-short isoform, the binding of 
PA using the first twenty-five amino acids of the unique N-terminal region 
confers predominance (approximately 93%) for the enzyme to be membrane 
bound [Shakur et al., 1994 and Scotland and Houslay, 1995]. The structure of 
this region was delineated using NMR and identified the membrane 
association region to be composed of two helical structures separated by a 
so-called “hinge” region [Smith et al., 1996]. The first helical structure is 
composed of residues 1-7 and this forms a typical amphipathic a-helix. The 
“hinge” region is composed of residues 8-13. Deletion of either of these
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1.7.6.3 XAP2/AIP
Hepatitis B virus X-associated protein (XAP2) or aryl hydrocarbon 
receptor-interacting protein (AlP) is an immunophilin-like protein, which was 
originally identified in a yeast-2-hybrid screen as interacting with and 
repressing hepatitis B virus X protein-mediated gene expression
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regions of PDE4A1 does not disrupt the membrane association. Similarly, the 
deletion of amino acids 21-25 does not trigger release from the plasma 
membrane. Amino acids 14-20 are hydrophobic and located towards the N- 
terminal end of the second helical region. These have been deduced to be 
critical in directing the membrane association of PDE4A1. Further work has
■ ■identified the second helix to contain a novel domain that allows the 
interaction with PA, an interaction that is modulated by intra-cellular Ca^^ 
concentrations [Baillie et al., 2002]. Due to its high tryptophan content this 
domain has become known as the tryptophan anchoring PA selective binding 
domain (TAPAS-1). TAPAS-1 has the consensus sequence Leu-Val-Xaa- 
Trp-Trp-Asp-Xaa-Xaa-(LysZArg). The first five amino acids are responsible for 
lipid bi-layer insertion with the final four amino acids responsible for the Ca^  ^
dependent control of the process. A similar hydrophobic region binding PA 
was identified within the N-terminal region of PDE4D3 (Asp-31 to Ser-59) :
[Grange et al., 2000]. The binding of endogenous PA in this case served to 
activate over-expressed long isoform PDE4D3, indicating a role for PA to 
control the levels of cAMP within cells. This activating effect was also 
measured with the other long isoforms PDE4A5 and PDE4B1 [Némoz et al.,
1997]. The level of activation was analogous to that measured for the PKA 
activation of long isoforms, as discussed in Section 1.7.5.1, but not related to 
any phosphorylation event. Thus, it can be inferred that both events induce a 
similar conformational change on the catalytic unit. Furthermore, no 
synergistic activation of PDE4 long isoforms was measurable when both PKA 
phosphorylation and PA activation was induced. The binding and/or 
activation of PDE4 isoforms by PA add further complexity to the shaping of
cAMP gradients within cells and the generation of localised pools of cAMP 
and the compartmentalisation of cAMP signalling.
Î.
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[Kuzhandaivelu et al., 1996 and Kashuba et al., 2000]. XAP2 is highly 
expressed in the spleen and thymus, with lower levels of expression in the 
liver, kidney and lung [Sumanasekera et al., 2003]. Specific activation of lung 
AhRs by pollutants and carcinogens, such as dioxin and poly-halogenated 
aromatic hydrocarbons, increases neutrophil recruitment and the onset of the 
excessive inflammatory response, characteristics of COPD [Martinez et al., 
2002 and Teske et al., 2005]. Therefore, activation of the AhR may be 
important in the pathogenesis of inflammatory lung disease. XAP2 is also 
proposed to modulate AhR stability and nucleocytoplasmic shuttling, thereby 
regulating gene transcription [Meyer and Perdew, 1999, Sumanasekera et al., 
2003, Lees et al., 2003, Ramadoss et al., 2004 and Pollenz and Dougherty, 
2005]. Recently, XAP2 has been assigned a role as a tumour suppressor, 
consistent with its role as a potent repressor of peroxisome proliferator- 
activated receptor a (PPARa) activity and with the identification of XAP2 
mutations that increase susceptibility for pituitary adenomas [Sumanasekera 
et al., 2003 and Vierimaa et al., 2006]. Conversely, XAP2 may also be 
tumour promoting due to its recently identified interaction with survivin, an 
inhibitor of apoptosis via the inhibition of caspases [Kang and Altieri, 2006]. 
Its perceived mode of action is thought to be through the stabilisation of 
survivin and prevention of ubiquitination and subsequent proteasomal 
degradation. This may provide the first evidence of XAP2 promoting cancer 
cell survival although it is consistent with its ability to stabilise cytosolic 
proteins and prevent degradation.
;
XAP2 is a 38kDa protein composed of N-terminal immunophilin 
homology domains and a C-terminal tetratricopeptide repeat (TPR) domain. 
The TPR domain of XAP2 interacts with a Glu-Glu-Val-Asp binding motif on 
heat shock protein 90 (HSP90). PDE4A5 contains a highly conserved TPR 
binding motif in the UCR2 regulatory region, where the hydrophobic valine 
residue is replaced with a similarly hydrophobic leucine. Together with Ser-11 
to Iso-43, within the unique N-terminal region, XAP2 can interact with 
PDE4A5 through its C-terminal TPR domain, with Arg-271 identified as the 
key residue [Bolger et al., 2003]. The XAP2-PDE4A5 interaction is specific in 
that PDE4A5 did not interact with other immunophilin family proteins and
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neither did XAP2 interact with other PDE4 isoforms across all gene families.
Interaction with the human PDE4A4B can occur due to species conservation 
of the critical residues. The N-terminal interaction is responsible for 
ameliorating PDE4A5 activity by approximately 60%, acting as a non­
competitive inhibitor, i.e. it does not bind directly to the enzyme active site.
XAP2 interaction with PDE4A5 also resulted in a 5-fold Increase in the 
sensitivity to inhibition by rolipram, indicating a likely conformational change in 
the catalytic unit. Furthermore, it appears to protect PDE4A5 from activation 
by PKA.
1.7.6.4 Foci Formation
i iAccretion foci can form in cells over-expressing green fluorescent 
protein (GFP) fusion proteins of human PDE4A4B, and to a lesser extent rat
PDE4A5, following extensive rolipram treatment [Terry et al., 2003]. The 
formation of foci is clearly dependent upon protein synthesis and the timely 
reformation of foci with subsequent rolipram treatment is likely to be 
representative of the required proteins being available. As a general rule 
formation of these accretion foci occurs with inhibitors known to sense 
HARBS, e.g. rolipram and Ro 20-1724, and not inhibitors that only sense 
LARBS, e.g. Ariflo®. A rolipram-induced conformational change within the 
catalytic unit of PDE4A4B may be enough to re-distribute PDE4A4B within the 
cell and modulate cAMP compartmentalisation in such a way that it promotes 
the formation of PDE4 oligomers [Lee et al., 2002 and Richter and Conti,
2004]. Simply increasing cAMP concentrations with forskolin or non-foci Ùforming PDE4 inhibitors can also attenuate foci accumuiation. The propensity 
for PDE4A4B and PDE4A5 to form foci appears to lie within the unique N- 
terminal region and not with any other property of GFP, other PDE4A 
isoforms, or PDE4 isoforms from the other gene families [Terry et al., 2003 'and Wallace et al., 2005]. Alternatively, this effect may be of importance for 
PDE4 inhibitor development in dissecting whether compounds can sense 
HARBS, a state that is thought to underlie the severe side effects associated 
with the current avaiiable compounds [Huang et al., 2001].
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1.7.6.5 Disrupted in Schizophrenia 1
The Disrupted in Schizophrenia 1 (DISCI) gene locus has been 
implicated in the generation of psychiatric illness through a balanced
V'S 
%
chromosomal translocation [Millar et al., 2005]. One such translocation 
occurs to the PDE4B gene on chromosome 1p31. DISCI is a 71kDa protein 
expressed in the brain. Endogenous DISCI and PDE4B co-localise at the 
mitochondria in human neuroblastoma-derived cells. The interaction of both
proteins is confirmed by co-immuno-precipitation and is mediated through a
direct interaction with the N-terminal region of DISCI and the UCR2 
regulatory module of PDE4B. As the UCR2 domain is conserved throughout 
all PDE4 isoforms then it is likely that DISCI will interact with all long and 
short PDE4s. The activation of PDE4 long isoforms by PKA phosphorylation 
of the UCR1 domain results in release of DISCI from PDE4B [Millar et al., 
2005].
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1.7.6.6 p-arrestin
1
P-arrestin is a cytosolic signalling scaffold protein involved in the 
integration of countless signal transduction pathways [Lefkowitz and Shenoy,
2005]. These include receptor mediated endocytosis via clathrin binding, 
activation of multiple components of MAPK cascades, regulation of cytosolic 
tyrosine kinases, scaffolding of E3 ligase for ubiquitination and degradation of 
target proteins, recruitment of PDE4s in receptor signalling, and de­
phosphorylation events through PP binding. There are four types of arrestin, 
p-arrestin 1, p-arrestin2 and two visual arrestins [Luttrell and Lefkowitz, 2002].
Extensive investigation of p-arrestin in p2-adrenoreceptor signalling has 
uncovered important functionai properties of this scaffolding protein. Agonist 
stimulation of the P2-adrenoreceptor results in the coupling of the stimulatory 
G-protein, G$, which in turn stimulate AC to catalyse the formation of cAMP, 
as shown in Figure 1.2. cAMP instigates a plethora of signalling events 
through AKAP-bound PKA, EPAC and CNG ion channels, as discussed in 
more detail in Section 1.5 and illustrated in Figure 1.3. The p2-adrenoreceptor 
is phosphorylated directly by constitutively AKAP5-bound PKA or agonist-
■I
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dependent AKAP 12-bound PKA resulting in the uncoupling of Gs, the coupling 
of Gi, the subsequent attenuation of PKA activity and the activation of ERK1/2 
activity through Src [Fraser et al., 2000, Baillie et al., 2003, Tao et al., 2003,
Lynch et al., 2005 and Willoughby et al., 2006]. Of course, ERK1/2 may also, 
in certain cells, be activated directly by cAMP through the activation of Rap1
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[Houslay and Kolch, 2000, Lefkowitz et ai., 2002 and Wang et al., 2006]. 
Adding further complexity to this signalling system, it has been recently shown 
that phosphorylation of the p2 -adrenoreceptor by GRK5/6 can also recruit P- 
arrestin and activate ERK1/2 unaided by G-protein interactions [Shenoy et al.,
2006]. Continued agonist occupancy results in the PKA phosphorylation of 
GRK2 at Ser-685, activation and translocation to the plasma membrane, 
through the enhanced interaction of Gpy subunits, where it phosphorylates 
and desensitises the p2 -adrenoceptor [Kohout and Lefkowitz, 2003 and Li et
al., 2006]. incidentally, the phosphorylation of GRK2 by ERK1/2 reduces its i“ability to interact with the GPy subunits and removes it from the plasma 
membrane. This phosphorylation recruits p-arrestin2 and specific PDE4 
isoforms, predominately PDE4D5, to the p2 -adrenoreceptor where they 
degrade the localised pool of cAMP attenuating PKA activity [Perry et al.,
2002]. The recruitment of p-arrestin also mediates p2 -adrenoreceptor 
internalisation into early endosomes via clathrin-coated pits, dissociation of p- 
arrestin through receptor de-phosphorylation by PP2, and the rapid re-cycling 
of the functional receptor to the plasma membrane [Oakley et al., 1999, 
Simaan et al., 2005 and Vaughan et al., 2006]. It has been shown that p- 
arrestin can interact with all PDE4 isoforms from each sub-family and does 
not distinguish between long, short and super-short forms [Perry et al., 2002 
and Wallace et ai., 2005]. This implies that the primary interaction site on 
PDE4 isoforms is the catalytic unit, as the catalytic unit is highly conserved 
[Xu et al., 2000]. However, p-arrestin preferentially interacts with the PDE4D5 
isoform by virtue of the unique N-terminal targeting region, which provides 
additional binding sites for p-arrestin [Bolger et ai., 2003]. Indeed, small 
interfering RNA (siRNA) knockdown of PDE4D does not induce a 
compensatory mechanism whereby PDE4s from the other gene families are 
recruited to the p2 -adrenoreceptor by p-arrestin [Xiang et al., 2005 and Lynch 
et al., 2005]. There are two distinct binding sites on p-arrestin, one at the
. . . J l
Chapter 1 Introduction
enhancing T-cell receptor (TCR) function [Abrahamsen et al., 2004]. On TCR 
stimulation, coupling to Gs, activation of AC, production of intra-celluiar pools
extreme N-terminal region (residues 1-28) and one at the N-terminal region of 
the C-terminal domain (residues 192-255) [Bolger et al., 2003]. These
regions mediate the interaction with Thr-11 to Ala-85 of the unique N-terminal 
region and Phe-670 to Leu-676 of the C-terminai region of the catalytic unit of 
PDE4D5 [Bolger et al., 2006].
The p-arrestin-PDE4 interaction also plays a fundamental role
of cAMP and activation of PKA results In the amelioration of TCR function 
through the activation of C-terminal Src kinase. Co-stimulation and ligation of 
CD28 recruits the p-arrestin-PDE4 complex and degrades the localised pool 
of cAMP preventing the PKA phosphorylation of C-terminal Src kinase and 
enhancing TCR function. This dissects one mechanism of the anti- 
inflammatory effects of PDE4 inhibition by preventing optimal TCR activation. ■;S
■I
1.7.6.7 A-kinase Anchoring Proteins
An introduction to AKAPs and their functional role has been given in 
Section 1.5.2.1. PKA co-iocalises with PDE4 isoforms through interactions 
mediated by AKAPs [Dodge et al., 2001, Taskén et al., 2001, Asirvatham et 
al., 2004 and Bajpai et al., 2006]. This trimeric complex facilitates the 
generation of cAMP gradients and compartmentalised phosphorylation of PKA
i
9
target proteins, coupled with the control of such response by the recruited 
PDE4 [Houslay and Adams, 2003].
PDE4D3 interacts with AKAP6 (or m-AKAP) in rat cardio-myocytes 
using the first fifteen residues contained within the unique N-terminal region of 
the PDE4 and residues 1286 to 1831 of the AKAP6 [Dodge et al., 2001]. As 
previously discussed in Section 1.7.5.1, PDE4 enzymes are phosphorylated 
by PKA at sites within the unique N-terminal region and UCR1 and the PDE4 
interaction with AKAPs is likely to control this event. The N-terminal 
phosphorylation at Ser-13 serves to increase the affinity of PDE4D3 for 
AKAP6 binding [Carlisle Michel et al., 2004]. Thus, increases in cAMP
SiI
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concentrations within micro-domains will activate AKAP-tethered PKA to 
phosphorylate PDE4, increasing PDE4 activity and AKAP affinity, coupled 
with the simultaneous degradation of cAMP and recruitment of PP1/2 [Bailiie 
et al., 20051. Furthermore, EPAC1 and ERK5 have been shown as additional 
signalling molecules in these protein complexes in cardiac myocytes [Dodge- 
Kafka et al., 2005]. PDE4D3 is the crucial signalling molecule and is 
regulated by localised changes in intra-cellular cAMP concentrations. PKA is 
activated by sub micro-molar concentrations of cAMP whereas PDE4D3 and 
EPAC1 require concentrations in the micro-molar range. Thus, increasing 
cAMP activates PKA then PDE4D3 with a concomitant activation of EPAC1.
The phosphorylation promotes the mAKAP interaction through Ser-13 and the 
activation of PDE4D3 through Ser-54 [Carlisle Michel et al., 2004, Bette and 
Conti, 1996, Hoffman et al., 1998 and MacKenzie et al., 2002]. EPAC1 
activation prevents ERK5 inhibition of PDE4D3. Ultimately, cAMP 
concentrations decrease, the de-phosphorylation of target proteins occurs 
through PP1/2, and the system is reset.
In Sertoli cells of the rat testis, PDE4D3 has been observed to co- 
immuno-precipitate with PKA-Rlla and PKA-Rllp subunits, and AKAP9 (or 
AKAP450) [Taskén et al., 2001]. The RII-AKAP9-PDE4D3 complex was 
distributed within the golgi/centrosomal region of the cells. PDE4D3 interacts 
with amino acids 1710 to 2872 of AKAP9. A similar interaction has been 
observed in COS1 cells where dominant negative forms of PDE4C2 and 
PDE4D3 interact with the RII-AKAP9 complex and are constitutively PKA 
phosphorylated, whereas PDE4A4B and PDE4B1 phosphorylation requires a 
global increase in cAMP, indicating a degree of compartmentalisation tailored 
through AKAP9 [McCahill et al., 2005]. Over-expression of PDE4A5 or 
PDE4A8 with AKAP3 (or AKAP 110) facilitated the co-immuno-precipitation of 
PDE4A and AKAPS but co-immuno-precipitation was not achieved with 
PDE4D3, indicating a PDE4A specific effect [Bajpai et al., 2006]. The likely 
interaction sites for AKAPS binding are the conserved regions of rat PDE4A 
isoforms. It will be interesting to elucidate whether human PDE4A isoforms 
can interact with AKAPS thus indicating whether the species difference at C- 
terminal region or the common LRs are responsible. These interactions
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support the notion that the endogenous co-iocalisation of both proteins 
indicates a functional interaction in spermatozoa [Bajpai et al., 2006].
Further indication for PDE4A binding of AKAPs has been proposed in 
T-lymphocytes [Asirvatham et al., 2004]. PDE activity was detected from 
Rlia-AKAP immuno-precipitates and identified as PDE4A and PDE7A, by 
immuno-probing with specific anti-sera. PDE4A interacts with AKAP1, AKAP8
and MTG, but not AKAPS, whereas PDE7A only interacts with MTG. Thus, ■Îone would expect the interaction of PDE4 with these AKAPs to direct their '
sub-cellular localisation, e.g. AKAP1 directing PDE4A to the mitochondria and 
MTG directing PDE7A to the golgi apparatus.
“ fReceptor for activated C-kinase 1 (RACK1) is a unique, high affinity 
partner protein of 36kDa that specifically interacts with PDE4D5 through a 
domain known as the RACK1 interaction domain (RAID1) [Yanvood et ai.,
1999, Steele et al., 2001 and Bolger et al., 2006]. RACK1 contains seven 
repetitive tryptophan and aspartate residues, known as WD-repeats, in a 
propelier-like structure, and scaffolds activated PKC isoforms in a similar way 
to AKAPs for PKA [McCahill et al., 2002]. Such activation of PKC with PMA 
has no effect on the interaction with PDE4D5 and thus it is likely that the 
interaction is constitutive in cells where they are endogenously expressed 
[Yarwood et al., 1999]. RACK1 interacts at an exclusive site within the 
catalytic unit, i.e. Gly-609 to Asp-658, but the primary interaction site is the 
unique N-terminal region, i.e. Asp-22 to Leu-38, analogous to that of (3- 
arrestin [Bolger et al., 2006]. On RACK1, the interaction sites have been 
mapped to the final three WD-repeats, amino acids 179-317 although the
interaction with the truncated protein was approximately 25% of wild type, IÎindicating the requirement of additional interaction sites or a failing in the 
truncated protein to form the correct quaternary structure [Steele et al., 2001].
The functional consequence of this interaction Is currently unknown as no 
effect on PDE4D5 enzymatic activity was measured, but a significant 4-fold 
reduction in sensitivity to inhibition by rolipram occurred indicating a possible
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conformational change of the PDE4D5 catalytic unit mediated through the 
unique N-terminal region [Yarwood et ai., 1999]. RACK1 can also trans­
locate to the nucleus on treatment with forskolin and may play a role in cAMP- 
PKA-CREB gene expression, and perhaps of PDE4D5 itself [Le Jeune et al., 
2002 and McCahill et al., 2002].
1.7.6.9 Myomegalin
Myomegalin is a scaffold protein that Is involved in cytoskeletal 
organisation and/or cell movement [Verde et al., 2001]. The 240kDa full- 
length protein is abundantly expressed in both skeletal and cardiac muscle, 
with a 65kDa splice variant occurring in testis [Verde et al., 2001]. It is 
localised at the sarcoplasmic reticulum in the muscle cells and at the golgi 
apparatus in COS7 cultured cells, via its C-terminal region. The long PDE4D 
isoforms, PDE4D3, PDE4D4 and PDE4D5 are targeted to sub-cellular 
particulate locations within the cell and are present within the cytosol. The 
65kDa species of myomegalin is able to interact with PDE4D isoforms through 
a putative site at the N-terminal of UCR2 and as such is likely to play a key 
role in the particulate localisation of long form PDE4Ds. As with DISCI, any 
protein interactions mediated through the UCR2 domain are likely to be 
conserved across the four PDE4 gene families.
1.7.6.10 Phosphodiesterase-4 Dimérisation
It has been suggested that PDE1 to PDE6 may exist as dimers and 
that this interaction is mediated through their N-terminal regulatory domains 
and, as such, is likely to represent an important structural property [Richter 
and Conti, 2004]. Various studies have proposed that PDE4 enzymes may 
exist as dimers or oligomers [Rocque and Holmes et al., 1997, Rocque and I-
Tian et al., 1997, Richter et al., 2000, Lee et al., 2002, Richter and Conti, 
2002 and Richter and Conti, 2004]. From expression, purification and 
analyses, by size exclusion chromatography and ultra-centrifugation, of the 
short PDE4B2 isoform it was appreciated that the protein could exist in an 
oligomeric state, with a molecular weight in excess of 600kDa compared to
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the monomeric molecular weight of approximately 64kDa [Rocque and 
Holmes et al., 1997]. Interestingly, removal of the first 80 amino acids from 
PDE4B2 results in a protein species that is expressed in a significantly 
reduced oligomeric state, i.e. monomer to tetramer [Rocque and Holmes et 
al., 1997 and Rocque and Tian et al., 1997]. Thus, it can be inferred from 
these studies that the unique N-terminal region and UCR modules play a 
pivotal role in the oligomerisation of PDE4 enzymes. Furthermore, this 
function for the unique N-terminal and UCR domains may underlie the 
difficulties encountered to date in expression and purification studies to 
resolve the crystal structure of these regions. Expression and purification of 
PDE4A4B has also assigned a potential role for the C-terminal region in the 
formation of dimers and oligomers of PDE4 enzymes [Richter et al., 2000].
Analyses, by size exclusion chromatography and ultra-centrifugation, have 
shown that the presence of an intact C-terminal region results in 
oligomerisation whereas truncation of the C-terminal region returns a dimeric 
form. It is proposed that a dimérisation interface exists involving helices nine, 
ten and eleven of the catalytic unit and mutation of one of two residues (Arg- 
358-Asp or Asp-322-Arg) can prevent dimérisation [Lee et at., 2002]. This 
change In charge prevents dimérisation as assessed by later elution on a gel 
filtration column. The residues involved in the dimérisation interface are 
highly conserved in PDE1, 3, 4, 8 and 9, but not in the other PDE families and 
thus one would expect only isoforms from these families to exist as dimers.
Data from both the Houslay and Conti laboratories claim that the UCR 
modules are the major players responsible for mediating dimérisation of PDE4 
enzymes, whereas the catalytic unit and C-terminal region may be involved in 
stabilising such a complex [Beard et al., 2000, Richter and Conti, 2002 and 
Richter and Conti, 2004]. It is now understood that the C-terminal region of 
UCR1 and the N-terminal region of UCR2 of PDE4 enzymes interact with 
each other and regulate catalytic activity [Beard et al., 2000]. This contact is 
formed through the interaction of positively charged residues contained within 
the UCR1 domain (Arg-98 and 101 in PDE4D3) and negatively charged 
residues present within the UCR2 domain (Glu-146 and 147, and Asp-149).
Although this interaction was thought to represent intra-molecular contacts, it 
may also be able to mediate inter-molecular complex formation, and thus may
59
,-'IChapter 1 Introduction
contribute to the formation of PDE4 dimers or oligomers [Richter and Conti, 
2002 and Richter and Conti, 2004]. Indeed, the long isoform PDE4D3 was 
shown to exist as a dimer, whereas the super-short isoform PDE4D2 was 
shown to exist as a monomer. These data indicate the invoivement of UCR1 
and at least the N-terminai portion of UCR2. Interestingly the regions involved 
in inter-molecular dimérisation appear to be distinct from those Involved in the
■9;:“
1 .electrostatic intra-molecular interactions, as mutation of the respective 
charged residues does not ablate the dimérisation of PDE4 long isoforms.
Site-directed mutagenesis of hydrophobic amino acids, distinct from those 
involved in mediating UCR1-UCR2 intra-molecular interactions (Val-100, Phe- 
104, and Leu-145, 148, 152 and 155), ablates the ability of PDE4D3 to exist 
as a dimer [Richter and Conti, 2004]. PKA phosphorylation status of PDE4 
enzymes does not affect dimer formation. PKA phosphorylation of PDE4 
enzymes is discussed in Section 1.7.5.1.
The role of the C-terminal region of PDE4 sub-families with respect to 
dimérisation should be approached with caution, as it is well understood that 
the apparent molecular weights of PDE4 isoforms migrate with a larger 
mobility on SDS-PAGE, and are eluted at larger molecular weights using gel 
filtration techniques than is predicted from its primary structure [Conti and 
Richter, 2002 and Johnston et al., 2004].
What is the functional significance of PDE4 dimérisation? Richter and 
Conti have shown that PDE4 dimérisation causes an increase Vmax but not the 
Km over the monomeric form, that it is a pre-requisite for activation by both 
PKA and phosphatidic acid (PA), and that it results in increased affinity for 
rolipram binding; a likely consequence of stabilisation in a high affinity 
rolipram binding state (HARBS) [Richter and Conti, 2004]. Thus, disruption of 
PDE4 dimérisation will promote a low affinity rolipram binding state (LARBS) 
and may attenuate the undesirable side effects associated with the current 
PDE4 inhibitors.
1:
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PDE4B expression is up-regulated [Smith et al., 2005].
The cystic fibrosis transmembrane conductance regulator (CFTR) in 
airway epithelial cells drives mucociliary clearance [Houslay et al., 2005].
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1.7.7 Phosphodiesterase-4 as a therapeutic target
PDE4 inhibitors are currently being developed by many of the major 
pharmaceutical companies to treat a variety of inflammatory diseases such as 
asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis 
and psoriasis [Houslay et al., 2005 and Zhang et al., 2005]. Furthermore, 
their potential is being investigated for the treatment of a number of CNS 
disorders such as depression, Schizophrenia, Parkinson’s and Alzheimer’s 
disease [O’Donnell and Zhang, 2004 and Millar et al., 2005]. Inhibition of 
PDE4 enzymes has also been proposed for the treatment of cardiovascular 
disorders such as stroke, restenosis, and pulmonary hypertension
■r
[Gretarsdottir et al., 2003, Maurice et al., 2003, Tilley and Maurice, 2005,
Houslay, 2005 and Millen et al, 2006]. Moreover, PDE4 inhibition may 
promote cancerous cell apoptosis, e.g. in diffuse large B-cell lymphoma where
- :6 :
a
PDE4 isoforms are localised within the airway smooth muscle cells 
[Burnouf and Pruniaux, 2002]. PDE4 inhibition reduces airway smooth 
muscle tone through cAMP-mediated activation of PKA. PKA phosphorylation 
inhibits the myosin light chain kinase thereby preventing the phosphorylation 
of the myosin fibres in the smooth muscle cells. PDE4D isoforms are critical
in the control smooth muscle contraction [Méhats et al., 2003]. Indeed,
,PDE4D knockout (PDE4D ) mice show a loss of muscarinic cholinergic 
airway signalling and a loss of airway hyper-reactivity [Hansen et al., 2000]. 
Interestingly, the PDE4D‘ '^ mice showed an equivalent lung inflammatory 
response compared to wild type mice. This loss of function was specific to 
the airway smooth muscle cells and these data support the notion that sub­
family specific PDE4 isoforms have distinct, not coincidental functions.
Inhibition of PDE4 may prevent mucus accumulation by promoting the PKA 
phosphorylation of the CFTR and increasing probability of channel 
conductance. The cAMP-dependent regulation of the CFTR has also been
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identified in the corneal endothelium and this mechanism may translate to 
airway epithelial cells [Sun et al., 2003].
The pathogenesis of inflammation is a complex process involving a 
multitude of inflammatory cells such as B-cells, T-cells, neutrophils, 
eosinophils, basophils, monocytes, macrophages and mast cells, and their 
function is regulated by the generation of both pro- and anti-inflammatory 
cytokines. cAMP is known to antagonise the action of pro-inflammatory 
mediators and PDE4 is localised within immune and inflammatory cells [Wong 
and Koh, 2000, Souness et al., 2000 and Barber et al., 2004]. Thus, inhibition 
of sub-family specific PDE4s and the elevation of intra-cellular cAMP 
concentrations may dampen the inflammatory response. This is corroborated 
in studies undertaken in PDE4B'^‘ and PDE4D'^' mice that show that PDE4B 
activity is essential for the expression of the pro-inflammatory cytokine tumour 
necrosis factor a (TNFa) where knockout elicits a 90% reduction in expression 
[Jin and Conti, 2002]. At the level of gene transcription, T-cell expression of 
TNFa is inhibited via PDE4 inhibition by rolipram and is accompanied by an 
increase in the expression of the anti-inflammatory cytokine interleukin-10 (IL- 
10) [Houslay et al., 2005]. Similar attenuation of TNFa expression occurred in 
monocytes with the more potent PDE4 inhibitor, roflumilast [Hatzelmann and 
Schudt, 2001, Bundschuh et al., 2001 and Muise et al., 2002]. The 
recruitment of PDE4 and p-arrestin with CD28 to the T-cell receptor is a pre­
requisite for full T-cell activation [Abrahamsen et al., 2004]. Inhibition of PDE4 
will blunt such co-ligation and activation providing a potential mechanism for 
the associated anti-inflammatory effects. Increased intra-cellular levels of 
cAMP are known to attenuate the de-granulation of neutrophils and 
eosinophils [Teixeira et al., 1997, Pryzwansky and Madden, 2003 and Jones 
et al., 2005]. In PDE4B" ‘^ and PDE4D'^' mice neutrophil recruitment to the 
bronchoalveolar lavage was attenuated and this effect was hypothesised to 
be due to decreased cell surface expression of adhesion molecules and 
chemotaxis [Ariga et al., 2004]. Reductions in endothelial cell permeability 
and the endothelial cell expression of adhesion molecules also results from 
PDE4 inhibition [Teixeira et al., 1997]. Moreover, adaptation of inflammatory 
cell expression of PDE4 isoforms has been observed in people diagnosed
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with the inflammatory respiratory disease COPD, indicating a need for sub­
family or even isoform specific inhibitors of PDE4 [Barber et al., 2004].
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Learning and memory are affected by disruptions in intracellular cAMP 
concentrations. PDE4 enzymes are related to the dunce gene product of 
Drosophila melanogaster, the learning and memory gene [Bolger et al., 1993]. 
Therefore, it is hardly surprising that modulation of cAMP by PDE4 affects 
cognition. N-methyl-D-aspartic acid (NMDA) and a-amino-5-hydroxy-3- 
methyl-4-isoxazole propionic acid (AMPA) receptor expression in the 
hippocampal and cerebral cortical neurons underlie the ability to learn and the
formation of long- and short-term memory. NMDA receptor activation results 
in an increase in intra-cellular Ga^  ^ levels and the activation of AC to generate 
a cAMP-PKA-CREB-mediated synaptic plasticity [Zhang et al., 2005]. RACK1 
is known to associate with the NMDA receptor [Ron et al., 2004]. As
Idiscussed above in Section 1.7.6.8, RACK1 also specifically interacts with PDE4D5 [Yarwood et al., 1999]. AKAPs also interact with both the NMDA 
receptors and PDE4D isoforms [Taskén and Aandahl, 2004]. Therefore, it is 
not difficult to appreciate the control of cAMP compartmentalisation and PKA 
activity in close proximity to the NMDA receptor. Indeed, PDE4D specific 
knockout has been assigned as cognitive enhancing [Housiay et al., 2005]. 
The PKA phosphorylation of AM PA receptors is a pre-requisite for synaptic 
delivery in hippocampal cells [Esteban et al., 2003 and Esteban, 2003]. 
Again, prevention of cAMP degradation through PDE4 inhibition will enhance 
AM PA receptor delivery to neuronal synapses via a similar mechanism to the 
NMDA receptors in mediating cognitive enhancement.
I
The pharmacological explanation of depression is a lack of the 
monoamine transmitters nor-adrenaline and 5-hydroxytryptamine (5-HT or 
serotonin) in the brain. Current anti-depressants promote the synthesis, and 
prevent the degradation and re-uptake of both transmitters. They have also 
been shown to induce the expression of PDE4A and PDE4B isoforms, two 
examples being despiramine and fluoxetine [O'Donnell and Zhang, 2004]. 
Thus, the anti-depressant effects of cAMP have been promoted because both 
cAMP generation is fundamental in intra-cellular signalling induced by nor-
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adrenaline and 5-HT, and because PDE4 isoforms are differentially expressed 
in the brain. At present it is difficult to reconcile which PDE4 sub-family is 
important in mediating the anti-depressant effects elicited by PDE4 inhibitors 
but PDE4B'^‘ and PDE4D'^‘ mice show similar anti-depressant properties to
....
mice treated with current compounds. It is now appreciated that PDE4 
enzymes expressed in the brain predominate in HARBS and may also 
underlie the anti-depressant effects.
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However, many of the current inhibitors to date have nausea, emesis 
and sedation as particularly severe side effects [Huang et al., 2001 and Zhang 
et al., 2005]. Such has been the hindrance of the side effects associated with 
PDE4 inhibition, the development of a highly emetic photo-affinity probe able 
to inhibit PDE4 has been developed to try and elucidate the emetic targets 
[MacDonald et al., 2000]. In simplistic terms, it has been proposed that 
inhibition of high affinity PDE4 conformera may be involved in manifestation of 
these side effects with inhibition of low affinity conformera providing the 
beneficial effects [Giembycz, 2000 and O’Donnell and Zhang, 2004]. 
However, this theory is now not given much credence. Another theory is 
isoform specific, where it is thought that PDE4 inhibitors selective for PDE4B 
over PDE4D may be more successful in overcoming the side effects 
associated with the current compounds [Giembycz, 2002, LIpworth, 2005 and 
Zhang et al., 2005]. PDE4D is expressed at very high levels in the area 
postrema of the hindbrain [Giembycz, 2002]. The area postrema contains the 
chemoreceptor trigger zone, which is involved in the reflex mechanism of 
vomiting. Receptors are expressed on the chemoreceptor trigger zone and 
are coupled to the stimulation and inhibition of AC. Thus, disruption of cAMP 
signalling through these receptors within this brain region by inhibition of 
PDE4D may explain the emetic effects [O’Donnell and Zhang, 2004]. 
Furthermore, the generation of PDE4 inhibitors that do not permeate the 
blood brain barrier may significantly reduce these side effects [Zhang et al.,
2005]. However, PDE4 inhibitors have been produced that exhibit broncho­
dilatation, anti-inflammatory and non-emetic properties but many have been 
discontinued as development compounds due to aberrant metabolism 
[Alexander et al., 2002, Guay et al., 2002 and Burnouf and Pruniaux, 2002].
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1.8 Thesis Aims
"1
■'-1
PDE4 Inhibitors show much promise as potential targets for the 
treatment of respiratory failure, inflammation, cardiovascular disease, CNS 
disorders and cancer. However, the design of sub-family specific inhibitors, 
inhibitors with affinity for LARBS, and inhibitors that are unable to penetrate 
the blood brain barrier provide the best opportunity to further evaluate PDE4 
inhibition for therapeutic benefit. Furthermore, the elucidation of the full 
crystal structure of PDE4 long isoforms will provide much needed insight into 
isoforms specific regulation of activity.
The work in this thesis can be separated into three distinct chapters. 
Each of these chapters focuses upon the PDE4A sub-family of enzymes and 
the expression and regulation #f distinct isoforms. These isoforms are likely 
to contribute to the compartmentalisation of cAMP signalling in cells in which 
they are expressed. Modifications of PDE4A isoforms, by phosphorylation 
and/or protein-protein interactions, add further complexity to the PDE4A 
regulation of intra-cellular cAMP concentrations and the downstream 
signalling events.
The human PDE4 family currently comprises of twenty-one isoforms. 
Of these, five are assigned to the PDE4A gene family. The PDE4A gene, 
located on chromosome 19p13.2, encodes an active super-short form called 
PDE4A1, a catalytically inactive isoform called PDE4A7, and three active long 
isoforms called PDE4A4B, PDE4A10 and a new isoform, PDE4A11. This 
thesis aims to characterise the novel PDE4A11 isoform, summarise its key 
distinguishing features, and attempts to elucidate the functional significance of 
its expression. i
Previous studies from the Houslay laboratory have described the
.
regulation of PDE4 activity through direct phosphorylation by both PKA and 
ERK1/2 [Hoffman et al., 1998, Baillie et al., 2000, Baillie et al., 2001 and 
MacKenzie et al,, 2002]. PDE4 long isoforms are phosphorylated and }
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However, the molecular mechanism through which PDE4 inhibitors achieve 
this is largely unknown. Preliminary work to address this is described in the 
final chapter of this thesis. This chapter aims to elucidate the mechanism 
through which cAMP signalling controls the production of ROS.
' î : | i i  ' ;
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activated by PKA at one distinct serine site within the UCR1 regulatory 
module, which is conserved in all PDE4 isoforms. ERK1/2 phosphorylation of 
all PDE4 isoforms, except PDE4A, occurs at a single serine residue within the 
catalytic unit. This phosphorylation exerts differential effects upon PDE4 
catalytic activity dependent upon the inclusion of the UCR regulatory domains.
Work in this thesis strives to identify novel phosphorylation sites for PDE4
enzymes, which may contribute to the regulation of cAMP |
■-compartmentalisation, PDE4 activity, and cross talk between cAMP and other 
signalling pathways.
The production of super-oxide (O2 ) and other reactive oxygen species 
(ROS) constitutes a key component of the inflammatory response. The 
expression of PDE4 enzymes is particularly abundant in immune and 
inflammatory cells. Inhibition of PDE4 attenuates the production of ROS.
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2.1 Materials
All equipment, materials and chemicals were supplied by Sigma- 
Aldrich® (Poole, U.K.) unless otherwise stated.
2.2 Plasmid Preparation
All molecular biology techniques were undertaken in a sterile 
environment using sterilised equipment. Buffers were of molecular biology 
grade and were sterilised by autoclaving or sterile filtration.
■1:
2.2.1 Transformation o f Competent Cells
Competent cells are cells that have the ability to incorporate DNA 
plasmids. Not all cells are competent and have this capacity so cells can be 
manipulated to become chemically competent. Most competent cell types 
have their own optimal transformation protocol but they follow the same 
general principle described below. Follow the manufacturers instructions for 
protocols tailored to individual bacterial cell types. Competent bacterial cells
were stored at -80 C and thawed on ice. 50pl of competent cells were
■ 9required per transformation reaction. 1-1 Ong of DNA was added to each 50pl 
aliquot of cells and the cells were incubated on ice for up to 15min. Longer 
incubations generally have no effect on transformation efficiency. The cells 
were then heat shocked for 45-90s at 42°C and returned to ice for a further 
2min. 45Qpl of pre-warmed LB media (1% (w/v) bacto-tryptone, 0.5% (w/v) 
bacto-yeast extract and 170mM NaCI) was added to the cells and then 
incubated in the orbital shaking incubator for 45min at 37°C. Agar plates 
containing the appropriate antibiotic(s) were produced using LB media 
containing 1.5% (w/v) agar. The commonly used antibiotics and their effective
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final concentrations are shown in Table 2.1. The LB media/agar solution was 
autoclaved and cooled to less than 50°C before the addition of the 
antibiotic(s). 100-200|jl of transformation mix was then spread on the agar 
plates and the plates incubated overnight at 37°C. Colony growth on the 
plates was indicative of successful cell transformation. Plates were stored at 
4°C for up to 1 month before being discarded.
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Antibiotic Stock Concentration Storage Working Concentration
Ampicillin lOOmg/ml in H2O -20°C lOOpg/ml
Kanamycin 10mg/ml in H2O -20°C 50pg/ml
Chloramphenicol 17mg/ml in ethanol -20°C 34pg/ml
■■‘I .
Table 2.1 -  Concentrations of commonly used antibiotics.
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2.2.2 Isolation o f Plasmid DNA
2.2.3 Storage o f Plasmid DNA
2.2.3.1 Glycerol Stocks
70
From single colonies on agar plates, see Section 2.2.1, or glycerol 
stocks, see Section 2.2.3.1, 5ml bacterial cultures were grown overnight in LB 
media containing the appropriate antibiotic(s) in the orbital shaking incubator 
at 37°C. 1ml of the bacterial culture was used directly for glycerol stock 
production and the remaining bacterial culture for plasmid DNA isolation using
the QIAGEN (Crawley, U.K.) QIAprep Miniprep Kit. Alternatively, the 5ml
,vovernight bacterial culture was used to inoculate a larger LB media culture 
flask (approximately 500ml), supplemented with the appropriate antibiotic(s), 
for overnight growth and isolation of significantly greater plasmid DNA 
concentrations and volumes using the QIAGEN® (Crawley, U.K.) QIAprep®
Maxiprep Kit. For in-depth details of the plasmid DNA isolation protocols 
please refer to the manufacturers instructions.
To produce a glycerol stock, 1ml of overnight bacterial culture was 
removed and mixed with 500pl of sterile glycerol in a sterile cryo-vial. The 
cryo-vial was snap frozen and stored at ~80°C until required. Generally, the 
E.coli bacterial strain, JM109, was used as the host strain for the generation 
of glycerol stocks for long-term storage.
To inoculate culture media from a glycerol stock, the glycerol stock was 
stabbed with a sterile pipette tip, which was then transferred to approximately 
5ml of sterile LB media containing the appropriate antibiotic(s) for the bacterial 
host strain and/or the DNA plasmid with which they are transformed. The 
inoculated culture was then grown overnight at 37°C in an orbital shaking 
incubator.
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2.2.3.2 Purified Plasmid DNA
Purified plasmid DNA produced, as described in Section 2.2.2, using 
the QIAGEN® (Crawley, U.K.) QIAprep® Kits was stored at 4°C, if eluted in 
10mM Tris-CI; pH 8.5, and -20°C, if eluted in sterile water.
2.2.4 Analysis o f Plasmid DNA
2.2.4.1 Agarose Gel Electrophoresis
Agarose gel electrophoresis is a method of separating DNA plasmids 
or fragments by virtue of their charge, by the migration of the DNA through a 
matrix under the influence of an electric field, DNA is highly negatively 
charged and therefore moves through the matrix towards the positive 
electrode. 1% (w/v) agarose gels resolves DNA fragments between 0.5-1 Okb 
and allows detection of 20-500ng of DNA per band, which can be used to 
determine the DNA concentration of a plasmid preparation or fragment. 1 % 
(w/v) agarose was dissolved in 40mM Tris-CI; pH 8.5, 0.114% (v/v) glacial 
acetic acid and 2mM EDTA (TAE) by heating in a microwave oven. Care was 
taken not to super-heat the solution. 0.5pg/ml (final concentration) ethidium 
bromide was added to the cooled (55-60°C) 1% (w/v) agarose solution and 
poured into the Bio-Rad® (Hemet Hempstead, U.K.) Sub-Cell GT gel 
apparatus, with the well comb in place and the ends sealed with autoclave 
tape, and allowed to set. For more details about the Bio-Rad Sub-Cell GT 
gel apparatus please consult the manufacturers instructions. Once set, 
normally around 30-40mln, the comb and autoclave tape were removed and 
the gel was placed in the tank and immersed in a volume of 1x TAE buffer 
that was sufficient to cover the top of the gel by approximately 1mm. 6x 
loading buffer composed of 0.25% (w/v) bromophenol blue, 0.25% (w/v) 
xylene cyanol FF and 40% (w/v) sucrose was diluted 1:6 into the DNA 
solution and mixed gently. 5pl of Promeg a® (Southampton, U.K.) Ikb DNA 
ladder was also loaded to an appropriate well of the gel to allow the size of 
the DNA plasmid or fragment within the sample to be determined. The gels
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were run at 100V for approximately 1h. The gel was removed from the tank 
and analysed under ultra-violet light where ethidium bromide stained DNA is 
visualised. All DNA agarose gel images were captured using a Kodak® 
DC290 camera controlled via Kodak® ID, Version 3.5.4 computer software.
2.2 4.2 Quantification of DNA Concentration
f
The concentration of any DNA sample, produced following the protocol 
described in Section 2.2.2, was determined using a Jenway and Genova MK2 
spectrophotometer, measuring the absorption at 260nm (Aaeo). 1ml of sterile
-
water was added to a quartz cuvette and the absorption measured. The DNA
i.solution was diluted 1:200 in the sterile water and the new absorption reading
’ ï j
measured. The concentration of DNA was determined on the basis that an 
absorbance of 1 unit at 260nm corresponds to 50pg plasmid DNA per millilitre 
based on a standard quartz cuvette with a 1cm path length. The ratio of the 
absorbance readings at 260nm (A260) over 280nm (A280) is indicative of the 
purity of the DNA preparation. An A260/A280 ratio of 1.8 is typical of a pure 
DNA preparation in a low-salt buffer and is generally reproducible.
2.2.4.3 DNA Sequencing
9
" T
DNA samples for sequencing were prepared as described in Section 
2.2.2. BaseClear Lab Services (Leiden, Netherlands) carried out the 
sequencing of 500bp lengths of plasmid DNA using standard and/or custom 
DNA sequencing primers. Analyses of the DNA sequencing reactions aligned 
with the predicted DNA sequences was done using either Gene Jockey®, 
Version 2.2 or Chromas® 1.45 computer software programmes.
f
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2.2.5 Site-Directed Mutagenesis o f Plasmid DNA
Site-directed mutagenesis of plasmid DNA was carried out using the 
Stratagene® (La Jolla, CA, U.S.A.) QuikChange® Site-Directed Mutagenesis 
Kit, according to the manufacturers instructions. Briefly, sample polymerase 
chain reactions (PCRs) were set up in 1x reaction buffer containing various 
concentrations of purified, template plasmid DNA (5-50ng), 125ng of each 
primer and 1pl of deoxynucleotide tri-phosphate (dNTP) mix in a final reaction 
volume of 50pl. Primer pairs used for site-directed mutagenesis are shown in 
Table 2.2. 1pl of Pfu Turbo DNA polymerase (2.5U/pl) was added to each 
reaction. The PCR conditions used were 95°C for 30s, and 18 cycles of 95°C 
for 30s, 55°C for Imin, and 68°C for Imin per kb of the plasmid length. 1-4pl 
of the Dpn I restriction enzyme was added to each reaction and incubated at 
37°C for 1 h. 1 pi of the Dpn /-treated DNA was used to transform 50pl of XL1- 
Blue super-competent cells as described in Section 2.2.1. Plasmid DNA was 
isolated from single colonies on agar plates, as described in Section 2.2.2, 
and subsequently the DNA sequenced, as described in Section 2.2.4.3, to 
assess whether successful site-directed mutagenesis had been achieved.
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Protein Mutation Forward (S’) Primer Reverse (3 ) Primer
CCACCAGCCAGCGCCGG CTGTCTGAGCGGTACAG
PDE4A11 Ser119Ala GAGGCCTTCCTGTACCG GAAGGCCTCCCGGCGCT
CTCAGACAG GGCTGGTGG
CTTCCTCTACCGCTCAGA CTTCGGTGACATGTCATA
PDE4A5 Ser147Ala CGCC GACTATGACATGTC GTCGGCGTCTGAGCGGT
ACCGAAG AGAGGAAG
GCTGTGTCCAGGAGCTC CGTGCGCTTCGCTGGCG
PDE4A5 Ser161Ala GGCTGTCGCCAGCGAAG ACAGCCGAGCTCCTGGA
CGCACG CACAGC
CACACGTGCTGCTGGCC CACAGCGTCCAGTGCGG
PDE4A5 Thr437Ala GCGCCCGCACTGGACGC GCGCGGCCAGCAGCACG
TGTG TGTG
CTGTTCCTTCAGCCCTGG CGTCAGGCAGAATAGGG
PDE4A5 Thr776Ala GGCCCCTATTCTGCCTGA GCCCCAGGGCTGAAGGA
CG ACAG
GGCGCCGCCCCGCAGGT GCTGTGCGCGTTGCGGA
p47-phox Ser304Ala CGGCCATCCGCAACGCG TGGCCGACCTGCGGGGC
CACAGC GGCGCC
GGTCGCGGAAGCGCCTC GCGGCGATAGGCGTCCT
pA7-phox Ser320Ala GCCCAGGACGCCTATCG GGGCGAGGCGCTTCCGC
CCGC GACC
GGACGCCTATCGCCGCA CTGCTGCAGAAAACGGA
pA7-phox Ser328Ala ACGCC GTCCGTTTTCTGC CGGCGTTGCGGCGATAG
AGCAG GCGTCC
Table 2.2 -  Primer pairs used for site-directed mutagenesis.
The nucleotides highlighted in red indicate the nucleotide sequence change to 
alanine codons.
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2.3 Reverse Transcriptase Polymerase Chain Reaction
2.3.1 Using mRNA
2.3.2 Using cDNA for Tissue Expression Profiling
supplied by OriGene Technologies Inc. (Rockville, MD, U.S.A) were used
'■ i
Amplification of generic PDE4A and specific PDE4A11 fragments were 
carried out using intron-spanning primer pairs as detailed in Table 2.3, 
primers pairs 1-4. Reverse transcriptase polymerase chain reaction (RT- 
PCR) was done with 2pg of mRNA extracted from brain tissue or HEK293 
cells using the QIAGEN® One-Step RT-PCR Kit (Crawley, U.K.). PCR 
conditions of 50°C for 30min, 94°C for 15min, and 35 cycles of 94°C for Imin, 
50°C for Imin, and 72°C for Imin. Final extension was undertaken at 72°C 
for lOmin. The PCR products were visualised by 1% (w/v) agarose gel 
electrophoresis, as described in Section 2.2.4.1.
To assess the expression profile of PDE4A11 in twenty-four human 
tissues, a Rapid-Scan™ Gene Expression Panel of first strand cDNAs
according to the manufacturers instructions. These were used as PCR
templates and primer pair 5 used to generate the 494bp product is detailed in 
Table 2.3. QIAGEN® HotStar Taq DNA Polymerase (Crawley, U.K.) was used 
together with PCR conditions of 95°C for 15min, and 35 cycles of 95°C for 
30s, 50°C for 30s and 72°C for 1 min. Final extension was undertaken at 
72°C for 10 min. The PCR products were visualised by 1% (w/v) agarose gel 
electrophoresis, as described in Section 2.2.4.1.
:■
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Primer
Pair
Region of 
PDE4A11
Fragment 
Length (bp) Forward (5’) Primer Reverse (3 ) Primer
1 UCR2 to catalytic unit 506
ATGCAGACCTATCGC
TCTGTCAGC
ACCATCGTGTCCACAGG
GATGC
2 Unique N-terminal to UCR1 497
ATGGCGCGGCCGCG
CGGCCTAGGCC
CGGACGCTCCGGAGGC
TGGCCAGCACC
3 Unique N-terminal to LR2 886
ATGGCGCGGCCGCG
CGGCCTAGGCC
GCGGCTGGGAGGGTCT
TGGTCGCGGCGC
4 Unique N-terminal to catalytic unit 1794
ATGGCGCGGCCGCG
CGGCCTAGGCC
GCCACGCTCGCGCTCT
CGGTCACCCTGC
5 Unique N-terminal to LR1 494
GGAGCTGCAACTGG
TGGC
GGCACATTGGTCAGGA
GTGAG
Table 2.3 -  Primer pairs used for RT-PCR.
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2.4 Expression and Purification of Recombinant Fusion Proteins
2.4.1 Maltose Binding Protein (MSP) Fusion Proteins I
Competent E.coli BL21 pLysS (DE3) cells were transformed, as 
described in Section 2.2.1, with the appropriate pMAL plasmid, as described 
in Table 2.4, and grown directly in 30ml of sterilised LB media, supplemented 
with 100ug/ml ampicillin, overnight in an orbital shaking incubator at 37°C. 
450ml of sterilised LB media, supplemented with lOOug/ml ampicillin, was 
inoculated with the overnight culture and grown in the orbital shaker at 37 0 
for 1-2h. A 1ml sample of culture was removed to a plastic cuvette and the 
optical density measured at 600nm (ODeoo) against an LB media control. 
Expression of the fusion protein was induced with 0.2mM isopropyl-(3-D- 
thiogalactopyranoside (IPTG) when an ODeoo of 0.6-1 was achieved. An 
ODeoo at this level ensured that the culture was in the logarithmic phase, 
where bacteria will grow exponentially. Expression of the target protein was 
undertaken for 4h in an orbital shaker set at 30°C. Hourly 1ml samples of LB 
media were removed to monitor protein expression. These samples, 
including the sample used for ODeoo measurement (un-induced control 
sample), were centrifuged at 16,060 x g and the pellet was re-suspended in 
lOOpI SDS sample buffer for analysis by SDS-PAGE and Coomassie® 
staining, as described in Section 2.12. The cells were then harvested by 
centrifugation at 6,500 x g for lOmin. The cells were re-suspended in 12ml of 
50mM Tris-HCI; pH 8.0, lOmM NaCI and lOmM p-mercaptoethanol containing
:
I
a 1x solution of Roche Diagnostics (Mannheim, Germany) protease inhibitor 
cocktail tablets. The re-suspended cells were then frozen at -80°C and 
thawed on ice. Lysozyme was added at a final concentration of 1 mg/ml and 
the cell suspension subjected to sonication to achieve sufficient cell lysis. A 
final concentration of 0.05% (v/v) NP-40 was added to aid cell lysis and the 
subsequent cell debris removed by centrifugation at 20,000 x g for 15 min. 
1ml of New England BioLabs® (Hitchin, U.K.) amylose resin was pre­
equilibrated with re-suspension buffer containing 0.05% (v/v) NP-40. The cell 
supernatant was applied to the pre-equilibrated resin and incubated end-over-
77
Chapter 2 Materials and Methods
2.4.2 Glutathione-S-Transferase (GST) Fusion Proteins
The E.coii expression and purification of recombinant GST fusion
2.5 Mammalian Cell Culture
All cell culture techniques were performed in a class two hood using 
jrd aseptic techniques c 
autoclaving or sterile filtration.
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end for 1h at 4°C to bind the expressed fusion protein. The resin was
.collected by centrifugation at 5,200 x g for 2min and washed three times with 
750pl of re-suspension buffer containing 0.05% (v/v) NP-40. The fusion 
protein was eluted from the amylose resin with 500pl of 10mM maltose, 50mM 
Tris-HCI; pH 8.0 by incubating end-over-end for 20min at 4°C. This was 
repeated up to three times, if necessary. The eluted fractions were pooled 
and dialysed using Pierce® (Rockford, IL, U.S.A.) Slide-A-Lyser® dialysis 
cassettes against three 650ml volumes of lOOmM NaCI, 50mM Tris-HCI; pH :v|;:
8.0, 5% (v/v) glycerol, for 1h each at 4°C. The purified fusion protein was 
frozen on dry ice, and stored as aliquots, at ~80°C. The expression time- Écourse and final purification to homogeneity was analysed by SDS-PAGE and 
Coomassie® staining, described in Section 2.12.
Iproteins mirrors the experimental protocol described in Section 2.4.1 for the 
expression and purification of MBP fusion proteins. Competent E.coli BL21 
pLysS (DE3) cells were transformed, as described in Section 2.2.1, with the 
appropriate pGEX plasmid, as described in Table 2.4. For the purification of 
GST fusion proteins the use of Amersham Biosciences (Little Chalfont, U.K.)
■'sglutathione sepharose resin was required and successful elution required an 
elution buffer composition of lOmmM glutathione, 50mM Tris-HCI; pH 8.0.
The expression time course and final purification to homogeneity was 
analysed by SDS-PAGE and Coomassie® staining, described in Section 2.12.
&standa and reagents that had been sterilised by either
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2.5.1 Maintenance o f Cell Lines
2.5.1.1 C0S1 and C0S7 Cells
The storage of cells with a low passage number at -200°C ensured the 
long-term integrity of the specific cell line. To revive cells from this 
temperature the individual vial was quickly thawed and added directly to 10ml 
of pre-warmed fresh growth media, under sterile conditions. Once the cell line 
was established and confluent, further 1ml aliquots of cells were re­
suspended in cell freezing media. These were initially frozen at -80°C before 
being transferred to -200°C for long-term storage.
COS1 and COS7 cell lines are derived from African green monkey 
kidney cells and have been transformed with the SV40 virus. The cells were 
propagated in growth media containing Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 0.1% (v/v) penicillin/streptomycin (10000U/ml),
2mM glutamine and 10% (v/v) foetal calf serum (PCS). The cell line was
maintained at 37°C in an atmosphere of 95% (v/v) air and 5% (v/v) CO2 . The
cells were passaged when approximately 90% confluence was reached. To
passage the cells the growth media was removed and 5ml of pre-warmed
sterile phosphate buffered saline (PBS) was added. The cells were washed
by gentle agitation with sterile PBS, which was then aspirated. 5ml of trypsin-
EDTA solution was added and cells were incubated for 5min at 37°C. The
cells were vigorously agitated and then analysed under the microscope to
check for efficient cell detachment. Once this state was achieved, 10ml of
growth media was added to inactivate the trypsin-EDTA solution. The cells 1
were collected by centrifugation at 1,000 x g for 3min. The growth media
supernatant was removed and the cell pellet re-suspended in the appropriate
volume of growth media. Once fully re-suspended 1ml of cells were added to
fresh growth media in a sterile flask(s). The cells were returned for incubation
at 37°C in an atmosphere of 95% (v/v) air and 5% (v/v) CO2 until required or
confluent.
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2.5.1.2 HEK293 Cells
The human embryonic kidney 293 (HEK293) cell line has epithelial cell 
morphology. These cells were maintained as described in Section 2.5.1.1 for 
C0S1 and C0S7 cells.
2.6 Mammalian Cell Transfection of Plasmid DNA
A list of DNA plasmids used for the transfection of mammalian cell lines 
are described in Table 2.4.
2.6.1 DEAE-Dextran Transient Transfection
This method of mammalian cell transfection was used for the 
transfection of 0081 and 0087  cell lines only. Flasks of confluent cells were 
passaged the day prior to transfection and plated to ensure 70% confluence 
on the day of transfection. These plates were incubated overnight at 37°0 in 
an atmosphere of 95% (v/v) air and 5% (v/v) OO2 . The amount of DNA 
required for each transfection plate is dependent on the number of cells to be 
transfected and should be scaled accordingly. This protocol is accurate for 
100mm plates of 70% confluent cells in 10ml of growth media. lOpg of the 
desired DNA plasmid was diluted in lOmM Tris-CI; pH 7.6, 0.1 mM EDTA to a 
final volume of 250pl. 200pl of 10mg/ml DEAE-Dextran was added to the
DNA solution, mixed, and incubated for 15min at room temperature. Where 
co-transfection of two DNA plasmids was required lOpg of each plasmid, in a 
final volume of 250pl of lOmM Tris-CI; pH 7.6, 0.1 mM EDTA, was added to 
200pl of lOmg/ml DEAE-Dextran. During the incubation period the growth 
media was removed from the plates and replaced with 10ml of fresh growth 
media supplemented with lOOpM sterile chloroquine. Following incubation, 
the DNA-DEAE-Dextran solution was added directly to the appropriate 
transfection plate and incubated for 3-4 hrs at 37°C. The growth medium was 
removed from the plates and 10ml of sterile PB8 containing 10% (v/v) di­
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methyl sulphoxide (DMSO) added and aspirated immediately. The plates 
were washed twice with 10ml of sterile PBS before the introduction of 10ml of 
fresh growth media. The plates were incubated for approximately 2 days at 
37°C in an atmosphere of 95% (v/v) air and 5% (v/v) CO2 prior to any cell 
treatments and harvesting. Details of ligands and inhibitors used for cell 
treatments are described in Table 2.5.
2.6.2 PolyFecfi Transient Transfection
v f
The PolyFect® method of mammalian cell transfection, from QIAGEN® 
(Crawley, U.K.), was used for the transfection of C0S1, C0S7 and HEK293 
cell lines. Flasks of confluent cells were passaged the day prior to 
transfection and plated to ensure 40-80% confluence on the day of 
transfection. These plates were incubated overnight at 37°C in an 
atmosphere of 95% (v/v) air and 5% (v/v) CO2 . The amount of DNA required 
for each transfection plate is dependent on the number of cells to be 
transfected and should be scaled accordingly. This protocol is accurate for 
100mm plates of 40-80% confluent cells in 8ml of growth media. 4pg of the 
desired DNA plasmid for the transfection of C0S1 or C0S7 cells was diluted 
in antibiotic- and FCS-free DMEM to a final volume of 300pl. 8pg of the 
desired DNA plasmid for the transfection of HEK293 cells was diluted in 
antibiotic- and FCS-free DMEM to a final volume of 300pl. 25pl of PolyFect® 
Transfection Reagent was added to the DNA solution for COS cell 
transfections whereas 80pl was required for efficient transfection of HEK293 
cells. The transfection reagents were incubated at room temperature for 5- 
lOmin to allow complex formation. Where co-transfection of two DNA 
plasmids was required the amount indicated above of each plasmid was 
diluted in 300pl of antibiotic- and FCS-free DMEM before the addition of the 
specific volume of PolyFect® Transfection Reagent indicated above for the 
cell type. During the incubation period the growth media was removed from 
the plates and replaced with 7ml of fresh DMEM supplemented with 0.1% 
(v/v) penicillin/streptomycin (10000U/ml), 2mM glutamine and 10% (v/v) foetal 
calf serum (FCS). Following incubation, 1ml of supplemented DMEM
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containing the antibiotics and 10% (v/v) FCS was added to the DNA-DMEM- 
PolyFect® complex. This was mixed gently and added directly to the 
appropriate transfection plate. The plates were then incubated for 
approximately 2 days at 37°C in an atmosphere of 95% (v/v) air and 5% (v/v) 
COz prior to any cell treatments and harvesting. Details of ligands and 
inhibitors used for cell treatments post-transfection are described in Table 2.5.
2.6,3 F u G E N ^  6 Transient Transfection
The FuGENE® 6 method of mammalian cell transfection, from Roche 
Diagnostics (Mannheim, Germany), was used for the transfection of C0S1, 
C0S7 and HEK293 cell lines that were to be used for confocal microscopy 
analyses. Flasks of confluent cells were passaged the day prior to 
transfection and plated to ensure 50-80% confluence on the day of 
transfection. These plates were incubated overnight at 37°C in an 
atmosphere of 95% (v/v) air and 5% (v/v) COz. The amount of DNA required 
for each transfection plate is dependent on the number of cells to be 
transfected and should be scaled accordingly. This protocol is accurate for 
one well of a 6-well plate containing 40-80% confluent cells in 2ml growth 
media per well. 5pl of FuGENE® 6 Transfection Reagent was added to 95pl 
of antibiotic- and FCS-free DMEM and incubated at room temperature for 5 
min. Ipg of the desired DNA plasmid for cell transfection was added to the 
FuGENE 6-DMEM solutions and this were incubated for 15-45min allowing 
complex formation. The transfection reagents were then added directly to the 
appropriate well of the transfection plate. The plates were incubated for 
approximately 24h at 37°C in an atmosphere of 95% (v/v) air and 5% (v/v) 
COz prior to any cell treatments and harvesting. Details of ligands and 
inhibitors used for cell treatments post-transfection are described in Table 2.5.
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Plasmid AntibioticResistance Expression Description Source
hRD1/pcDNA3 Ampicillin Mammalian
Full open reading 
frame of human 
PDE4A1 in pcDNA3
Dr. Fiona Begg 
(Houslay 
Laboratory)
pcDNA46 Ampicillin Mammalian
Full open reading 
frame of human 
PDE4A4B in pcDNAS
Prof. Graeme Bolger 
University of 
Alabama, Alabama, 
U.S.A.
pcDNARG-VSV Ampicillin Mammalian
Full length open 
reading frame of rat 
PDE4A5 in pcDNA3 
tagged with VSV
Prof. Graeme Bolger 
University of 
Alabama, Alabama, 
U.S.A.
pcDNAR6-VSV
S147A Ampicillin Mammalian
Full length open 
reading frame of rat 
PDE4A5 with Serine 
147 mutated to 
Alanine in pcDNA3 
tagged with VSV
Derek Wallace 
(Houslay 
Laboratory)
PCDNAR6D147 Ampicillin Mammalian
Full length open 
reading frame of rat 
PDE4A5 with Serine 
147 mutated to 
Aspartate in pcDNA3
Prof. Graeme Bolger 
University of 
Alabama, Alabama, 
U.S.A.
pcDNAR6~VSV
S161A Ampicillin Mammalian
Full length open 
reading frame of rat 
PDE4A5 with Serine 
161 mutated to 
Alanine in pcDNA3 
tagged with VSV
Derek Wallace 
(Houslay 
Laboratory)
pSV.R6AP5 Ampicillin Mammalian
Rat PDE4A5 with N- 
terminal region 
removed (Serine 135 
to end) in pSV
Dr. Grant Scotland 
(Houslay 
Laboratory)
pSV.R6AP6 Ampicillin Mammalian
Rat PDE4A5 with N- 
terminal region and 
UCR1 removed 
(Proline 197 to end) 
in pSV
Dr. Grant Scotland 
(Houslay Laboratory
pMalR6 Ampicillin E.coli
Full open reading 
frame of rat PDE4A5 
in pMalC2X with 
MBP In fusion with 
the N-terminal region
Prof. Graeme Bolger 
University of 
Alabama, Alabama, 
U.S.A.
I
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Plasmid AntibioticResistance Expression Description Source
pMalR6 S147A Ampicillin E.coli
Full open reading 
frame of rat PDE4A5 
with Serine 147 
mutated to Alanine in 
pMalC2X with MBP 
in fusion with the N- 
terminal region
Derek Wallace 
(Houslay 
Laboratory)
pMalR6S161A Ampicillin E.coli
Full open reading 
frame of rat PDE4A5 
with Serine 161 
mutated to Alanine in 
pMalC2X with MBP 
in fusion with the N- 
terminal region
Derek Wallace 
(Houslay 
Laboratory)
pMalR6 T437A Ampicillin E.coli
Full open reading 
frame of rat PDE4A5 
with Threonine 437 
mutated to Alanine in 
pMalG2X with MBP 
in fusion with the N- 
terminal region
Derek Wallace 
(Houslay 
Laboratory)
pMalR6 T776A Ampicillin E.coli
Full open reading 
frame of rat PDE4A5 
with Threonine 776 
mutated to Alanine in 
pMalC2X with MBP 
in fusion with the N- 
terminal region
Derek Wallace 
(Houslay 
Laboratory)
pcDNA3
PDE4A8VSV Ampicillin Mammalian
Full open reading 
frame of rat PDE4A8 
in pcDNA3 tagged 
with VSV
Prof. Graeme Bolger 
University of 
Alabama, Alabama, 
U.S.A.
4A10 ATG2 Ampicillin Mammalian
Full open reading 
frame of human 
PDE4A10 in pSV 
Sport
Dr. Fiona Begg 
(Houslay Laboratory
TM3 Ampicillin Mammalian
Full open reading 
frame of human 
PDE4A11 in pcDNA3
Dr. Ian McPhee 
(Houslay 
Laboratory) I
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Plasmid AntibioticResistance Expression Description Source
PDE4A11
S119A Ampicillin Mammalian
Full open reading 
frame of human 
PDE4A11 in pcDNA3 
with Serine 119 
mutated to Alanine in 
pcDNA3
Derek Wallace 
(Houslay 
Laboratory)
PDE4B1 Ampicillin Mammalian
Full open reading 
frame of human 
PDE4B1 in pEE7 
(Cell-Tech)
Dr. Elaine Huston 
(Houslay 
Laboratory)
PDE 4B2 Ampicillin Mammalian
Full open reading 
frame of human 
PDE4B2 in pEE7 
(Cell-Tech)
Dr. Elaine Huston 
(Houslay Laboratory
PDE
4B3/pCMV4A Ampicillin Mammalian
Full open reading 
frame of human 
PDE4B3 in pCMV4A
Dr. Shaun Mackie 
University of 
Edinburgh, 
Edinburgh, U.K.
PDE 4B4 Ampicillin Mammalian
Full open reading 
frame of human 
PDE4B4 in pEE7 
(Cell-Tech)
Prof. Graeme Bolger 
University of 
Alabama, Alabama, 
U.S.A.
pcDNANDUN Ampicillin Mammalian
Full open reading 
frame of human 
PDE4D1 in pcDNA3
Prof. Graeme Bolger 
University of 
Alabama, Alabama, 
U.S.A.
pcDNAN43 Ampicillin Mammalian
Full open reading 
frame of human 
PDE4D3 in pcDNA3
Prof. Graeme Bolger 
University of 
Alabama, Alabama, 
U.S.A.
PCDNAN79-
VSV Ampicillin Mammalian
Full open reading 
frame of human 
PDE4D5 in pcDNAS 
tagged with VSV
Prof. Graeme Bolger 
University of 
Alabama, Alabama, 
USA.
pFLAG CMV 
RB3 Ampicillin Mammalian
Full open reading 
frame of XAP2 in 
pFLAG CMV with 
FLAG in fusion with 
the N-terminal region
Prof. Graeme Bolger 
University of 
Alabama, Alabama, 
U.S.A.
■i1
"S3
,1
I
85
Chapter 2 Materials and Methods
Plasmid AntibioticResistance Expression Description Source
pcDNAARB2
FLAG Ampicillin Mammalian
Full open reading 
frame of p-arrestin2 
in pcDNA3 with 
FLAG in fusion with 
the C-terminal
Prof. Graeme Bolger 
University of 
Alabama, Alabama, 
USA
pGEX NARB2 Ampicillin E.coli
Full open reading 
frame of human p- 
arrestin2 in pGEX- 
5X3 with GST in 
fusion
Prof. Graeme Bolger 
University of 
Alabama, Alabama, 
USA
pGEX-hLyn Ampicillin E.coli
SH3 domain of 
human Lyn tyrosyl 
kinase in pGEX-2T 
with GST in fusion
Dr. William Wishart 
Sandoz Pharma, 
Basel, Switzerland
pGEX-
pAlphox Ampicillin E.coli
Human p47-phox in 
pGEX-6P1 with GST 
in fusion
Dr. Katrin Rittinger 
N.I.M R., London, 
U.K.
pGEX- 
p47phox 
S304A
Ampicillin E.coli
Human p47-phox in 
pGEX-6P1 with 
Serine 304 mutated 
to Alanine with GST 
in fusion
Derek Wallace 
(Houslay 
Laboratory)
pGEX-
p47phox
S320A
Ampicillin E.coli
Human p47-phox in 
pGEX-6P1 with 
Serine 320 mutated 
to Alanine with GST 
in fusion
Derek Wallace 
(Houslay 
Laboratory)
pGEX-
p47phox
S328A
Ampicillin E.coli
Human p47-phox in 
pGEX-6P1 with 
Serine 328 mutated 
to Alanine with GST 
in fusion
Derek Wallace 
(Houslay 
Laboratory)
pGEX- 
p47phox PX Ampicillin E.coli
Phox domain (5-122) 
of human p47-phox 
in pGEX-6P1 with 
GST in fusion
Dr. Katrin Rittinger 
N.I.M.R., London, 
U.K.
pGEX- 
p47phox SH3 Ampicillin E.coli
SH3 domains (155- 
390) of human p47- 
phox in PGEX-6P1 
with GST in fusion
Dr. Katrin Rittinger 
N.I.M.R., London, 
U.K.
pGEX-
p67p/?ox Ampicillin E.coli
Human p67-phox in 
pGEX-4T1 with GST 
in fusion
Dr. Katrin Rittinger 
N.I.M.R., London, 
U.K.
f
■i
Table 2 .4 -  cDNA plasmid constructs used for protein over-expression 
in either E.coli or mammalian cells.
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2.7 Mammalian Cell Transfection of siRNA
Small interfering RNAs (siRNAs) are 19-25 nucleotides long and can 
be used to knockdown protein expression in a plethora of mammalian cell
siRNA-DMEM solution for COS1 cell transfection. The transfection reagents
'3
types. The PolyFect® method of mammalian cell transfection, from QIAGEN®
(Crawley, U.K.), was used for the transfection of the COS1 cell line with the 
Santa Cruz Biotechnology Inc. (Santa Cruz, CA, U.S.A.) MAPKAPK2 siRNA 
nucleotide. Flasks of confluent cells were passaged the day prior to
transfection and plated to ensure 40-80% confluence on the day of
transfection. These plates were incubated overnight at 37°C in an 
atmosphere of 95% (v/v) air and 5% (v/v) COz. The amount of siRNA
required for each transfection plate is dependent upon the number of cells to 
be transfected and should be scaled accordingly. This protocol is accurate for 
100mm plates of 40-80% confluent cells in 8ml growth media. 50-1 OOnM of 
the siRNA nucleotide was diluted in antibiotic- and FCS-free DMEM to a final 
volume of 300pl. 25pl of PolyFect® Transfection Reagent was added to the
were incubated at room temperature for 5-10min to allow complex formation. 
Where co-transfection of a DNA plasmid and siRNA nucleotide was required 
4pg of plasmid DNA and 50-1 OOnM of siRNA was diluted In a final volume of 
300pl of antibiotic- and FCS-free DMEM. 25pl of PolyFect® Transfection 
Reagent was then added to this DNA-siRNA-DMEM mix and incubated as 
described above. During the incubation period the growth media was 
removed from the plates and replaced with 7ml of fresh DMEM supplemented 
with 0.1% (v/v) penicillin/streptomycin (10000U/ml), 2mM glutamine and 10% 
(v/v) foetal calf serum (FCS). Following incubation, 1ml of supplemented 
DMEM containing antibiotics and 10% (v/v) FCS was added to the 
siRNA/DNA-DMEM-PolyFect® complex. This was mixed gently and added 
directly to the appropriate transfection plate. The plates were then incubated 
for approximately 2 days at 37°C in an atmosphere of 95% (v/v) air and 5% 
(v/v) COz prior to any cell treatments and harvesting. Details of ligands and 
inhibitors used for cell treatments post-transfection are described in Table 2.5. 
Samples of native and siRNA transfected cell lysate were subjected to SDS-
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PAGE and Western immuno-blotting, as described in Section 2.12, to 
determine protein expression knockdown.
2.8 Preparation of Rat Cardiac Myocytes
The preparation of rat cardiac myocytes from isolated rat hearts was
undertaken in a sterile hood, according to the procedure described by Dostal 
et al., 1992. In detail, ADS buffer was prepared containing 120mM NaCI,
20mM N-2“hydroxyethylpiperazine-N’-2-ethanesulphonic acid (HEPES)-OH; 
pH 7.35, 0.8mM NaHzPO^HzO, 5mM KCI, 0.4mM MgS0 4 /7 H2 0 , 1% (w/v) 
glucose and 1% (v/v) penicillin/streptomycin (10000U/ml). To culture rat 
cardiac myocytes 100ml of ADS buffer alone, 100ml of ADS buffer containing 
48mg collagenase II and 100ml of ADS buffer containing 60mg pancreatin 
were prepared and filter sterilised to produce the enzyme solution. Non-heart 
tissue was removed using forceps and blood drained by teasing apart the 
heart. The hearts were then diced using a scalpel and then removed to a 
50ml universal. 25ml of ADS was used to wash any residual tissue into the 
universal and the tissue was allowed to settle at the bottom of the tube. The 
supernatant was then removed and discarded. 10ml of enzyme solution was 
added to the universal and incubated, at an angle, in a shaking water bath at 
37°C, 130rpm for 4min. The supernatant was removed, discarded and a 
further 10ml of enzyme solution was added and the universal incubated at 
37°C, 160rpm for 20min. This supernatant was added to 8ml of FCS in a 
fresh universal and tube inverted on ice. A further 10ml of enzyme solution 
was added to the rat hearts and incubated at 37°C, 160rpm for 20min. The 
supernatant was again removed and added to the tube containing FCS. This 
digestion process was repeated a further three times and each time the 
supernatant was added to FCS-containing tube. The tube was then 
centrifuged at 1,300 x g for lOmin. The supernatant was discarded and the 
small pellet of cardiac myocytes carefully re-suspended, by pipetting, in 25ml 
of plating media composed of 66% (v/v) DMEM, 20% (v/v) M l99, 8% (v/v) 
horse serum, 5% (v/v) FCS and 1% (v/v) penicillin/streptomycin (10000U/ml).
The cell re-suspension was then centrifuged again, the supernatant
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discarded, and re-suspended in 20ml of plating media (this was approximate 
for fifty rat hearts and scaled accordingly). The re-suspension solution was 
then added to a 100mm culture plate and incubated at 37°C for 1h. This 
allowed fibroblasts to adhere to the culture dish and cardiac myocytes to 
remain in the plating media. During this incubation, 10ml of sterile 70% (w/v) 
gelatin solution was added to each 100mm culture plate, incubated for 5- 
lOmin at room temperature, and then removed. Following incubation the cell 
media containing the cardiac myocytes was removed and centrifuged at 1,300 
X g for lOmin. The supernatant was discarded and the cells re-suspended in 
a sufficient volume of plating media for the number of 100mm plates required. 
For a single 100mm culture plate of cardiac myocytes approximately five rat 
hearts were required. The cells were incubated for approximately 24h at 37°C 
in an atmosphere of 95% (v/v) air and 5% (v/v) COz. The plating media was 
then replaced with maintenance media consisting of 75% (v/v) DMEM, 20% 
(v/v) M l99, 4% (v/v) horse serum and 1% (v/v) penicillin/streptomycin 
(10000U/ml). The cells were then incubated for a further 24h at 37°C in an 
atmosphere of 95% (v/v) air and 5% (v/v) COz prior to any cell treatments and 
harvesting. Details of ligands and inhibitors used for cell treatments are 
described in Table 2.5.
89
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Compound Desired Mode of Action Concentration Time
Forskolîn Directly activates adenylyl cyclase 100pM 10-20min
EGF Activation of ERK1/2 and Akt/PKB 50ng/ml 30min
PMA Activation of ERK1/2 lOOnM 20min
Insulin Activation of Akt/PKB 1-10nM 15min
Anisomycin Activation of p38 MAPK and MAPKAPK2 lOpg/ml 60min
TNFa Activation of p38 MAPK and MAPKAPK2 10ng/ml 5min
Angiotensin II Assembly and activation of NADPH Oxidase iOOnM 5min
H89 PKA inhibitor 1-10pM 10min
U0126 MEK inhibitor 10uM 60min
SB203580 p38 MAPK inhibitor 10pM 60min
IBMX Non-specific PDE inhibitor 100pM 10min
Rolipram Specific PDE4 inhibitor 10pM 10min
t
Table 2.5 -  Desired mode of action, final concentrations and incubation 
times for ligands and inhibitors used for the treatment of mammalian 
cell lines.
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2.9 Confocal Microscopy Analysis
C0S1 or C0S7 cells were transfected in 6-well plates with the 
appropriate DNA plasmid using the Roche Diagnostics (Mannheim,
Germany) FuGENE® 6 Transfection Reagent, as described in Section 2.6.3.
Following protein expression for 24h and any subsequent cell treatments, as 
detailed in Table 2.5, the cells were fixed in sterile PBS containing 4% (v/v) 
para-formaldehyde, 5% (w/v) sucrose, lOmM MgCb, 150mM NaOH, and the 
pH was adjusted to 7.5 with 1.2ml HCI. The cells were then washed three 
times with 2ml of sterile PBS and the cover slips removed to the 
immunohistochemistry box. The cells were permeabilised with 200p! of 0.2%
(v/v) TritonX-100. This was repeated three times and excess TritonX-100 
removed by blotting with napkins. The proteins were then blocked using 10%
(v/v) goat serum (dependent upon primary antibody host animal) and 2% (w/v)
BSA diluted in 20mM Tris-CI; pH 7.5 and 150mM NaCI. The protein of 
interest was detected using a specific primary anti-serum. 200pl of primary 
anti-serum diluted in TBS and blocking solution was added to the cover slips 
for 2h at room temperature. The cover-slips were washed three times with 
200pl of blocking solution and incubated with 200pl of secondary antibody 
conjugated to Alexa® 594 from Molecular Probes (Eugene, OR, U.S.A.). The 
cells were fixed to the confocal slide using immuno-mount and observed using 
a Zeiss® Pascal laser-scanning microscope (Jena, Germany).
2.10 Preparation of Cell Lysates
2.10.1 Whole Cell Lysate
Confluent cells were harvested at temperatures less that 4°C using 
buffers that had been previously chilled to minimise protein degradation in the 
whole cell extract. The cell culture media was aspirated and the cells were 
washed twice with ice cold sterile PBS. The cell plates were drained 
thoroughly and the appropriate volume of cell lysis buffer added. For a 6-well
plate, lOOpI of cell lysis buffer was added whereas a 100mm plate received
.life??'
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as the S fraction (enriched cytosolic proteins) and the volume noted. Both P1
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500pl of cell lysis buffer. For the production of whole cell lysate, 3T3 lysis 
buffer composed of 25mM HEPES-OH; pH 7.5, 50mM NaCI, 10% (v/v) 
glycerol, 1% (v/v) Triton, 50mM NaF, 30mM Na pyrophosphate, 5mM EDTA 
and 1x solution of Roche® Diagnostics (Mannheim, Germany) protease 
inhibitor cocktail tablets was used. The cells were incubated for 5min with 
buffer on ice and then scraped into a 1.5ml Eppendorf® tube. The cell lysates 
were centrifuged in a bench-top, refrigerated centrifuge at 16,060 x g at 4°C 
and the supernatant retained. The cell lysates were then snap frozen on dry 
ice and stored at -80°C until required.
2.10.2 Sub-cellular Fractionation
This procedure was undertaken as described in numerous publications 
[Sullivan et al., 1998, McPhee et al., 1999, Rena et al., 2001 and Wallace et 
al., 2005]. Confluent cells were harvested at temperatures less that 4°C using 
buffers that had been previously chilled to minimise protein degradation in the 
sub-cellular fractions. The growth media was removed from the plates and 
the cells washed twice with ice cold, sterile PBS. The PBS was aspirated and 
the plates were left to drain. The plates were then washed with 500pl of 
sterile 50mM KCI, 50mM HEPES; pH 7.2, lOmM EGTA, 1.92mM MgClz, ImM 
dithiolthreitol (DTT) and 1x solution of Roche® Diagnostics (Mannheim, 
Germany) protease inhibitor cocktail tablets (KHEM). The plates were left to 
drain for 5min and any excess KHEM was aspirated. The cells were then 
isolated by scraping into a 1.5ml Eppendod® tube. The cells were 
homogenised on ice by drawing through a 26G needle and 1ml syringe, 
approximately 30 times, and centrifuged at 950 x g in a bench-top, 
refrigerated centrifuge for lOmin at 4°C. The pellet formed at this stage was 
the PI fraction (unbroken cells and nuclei). The supernatant was transferred
into an ultra-centrifuge tube and centrifuged at 154,000 x g in a Beckman TL- 
100 ultra-centrifuge for 30min at 4°C. The pellet formed at this stage was the 
P2 fraction (plasma membrane, golgi vesicles, endoplasmic reticulum, 
lysosomes and endosomes). The supernatant from this fraction was retained
i; 
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and P2 fractions were washed twice in SOOpI of KHEM at the centrifuge 
speeds described above for the relevant fraction (P1 = 950 x g for 10min and
,;,3
P2 = 154,000 X g for 30min). The pellets were then re-suspended in a volume 
of KHEM analogous to that of the supernatant fraction. All fractions were
:ir
snap frozen on dry ice and stored at ~80°C until required. To assess the sub- 
cellular distribution of a given protein equal volumes of P I, P2 and S fractions 
were subjected to SDS-PAGE and Western immuno-blotting, as described in 
Section 2.12. Western immuno-blots, within the linear range to the light
feproduced from ECL, were then scanned and quantified using The Discovery 
Series™ Quantity One® 1-D Analysis Software, Version 4.4.0. The specific 
intensity of the immuno-reactive bands in the PI, P2 and S fractions, together 
with an appropriate background control reading, was determined within a
constant measurement area. The sub-cellular distribution was then calculated '1as the relative percent contribution of PI, P2 and S immuno-reactivity, less 
the background response, as a function of the total densitometry readings 
(100%). Where any alteration in the sub-cellular distribution of a protein was 
to be determined Two-Sample t-test statistical analysis was applied to the 
densitometry data using MINITAB® Release 14.13 computer software. 
Alterations in the relative expression of a protein within a sub-cellular fraction 
was determined as statistically significant when p < 0.05 compared to the no 
treatment control.
2.11 Determination of Protein Concentrations (Bradford’s Assay)
The protein concentration of purified recombinant proteins or cell 
lysates (whole or sub-cellular fractions) was determined using bovine serum 
albumin (BSA) as a standard in a spectrophotometric assay. The assays 
were undertaken in clear 96-well micro-titre plates. A standard curve of 
known BSA concentrations between Opg/pl and 5pg/pl was generated diluted 
in sterile water to a final volume of 50pl. The protein sample of interest was 
assayed at various dilutions in a final volume of 50pl to ensure it was within 
the range of the standard curve. The extent of the dilution was factored into 
the final determination. Bradford reagent from Bio-Rad® (Hemel Hempstead,
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U.K.) was diluted 1:5 with sterile water and 200|jl was added to each well of 
the 96-well micro-titre plate [Bradford, 1976]. The intensity of the colour 
change (brown to blue) produced with this reagent on interaction with protein 
is directly proportional to the protein concentration. The 96-well plate was 
analysed with a 590nm test filter using a Dynex MRX micro-titre plate reader 
controlled through Dynex Revelation, Version 3.04 computer software. 
Protein concentrations were determined by plotting the standard curve and 
using least squared regression analysis to obtain the best-fit line. The 
equation of the line was used to determine the concentration of the protein 
samples and adjusted to account for any dilution factor.
2.12 Protein Analysis
2.12.1 SDS-PAGE
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS- 
PAGE) is a method that is routinely employed to separate proteins by virtue of 
their molecular weight. Protein samples of 1-100pg were denatured and 
reduced by dilution in 10% (w/v) SDS, 300mM Tris-CI; pH 6.8, 0.05% (w/v) 
bromophenol blue, 50% (v/v) glycerol and 10% (v/v) p-mercaptoethanol, 
herein referred to as 5x SDS sample buffer. The samples were boiled for 
5min and then loaded directly to an appropriate well of an Invitrogen™ 
(Paisley, U.K.) NuPAGE® 4-12% Bis-Tris polyacrylamide gel immersed in 
Invitrogen™ NuPAGE® MES or MOPS SDS running buffer. 5pl of Bio-Rad® 
(Hemel Hempstead, U.K.) pre-stained molecular weight protein marker was 
also loaded to an appropriate well of the gel to allow the molecular weight of 
the proteins within the sample to be determined. The gels were run at 200V 
for 1h. For a more detailed description of Invitrogen™ NuPAGE® pre-cast 
gels and associated XCell II™ apparatus please consult the manufacturers 
instructions.
I
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2.12.2 Coomassie® Staining
Proteins separated by SDS-PAGE can be visualised by a variety of 
methods. The limit of Coomassie® staining is approximately 0.1-0.5pg of 
protein per band on a polyacrylamide gel and resolves all proteins within a 
sample. Gels that required Coomassie® staining were removed form the pre­
cast gel cassette and washed with sterile water to remove residual running 
buffer. Coomassie® stain consisting of 1.25g Coomassie® Brilliant Blue R250 
(omit for de-stain), 444ml methanol, 56ml acetic acid in a final volume of 
1000ml sterile water was added to the gel with gentle shaking for 2h at room 
temperature. The Coomassie® stain was removed and replaced with de-stain. 
De-stain removed all background staining with the Coomassie® stain 
remaining bound to the proteins resulting in the detection of all proteins 
present in the sample. The gel was then washed with sterile water and 
incubated with sterile water plus 10% (v/v) glycerol to aid the prevention of gel 
cracking following drying.
2.12.3 Western Immuno-blotting
t
Proteins separated by SDS-PAGE can be visualised by a variety of 
methods. Western immuno-blotting allows the detection of individual proteins 
with specific anti-sera. The proteins separated by SDS-PAGE were 
transferred to a nitrocellulose membrane using the XCell II™ blotting 
apparatus and NuPAGE® Transfer Buffer containing 20% (v/v) methanol. The 
proteins were transferred with an applied voltage of 30V for 1h. For a more 
detailed description of the XCell II™ apparatus set-up and buffer compositions 
please consult the manufacturers instructions. Following transfer of the 
sample proteins, as indicated by successful transfer of the pre-stained 
molecular weight markers, the nitrocellulose membrane was incubated or 
blocked in 5% (w/v) milk powder (Marvel®), re-constituted in 20mM Tris-CI; pH 
7.6, 150mM NaCI and 0.1% (v/v) Tween20 (TBST), for 1h at room 
temperature with gentle agitation. The primary antibody was added at the 
appropriate dilution (general dilution range 1:1000 to 1:10000) to a 1% (w/v)
95
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milk powder TBST solution. Details of the primary antibodies used in 
experiments described in this thesis are shown in Table 2.6. The blocked 
nitrocellulose membrane was then sealed in an airtight plastic carrier
,.3containing the primary antibody solution and this was incubated for 1 h at room 
temperature, or overnight at 4°C, with vigorous agitation. The membrane was 
then washed several times with TBST before the application of the 
appropriate horseradish peroxidase (HRP) conjugated anti-immunoglobulin G 'I(IgG) secondary antibody diluted 1:5000 in 1% (w/v) milk powder TBST 
solution in a sealed, airtight plastic carrier. Similarly, this was incubated for 1 h 
at room temperature, or overnight at 4°C, with vigorous agitation. The 
membrane was again washed several times with TBST before employing the liAmersham Biosciences (Little Chalfont, U.K.) enhanced chemiluminescence 
(ECL) Western immuno-blotting kit as the visualisation protocol for detecting 
bound antibodies. Briefly, the bound antibodies were detected by exposure of
■the membrane, following washing in ECL solution, to blue-light sensitive 
autoradiography film and developed using the Kodak® X-Omat Model 2000 
processor. For a more detailed description of the visualisation kit and 
autoradiography film processor please consult the manufacturers instructions. ■fe
I
2.12.4 Antibody Generation
The generation of anti-sera specific for the unique N-terminal region of 
PDE4A11 and the phosphorylated Ser-147 residue of PDE4A5 was 
undertaken by Cambridge Research Biochemicals Limited (Cleveland, U.K.). 
Briefly, rabbit anti-sera were generated against the following keyhole limpet 
haemocyanin (KLH)-conjugated peptides, Ala-Arg-Pro-Arg-Gly-Leu-Gly-Arg- 
lso-Pro-Glu-Leu-Gln-Leu-Val-[Cys]-amide for PDE4A11 and [Cys]-Ser-Phe- 
Leu-Tyr-Arg-Ser-Asp-(p-Ser)-Asp-Tyr-Asp-Met-Ser-Pro-Lys~amide for the 
phosphorylated PDE4A5. The crude anti-sera for PDE4A11 were purified by 
affinity chromatography on Thiopropyl Sepharose 6B derivatised with antigen. 
The phospho-reactive serum to phosphorylated PDE4A5 peptide was affinity 
purified on a Thiopropyl Sepharose 6B column derivatised with non- 
phosphorylated antigen. The unbound serum was then applied to a similar
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column derivatised with phosphorylated antigen. The eluate was retained 
where significant phospho-specific immuno-reactivity was demonstrated on 
peptide coated ELISA plates. Resultant glycine eluates for both PDE4A11 
and Ser-147 phosphorylated PDE4A5 were used for Western immuno-blot 
analysis, as described above in Section 2.12.3.
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Protein Specificity Type Dilution* Animal Source
Human PDE4A
Conserved C- 
terminal region of 
human PDE4A 
isoforms
Serum 1:10000 Goat HouslayLaboratory
Rat PDE4A
Conserved C- 
terminal region of 
rat PDE4A isoforms
Serum 1:5000 Goat HouslayLaboratory
Rat PDE4A
Conserved C- 
terminal region of 
rat PDE4A isoforms
Serum 1:5000 Rabbit HouslayLaboratory
PDE4B
Conserved C- 
terminal region of 
PDE4B isoforms in 
all species
Serum 1:5000 Goat HouslayLaboratory
PDE4D
Conserved C- 
terminal region of 
PDE4D isoforms in 
all species
Serum 1:10000 Goat HouslayLaboratory
PDE4A11 Unique N-terminal region of PDE4A11 Polyclonal 1:2000 Rabbit
Cambridge
Research
Biochemicals
PKA
phosphorylated
PDE4
Phosphorylated Ser 
residue in RRES*F 
motif in UCR1 of all 
PDE4 long isoforms
Serum 1:1000 Rabbit HouslayLaboratory
MAPKAPK2
phosphorylated
PDE4
Phosphorylated Ser 
residue in LYRSDS* 
motif in UCR1 of all 
PDE4 long isoforms
Polyclonal 1:1000 Rabbit
Cambridge
Research
Biochemicals
p44/p42 MAPK 
(ERK1/2)
Endogenous levels 
of p44/p42 MAPK. 
More specific for 
p42 MAPK
Polyclonal 1:1000 Rabbit
Cell
Signaling
Technology®
Activated 
p44/p42 MAPK 
(ERK1/2)
Endogenous levels 
of phosphorylated 
p44/p42 MAPK at 
Thr202 and Tyr204
Monoclonal 1:2000 Mouse
Cell
Signaling
Technology®
Akt
Endogenous levels 
of Akt1, Akt2 & Akt3 
proteins
Polyclonal 1:1000 Rabbit
Cell
Signaling
Technology®
Activated Akt
Endogenous levels 
of phosphorylated 
Akt at Ser473 only 
& not Thr308
Monoclonal 1:1000 Mouse
Cell
Signaling
Technology®
p38 MAPK Endogenous levels of p38 MAPK Polyclonal 1:1000 Rabbit
Cell
Signaling
Technology®
%
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Protein Specificity Type Dilution* Source Supplier
Activated p38 
MAPK
Endogenous levels 
of phosphorylated 
p38 MAPK at 
Thr180&Tyr182
Polyclonal 1:1000 Rabbit
Cell
Signaling
Technology®
MAPKAPK2 Endogenous levels of MAPKAPK2 Polyclonal 1:1000 Rabbit
Cell
Signaling
Technology®
Activated
MAPKAPK2
Endogenous levels 
of phosphorylated 
MAPKAPK2 at 
Thr334 only & not 
Thr25, Thr222 & 
Ser272
Polyclonal 1:1000 Rabbit
Cell
Signaling
Technology®
XAP2
Recognises 
immunophilin ARA9, 
AIPorXAP2
Serum 1:1000 Rabbit HouslayLaboratory
(3-arrestin2
Recognises C- 
terminal region of p- 
arrestin1/2
Polyclonal 1:1000 Rabbit HouslayLaboratory
p47-phox
Human p47-phox 
with minimal cross­
reactivity with bovine 
p47-phox
Serum 1:1000 Rabbit Upstate®
GST Recognises GST-tag fusion proteins Polyclonal 1:1000 Rabbit
Houslay
Laboratory
VSV
Recognises an 
epitope containing 
the five C-terminal 
amino acids of VSV 
glycoprotein
Monoclonal 1:5000 Mouse Sigma-Aldrich®
FLAG
Recognises an 
epitope containing 
DYKDDDDK
Monoclonal 1:5000 Source Sigma-Aldrich®
Table 2.6 -  Anti-sera used for Western immuno-blotting.
^Dilution factor is correct for Western immuno-blotting. Antibody titrations 
should be undertaken for immuno-precipitation and immuno-histochemistry.
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2.13 Fusion Protein Interactions
2.13.1 Pull-down Assays
fel
The expression and purification of GST fusion proteins in E.coli was 
undertaken as described in Section 2.4.2. C0S7 cells were transfected to 
transiently express specific PDE4A isoforms as described in Section 2.6.1 
and subjected to sub-cellular fractionation as described in Section 2.10.2. 
Assessment of the interaction of PDE4A isoforms with GST fusion proteins 
has been described previously [McPhee et al., 1999, Huston et al., 2000 and 
Rena et al., 2001]. Briefly, 400pg of the GST fusion protein, or GST alone as 
a control, was immobilised on a 40pl bed volume of Amersham Biosciences 
(Little Chalfont, U.K.) glutathione sepharose resin. The resin was pelleted by 
centrifugation at 1,000 x g for 5min at 4°C using a refrigerated bench-top 
centrifuge. The supernatant was discarded. The pellets were then re­
suspended in 500pl (approximately 200pg of protein) of cytosolic, or S 
fraction, produced from C0S7 cells expressing equal immuno-reactive 
amounts of PDE4A isoforms, as determined by Western immuno-blotting with 
a PDE4A C-terminal specific anti-serum. The protein samples were diluted in 
KHEM, the buffer used for sub-cellular fractionation of mammalian cells. The 
immobilised fusion protein and cytosol were incubated together for 1 h end- 
over-end at 4°C. The glutathione sepharose resin was then collected by 
centrifugation at 1,000 x g for 5min at 4°C. The supernatant was retained for
Western immuno-blotting to measure the extent of PDE4A remaining unbound 
to the GST fusion protein. The beads were washed three times with SOOpI of 
KHEM by centrifugation at 1,000 x g for 5min at 4°C. The supernatant was 
discarded and the beads re-suspended in 40pl of SDS sample buffer to elute 
the bound proteins. Protein samples of PDE4A expressed in cytosolic cell 
lysate, PDE4A bound to GST, PDE4A unbound to the GST fusion protein and 
PDE4A bound to the GST fusion protein were analysed by SDS-PAGE, as 
described in Section 2.12.1, and immuno-probed for PDE4A using a C- 
terminal, species and sub-family specific anti-serum, as described in Section 
2.12.3.
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2.13.2 Peptide Arrays
Peptide arrays are Whatman® 50 cellulose membranes on which 
peptide sequences are directly synthesised [Reineke et al., 2001 and Frank, 
2002]. These peptide arrays are able to bind purified recombinant proteins 
and provide evidence for direct protein interaction and the elucidation of the 
critical domains and residues involved [Espanel and Hooft van Huijsduijnen, 
2005 and Bolger et al., 2006]. The peptide arrays used in the experiments 
detailed in this thesis were kindly produced by Dr. E. Klussmann 
(Forschungsinstitut fur Molekulare Pharmakologie, Berlin, Germany) using the 
Intavis Bioanalyical Instruments (Kohn, Germany) AutoSpot-Robot ASS 222 
and utilising Fmoc-chemistry. Recombinant GST fusion proteins were 
produced to homogeneity, as described in Section 2.4.2. The peptide arrays 
were activated by immersion in 100% (v/v) ethanol and then washed in TBST 
for lOmin at room temperature on an orbital shaker. The peptide arrays were 
then incubated or blocked with 5% (w/v) milk powder (Marvel®), re-constituted 
in 20mM Tris-CI; pH 7.6, 150mM NaCI and 0.1% (v/v) Tween20 (TBST) for 1h 
at room temperature with vigorous agitation. 3-10pg/ml of recombinant GST 
fusion protein, or GST alone as a control, was then diluted in 1% (w/v) milk 
powder TBST solution and incubated with the peptide array in an airtight 
plastic carrier overnight at 4°C with vigorous agitation. The peptide array was 
then subjected to three lOmin washes in TBST, The recombinant GST fusion 
protein was then detected for direct binding to the peptide array by probing 
with a specific primary anti-serum or an anti-serum specific for GST. As a 
general rule the primary anti-sera were used at two-fold less than the 
recommended dilution for Western immuno-blotting. Details of the primary 
antibodies used in the experiments described in this thesis are shown in Table 
2.6. The membrane was then washed several times with TBST before 
application of the appropriate horseradish peroxidase (HRP) conjugated anti­
immunoglobulin G (IgG) secondary antibody diluted 1:5000 in 1% (w/v) milk 
powder TBST solution in a sealed, airtight plastic carrier. Similarly, this was 
incubated for 1h at room temperature, or overnight at 4°C, with vigorous 
agitation. The membrane was again washed several times with TBST before
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2.14 Co-immuno-precipitation
employing the Amersham Biosciences (Little Chaifont, U.K.) enhanced 
chemiluminescence (ECL) Western immuno-blotting kit as the visualisation 
protocol for detecting bound antibodies. Briefly, the bound antibodies were 
detected by exposure of the peptide array, following washing in ECL solution, 
to blue-light sensitive autoradiography film and developed using the Kodak® 
X-Omat Model 2000 processor. For a more detailed description of this kit or 
the autoradiography film processor please consult the manufacturers 
instructions. The resolution of spots, distinct from the GST control peptide 
array, on the autoradiography film were indicative of a positive interaction of 
the recombinant fusion protein with the peptide array and the critical 
sequences were analysed for putative consensus sites or binding motifs.
i
Mammalian cell lines were co-transfected, as described above in 
Section 2.6 and cell lysates were produced by sub-cellular fractionation as
described above in Section 2.10.2. The protein concentrations of the 
cytosolic, or S fractions were determined, as described above in Section 2.11, 
and the concentrations equalised for all samples to contain approximately
-I.-250pg of protein in a SOOpI volume of ice-cold KHEM. A 30pl sample of the 
diluted lysate was removed for Western immuno-blotting to determine the 
relative immuno-reactive inputs of the co-expressed proteins for the co~ 
immuno-precipitation experiment. Anti-FLAG or anti-VSV agarose beads 
were pre-equilibrated in ice-cold KHEM to produce a 50% slurry. 60pl of the 
slurry was added to each 500pl protein sample and these were incubated
end-over-end for 2h at 4 C. The samples were centrifuged at 16,060 x g for 
5min at 4°C using a bench-top refrigerated centrifuge. 30pl of supernatant 
was removed to screen for unbound proteins. The agarose resin was washed 
three times in SOOpI of ice-cold KHEM and once in 500pl of ice-cold PBS by 
centrifugation at 16,060 x g for Imin at 4°C. Bound proteins were then eluted 
in SDS sample buffer and subjected to SD8-PAGE and Western immuno- 
blotting, as described in Sections 2.12.1 and 2.12.3 respectively. Using The 
Discovery Series™ Quantity One® 1-D Analysis Software, Version 4.4.0, the
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intensity of the immuno-reactive amounts of the co-expressed proteins, in 
both the initial cell lysate and following co-immuno-precipitation, was 
determined. Each measurement was undertaken within a constant 
measurement area using scanned Western immuno-blots within the linear 
range to the light produced from ECL. In each case the densitometry 
readings were corrected with an appropriate background control. The 
immuno-reactive amounts of protein co-immuno-precipitated were then 
corrected for the immuno-reactivity of the same protein in the initial cell lysate. 
These ratios were then used to compare the interaction efficiency of the two 
proteins and to assess conditions that may facilitate the modulation of the 
specific interaction. Any modifications to the interaction efficiency were 
compared relative to the control co-immuno-precipitation (100%). Paired t- 
test statistical analysis was applied to the quantified data using MINITAB® 
Release 14.13 computer software, where p < 0.05 indicates a statistically 
significant difference in the relative amounts of protein co-immuno- 
precipitated compared to the untreated control. Control immuno-precipitations 
were undertaken in a similar manner with cell lysates produced from cells 
singly transfected with the protein that was to be co-immuno-precipitated. 
This facilitated screening for non-specific binding to the chosen agarose bead 
conjugate.
2.15 Phosphodiesterase Activity Assay
To measure PDE activity a radioactive cAMP hydrolysis assay was 
employed. This procedure has been described previously [Marchmont and 
Houslay, 1980] and is a modification of a historical two-step procedure 
[Thomson and Appleman, 1971]. PDE enzymes hydrolyse cAMP, which 
results in the formation of 5' AMP. In this assay, both [8-^H] adenosine 3% 5 - 
cyclic mono-phosphate from Amersham Biosciences (Little Chaifont, U.K.) 
and adenosine 3', 5’- cyclic mono-phosphate are hydrolysed. Addition of 
Snake Venom from Ophiophagus Hannah prevents re-circularisation of 
uncharged 5’ AMP by further hydrolysis to adenosine and the Dowex slurry 
binds charged, un-hydrolysed cAMP. %
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incubated on ice for a further 15min. Following incubation the tubes were 
then mixed again and centrifuged at 16,060 x g for 3min at 4°C in a
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2.15.1 Activation o f Dowex 1x8-400 Anion Exchange Resin
Dowex 1x8-400 was prepared and activated by dissolving 400g of 
Dowex resin in 41 of 1M NaOH. The solution was stirred for 15min at room 
temperature and the resin allowed to settle. The supernatant was removed 
and the Dowex resin extensively washed thirty times with 41 of distilled water 
and allowed to settle after each wash. After thirty washes the resin was 
washed with 41 of 1M FICI for 15min at room temperature and allowed to 
settle. The resin was then washed a further 5 times with distilled water and 
stored at 4°C as 1:1 slurry with distilled water. Following this procedure 
generally produced approximately II of Dowex slurry. This Dowex slurry was 
utilised in the PDE assay as a 2:1 solution of slurry to 100% (v/v) ethanol.
%
2.15.2 Assay Procedure
The entire assay procedure was undertaken using 1.5ml Eppendorf® 
tubes per reaction. The cAMP substrate solution for the assay was composed |
of 2pl of ImM 3’, 5’ cyclic adenosine mono-phosphate and 3pl of [8-^H] 3’, 5’ 
cyclic adenosine mono-phosphate per millilitre of 20mM Tris-CI; pH 7.4 and 
10mM MgCL. The appropriate volume of purified protein or cell extract was 
diluted to a final volume of 50pl in 20mM Tris-CI; pH 7.4. 50pl in 20mM Tris- 
CI; pH 7.4 was used as the blank control. The exact volume of purified 
protein or cell extract required in the assay was pre-determined in a pilot 
assay using increasing concentrations of protein samples. 50pl of cAMP 
substrate was added to 50pl of the PDE containing sample, mixed, and these 
were then incubated in a water bath at 30°C for lOmin. The samples were 
then placed in a boiling bath for 2min to inactivate the PDE and stop the 
reaction. The tubes were then cooled on ice for a minimum of 15min. 25pl of #1 mg/ml snake venom from Ophiophagus Hannah was then added to the 
reaction tubes, mixed, and incubated for a further lOmin at 30°C. 400pl of 
Dowex/ethanol solution was added to each reaction tube, mixed, and a ■a.
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refrigerated bench-top centrifuge. 1ml of Opti-Flow SAFE 1 scintillant was 
added to fresh 1.5ml Eppendorf® tubes. 150pl of supernatant from the 
reaction tubes was added to an individual tube containing scintillant with 50pl 
of cAMP substrate solution added to a scintillant vial to determine total counts 
per minute for the assay. All tubes containing scintillant were mixed and 
hydrolysed 3', 5' cyclic adenosine mono-phosphate and [8-^H] 3', 5' cyclic 
adenosine mono-phosphate was measured using a Wallac® 1409 Liquid 
Scintillation Counter.
2.15.3 Determination o f Phosphodiesterase Activity
To determine specific PDE activity contained within any reaction tube 
the following formula was applied, 2.61 x (value -  blank / average total) x 10"^  ^
X 10^  ^X (1000 / pg protein) resulting in PDE activity in pmoles/min/mg protein. 
To assess the effect of PDE inhibition, the activity of samples containing 
inhibitor were directly compared to an uninhibited control reaction and was 
expressed as the percentage of the aforementioned uninhibited control.
2.16 Thermal Stability Assays
Twenty assay tubes were set-up for a PDE activity assay, as described 
in Section 2.15.2. Each tube contained a pre-determined volume of cell 
extract, expressing the desired PDE4A, in a final volume of 50pl in 20mM 
Tris-CI; pFI 7.4. The assay tubes were placed in a 55°C water bath and one 
assay tube was removed to ice every 30s until none were remaining. 50pl of 
cAMP substrate was then added to 50pl of the de-natured PDE sample and 
the activity assay continued as described above. The log residual PDE 
activity was determined against a control cell extract and the thermal stability 
profile plotted as a function of time, with the half-life (ti/2) determined as the 
time in which 50% of the activity remained. Statistical comparison of the 
determined half-life values for each PDE4A enzyme preparation was 
undertaken using MINITAB® Release 14.13 computer software and a Paired t- 
test, where p < 0.05 indicates statistical significance.
105
Chapter 2 Materials and Methods
2.17 Phosphorylation Assays
All phosphorylation assays were undertaken using Amersham 
Biosciences (Little Chaifont, U.K.) labelled radioisotopes. All radioactive
experiments were undertaken in accordance with the Ionising Radiations 
Regulations 1999 and local rules. All experiments requiring the use of ^^ P 
labelled radioisotopes were undertaken behind Perspex® shields. The 
wearing of a film badge dosimeter monitored all personal exposure. In every 
phosphorylation experiment using ^^P labelled radioisotopes, the rate of 
disintegration (half-life = 14.3 days) was taken into account and the activity of 
the source adjusted accordingly.
2.17.1 In Vitro Phosphorylation
The expression and purification of MBP or GST fusion proteins in E.coli 
was undertaken as described in Section 2.4 and the concentration of the 
purified protein determined as described in Section 2.11. Ipg of fusion 
protein and a defined amount of Upstate (Dundee, U.K.) recombinant protein 
kinase (concentration required was detailed on the accompanying information 
sheet for the specific lot of recombinant protein kinase) were diluted in 20mM 
MOPS; pH 7.2, 25mM p-glycerol phosphate, 5mM EGTA, ImM sodium 
orthovanadate and ImM DTT to a final volume of 40pl. lOpI of IpCi/pl ^^P- 
ATP diluted in 75mM MgCb and 500pM ATP was added to the target
srecombinant fusion protein and specific kinase mix. The reaction was 
incubated at 30°C for lOmin. The reaction was stopped by the addition of 
12.5pl of 5x SDS sample buffer. The reaction tubes were mixed and heated 
for 10min at 70°C on a heating block. The tubes were then centrifuged at 
16,060 X g for Imin and 30pl of the sample subjected to SDS-PAGE and 
transferred to a nitro-cellulose membrane, as described in Sections 2.12.1 
and 2.12.3 respectively. The nitro-cellulose membranes were then air-dried 
and scanned using the Bio-Rad® (Hemel Hempstead, U.K.) Personal 
Molecular Imager® FX to resolve the radioactive regions utilising phosphor 
image screen technology. The Discovery Series™ Quantity One® 1-D
106
Chapter 2 Materials and Methods
Analysis Software, Version 4.4.0 was used to quantify the intensity of each 
radioactive band. These measurements were undertaken within a constant 
measurement area and any appropriate background readings were 
subtracted. The membranes were then used for standard Western immuno- 
blotting, as described in Section 2.12.3. Western immuno-blots, within the 
linear range to the light produced from ECL, were scanned and quantified as 
a measurement of the relative immuno-reactive amount of target protein in the 
assay Again, these data were generated using The Discovery Series™ 
Quantity One® 1-D Analysis Software, Version 4.4.0. In all cases the extent of 
the phosphorylation was corrected for the immuno-reactive amount of target 
protein in the assay and any change expressed as a percentage of the wild 
type control (100%). Paired t-test statistical analysis of data were undertaken 
using MINITAB® Release 14.13 computer software, where p < 0.05 indicates 
a statistically significant change in the degree of phosphorylation compared to 
the wild type control.
I
2.17.2 In Vivo Phosphorylation
2.17.2.1 Detection by Western Immuno-blotting
Mammalian cells were transfected to express the desired protein using
any of the transfection methods described in Section 2.6. Approximately 24- 
48h after transfection the cells were treated with the appropriate ligands and 
inhibitors as detailed in Table 2.5. The cells were then harvested in 3T3 lysis 
buffer, as described in Section 2.10.1 and the protein concentration 
determined, as described in Section 2.11. All samples were diluted to contain 
equal protein concentrations and 30p! was subjected to SDS-PAGE, as 
described in Section 2.12.1. The resolved proteins were then transferred to a 
nitro-cellulose membrane and probed for the specific phosphorylated residue 
on the expressed target protein using a specific phospho anti-serum. The 
native protein was also probed using a specific anti-serum to assess 
expression levels. The Western immuno-blotting procedure is described in 
Section 2.12.3 and the anti-sera used to probe for phosphorylated and native
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proteins detailed in Table 2.6. Using The Discovery Series™ Quantity One® 
1-D Analysis Software, Version 4.4.0 and scanned Western immuno-blots 
within the linear range to the light produced from ECL, the relative intensity of 
the immuno-reactive amounts of phosphorylated protein, as detected using 
the specific phospho anti-serum, was determined. These data were then 
corrected against the intensity of the immuno-reactive amounts of native, non- 
phosphorylated protein, using an anti-serum to detect expression levels. 
Each densitometry reading was undertaken within a constant measurement 
area and was corrected using an appropriate background control. The degree 
of phosphorylation was calculated as the ratio of the phosphorylated protein 
densitometry reading over the corresponding non-phosphorylated 
densitometry reading. Changes in the degree of phosphorylation were 
expressed as a percentage of the maximum response (100%).
2.17.2.2 Radioactive Whole Cell Labelling
C0S1 cells were transfected to express the desired protein using any 
of the transfection methods described in Section 2.6. Approximately 24h after 
transfection the DMEM supplemented with 0.1% (v/v) penicillin/streptomycin 
(lOOOOU/ml), 2mM glutamine and 10% (v/v) PCS was removed and replaced 
with 5ml of phosphate-free DMEM containing 0.1% (v/v)
penicillin/streptomycin (10000U/ml), 2mM glutamine and 10% (v/v) PCS. The
[32p]_
orthophosphate. The cells were then incubated overnight in an atmosphere of
phosphate was then re-introduced to the medium using 500pCi of [ P]-
sucrose, 80mM (3-glycerol phosphate, 20mM EGTA, 15mM MgCb, ImM DTT, 
2mM ATP, 0.5% (v/v) NP-40 and containing 1x Roche® Diagnostics
95% (v/v) air and 5% (v/v) CO2 in a Perspex® box with the lid slightly open to 
allow for sufficient aeration. The cells were then treated with the appropriate 
ligands and inhibitors, as detailed in Table 2.5. The cell media was removed, 
washed twice with ice-cold PBS and then harvested in ice-cold lOOmM
,,a:
(Mannheim, Germany) protease inhibitor cocktail tablets. The whole cell 
lysate was subsequently prepared as described in Section 2.10.1. 30pl of 
whole cell lysate was removed for standard Western immuno-blotting to
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ensure that the appropriate endogenous kinase had been activated and 
inhibited by the respective cell treatments, as shown in Table 2.5. Anti-sera 
specific for activation and expression of the kinases are detailed in Table 2.6.
The cell lysates were then divided equally and 5pl of anti-sera for the specific 
protein or appropriate fusion tag was added to one aliquot for immuno- 
precipitation. Aliquots of cell lysate without antibody were used as agarose 
resin only control immuno-precipitations. The lysates were incubated for 1h 
on ice with mixing every 10min. Amersham Biosciences (Little Chaifont, U.K.)
Protein G agarose resin was pre-equilibrated with cell lysis buffer to produce a 
50% slurry. Following the 1h incubation on ice with antibody, 60pl of Protein 
G agarose resin slurry was added to each tube, i.e. both control and PDE4 
immuno-precipitations. The lysates were incubated for 1h on ice with mixing 
every 10min. The samples were then centrifuged at 16,060 x g for Imin and 
the supernatant removed. The immuno-precipitated proteins bound to the 
Protein G agarose resin were washed twice in 500pl of lysis buffer before a 
final wash in 500pl of ice-cold PBS. The final supernatant was removed and 
the bed volume of agarose resin was re-suspended in 30pl of 5x SDS sample 
buffer. The reaction tubes were mixed and heated for lOmin at 70^0 on a 
heating block. The tubes were then centrifuged at 16,060 x g for Imin and 
30pl of the sample subjected to SDS-PAGE and transferred to a nitro­
cellulose membrane, as described in Sections 2.12.1 and 2.12.3 respectively.
The nitro-cellulose membranes were then air-dried and scanned using the 
Bio-Rad® (Hemel Hempstead, U.K.) Personal Molecular Imager® FX to 
resolve the radioactive regions utilising phosphor image screen technology.
The Discovery Series™ Quantity One® 1-D Analysis Software, Version 4.4.0 
was used to determine the densitometry of the relevant radioactive regions, 
less an appropriate background control. Each densitometry reading was 
taken within a consistent measurement area. The membranes were then 
used for standard Western immuno-blotting, as described in Section 2.12.3, to 
assess the immuno-reactive amounts of target protein immuno-precipitated.
The Discovery Series™ Quantity One® 1-D Analysis Software, Version 4.4.0
was also used to assess the relative immuno-reactive band intensity of the I
target protein immuno-precipitated using scanned Western immuno-blots
■■within the linear range to the light produced from ECL. All measurements
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were undertaken in a consistent measurement area, less any relevant 
background control reading. To determine the degree of phosphorylation the 
densitometry of specific radioactive bands were corrected for the densitometry 
reading for the corresponding immuno-precipitated target protein. All data 
were expressed as a percentage of the no treatment control (100%). Paired t- 
test statistical analysis of data were undertaken using MINITAB® Release 
14.13 computer software, where p < 0.05 indicates statistical significance in 
the level of phosphorylation as a result of the indicated cell treatments 
compared to the no treatment control.
2.17.3 Peptide Array Phosphorylation
Peptide arrays are Whatman 50 cellulose membranes on which
Vpeptide sequences are directly synthesised [Reineke et al., 2001 and Frank, .k:2002]. The peptide arrays used in the experiments detailed in this thesis were 
kindly produced by Dr. E. Klussmann (Forschungsinstitut fur Molekulare 
Pharmakologie, Berlin, Germany) using the Intavis Bioanalyical Instruments 
(Kohn, Germany) AutoSpot-Robot ASS 222 and utilising Fmoc-chemistry. 
The peptide array was activated by immersion in 100% (v/v) ethanol and then
incubated in 20mM FIEPES; pH 7.4, lOOmM NaCI, 5mM MgCb, ImM DTT
’Iand 0.2mg/ml BSA, herein referred to as membrane phosphorylation buffer, 
for 1h at room temperature on an orbital shaker. The peptide array was then 
blocked overnight at 4°C in membrane phosphorylation buffer containing 
1 mg/ml BSA and lOOpM ATP. The peptide array was then incubated in 
membrane phosphorylation buffer containing 50pM ATP, lOpCi pP]-ATP 
plus Upstate (Dundee, U.K.) recombinant protein kinase (concentration 
required was detailed on the accompanying information sheet for the specific 
lot of recombinant protein kinase). The peptide array was incubated for 30min
,
at 30°C on an orbital shaker contained in a Perspex® box. A control peptide 
array phosphorylation was undertaken without the addition of the recombinant 
protein kinase to screen for any non-specific [ P]-ATP binding. The peptide 
array was extensively washed ten times for 15min in 1M NaCI, three times for 
5min in water, three times for 15min in 5% (w/v) H 3 PO 4  in water, three times
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for 5min in water and finally twice for 2min in 100% (v/v) ethanol. The peptide 
arrays were then air-dried and scanned using the Bio-Rad (Hemel 
Hempstead, U.K.) Personal Molecular Imager® FX to resolve the radioactive 
regions utilising phosphor image screen technology.
I l l
2.18 Caspase-3 Cleavage Assay
Recombinant caspase-3 was produced as an active species, as 
described elsewhere [Huston et al., 2000]. C0S7 cells were transfected to 
transiently express specific PDE4A isoforms as described in Section 2.6.1 
and subjected to sub-cellular fractionation as described in Section 2.10.2. 
10pg of cytosolic, of S fraction, expressing the required PDE4A isoform, was 
incubated with 147ng of active p20 caspase-3 for 2h at 37°C and the final 
reaction-volume made up to 25pl with KHEM. 5pl of 5x SDS sample buffer 
was added to stop the reaction and the resultant protein degradation analysed 
by SDS-PAGE, as described in Section 2.12.1, and immuno-probed for 
PDE4A using a C-terminal, species and sub-family specific anti-serum, as 
described in Section 2.12.3.
2.19 Analysis Software
The primary amino acid sequences of proteins were analysed by 
ScanSite (http://scansite.mit.edu/cqi-bin/motifscan seq). a protein
phosphorylation and protein-protein interaction database centred upon 
peptide library data. These protein scans were carried out on high or medium 
stringency to identify putative phosphorylation and interaction motifs.
All schematic diagrams were generated using Microsoft® PowerPoint® 
and all graphs were generated using Microsoft® Excel®. All concentration 
response curves were generated using Kaleidograph® curve fitting computer 
software and fitting the IC50 equation. All densitometry of Western immuno- 
blots, within the linear range to the light produced from ECL, and phosphor 
image scans were quantified using The Discovery Series™ Quantity One® 1-
1
I
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D Analysis Software, Version 4.4.0. Paired t-test or Two-Sample t-test 
statistical analysis of data were undertaken using MINITAB® Release 14.13 
computer software and statistical significance is indicated using the 
convention * p < 0.05, ** p < 0.01 and *** p < 0.001.
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Chapter 3 Characterisation of a novei PDE4
-isoform, PDE4A11
s
3.1 Introduction
There are now approximately 21 proteins within the human PDE4 ?»
family of enzymes and these are encoded by up to four genes, PDE4A -  4D 
[Zhang et al., 2005]. A single gene mapped to the p13.2 region on human
chromosome 19 encodes the PDE4A isoforms [Sullivan et al., 1998]. PDE4A
isoforms are individually characterised by their unique N-terminal regions, 
which are encoded by a single 5’ exon. Furthermore, three distinct types of 
enzyme are generated as a consequence of alternative mRNA splicing 
[Bolger et al., 1996 and Bolger et al., 1997]. Splicing results in the differential 
inclusion of UCR1 and/or UCR2 regulatory modules. This generates long 
isoforms that include both UCR1 and UCR2, short isoforms that lack UCR1, 
and super-short isoforms that lack UCR1 and have a truncated UCR2. To 
date, five human PDE4A isoforms have been identified and characterised. 
These include the long isoforms PDE4A4B (pde46) [Huston et al., 1996], 
PDE4A10 [Rena et al., 2001] and PDE4A11 [Wallace et al., 2005]. PDE4A1 
(hRDI) is expressed as a super-short enzyme [Sullivan et al., 1998]. 
PDE4A7 (2el) is a unique PDE4 in that it is truncated from both the N- and C- 
terminal regions rendering the enzyme catalytically inactive [Horton et al., 
1995 and Johnston et al., 2004]. PDE4A isoforms are ubiquitously expressed 
on a cell-type specific basis and endogenous expression is considered to be 
lower than that of the PDE4B and PDE4D isoforms.
The sequencing and analysis of the PDE4A gene locus on 
chromosome 19 proposed that a third PDE4A long isoform exists [Sullivan et 
al., 1998]. The identification and characterisation of the third human PDE4A 
long isoform, known as PDE4A11, is described here in Chapter 3.
'y
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3.2 Results
3.2.1 Identification of the PDE4A11 Exon and Predicted Amino Acid
Sequences
Genomic analysis of the 38kb human PDE4A gene locus identified a 
putative unique 5’ exon thought to encode a novel PDE4A long isoform, now 
known as PDE4A11 [Sullivan et al., 1998 and Wallace et al., 2005]. Figure
3.1 illustrates the positioning of this 5' exon that encodes the unique N- 
terminal region of PDE4A11. The PDE4A gene is orientated 5’ to 3’ telomere 
to centromere with exon 1 of PDE4A4B positioned furthest, in the 5’ direction, 
from the PDE4A common exon 2. Exon 1 of PDE4A11 is located 
approximately lOkb in the 3' direction with exon 1 of PDE4A10 found a further 
Ikb downstream. Using the putative nucleotide sequence of the PDE4A11 
encoding exon, the BLAST algorithm, and the expressed sequence tag (EST) 
and high-throughput sequence nucleotide databases, PDE4A11 sequences 
were identified in a number of species including human, mouse, rat, bat and 
pig [Wallace et al., 2005]. These EST data clearly exhibited sequence 
homology akin to a PDE4A long form and supports the notion that exon 1 of 
PDE4A11 splices directly to exon 2, which encodes the PDE4A common long 
form region (CLFR) and a proportion of UCR1. Expression of exon 1 
encoding PDE4A11 yields an 81 amino acid unique N-terminal region. Figure
3.2 shows the comparison of the similar sequences found in mouse, rat, bat 
and pig where distinct homology is observed. Although the homology 
between human and mouse sequences is only approximately 50%, and the 
human sequence is 81 amino acids compared to the mouse sequence at 66 
amino acids, and at variance with the sequences for PDE4A1 [Sullivan et al.,
1998], PDE4A4B [Huston et al., 1996 and Sullivan et al., 1998] and PDE4A10 
[Rena et al., 2001], a cross species consensus sequence that accurately 
represents the PDE4A11 N-terminal region can be resolved. Bat and pig
homology is much greater with approximately 90% of amino acids conserved.
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3.2.2 Analysis o f 5 ' Promoter Activity
Analysis of the 5’ sequence preceding the PDE4A11 exon identified 
possible DNA polymerase II promoter regions capable of supporting DNA 
transcription complexes [Wallace et al., 2005]. Promoter activity of the 1kb 
region preceding the initiating ATG start codon for PDE4A11 was assessed 
using a luciferase reporter assay system [Wallace et al., 2005]. Luciferase 
activity was optimal when transcription was driven by the first 250bp 
immediately upstream of the PDE4A11 start codon. Luciferase activity was 
attenuated by approximately 50% when the preceding SOObp were assessed 
indicating a level of repressive transcription control in the second 250bp 
region. Similar levels of promoter activity were measured with the first 1kb 
preceding the PDE4A10 start codon whereas lower promoter activity was 
measured with the corresponding region preceding the PDE4A4B start codon 
[Rena et al., 2001 and Wallace et al., 2005].
3.2.3 Expression Profile o f PDE4A11
As discussed previously in Section 1.7.1, the structure of long form 
PDE4 enzymes is generally constructed of a unique N-terminal region, two 
common UCRs, linked to each other and the common catalytic unit through 
two sub-family specific LRs, and terminate with a sub-family specific 0- 
terminal tail. This modular structure is shown schematically in Figures 1.5 
and 3.3. Intron-spanning primers to the unique N-terminal region of PDE4A11 
and the common UCR1, LR1 and LR2 domains were designed, as detailed in 
Table 2.3, to establish the authenticity of the novel PDE4A11 isoform.
Generic PDE4A primers to the common UCR2 and catalytic domain were also '
designed to function as control primers. Using mRNA from HEK293 cells and 
brain tissue respectively, the validity of the PDE4A11 isoform was 
demonstrated utilising RT-PCR across the long form splice junctions. Generic 
PDE4A transcripts of 506bp (UCR2 to catalytic unit), and two PDE4A11 
specific transcripts of 497bp (N-terminal to UCR1) and 886bp (N-terminal to 
LR2) respectively were generated, as shown in Figure 3.3, confirming the
115
Chapter 3 Characterisation of a novel PDE4 isoform, PDE4A11
aforementioned EST data demonstrating PDE4A11 as a bona fide PDE4A 
long isoform.
To profile the tissue expression of PDE4A11, a panel of first strand 
cDNA isolated from various human tissues were used as PCR template 
sequences. Utilising RT-PCR and a primer pair designed to the unique N- 
terminal region of PDE4A11 and the PDE4A common LR1 domain, PDE4A11 
specific transcripts of 494bp were detected, as shown in Figure 3.4.
Significant detection of PDE4A11 transcripts was observed in adult liver, 
Stomach, testis, thyroid, adrenal gland, polymorphonuclear blood leukocytes
(PBLs), and foetal brain. To a lesser degree transcripts were also detected in 
adult brain, kidney, placenta, pancreas, ovary, uterus, skin and foetal liver. IThis expression profiling shows PDE4A11 to be widely expressed in various 
human tissues. Of particular interest is the change in transcript levels from 
foetal to adult tissue indicating the possibility for developmental changes in 
PDE4A11 expression. PDE4A11 transcripts in the brain were attenuated in 
adult on comparison with the transcript levels in foetal brain tissue.
Conversely, PDE4A10 transcripts were not detected in foetal brain, but are 
clearly present in the adult [Rena et al., 2000]. PDE4A11 transcripts in the 
liver are enhanced in adult tissue when compared to the foetal tissue 
transcript level. Significant detection of PDE4A11 transcripts emerged in 
PBLs. Indeed, it appears that PDE4A11 transcripts are the major transcripts 
in nearly all immune and inflammatory cell types [Wallace et al., 2005]. Mast
’ -'tcells, eosinophils, macrophages, natural killer cells and monocytes show 
significant PDE4A11 transcripts when compared to PDE4A4B and PDE4A10.
Interestingly, PDE4/ 
smooth muscle cells.
3.2.4 Expression o f Recombinant PDE4A11 in C 0S7 Cells
A11 is also the major PDE4A transcript in bronchial
The entire open reading frame (ORF) of human PDE4A11 was 
generated by PCR and sub-cloned into pcDNA3 for transient expression in 
C0S7 cells. C0S7 cells have basal PDE activity of 4-6pmol/min/mg of
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protein. On transient transfection of the PDE4A11 expression construct this
,activity increases to 4-6nmol/min/mg of protein [Wallace et al., 2005]. Cell 
lysates from C0S7 cells expressing human PDE4A1, PDE4A4B, PDE4A10 
and PDE4A11 were subjected to SDS-PAGE and Western immuno-blotting 
with a human PDE4A sub-family specific C-terminal anti-serum and a 
PDE4A11 specific N-terminal antibody. Figure 3.5(a), left panel, shows the 
detection of immuno-reactive bands for all PDE4A isoforms with the PDE4A 
sub-family specific anti-serum. The molecular weight of the super-short 
PDE4A1 was approximately 85kDa whereas the molecular weights of 
PDE4A4B, PDE4A10 and PDE4A11 were virtually indistinguishable at 
approximately 120-125kDa. Because these isoforms are of similar molecular 
weights specific detection requires the use of an anti-serum to the N-terminal 
regions. Figure 3.5(a), right panel, shows the same Western immuno-blot 
probed with an anti-serum generated specifically for the unique N-terminal 
region of PDE4A11 and this allowed the sole detection of a single immuno- 
reactive species at 126kDa +/- 4kDa. An intriguing attribute of all PDE4 
isoforms is their ability to migrate on SDS-PAGE at molecular weights larger 
than those predicted by their primary structure. The predicted molecular 
weight of PDE4A11 is 95.3kDa. As this characteristic is consistent amongst 
all PDE4 isoforms a common domain must drive it, and indeed, the catalytic 
core is responsible for mediating this aberrant SDS-PAGE migration 
[Johnston et al., 2004].
3.2.4.1 Intra-cellular Distribution of PDE4A11
Using differential centrifugation the intra-cellular distribution of a protein 
can be quantified. Cell lysates can be separated into PI (low-speed pellet) 
that contains intact cells and other cellular debris, P2 (high-speed pellet) that 
contains the plasma membrane and internal organelles, and S2 (high-speed ■ V
supernatant) that contains cytosolic cellular components. The sub-cellular 
distribution of PDE4A1, PDE4A4B and PDE4A10 in C0S7 cells has been 
determined [Sullivan et al., 1998, McPhee et al., 1999 and Rena et al., 2001].
PDE4A1 is considered to be primarily membrane-bound with approximately 
85% located in the pellet fractions and only 15% found in the cellular cytosol.
I
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Membrane insertion is mediated through a novel micro-domain called TAPAS- 
1 [Baillie et al., 2002]. PDE4A4B shows a more equal distribution with 45% 
located in the pellet fractions and 55% in the cellular cytosol. PDE4A10 is
The PDE4A11 primary amino acid sequence was analysed by 
ScanSite (http://scansite.mit.edu/cqi-bin/motifscan sea). a protein 
phosphorylation and protein-protein interaction database centred upon 
peptide library data. On high stringency, i.e. using tight motif scanning 
parameters, it was postulated that the unique N-terminal region contained 
putative phosphorylation sites for ERK1 at Ser-48, which may prime for a 
putative GSK-3 phosphorylation at Ser-44, and a potential SH3 binding 
domain at Pro-39 and a phosphatidyl-inositol-3,4,5-phosphate (PIP3) binding 
Pleckstrin homology (PH) domain at Phe-59. Analyses of the identified 
phosphorylation sites are shown in Figures 3.12 and 3.13 and the interaction 
with the SH3 domain of Lyn via the putative PDE4A11 N-terminal SH3 binding 
domain is assessed in Figure 3.15.
It was hypothesised that N-terminal PDE4A11 binding of PIP3 may be 
responsible for its intra-cellular targeting. To investigate this hypothesis, the 
activation of PI-3K to generate PIP3 was initiated using EGF in C0S7 cells
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different again with only 17% located in the pellet fractions and 83% found in 
the cellular cytosol. Assessment of the sub-cellular localisation of PDE4A11 
by sub-cellular fractionation and analysis by SDS-PAGE, is shown in Figure 
3.5(b), and concluded that 57% of PDE4A11 was located in the pellet 
fractions with 43% found as a cellular cytosolic protein. These data are 
shown in more detail in Table 3.1. However, sub-cellular distribution is a 
crude means of assessing the intra-cellular distribution. Analysis of PDE4A11 
intra-cellular distribution using laser-scanning confocal microscopy and 
immuno-histochemistry is shown in Figure 3.5(c) and deemed PDE4A11 
expression to be localised at the peri-nuclear regions of the cell and distinct 
distribution within membrane ruffles, unlike both PDE4A4B and PDE4A10 
[Huston et al., 1996 and Rena et al., 2001]. No nuclear expression of 
PDE4A11 was detected.
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and Insulin in HEK293 cells. The intra-cellular distribution of PDE4A11 was 
determined.
A time- and concentration-dependent activation of PI-3K was detected
I
Figure 3.6(a) shows a timely and robust activation of the PI-3K |J
signalling pathway, through phosphorylation of PKB/Akt, after 2.5min and that 
this activation was sustained for up to 30min. Figure 3.6(b) shows no 
significant visual change in the sub-cellular distribution of native PDE4A11 
and following EGF treatment. Quantification of the sub-cellular distribution as 
shown in Figure 3.6(c), confirms that no change in the sub-cellular distribution 
of PDE4A11 was achieved on activation of the PI-3K pathway in C0S7 cells.
The percentage of PDE4A11 that was located in the membrane P2 fraction in 
untreated cells was calculated as 27% +/- 4%. No statistically significant 
change was observed with EGF where the distribution of PDE4A11 P2 
expression was 26% +/- 3% (p > 0.05) with 10ng/ml EGF, 26% +/- 2% (p >
0.05) with 20ng/ml EGF and 22% +/- 9% (p > 0.05) with 50ng/ml EGF.
iby phosphorylation of PKB/Akt in HEK293 cells, on treatment with insulin, as
■fshown in Figure 3.7(a). Figure 3.7(b) exhibits a potential change in PDE4A11 
sub-cellular distribution on insulin treatment but this was not confirmed 
through quantification of the PDE4A11 localisation in the membrane P2 
fraction, as shown in Figure 3.8(c). In native cells 16% +/- 2% of total 
PDE4A11 expression was located in the P2 fraction. With 0.1 riM insulin, this 
increased directionally, but not significantly to 25% +/- 11% (p > 0.05), 
compared to 25% +/- 7% (p > 0.05) and 28% +/- 11% (p > 0.05) with 1 qM and 
10r|M insulin respectively.
Transient over-expression of PDE4A4B, tagged with green fluorescent 
protein (GFP) in HEK293, CHO, and rat basophilic leukaemia cells coupled 
chronic rolipram treatment induces a redistribution of PDE4A4B into accretion 
foci [Terry et al., 2003]. Similar experiments using GFP-tagged PDE4A10 and 
PDE4A11 exhibited no change in the localisation and no formation of 
accretion foci indicating a PDE4A4B isoform-specific effect [Wallace et al.,
2005].
119
 .
i
Chapter 3 Characterisation of a novel PDE4 isoform, PDE4A11
3.2.4.2 Kinetic Profile of PDE4A11
-The hydrolysis of cAMP by PDE4 follows a simple scheme where 
cAMP binds to the active site of PDE4 and forms an intermediate complex.
The PDE4 is available to participate in further hydrolysis following release of 
the 5' AMP product. At steady state, cAMP and PDE4 form a complex for 
hydrolysis that reaches equilibrium. This is defined by the Michaelis-Menten 
constant, Km, which is described as the concentration of cAMP at which PDE4 
is hydrolysing at 50% of its maximal rate (Vmax)- As with other enzyme
reactions, PDE4s follow saturation kinetics. Vmax is reached with excess 
concentrations of cAMP and in these conditions, PDE4 is saturated with 
cAMP as the Michaelis intermediate complex.
PDE4A11 forms an active cAMP-hydrolysing enzyme when over­
expressed in mammalian cells. As described above, PDE4A11, when I;
transiently over-expressed in COS7 cells, was localised at both the plasma 
membrane and within the cytosolic compartment of the cell. Cytosolic 
PDE4A11 has a Km of 4.2pM +/- 1.1 pM [Wallace et al., 2005], As a 
membrane-bound species the Km of PDE4A11 showed no change at 3.7pM 
+/- 1.8pM [Wallace et al., 2005]. These values are comparable to the other 
PDE4A long isoforms PDE4A4B and PDE4A10 [Huston et al., 1996 and Rena 
et al., 2001]. The “relative Vmax” values were also determined by assaying 
equal immuno-reactive amounts of cytosolic PDE4A11 against cytosolic 
PDE4A4B and cytosolic PDE4A10. Using cytosolic PDE4A4B and PDE4A10 
as a reference point, as they both have similar “relative Vmax” values, the
analogous “relative Vmax” for PDE4A11 was 1.1 +/- 0.1. Moreover, no change 
in “relative Vmax” was determined between cytosolic and membrane-bound 
PDE4A11, with the “relative Vmax” for membrane-bound 1.1 +/- 0.1. An 
alteration in the Vmax value between particulate and cytosolic forms has been 
observed for PDE4A4B where the particulate form has a 50% lower “relative 
Vmax" value [Huston et al., 1996].
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3.2.4.3 Inhibition of PDE4A11 by PDE4-selective Inhibitors
Inhibition of PDE4 enzymes has been the subject of much 
pharmaceutical research and has led to the production of many PDE4 
chemical inhibitors [Burnouf and Pruniaux, 2002, Houslay et al., 2005 and 
Zhang et al., 2005]. Rolipram (Schering-Plough) is the established PDE4 
inhibitor and is generally classified as a first generation compound, together 
with its derivative Ro 20-1724. Second generation inhibitors include Ariflo®, or 
cilomilast, (GlaxoSmithKline) and roflumilast (Altana). Xanthine derivatives 
such as denbufylline are also effective inhibitors of PDE4 enzyme activity. 
The chemical structures of these inhibitors are shown in Figure 3.8.
Each of these inhibitors concentration-dependently inhibited PDE4A11 
activity in both membrane (P2) and cytosolic (S2) sub-cellular fractions from 
COS7 cells transiently over-expressing PDE4A11. The concentration range 
required to inhibit PDE4A11 is indicated in the concentration response curves 
in Figure 3.9.
PDE4A4B can exist in two conformations as indicated by differential 
sensitivity to inhibition by rolipram [Huston et al., 1996 and McPhee et al.,
1999]. PDE4A4B localised in the cytosol of the cell was approximately 5-fold 
less sensitive to inhibition by rolipram than the particulate or membrane- 
bound form (0.26pM +/- 0.09pM), and as such the concentration-response 
curve showed a distinct shift to the left (data not shown). This effect is not 
observed with PDE4A10, as it is predominantly expressed as a cytosolic 
species [Rena et al., 2001]. PDE4A11 has a similar intra-cellular distribution 
profile to PDE4A4B but was not subject to increased affinity to rolipram when 
present in the particulate fraction. Rolipram inhibits cytosolic PDE4A11 with 
an IC50 of 0.72pM +/- O.OSpM and the particulate form with an IC50 of 0.66pM 
-+•/- 0.12pM. Cytosolic PDE4A10 appears to be the most sensitive PDE4A 
long isoform to inhibition by rolipram with an IC50 of 0.13pM +/- 0.03pM, 
followed by cytosolic PDE4A11 and then cytosolic PDE4A4B with an IC50 of 
1.31pM +/- O.OBpM.
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No significant difference between the IC50 for inhibition of cytosolic 
versus particulate preparations of PDE4A4B by Ariflo®, denbufylline or Ro 20- 
1724 was determined, but a 3-fold increase in the sensitivity for inhibition of 
the particulate form was measured with roflumilast. Cytosolic PDE4A10 had 
similar sensitivity to inhibition by Ariflo® and denbufylline, compared to 
cytosolic PDE4A4B, but was 2-fold more sensitive to inhibition by Ro 20-1724 
and roflumilast. PDE4A11 was more sensitive to inhibition by Ariflo®, 
denbufylline and Ro 20-1724 on comparison to the relevant sub-cellular 
preparation of PDE4A4B. In the case of roflumilast, cytosolic PDE4A11 was 
more sensitive than cytosolic PDE4A4B, whereas the converse was true for 
the particulate preparations.
The precise IC50 values for inhibition of particulate, where appropriate, 
and cytosolic preparations of PDE4A4B, PDE4A10 and PDE4A11 are detailed 
in Table 3.2. ;
Thermal stability or dénaturation of an enzyme is described as the loss 
of catalytic activity over time, when heated. This technique allowed a 
rudimentary structural comparison of PDE4A11 expressed at distinct locals 
within the cell. When particulate and cytosolic forms of PDE4A11 were 
heated at 55°C, their dénaturation, and subsequent loss of cAMP hydrolysing 
activity occurred at different rates. As shown in Figure 3.10, PDE4A11 activity 
decayed as a single exponential and the half-life (ti/2) of inactivation was 
determined. The cytosolic form of PDE4A11 had a t i /2 of 2.5min +/- 0.3min 
whereas the particulate form was significantly more stable with a t i /2 of 4.4min :+ /-0.3min (p < 0.05).
I
3.2.5 Phosphorylation o f PDE4A11
1Long isoforms from all four PDE4 sub-families are phosphorylated and 
activated by PKA at a single target serine residue contained within an Arg-
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Arg-Glu-Ser-Phe consensus motif located within the common UCR1 
regulatory module [Sette and Conti, 1996, Hoffmann et al., 1998 and 
MacKenzie et al., 2002]. Phosphorylation of this residue results in the 
activation of PDE4 enzymes. Isoforms from all PDE4 sub-families have 
appropriate docking sites for ERK2 but only PDE4B, PDE4C and PDE4D 
contains an ERK2 phosphorylation consensus sequence within the C-terminal 
catalytic unit [Hoffmann et al., 1999, MacKenzie et al., 2000 and Baillie et al.,
2000]. Functionally this phosphorylation exerts and inhibitory effect on PDE4 
long isoforms and activates PDE4 short isoforms. These phosphorylation 
events are discussed in more detail in Section 1.7.5.
3.2.5.1 Protein Kinase A
,1
Phosphorylation and activation of PDE4A11 was induced through the 
treatment of cells, transfected to transiently express PDE4A11, with the non­
specific PDE inhibitor, IBMX and the adenylyl cyclase activator, forskolin.
These treatments significantly raised the cAMP concentrations within the cells 
and induced activation of PKA. Figure 3.11(a) and Figure3.11(d) shows the 
time-dependent induction of a single phospho-UCRI immuno-reactive band of 
approximately 125kDa. The peak of the phosphorylation response was 
measured at 2.5min with IBMX/forskolin. A significant increase in cAMP 
hydrolysing activity, from the 100% +/- 8% control level to 184% +/- 16% with 
forskolin was measured and similarly peaked after 2.5min. The immuno- 
reactive band, indicative of PDE4 UCR1 PKA phosphorylation was not 
detected in non-transfected cells [Wallace et al., 2005], and the immuno- 
reactivity was severely attenuated at time zero and in cells concentration- 
dependently treated with the PKA inhibitor, H89, as shown in Figure 3.11(b).
Abolishment of PDE4A11 phosphorylation was detected in cells transfected to 
express a Ser-119-Ala phosphorylation defective mutant form of PDE4A11, as 
illustrated in Figure 3.11 (c).
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3.2.5.2 Extra-cellular Signal-regulated Kinase
As discussed above in Section 3.2.4.1, the unique N-terminal region of 
PDE4A11 contains a putative ERK1 phosphorylation site. Ser-48 was 
identified as the phosphorylation target residue contained within the 
consensus sequence, Pro-Ser-Ser-Pro. A possible ERK docking domain 
towards the extreme N-terminal of PDE4A11 was also presented following a 
further ScanSite (http://scansite.mit.edu/cai-bin/motifscan seq) analysis of 
PDE4A11, on medium stringency. Any change in the degree of PDE4A11 
phosphorylation, following ERK1/2 activation with either EGF or PMA in C0S1 
cells, was determined.
U0126.
PDE4A11 was analysed for alterations to the extent of phosphorylation 
by ERK1/2 in C0S1 cells, grown in phosphate-free media, and radiolabelled 
with [^^P]-orthophosphate. The cells were treated with EGF, which initiated a 
robust activation of ERK1/2 at 2.5min, which was sustained for 30min, as 
shown in Figure 3.12(a). Evaluation of Figure 3.12(b) indicated an increase in
the level of phosphorylation of PDE4A11 with EGF and comparable immuno- 
reactive amounts of PDE4A11 were immuno-precipitated. The quantification 
of any difference in phosphorylation, taking into account the relative amounts 
of PDE4A11 immuno-precipitated, showed no significant change in 
phosphorylation, with the degree of phosphorylation at 104% +/- 34% (p > 
0.05) with EGF, and reduced to 85% +/-12% (p > 0.05) with EGF plus U0126, 
as shown in Figure 3.12(b). Figure 3.12(c), top panel, confirmed low basal
levels of active ERK1/2 in COS1 cells, the strong induction of ERK1/2 
activation with EGF, and inhibition of active ERK1/2 with the MEK inhibitor,
C0S1 cells transfected to over-express PDE4A11, in media where the 
endogenous phosphate was replaced with [^^P]-orthophosphate, were treated 
with PMA to activate ERK1/2. PMA treatment of C0S1 results in the 
activation of ERK1/2, to a level comparable with that instigated by EGF, as 
shown In Figure 3.13(b), top panel, with PMA and Figure 3.12(c), top panel, 
with EGF. Indeed, appraisal of Figure 3.13(a), top panel, demonstrated a
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3.2.6 PDE4A11 Protein Interactions
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visible increase in the degree of PDE4A11 phosphorylation on treatment with 
PMA, and the effect was sensitive to inhibition by U0126. Analogous 
immuno-reactive amounts of PDE4A11 were immuno-precipitated, as shown 
in Figure 3.13(a), bottom panel. Quantification of the variation in
phosphorylation with PMA is shown in Figure 3.13(a) and revealed that no 
significant increase was observed at 128% +/- 23% (p > 0.05), with the effect 
of PMA plus U0126 measured at 85% +/- 5% (p > 0.05). I,.:0%
In characterising the significance of PDE4A11 expression, it was 
important to elucidate whether PDE4A11 was able to support similar protein 
interactions and confer the functional attributes akin to the other PDE4A long 
isoforms.
3.2.6.1 SFI3 Domain of Lyn
The SH3 domain of the tyrosyl kinase Lyn, interacts with PDE4A4B 
and PDE4A10 [McPhee et al., 1999 and Rena et al., 2001]. This interaction is 
discussed in more detail in Section 1.7.6.1. PDE4A4B contains four putative
SH3 binding domains for interaction with the SH3 domain of Lyn, i.e. the 
unique N-terminal region, the PDE4A specific LR2, the C-terminal portion of
the catalytic unit and the PDE4A specific C-terminal tail. Previously, the 
principal interaction site was mapped to the unique N-terminal region of 
PDE4A4B, with a secondary site confined within LR2 [McPhee et al., 1999]. 
Similarly, PDE4A10 exclusively interacts with the SH3 domain of Lyn through 
the common LR2 [Rena et al., 2001].
To assess the possible interaction of PDE4A11 with the SH3 domain of
Lyn, the recombinant GST fusion protein was expressed and purified in E.coli, 
to a single band on a Coomassie® stained SDS-PAGE, as shown in Figure 
3.14(a). Lyn-SFI3 was expressed as soluble protein in E.coli and purified to 
final concentration of 7.7mg/ml. In Figure 3.15(a), panel (i), it was observed
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that PDE4A4B interacted significantly with Lyn-SH3 accompanied with 
negligible non-specific interaction with the GST alone control. Interestingly,
PDE4A4B was not detected in the residual cell lysate following incubation with 
Lyn-SH3 indicating a potentially high affinity interaction. On the other hand,
PDE4A11 showed a significant reduction in binding to Lyn-SH3, as shown in 
Figure 3.15(c), panel (i). A similar level of non-specific interaction with the 
GST control was observed, but strikingly, a large proportion of PDE4A11 
remained unbound to Lyn-SH3, indicating a much-reduced affinity of 
interaction. The level of interaction with Lyn-SH3, using the pull-down assay 
was akin to that observed previously with PDE4A10 [Rena et al., 2001]. To 
map the critical residues for PDE4A long form interaction with Lyn-SH3, a 
peptide array approach was utilised using the recombinant GST fusion protein 
of Lyn-SH3. GST showed an absence of non-specific binding to all of the 
peptide arrays used in these experiments (data not shown). Using the 
peptide array of full length PDE4A4B, this approach accurately assigned the 
major interaction site for Lyn-SFI3 as Lys-306 to Lys-340 within LR2, as 
illustrated in Figure 3.15(a), panel (iii). A secondary interaction site was 
mapped to the PDE4A specific C-terminal tail, between Val-806 and Glu-835,
■as shown in Figure 3.15(a), panel (iv). Figure 3.15(a), panel (ii), showed 
nominal binding within the N-terminal region, compared to the detection of 
binding at the other sites. However, utilising the peptide array of the unique 
N-terminal region of PDE4A10, Figure 3.15(b) identified the first thirty amino 
acids as capable of supporting Lyn-SH3 binding. Removal of the first ten 
amino acids ablated the interaction of Lyn-SH3. Similarly, an extensive 
proline- and arginine-rich region exists within the unique N-terminal of 
PDE4A11. Pull-down analysis. Figure 3.15(c), panel (i), indicated that 
PDE4A11 was able to interact with Lyn-SH3 and the peptide array maps this 
interaction from Val-22 to Arg-60, as shown in Figure 3.15(c), panel (ii).
3.2.6.2 (3-arrestin
p-arrestin can interact with two distinct sites within PDE4D5, the unique 
N-terminal region and a site towards the C-terminal of the conserved catalytic
126
Chapter 3 Characterisation of a novel PDE4 isoform, PDE4A11
unit [Perry et al., 2002, Bolger et al., 2003 and Bolger et al., 2006]. Therefore, 
PDE4A isoforms also have the potential to interact with (3-arrestin.
A recombinant GST fusion protein of p-arrestin2 was expressed and 
purified in E.coli to a single band on a Coomassie® stained SDS-PAGE, as 
shown in Figure 3.14(b). p-arrestin2 was expressed at a lower level than Lyn- 
SH3 and consequently the yield was lower, with a final purified concentration 
of 1.2mg/ml. Using a pull-down assay with GST-(3-arrestin2 and C0S7 cell 
lysates expressing either PDE4A4B or PDE4A11, Figure 3.16 concluded that 
both PDE4A4B, (a), and PDE4A11, (b), were able to interact with p-arrestin2, 
with minimal interaction observed with GST alone.
3.2.6.3 Immunophilin XAP2
The immunophilin XAP2 specifically interacts with rat PDE4A5 and 
inhibits PDE4A5 cAMP hydrolysing activity [Bolger et al., 2003]. The 
interaction sites have been mapped to a region with the unique N-terminal of 
PDE4A5, responsible for the inhibition of catalytic activity, and the common 
PDE4 UGR2 domain. Thus, one would expect XAP2 to interact, at least to 
some extent, with PDE4 isoforms across all gene families, but this was not 
observed.
It was concluded in Figure 3.17(a) that PDE4A4B was able to interact 
with XAP2 when transiently co-expressed in COS7 cells. This is consistent 
with the previous data identifying XAP2 as a specific protein that can
■■exclusively interact with PDE4A5 because of sequence conservation between 
the human and rat homologues [Bolger et al., 2003]. A similar degree of 
interaction with XAP2 was indicated following immuno-precipitation of XAP2, 
as shown in Figure 3.17(b), in C0S7 cells over-expressing both XAP2 and 
PDE4A11. Non-specific co-immuno-precipitation interactions were negligible 
in both cases.
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S.2.6.4 Action of Caspase-3
The unique N-terminal region of PDE4A5 contains the sequence, Asp- :|Sis:Ala-Val-Asp at Asp-69, which is a consensus sequence for caspase-3 
cleavage. Thus, the unique intra-cellular targeting region of PDE4A5 is able 
to undergo caspase-3 cleavage, indicated by a increase in the migration 
mobility of PDE4A5 on SDS-PAGE from 109kOa to lOOkDa, to prevent its 
interaction with SH3 domain containing proteins [Huston et al., 2000].
PDE4A5 does not contain the required proline- and arginine-rich sequence 
within LR2 and therefore, does not provide any compensatory binding with 
SH3 domains [McPhee et al., 1999]. Homology between rat PDE4A5 and 
human PDE4A4B gives rise to a similar site in the N-terminal region of 
PDE4A4B, Asp-Ala-Met-Asp at Asp-69. Caspase-3 cleavage was able to 
occur in PDE4A4B, as indicated by a faster migrating species on SDS-PAGE, 
but no equivalent digestion of PDE4A10 or PDE4A11 followed due to their
unique N-terminal regions lacking the Asp-Xaa-Xaa-Asp consensus sequence
A . ,
[Wallace et ai., 2005].
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(a)
LR1 LR2
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Figure 3.1 -  Schematic representation of the PDE4A gene structure.
(a) shows the coding exons (boxes) of the active PDE4A enzyme and the 
non-coding introns (horizontal lines, black). The unique 5’ exons for the long 
isoforms PDE4A4B (hashed, blue), PDE4A11 (hashed, green) and PDE4A10 
(hashed, red) are shown and encode the unique N-terminal regions. The 
unique 5’ exon for the super-short PDE4A1 isoform (white) is embedded 
between exons 6 and 7 resulting in the expression of an active enzyme 
lacking UCR1 (yellow) and containing a truncated UCR2 module (orange).
The linker regions (black), LR1 and LR2, are encoded by exons 5 and 9
S';respectively. The unique 5' and 3’ exons for the catalytically inactive PDE4A7 : "!;-senzyme are also shown (blue). Exons 10-14 (green) encode the catalytic unit 
and exon 15 (purple) the sub-family unique C-terminal region, (b) shows the 'organisation of the unique 5’ exons (or exon 1) for the three human PDE4A 
long isoforms and their orientation 5’ -  3’ telomere to centromere on 
chromosome 19p13.2.
S
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Consensus m a r - r g l g r i p e l q l a a f p - a a a - a e d e a f l p e p p a p r a p r  
Human m a r p r g l g r i p e l q l v a f p v a v a * a e d e a f l p e p l a p r a p r
Mouse M A R *R G W G R IP E P C A A A FP E A V A * *E D D A F L P G P P T V S A F L
Rat MAR* R G C G R IP E P R A A A F P E A A A * *  E D D A FLP G P A S VS A FF
Bat M A R Q R G LG C IP ELQ LA A FPA A A A A A ED EA FLPEP PA PR A PR
Pig ------------S L G R IP E L Q L V A F P A A A T **E D E A F L P E P P A P R A P R
Consensus - - r s p p s s p v f f a s p s p t l r r r l r l l r g s f q d - g r q a w a g - -
Human r p r s p p s s p v f f a s p s p t f r r r l r l l r * s c q d l g r q a w a g a g
Mouse S S T T *  * * * * * * * * * PM PY*RR*LRLFRG SVQ DW G RQ AW AG * *
Rat S S T P *  * * * * * * * * *  P TP Y *R R *LR LFR G G IQ D W G R Q A W A G * *
Bat W LR S P P S S P V FFA S P S P TLR R R LR LLR *S FQ D FG R Q A W A G * *
Pig R P R S P P S S P V F F A S P S P T L R R R L R L L R *S F Q D F S R P A W A G **
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Figure 3.2 -  Sequence alignments of the predicted amino acid 
sequences encoded by the PDE4A11 unique 5’ exon in various species.
132
Alignment shows human (GenBank accession number AY618547), mouse 
(GenBank accession numbers AC027154 and AC073749), rat (GenBank |
accession number AC115140), bat (GenBank accession number AC148813) 
and pig predicted sequences. Conserved residues are highlighted (red). The 
predicted consensus sequence for the unique PDE4A11 N-terminal region is 
also shown (underlined, blue).
js.
.
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Figure 3.3 -  Schematic representation of the modular structure of 
PDE4A enzymes and authentication of PDE4A11 by RT-PCR.
(a) is a schematic representation of the key regions of a full length PDE4A 
enzyme. The unique N-terminal regions are shown for PDE4A4B (hashed, 
blue) (GenBank accession number L20965), PDE4A10 (hashed, red) 
(GenBank accession number AF110461) and PDE4A11 (hashed, green) 
(GenBank accession number AY618547). Note the common long form region 
(CLFR) located between the unique N-terminal region and UCR1 regulatory 
module. Also shown is the position for the primers used for RT-PCR. The 
generic PDE4A primers were designed to anneal to regions common to all 
PDE4A long isoforms, i.e. the UCR2 regulatory module and the catalytic unit. 
Assuming the PDE4A11 ATG start codon in the open reading frame is 
assigned nucleotides 1, 2 and 3 respectively then the 4A11 NT sense primer 
anneals at nucleotides 1 -  25, the UCR1 anti-sense primer anneals at 
nucleotides 471 -  497, and the 4A LR2 anti-sense primer anneals at 
nucleotides 859 -  886. The sequences of the primers and the primer pairs 
used for each RT-PCR are shown in Table 2.3 on Page 70 of Chapter 2, 
Materials and Methods, (b), shows the identification of PDE4A11 as an 
authentic PDE4A long isoform by RT-PCR from mRNA isolated from HEK293 
cells (top panel) and brain tissue (bottom panel). In both figures, track 1 
shows the RT-PCR products generated using the generic PDE4A sense and 
anti-sense primers. These were designed to amplify a 506bp product from 
the common UCR2 region to the catalytic unit. Tracks 2 and 3 show the RT- 
PCR products using the PDE4A11 N-terminal sense primer with either the 4A 
UCR1 anti-sense primer or the 4A LR2 anti-sense primer. These were 
designed to amplify products of 497bp and 886bp respectively. These data 
are from experiments done once.
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Figure 3.4 -  Expression profile of PDE4A11 by PCR using a cDNA panel 
derived from various human tissues.
cDNA derived from various human tissues was used to assess the distribution 
of transcripts for PDE4A11. PCR was undertaken using the 4A11 NT sense 
primer (nucleotides 33 -  50) and the 4A LR1 anti-sense primer (nucleotides 
507 -  527). The annealing positions of these primers are presented in Figure 
3.3(a). These primers were designed to amplify a 494bp product. These data 
are representative of experiments done twice.
I
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Figure 3.5 -  Expression of recombinant PDE4A11 in COST cells.
(a), left panel, shows a Western blot of whole cell lysate from COST cells that 
had been transfected with a plasmid allowing mammalian expression of 
human PDE4A1, PDE4A4B, PDE4A10 or the novel PDE4A11. In these cells 
immune-reactive bands at approximately 85kDa (PDE4A1) and 125kDa 
(PDE4A4B, PDE4A10 and PDE4A11) were identified using a specific anti­
serum that detects the conserved C-terminal region of all active PDE4A 
isoforms, (a), right panel, shows the same Western blot re-probed with an 
anti-serum specific to the unique N-terminal region of PDE4A11. This detects 
a single, 125-kDa protein in the lane containing cell lysate over-expressing 
human PDE4A11. (b), shows the distribution of PDE4A11 when transiently 
over-expressed in COST cells. COST cells were transfected to transiently 
express PDE4A11 before sub-cellular fractionation. This method, described 
previously [McPhee et al., 1995], separates the total cellular matter into the 
soluble, cytosolic cellular components (high-speed supernatant or S2), the 
plasma membrane and internal organelles (high-speed pellet or P2), and 
intact cells and other cellular debris (low-speed pellet or PI). Table 3.1 shows 
the quantification of the distribution of all the active human PDE4A isoforms 
over-expressed in COST cells. (c), shows laser-scanning confocal 
microscopy analysis of the PDE4A11 distribution in COST cells. COST cells 
were transfected to express PDE4A11 and then visualised immunologically 
using the PDE4A C-terminal specific anti-serum to evaluate the localisation of 
this novel isoform. All data shown are examples of experiments done at least 
three times with different cellular transfections.
138
Chapter 3 Characterisation of a novel PDE4 isoform, PDE4A11
Sub-cellular
Fraction PDE4A1* PDE4A4B* PDE4A10* PDE4A11
PI 22 +/- 6 19 +/- 4 7+ /-4 30 +/- 3
P2 63 +/- 8 26 +/- 3 10+/-7 27 +/- 4
S2 15+/-5 55 +/- 5 83 +/- 7 43 +/- 3
139
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Table 3.1 -  Distribution of PDE4A isoforms in COST cells.
COST cells were transfected to transiently express each isoform before sub- 
cellular fractionation into high-speed supernatant (S2), high-speed pellet (P2), 
and low-speed pellet (P1). The distribution of each isoform was determined 
by quantitative immuno-blotting and is expressed as a percentage of the total 
cellular expression. *Data here for the distribution of PDE4A1 [Sullivan et al., 
1998], PDE4A4B [McPhee et al., 1999] and PDE4A10 [Rena et al., 2001] as 
reported previously. These data are given as means +/- standard deviation 
for at least three different transfections and experiments.
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Figure 3.6 -  PDE4A11 translocation to the plasma membrane of COST 
cells following stimulation with EGF.
■Ï(a), top panels, are Western blots showing the endogenous activation time 
course of Akt (Protein Kinase B; PKB) in COST cells following treatment with 
EGF, at various increasing concentrations (10, 20 and 50ng/ml), between 0 
and 30min. The activation of Akt was detected using a phospho-specific anti­
serum to one of the phosphorylation sites required for Akt activation, (a), 
bottom panels, are Western blots showing the total endogenous expression 
levels of Akt in COST cells and also functions as loading controls for the 
activation time courses. PDE4A11 was transiently expressed in COST cells. 
The cells were stimulated with the various concentrations of EGF for 30min. 
The cells were then harvested and sub-cellular fractions produced by 
centrifugation. This method, described previously [McPhee et al., 1995], 
separates the total cellular matter into the soluble, cytosolic cellular 
components (high-speed supernatant or S2), the plasma membrane and 
internal organelles (high-speed pellet or P2), and intact cells and other cellular 
debris (low-speed pellet or PI), (b), shows Western blots probed with the C- 
terminal PDE4A-specific anti-serum to evaluate the effect of increasing EGF 
concentrations on the sub-cellular distribution of PDE4A11 in COST cells, (c).
is the quantification of these Western blots to reflect any change in the COST 
cellular distribution of PDE4A11 within each sub-cellular fraction (total 
PDE4A11 expression equals 100%). All data shown are either representative 
Western blots of three separate transfections and sub-cellular fractionations, 
or mean quantification data +/- standard deviation of the three separate 
transfections and sub-cellular fractionations. Two-Sample t-test statistical 
analysis of the quantification data were undertaken, where p < 0.05 indicates 
a statistically significant difference in the relative PDE4A11 immuno-reactivity 
within the P2 sub-cellular fraction between untreated and treated cells, as 
indicated.
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Figure 3.7 -  PDE4A11 translocation to the plasma membrane of HEK293 
cells following stimulation with insulin.
(a), top panels, are Western blots of the endogenous activation time 
course of Akt (Protein Kinase B; PKB) in HEK293 cells following treatment 
with insulin, at increasing concentrations (0.1, 1 and lOnM), between 0 and
Western blots probed with the C-terminal PDE4A-specific anti-serum to 
evaluate the effect of increasing insulin concentrations on the sub-cellular
Î
15min. The activation of Akt was detected using a phospho-specific anti­
serum to one of the phosphorylation sites required for Akt activation, (a),
bottom panels, are Western blots representing the total endogenous 
expression levels of Akt in HEK293 cells and also functions as loading 
controls for the Akt activation time courses. PDE4A11 was transiently 
expressed in HEK293 cells. The cells were stimulated with the increasing 
concentrations of insulin for 15min. The cells were harvested and sub-cellular 
fractionated as described previously [McPhee et al., 1995]. (b), shows
distribution of PDE4A11 in HEK293 cells, (c), is the quantification of these
Western blots to assess any change in the HEK293 cellular distribution of 
PDE4A11 within each sub-cellular fraction (total PDE4A11 expression equals 
100%). All data shown are either representative Western blots of two 
separate transfections and sub-cellular fractionations. Mean quantification
data of the Western blots +/- standard deviation are representative of the two 
separate transfections and sub-cellular fractionations. Two-Sample t-test 
statistical analysis of the quantification data were undertaken, where p < 0.05 
indicates a statistically significant difference in the relative PDE4A11 immuno- 
reactivity within the P2 sub-cellular fraction between untreated and treated 
cells, as indicated.
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Figure 3.8 -  Chemical structures of the common PDE4 inhibitors.
Structures taken from Houslay et al., 2005.
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Figure 3.9 -  Inhibition of PDE4A11 by selective PDE4 inhibitors.
C0S7 cells were transfected to transiently express each isoform before sub- 
cellular fractionation into high-speed supernatant (S2) and high-speed pellet I
(P2). PDE4 activity assays were done using 1pM cAMP as substrate against 
a range of inhibitor concentrations, as indicated. The data presented here are 
mean values +/- standard deviation of three separate transfections, sub- 
cellular fractionations and activity assays. The determinations of the 
respective IC50 values for each inhibitor are shown in Table 3.2.
%
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Inhibitor PDE4A4B (S2) PDE4A4B (P2) PDE4A10 (S2) PDE4A11 (S2) PDE4A11 (P2)
Rolipram 1.31 + / -  0.08 0.26 +/- 0 .09 0 .1 3 + /-0 .0 3 0.72 +/- 0 .08 0.66 + /-0 .1 2
Ariflo 0.061 +/- 0 .007 0.059 +/- 0 .004 0 .064 +/- 0.009 0.034 +/- 0.005 0.034  +/- 0.005
Denbufylline 0.56 + /-  0.30 0.46 +/- 0 .20 0.59 +/- 0.17 0.25 +/- 0 .06 0.31 +/- 0 .04
Ro 20-1724 2 .9 3 + /-  1.16 2.90 + /-0 .1 0 1.24 + /- 0.07 0 .9 9 + /-0 .1 1 0.91 +/- 0 .07
Roflumilast 0 .0 0 9 0 + /-0 .0 0 1 6 0.0025 +/- 0 .0009 0.0041 +/- 0.0008 0.0048 +/- 0 .0004 0.0039 +/- 0 .0002
s
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Table 3.2 -  IC50 values for inhibition of PDE4A11 by PDE4 selective 
inhibitors.
C0S7 cells were transfected to transiently express each isoform before sub- 
cellular fractionation into high-speed supernatant (S2) and high-speed pellet 
(P2). Assays were done using IpM cAMP as substrate against a range of 
inhibitor concentrations as indicated in Figure 3.7. Data is only shown for 
PDE4A10 expressed in the high-speed supernatant fraction (S2), as the 
majority (approximately 83%) of this isoform is soluble [Rena et al., 2001], as ï|
shown in Table 3.1. These data are given as IC50 values in micro-molar (pM) t
concentrations and are mean values +/- the standard deviation from three f
separate transfections, sub-cellular fractionations and activity assays.
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Figure 3.10 -  Thermo-stability of PDE4A11.
I
Recombinant PDE4A11 was transiently expressed in C0S7 cells before 
fractionation of the cells into high-speed supernatant (S2; blue) and high­
speed pellet (P2; red). Fractions were incubated at 55°C for the indicated
times and then assayed for PDE4 activity using 1 pM cAMP as substrate. The 
log% residual activity was calculated and plotted as a function of increasing 
time. The half-life (ti/2) was determined as the time at which 50% of the total 
PDE4 activity at time zero remained. Data shown are from three separate 
experiments using fractions from three separate transfections and are 
expressed as mean values +/- standard deviation. Two-Sample t-Test 
statistical analysis of the determined half-life values for thermo-stability was 
undertaken, where p < 0.05 indicates a statistically significant difference 
between PDE4A11 sub-cellular fractions.
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Figure 3.11 -  Phosphorylation and activation of PDE4A11 by PKA.
C0S7 cells were transfected to transiently express human PDE4A11. The 
transfected cells were pre-treated for 10min with the non-specific PDE 
inhibitor IBMX (100pM) before challenge, 0-20min, with the adenylyl cyclase 
activator forskolin (100pM). (a), top panel, is a Western blot probed with a 
specific anti-serum to the PKA phosphorylated serine residue in within the 
UCR1 regulatory module (herein referred to as phospho-UCR1) (a), bottom 
panel, shows the same Western blot re-probed with the PDE4A C-terminal 
specific anti-serum to provide both loading and PDE4A11 expression controls.
(b), top panel, is a Western blot probed with the phospho-UCR1 anti-serum.
C0S7 cells over-expressing PDE4A11 were pre-treated as above with IBMX 
and challenged with forskolin for 10 and 20min. This 20-min forskolin 
challenge was repeated in the presence of increasing concentrations of the 
PKA inhibitor H89 (0.1, 1 and lOpM). (b), bottom panel, shows the same 
Western blot re-probed with the PDE4A C-terminal specific anti-serum to 
provide both loading and PDE4A11 expression controls. The plasmid 
encoding wild type human PDE4A11 was engineered to express PDE4A11 
with the target phosphorylation Ser-119-Ala. The PKA phosphorylation time 
course described above was repeated with C0S7 cells transfected to 
transiently express the mutant form, (c), top panel, is a Western blot probed 
with the phospho-UCRI anti-serum and, bottom panel, is the same Western 
blot re-probed with the PDE4A C-terminal specific anti-serum to provide both 
loading and PDE4A11 expression controls, (d), shows the densitometry of 
the Western blots showing the PKA phosphorylation time course of PDE4A11.
These data are expressed as a percentage of the maximum phosphorylation,
■where the phospho-UCRI densitometry is corrected for PDE4A11 expression.
(e), shows the effect of the PKA phosphorylation on PDE4A11 catalytic 
activity. Assays were done using IpM cAMP as substrate with COS7 cell 
lysates expressing equal immuno-reactive amounts of PDE4A11, as 
determined by the quantification of PDE4A11 expression. All data shown are 
either representative Western blots of three separate transfections and 
experiments, or mean data +/- standard deviation of three separate 
transfections and experiments.
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Figure 3.12 -  Phosphorylation of PDE4A11 in C0S1 cells following 
stimulation with EGF.
three separate transfections and experiments, or mean data +/- standard 
deviation of the three separate transfections and experiments. Paired t-test
"iI
s
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■ti,
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C0S1 cells were transfected to over-express PDE4A11 and the cells were 
stimulated with EGF (50ng/ml) for up to 30min. (a), top panel, is a Western 
blot showing an EGF time course (0-30min) of endogenous ERK1/2 activation ,
in G0S1 cells. ERK1/2 activation was detected using a phospho-specific anti­
serum to the phosphorylation sites required for activation, (a), bottom panel, 
is a Western blot showing the total, endogenous levels of ERK1/2. C0S1 
cells were transfected to transiently express PDE4A11. The transfected cells 
were grown in phosphate-free media radio-labelled with pP]-orthophosphate.
The cells were retained as either untreated, stimulated with EGF for 30min 
alone or EGF in the presence of the MEK inhibitor, U0126 (10pM). The cells 
were harvested and PDE4A11 was immuno-precipitated using the C-terminal 
PDE4A-specific anti-serum conjugated to Protein G agarose resin. Protein G 
agarose resin was used alone as an immuno-precipitation control. The 
immuno-precipitated proteins were separated by SDS-PAGE and transferred 
to a nitrocellulose membrane where the radioactive proteins were resolved 
using phosphor image screen technology, (b), top panel, is a phosphor 
screen image of the phosphorylation status of PDE4A11 following immuno- 
precipitation from (un)treated whole cell lysates, (b), bottom panel, is a 
Western blot showing the relative immuno-reactive amounts of PDE4A11 
extracted from the cell lysate by immuno-precipitation. The level of
phosphorylation was quantified and corrected for the relative level of
PDE4A11 immuno-precipitated. (b), graph, quantifies the level of PDE4A11 
phosphorylation, in comparison to no treatment (100%), following EGF
stimulation of C0S1 cells. Also shown is the quantification of the effect of
ERK1/2 inhibition by U0126 on PDE4A11 phosphorylation, (c), top panel, is a 
Western blot showing the activation and inhibition of ERK1/2, as detected 
using the phospho-specific anti-serum, and (c), bottom panel, shows the total 
level of endogenous ERK1/2 expression in the C0S1 cell lysates. All data 
shown are either representative phosphor screen images or Western blots of
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statistical analysis of the quantified phosphorylation data were undertaken, 
where p < 0.05 indicates a statistically significant difference in the level of wild 
type PDE4A11 phosphorylation between untreated and treated cells, as 
indicated.
■tîi
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Figure 3.13 -  Phosphorylation of PDE4A11 in C0S1 cells following 
stimulation with phorbal 12-myristate 13-acetate (PMA).
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C0S1 cells were transfected to over-express PDE4A11 and stimulated with 
PMA (lOOnM) for 20min. The transfected cells were grown in phosphate-free 
media with phosphate re-introduced by the addition of pP]-orlhophosphate.
The cells were stimulated with PMA for 20min alone and in the presence of 
the MEK inhibitor, U0126 (lOpM). The cells were harvested and PDE4A11 
was immuno-precipitated using the C-terminal PDE4A-specific anti-serum 
conjugated to Protein G agarose resin. Protein G agarose resin was used 
alone as an immuno-precipitation control. The immuno-precipitated proteins 
were separated by SDS-PAGE and transferred to a nitrocellulose membrane 
where the radioactive proteins were resolved using phosphor image screen 
technology, (a), top panel, is a phosphor screen image of the phosphorylation 
level of PDE4A11 following immuno-precipitation from (un)treated cell lysates.
(a), bottom panel, is a Western blot showing the relative immuno-reactive 
amounts of PDE4A11 extracted from the cell lysate by immuno-precipitation.
(a), graph, quantifies any change in PDE4A11 phosphorylation in C0S1 cells,
,compared to no treatment (100%), following PMA stimulation. Similarly, the 
effect of ERK1/2 inhibition by U0126 on PDE4A11 phosphorylation is also 
quantified, (b), top panel, shows the activation and inhibition of ERK1/2, as 
detected using the phospho-specific anti-serum to the phosphorylation sites 
required for activation. The level of phosphorylation was quantified and 
corrected for the immuno-reactive level of PDE4A11 immuno-precipitated.
(b), bottom panel, shows the total level of endogenous ERK1/2 expression in 
the COS1 whole cell lysates. All phosphor screen images and Western blots 
are representative of two separate transfections and experiments. Mean 
quantification data +/- standard deviation are also the products of the two 
separate transfections and experiments. Paired t-test statistical analysis of 
the quantified phosphorylation data were undertaken, where p < 0.05 
indicates a statistically significant difference in the level of wild type PDE4A11 
phosphorylation between untreated and treated cells, as indicated.
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Figure 3.14 -  E.coli expression and purification of recombinant GST- 
tagged LynSH3 and GST-tagged p-arrestin2.
Coomassie® staining of SDS polyacrylamide gels showing the E.coli 
expression of recombinant Gluathione-S-Transferase (GST) fusion proteins. 
The proteins expressed were the SH3 domain of the tyrosyl kinase Lyn 
(LynSH3), panel (a), and the signalling scaffold protein p-arrestin2, panel (b). 
Briefly, competent E.coli BL21 pLysS (DE3) cells were transformed with 
pGEX plasmids encoding either GST-LynSH3 or GST-p-arrestin2. 
Expression of the proteins was induced with 0.2mM lsopropyl-f3-D- 
thiogalactopyranoside (IPTG) for 4h at 30°C. The cells were collected, re­
suspended in lysis buffer and subjected to sonication to produce total cell 
extract (P). The soluble proteins were isolated by centrifugation (8). The 
expressed recombinant GST fusion proteins were purified using glutathione 
sepharose resin and eluted using excess glutathione (10mM). Fractions of 
the GST fusion proteins remained unbound to the glutathione sepharose resin 
(Unb) whereas a significant proportion bound could be purified to a single 
band as detectable by Coomassie® staining of the SDS polyacrylamide gels 
(Purified). These gels represent the single successful expression experiment 
undertaken for both proteins in E.coli.
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(a) ... GST Lyn-SH3 Lyn-SH3 
V/ Unbound Bound
PDE4A4B
(ii)
♦  * PDE4A4B peptide array (Met1 to Ser85) 
Unique N-terminal regionMEPPTVPSERSLSLSLPGPREGQATVPSERSLSLSLPGPREGQATLKPPP
SLSLSLPGPREGQATLKPPPQHLWR
LPGPREGQATLKPPPQHLWRQPRTP
EGQATLKPPPQHLWRQPRTPIRIQQ
LKPPPQHLWRQPRTPIRIQQRGYSD
QHLWRQPRTPIRIQQRGYSDSAERA
QPRTPIRIQQRGYSDSAERAERERQ
IRIQQRGYSDSAERAERERQPHRPI
RGYSDSAERAERERQPHRPIERADA
SAERAERERQPHRPIERADAMDTSD
ERERQPHRPIERADAMDTSDRPGLR
PHRPIERADAMDTSDRPGLRTTRMS
(iii)
# # # PDE4A4B peptide array (Tyr286 to Asn345) 
Linker region 2YISTTFLDKONEVEIPSPTMKEREKFLDKQNEVEIPSPTMKEREKOQAPR
NEVEIPSPTMKEREKQQAPRPRPSQ
PSPTMKEREKQQAPRPRPSQPPPPP
KEREKQOAPRPRPSQPPPPPVPHLQ
QQAPRPRPSQPPPPPVPHLQPMSQI
PRPSQPPPPPVPHLQPMSQITGLKK
PPPPPVPHLQPMSQITGLKKLMHSN
(iv)
•  # PDE4A4B peptide array 
(Val806 to Ala855)VSHSSPSALALQSPLLPAWRTLSVS
C-terminal region
LPAWRTLSVSEHAPGLPGLPSTAAE
LSVSEHAPGLPGLPSTAAEVEAQR
EHAPGLPGLPSTAAEVEAQREHQAA
(b) # # PDE4A10 peptide array (Met1 to Glu50) 
Unique N-terminal regionMRSGAAPRARPRPPALALPPTGPESAPRARPRPPALALPPTGPESLTHFP
PRPPALALPPTGPESLTHFPFSDED
LALPPTGPESLTHFPFSDEDTRRHP
TGPESLTHFPFSDEDTRRHPPGRSV
LTHFPFSDEDTRRHPPGRSVSFEAE
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(c)
(i) GST Lyn-SH3 Lyn-SH3 Unbound Bound
(ii)
# # # # »
PDE4A11
PDE4A11 peptide array 
(Ala17 to Leu65) 
Unique N-terminal regionAFPVAVAAEDEAFLPEPLAVAAEDEAFLPEPLAPRAPR
EAFLPEPLAPRAPRRPRSP
EPLAPRAPRRPRSPPSSPV
RAPRRPRSPPSSPVFFASP
PRSPPSSPVFFASPSPTFR
SSPVFFASPSPTFRRRLRL
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Figure 3.15 -  Interaction of PDE4A long isoforms with the SH3 domain of 
the Src tyrosyl kinase, Lyn.
Pull-down assays were used to probe the interaction of the purified GST- 
LynSHS, immobilised on glutathione sepharose resin, with C0S7 cell lysate 
expressing equal immuno-reactive amounts of either PDE4A4B or PDE4A11, 
as determined using the C-terminal PDE4A-specific anti-serum, (a), panel (i), 
and (c), panel (i), shows the interactions of GST-LynSH3 with PDE4A4B or 
PDE4A11 respectively (Lyn-SH3 Bound). As a control, the pull-down of 
PDE4A4B or PDE4A11 with GST alone was compared (GST). To directly 
compare the interaction of PDE4A4B and PDE4A11 with GST-LynSH3, the 
cell lysate following the pull-down assay was also probed for PDE4A using the 
C-terminal PDE4A-specific anti-serum (Lyn-SH3 Unbound). This analysis |
was undertaken as described previously for PDE4A4B [McPhee et al., 1999] 
and PDE4A10 [Rena et al., 2001]. (a), panels (ii) -  (iv), map the interaction "M'sites of GST-LynSH3 on full-length PDE4A4B using peptide array technology.
Briefly, the entire PDE4A4B peptide sequence was synthesised on a 
membrane and the membrane incubated with the purified GST-LynSH3. The 
membrane was then essentially treated as a Western blot and probed for 
GST-LynSH3 binding using a GST-specific anti-serum, (b), and (c), panel (ii), 
shows similar peptide array analysis of the GST-LynSH3 binding sites on the 
unique N-terminal and UCR1 of PDE4A10 and PDE4A11 respectively. All 
Western blots shown are representative of the results obtained from three |
separate experiments. The peptide array interaction data are from 
experiments done once.
-I
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Figure 3.16 -  Interaction of PDE4A4B and PDE4A11 with the ^-arresting 
signalling scaffold protein.
Pull-down assays were used to probe the interaction of the purified GST-(3- 
arrestin2, immobilised on glutathione sepharose resin, with COS7 cell lysate 
expressing equal immuno-reactive amounts of either PDE4A4B or PDE4A11, 
as determined using the C-terminal PDE4A-specific anti-serum, (a) and (b) 
show the interactions of GST-p-arrestin2 with PDE4A4B or PDE4A11 
respectively. As a control, the pull-down of PDE4A4B or PDE4A11 with GST 
alone was compared (GST). All Western blots shown are representative of 
the results obtained from three separate experiments.
.s'
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Figure 3.17 -  Interaction of PDE4A4B and PDE4A11 with the 
Immunophilin XAP2.
C0S7 cells co-expressing untagged PDE4A4B or PDE4A11, and FLAG- 
tagged XAP2 were harvested. The FLAG-tagged XAP2 was immuno-purified 
using anti-FLAG agarose. The interaction of PDE4A4B or PDE4A11 with 
XAP2 was detected by probing the immuno-purified protein complexes with
' Ithe C-terminal PDE4A-specific anti-serum. (a), top panel, shows the 
expression of PDE4A4B in C0S7 cell lysate and the interaction of PDE4A4B 
with XAP2 following immuno-precipitation. As a control, anti-vsv agarose was 
used to determine the level of PDE4A4B non-specific interactions, (a), bottom 
panel, shows the immuno-reactive amounts of FLAG-tagged XAP2 expressed 
in C0S7 cells, interacting with anti-vsv agarose, and immuno-precipitated 
respectively, (b), top panel, shows the interaction between PDE4A11 and 
XAP2. Similarly, anti-vsv agarose was used as the control, (b), bottom panel, 
shows the immuno-precipitation of XAP2 and the initial expression in C0S7 
cells. As before, non-specific immuno-precipitation of FLAG-tagged XAP2 
was assessed in the control lane. All Western blots shown are representative 
of the results obtained from three separate experiments. I
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3.3 Discussion
cAMP signalling is the classical paradigm of the second messenger, 
participating in intra-cellular signal transduction pathways through a plethora 
of signalling molecules, allowing the cell to tailor specific responses to 
particular extra-cellular stimuli [Houslay and Milligan, 1997]. Intra-cellular 
cAMP is not homogeneously distributed within cells but exists in functionally 
relevant locals [Zaccolo and Pozzan, 2002 and Mongillo et al., 2004]. 
Numerous isoforms of both adenylyl cyclases and cAMP-specific PDE4s are 
responsible for the production and degradation of cAMP [Sunahara and 
Taussig, 2002 and Zhang et al., 2005]. The relationship between these 
enzymes provides the dynamic control of intra-cellular cAMP concentration 
[Houslay and Milligan, 1997 and Willoughby and Cooper, 2005]. There are 
now over twenty isoforms of PDE4 enzymes, some of which have been 
recently identified, and these primarily differ in their N-terminal region, which 
is responsible for intra-cellular targeting [Houslay et al., 1998, Shepherd et al., 
2003, Wallace et al., 2005 and Richter et al., 2005]. Each isoform must play a 
distinct role in generating cAMP compartmentalisation within cells in which 
they are expressed, and herein lays the rationale for such an abundance of 
PDE4 isoforms.
The presence of a third novel PDE4A long isoform was indicated from 
the sequencing and analysis of the PDE4A gene locus [Sullivan et al., 1998]. 
This highlighted a putative PDE4A exon located between the exons for 
PDE4A4B and PDE4A10, which is now known as the exon encoding the third 
long isoform, PDE4A11 (Figure 3.1a). The position of this exon was 
sufficiently distant from the upstream PDE4A4B encoding exon that the 
intronic sequence could theoretically support the interaction of DNA 
transcription complexes (Figure 3.1b). Analysis, in a luciferase reporter 
assay, of the Ikb region immediately preceding the ATG start codon, and 
deletions therein, identified the first 250bp as the functional promoter region 
for PDE4A11, with the second 250bp negatively impacting promoter activity, 
indicating a possible level of transcription repression [Wallace et al., 2005].
171
172
Chapter 3 Characterisation of a novel PDE4 isoform, PDE4A11
The promoter regions of some PDE4 isoforms contain a CRE, which conforms | |
to the general consensus sequence 5’-TGACGTCA-3’ [Mayr and Montminy,
2001, Rena et al., 2001 and Le Jeune et al., 2002]. The promoter regions of ^
these PDE4S also contain Stimulating protein 1 (Spl) binding sites, which are 
typical of genes that do not contain a TATA box [Le Jeune, 2002, Rena et al.,
2001]. Spl binding sites are generally located within GG-rich regions. The 
first 250bp region responsible for PDE4A11 promoter activity boasts up to six 
putative Sp1 binding sites, together with a number of binding sites for other 
transcription factors [Wallace et al., 2005]. Taken together these data 
indicates that the sequence immediately upstream of the PDE4A11 ATG start 
codon is sufficient for driving protein expression.
The unique N-terminal region of PDE4A11, encoded by the novel exon, 
is comprised of 81 amino acids that are substantially conserved across 
species including mouse, rat, bat and pig (Figure 3.2). In mouse and rat, the 
amino acid sequences are only 66 residues in length compared to the protein 
encoded by the human gene. In fact, only 50% of the human residues are ■i;?'conserved in rodents. The bat and pig PDE4A11 N-terminal sequences are 
approximately 77 amino acids in length and 80% of these are conserved with 
the human form. It will be interesting to ascertain whether the rat homologue 
of PDE4A11 has strikingly different properties because of sequence 
divergence at either extremity of the protein.
IRT-PCR utilising primers to the unique N-terminal region of PDE4A11, 
and across splice junctions to the PDE4A common regions, was a simple 
method of authenticating the existence of the PDE4A11 isoform. This allowed 
the detection of PDE4A11 transcripts in HEK293 cells and in an abundance of 
human tissues (Figure 3.3b and 3.4). PDE4A isoforms are known to be 
differentially expressed in many immune and inflammatory cells [Barber et al., "f2004, Shepherd et al., 2004, Abrahamsen, et al., 2004]. PDE4A11 provides
the major PDE4A transcript level in immune and inflammatory cells, and also |
in bronchial epithelia and bronchial smooth muscle, with the level of 
PDE4A4B transcripts generally in lowest abundance throughout [Wallace et 
al., 2005]. It is possible that this could be due to the reduced promoter activity
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of PDE4A4B compared to PDE4A10 and PDE4A11 [Wallace et al., 2005]. 
Subsequently to these studies, a PDE4A11 specific anti-serum was
Isuccessfully generated (Figure 3.5a) and in a future study should be used to immunologically assess the endogenous distribution of PDE4A11 in many cell 
types, because invariably transcript levels do not accurately reflect protein
■€expression.
Transient over-expression of PDE4A isoforms in mammalian cells 
shows distinct intra-cellular localisation per isoform (Table 3.1). PDE4A1 is 
predominantly membrane-bound, and this interaction is mediated through a 
novel helix-hinge-helix domain, known as TAPAS-1, which binds PA in 
phospho-lipid bi-layer of membranous structures [Smith et al., 1996 and 
Baillie et al., 2002]. PDE4A4B is can localise as both a soluble cytosolic and
membrane-bound protein [Huston et al., 1996]. On the other hand, PDE4A10 
is predominantly a soluble protein located within the cytosol of the cell with
minor association with cellular organelles [Rena et al., 2001]. How do similar 
structures exhibit such diverse intra-cellular localisations? The point of 
structural divergence of PDE4A isoforms, coupled with the differential 
inclusion of the UCR regulatory modules, is their unique N-terminal regions, 
and these confer their sub-cellular targeting [Beard et al., 2002 and Houslay 
and Adams, 2003]. From sub-cellular fractionation experiments a soluble and 
particulate component of PDE4A11 was identified (Figure 3.5b). These data 
should always be interpreted with caution, as cellular disruption may result in 
PDE4A11 release from particulate structures, biasing the intra-cellular 
distribution profiles. Yet, if this were indeed the case, it is likely that a 
significantly greater proportion of PDE4A1 and PDE4A10 would be released 
to the cytosolic compartment of the cell when their intra-cellular distribution fywere assessed in a similar manner. Visualisation of PDE4A11 intra-cellular A:localisation using the human PDE4A C-terminal antibody conjugated to a 
fluorescent probe and laser-scanning confocal microscopy of the intact cell, 
we see that PDE4A11 cannot traverse the nuclear membrane, but is widely 
distributed across the peri-nuclear region and can associate distinctly in 
membrane ruffles at the cell margins (Figure 3.5c).
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Rolipram is the archetypal PDE4-selective inhibitor. In cells chronically 
treated with rolipram, over-expressing a GFP chimera of PDE4A4B, results in 
a severe redistribution into accretion foci [Terry et al., 2003]. It is proposed
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Analysis of the N-terminal region of PDE4A11 revealed a possible 
PIP3-binding PH domain. PH domains can bind with moderate or high affinity 
with phospho-inositides (PI), which are integral components of the lipid bi­
layer of the plasma membrane. PIP2 is formed from PI by the action of PI-4K 
and PI-5K. The generation of PIP3 from PIP2 is catalysed by PI-3K.
Therefore, it was hypothesised that N-terminal PDE4A11 binding of PIP3, the 
region responsible for the intra-cellular targeting of PDE4s, may cause the 
translocation of PDE4A11 from the cytosolic compartment of the cell to the 
plasma membrane [Chen et al., 2003]. Furthermore, PDE4A11 could be i l
recruited to the appropriate location in the cell through an interaction with the 
SH3 domain of PI-3K and the putative SH3 binding domain within the unique 
N-terminal region (Figure 3.15c). In cells over-expressing PDE4A11 no such 
translocation or re-distribution was concluded (Figures 3.6 and 3.7). Similarly, 
in real-time laser-scanning confocal microscopy no redistribution of PDE4A11 
was observed on stimulating PI-3K activity [E. Huston and M.D. Houslay, 
unpublished observations]. However, it is possible that the extensive over- 
expression may conceal a translocation mediated in cells where endogenous 
levels of PDE4A11 are immunologically detectable. Therefore, these ;■
■ - Vexperiments should be replicated in cells where endogenous expression can |
be detected with the novel PDE4A11 anti-serum. If these putative interactions 
were true, it could reveal the pertinent region of PDE4A11 that is responsible 
for its distinct peri-nuclear distribution and it localisation within membrane 
ruffles. In fact, PI-3K activity and the activation of the small G-protein Rac, 
are pre-requisites for membrane ruffle formation [Doughman et al., 2003 and 
Jaffe and Hall, 2005]. Furthermore, in neuronal cells, it has been observed 
that cAMP activation of PKA prevents the subsequent phosphorylation of 
PKB/Akt indicating a reduction in the activity of PI-3K [Leemhuis et al., 2004].
Therefore, it is possible that PDE4A11 is recruited to the plasma membrane 
ruffles through PIP3 binding and may exclusively control the cAMP 
concentrations in the vicinity of PI-3K, regulating its activity.
I
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that the mechanism through which this occurs is a consequence of PDE4A4B 
conformational changes [Terry et a!., 2003]. Thus, one would not expect 
PDE4A10 or PDE4A11 to form such accretion foci as they are not subject to 
conformational changes as sensed by differential rolipram inhibition (Figure 
3.9 and Table 3.2). This is indeed the case with PDE4A10 and PDE4A11, 
and serves to provide credence to PDE4A10 and PDE4A11 not able to form 
distinct PDE4 conformers and that the formation of foci is an intrinsic property 
of PDE4A4B [Wallace et al., 2005].
PDE4 enzymes are being investigated as potential drug targets and the 
inhibition of PDE4 activity may provide considerable therapeutic benefits in a 
number of disease states including asthma, COPD and rheumatoid arthritis 
[Burnouf and Pruniaux, 2002 and Giembycz, 2002]. As such, there are many 
PDE4-selective inhibitors available (Figure 3.8). Here I note that PDE4A11 is 
concentration-dependently inhibited by rolipram, Ariflo®, denbufylline, Ro 20- 
1724 and rofiumilast (Figure 3.9). Roflumilast is by far the most potent PDE4 
inhibitor across all PDE4A isoforms, 150-fold more potent than the 
conventional PDE4 inhibitor rolipram (Table 3.2). As a membrane-bound 
protein PDE4A11 does not indicate any level of conformational change, as 
sensed by an increase in sensitivity to inhibition by rolipram nor does it extend 
to any adjustment in kinetic profile with respect to Km or Vmax- This 
phenomenon does not translate to PDE4A10, leaving PDE4A4B as the only 
PDE4A isoform to be subject to conformational change [Huston et al., 1996 
and McPhee et al., 1999].
The interaction with SH3 domain containing proteins, such as the 
tyrosyl kinase Lyn, with LR2 of PDE4A4B is able to induce the associated 
conformational change. Indeed, inhibition of cytosolic PDE4A4B in the 
presence of Lyn-SH3 results in a comparable IC50 value for that of the 
particulate form [McPhee et al., 1999]. Previous data have indicated that both 
the N-terminal and LR2 binding sites for Lyn-SH3 are responsible for 
instigating the conformational change on the catalytic unit [McPhee et al.,
1999]. Therefore, it was conceived that the lack of SH3 binding domains 
within the N-terminal region of PDE4A10 and PDE4A11 resulted in reduced
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affinity for Lyn-SH3 therefore preventing these isoforms from undergoing 
conformational change [Rena et a!., 2001 and Wallace et al., 2005].
However, exploiting peptide array technology has indicated that PDE4A10 
and PDE4A11 do contain SH3 binding domains within their unique N-terminal 
region (Figure 3.15). Furthermore, the interaction of Lyn-SH3 with full length 
PDE4A4B indicates that the contribution of binding within the unique N-
'terminal region is insignificant compared to other sites within the protein. The 
interaction site for the SH3 domain of Lyn on PDE4A4B lies between Lys-306 
and Arg-340 within LR2 and this region incorporates a class I SH3 binding 
motif from Arg-315 to Pro-321, immediately followed by an extensive core 
motif proline-rich region ending at Pro-327. These data co-relate closely with 
the previously published data indicating the same region by deletion analysis 
[McPhee et al., 1999]. A second site within the sub-family specific C-terminal 
region was also identified. This region incorporates the previously identified i
Pro-819 as the initiating proline residue of a putative class I SH3 binding motif 
[McPhee et al., 1999]. This is at variance with the published data that 
postulates Pro-3, Pro-37 and Pro-61 as initiating SH3 domain binding through 
distinct class I, class II and overlapping class I & II SH3 binding motifs 
respectively [McPhee et al., 1999]. The binding site for PDE4A10 was 
formerly assigned as the PDE4A common LR2, whereby deletion of this i
region ablated any interaction with Lyn-SH3 [Rena et al., 2001]. A class I 
SH3 binding domain, commencing at Arg-8, is present within this PDE4A10 
region together with a putative core motif at Pro-20. Removal of the first three 
amino acids of the class I consensus sequence, leaving a simple core motif, 
ablated the interaction of Lyn-SH3. Likewise, the unique N-terminal of 
PDE4A11 is also able to bind Lyn-SH3. Within this region there are core SH3 
binding motifs from Pro-33 with multiple, over-lapping class I and class II SH3 
binding consensus motifs from Pro-36, which are likely to support Lyn-SH3 
binding. To accurately map the critical residues for SH3 domain interactions 
with PDE4A long isoforms scanning alanine substitution peptide array 
analyses through the interacting regions are required, as described previously 
for the competing (3-arrestin and RACK1 interactions with PDE4D5 [Bolger et 
al., 2006]. Therefore, it is entirely possible that the primary site of interaction 
of Lyn-SH3 with PDE4A long isoforms differ in such a way that they confer
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distinct functional changes upon the catalytic unit. Lyn-SH3 preferentially 
interacts, with high affinity through, the LR2 of PDE4A4B eliciting profound 
conformational changes upon the catalytic unit. Conversely, PDE4A10 and 
PDE4A11 interact with Lyn-SH3, with lower affinity, through their unique N- 
terminal binding sites and this is sufficient to prevent Lyn-SH3 interaction with 
LR2 and the accompanying conformational change in catalytic function. 
Elucidation of full-length PDE4 crystal structures, perhaps in complex with 
Lyn-SH3, as has been achieved with cAMP analogues and PDE inhibitors, will 
be key to identifying this mechanism [Lee et al., 2002 , Sung et al., 2003 and 
Xu et al., 2004].
In spite of this, some conformational alteration between the particulate 
and cytosolic forms of PDE4A11 is implied from thermal stability experiments. 
These basic experiments show particulate PDE4A11 as being structurally 
more stable than the cytosolic form (Figure 3.10). A simple explanation of this 
is the stabilisation of the particulate form through protein interactions. 
Intriguingly, this is different for both PDE4A4B and PDE4A10, which show the 
cytosolic form as the more stable species with the particulate form in a 
conformation that makes it susceptible to dénaturation [Rena et al., 2001]. 
PDE4A4B and PDE4A10 have superior thermal stability profiles than 
PDE4A11, in either sub-cellular location.
In the case of PDE4D3, PKA phosphorylation of Ser-54, contained 
within a UCR1 Arg-Arg-Glu-Ser-Phe consensus motif in all PDE4 long 
isoforms, translates to an increase in catalytic activity and a conformational 
change that is indicated by dual affinity for rolipram [Sette and Conti, 1996, 
Hoffman et al., 1998 and MacKenzie et al., 2002]. At present, PDE4D3 is the 
only isoform to exhibit distinct kinetics of inhibition by rolipram and it is widely 
accepted that this effect is not replicated in PDE4A long isoforms [MacKenzie 
et at., 2002]. PDE4A11 is phosphorylated and activated by PKA at Ser-119 
within UCR1, an effect ablated by pre-treatment with the PKA inhibitor, H89 
(Figure 3.11).
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Analysis of the PDE4A11 unique N-terminal region indicates the 
presence of a putative ERK1 phosphorylation site at Ser-48, accompanied by 
an appropriately positioned possible docking domain further towards the N- 
terminal of the enzyme. Additionally, a potential GSK-3 site positioned four 
residues towards the N-terminal of the ERK1 site could further phosphorylate 
PDE4A11, where ERK1 primes for GSK-3 [Biondi and Nebreda, 2003 and 
Doble and Woodgett, 2003]. The phosphorylation efficiency of GSK-3 is 
enhanced up to 100-fold, if a priming phosphorylation is available.
Furthermore, the phosphorylation of this site has the potential to allow 14-3-3 
proteins to interact, indicating a prospective role for PDE4A11 in cell cycle 
regulation and apoptosis. No effect on PDE4A11 phosphorylation was 
observed with EGF (Figure 3.12). Therefore, it was hypothesised that EGF 
stimulation of ERK1/2 activity may disguise the potential ERK1/GSK-3 ■7Ïphosphorylation of PDE4A11 through the activation of the PI-3K signalling 
pathway. Although EGF elicits a substantial activation of ERK, the same 
concentration also induces a robust activation of PKB/Akt (Figure 3.6a), which 
directly inhibits the kinase activity of GSK-3 [Biondi and Nebreda, 2003 and 
Doble and Woodgett, 2003]. PMA directly activates ERK1/2 without affecting |
GSK-3 activity. Unfortunately, phosphorylation of PDE4A11 through the PMA 'ii-activation of ERK1 also proved inconclusive (Figure 3.13). These 
experiments should be repeated in vitro, in the isolation of other signalling 
components to ultimately determine whether this phosphorylation is evident.
However, the putative ERK1 docking domain does not contain the paired
.iv;'basic residues that form part of the KIM located approximately three to six 
residues downstream of the Leu-Xaa-Leu (LXL) motif and concomitantly also 
lacks the Phe-Gln-Phe (FQF) motif shown to be essential for the ERK2 
phosphorylation of PDE4D isoforms [MacKenzie et al., 2000 and Sharrocks et 
al., 2000]. A novel phosphorylation of the unique N-terminal region of 
PDE4A11 will give much needed insight into its intra-cellular targeting, the 
regulation of its catalytic activity and the signal transduction pathways in 
which this particular isoform plays a crucial role.
A pertinent way of delivering protein to particular locations within the
'"vcell is through the interaction of scaffold or adaptor proteins. This is of
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particular relevance in the delivery of PDE4D5 to the pg-adrenoceptor and its 
function in the desensitisation and internalisation of the receptor [Perry et al.,
2002 and Lynch et al., 2005]. PDE4 enzymes interact with the scaffold 
protein p-arrestin through a conserved binding region with the catalytic unit 
and an exclusive binding site within the unique N-terminal of PDE4D5, 
directing specificity of interaction [Bolger et al., 2003 and Bolger et al., 2006].
On this basis, PDE4A4B and PDE4A11 are able to interact through the 
conserved binding site located within the PDE4 catalytic unit (Figure 3.16).
A similar exclusive interaction has been determined for the rat PDE4A5 
isoform with the immunophilin XAP2 [Bolger et al., 2003]. As with the 
interaction of PDE4 isoforms with p-arrestin, a common binding site is 
available through the Glu-Glu-Leu-Asp motif within UCR2, coupled with a 
functionally relevant interaction within the N-terminal domain of PDE4A5.
■■These two regions both bind XAP2, but only the unique N-terminal interaction 
confers the inhibitory effect on PDE4A5 activity. Thus, one might expect all 
PDE4 isoforms containing a complete UCR2 domain to interact with XAP2, 
where functionally these interactions may not necessarily translate into any 
alteration in catalytic activity. However, yeast-2-hybrid data confirms that 
PDE4A5 specifically interacts with XAP2, suggesting that the N-terminal 
region elicits a conformational change within the regulatory modules, gating 
the UCR2 domain for further binding. Indeed, there is a precedent for such 
regulation through widespread appreciation of the UCR modules interacting 
with each other and in addition these regions provide the point of PDE4 
enzyme dimérisation [Beard et al., 2000 and Richter and Conti, 2004].
PDE4A4B is the human homologue of rat PDE4A5 and as such contains both 
binding sites for XAP2. Therefore, it is able to interact with XAP2 in co- 
immuno-precipitation experiments (Figure 3.17a). Interestingly, PDE4A11 is 
also able to interact with XAP2, with similar affinity, indicating that XAP2 
probably binds at a second site in PDE4A11, in additional to the common 
UCR2 domain, and in so doing allows the presentation of both interaction 
domains (Figure 3.17b).
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Completing our knowledge of the diverse range of PDE4 isoforms 
expressed in all cell types can we only begin to elucidate their functional role 
in cellular signalling pathways. In this chapter, I have identified and 
extensively characterised the novel PDE4A11 isoform. In doing so, I have 
identified the subtle differences between this protein and the other PDE4A 
long isoforms, with respect to our current knowledge. PDE4A11 is kinetically 
identical to the other PDE4A long isoforms and its unique N-terminal region 
confers its intra-cellular distribution profile. Like all PDE4 long isoforms it is 
activated by PKA and is able to bind many proteins assigned as interacting 
partners to PDE4 enzymes. However, it is not subject to cleavage by 
caspase-3. PDE4A11 is not able to form distinct PDE4 conformers as 
indicated by both differential rolipram inhibition and the formation of accretion 
foci, although differences in thermal stability may indicate a degree of 
conformational shift between the membrane and cytosolic species. Further 
investigations into modifications, by phosphorylation and/or protein 
interactions is required to elucidate novel functions for this isoform. PDE4A11 
is abundantly expressed across many human tissues and is the major 
transcript provider in immune and inflammatory cells. Consequently PDE4A11 
may be of physiologic and therapeutic significance for selective PDE4 
inhibition or knockdown using siRNA.
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4.1 Introduction
4A A  Mitogen-Activated Protein Kinases
Mitogen-activated protein kinases (MAPKs) form phosphorylation 
cascades that control a variety of cellular functions including the immune and 
inflammatory response, gene regulation and cell differentiation, proliferation 
and apoptosis [Kyriakis and Avruch, 2001, Pearson et al., 2001 and Dong et 
al., 2002]. This diverse range of cellular functions alludes to the involvement 
of MAPK signalling in many disease states, including asthma and COPD, 
rheumatoid arthritis, cardiac hypertrophy and cancer [Cowan and Storey, 
2003]. This super-family of protein kinases consists of three members; extra­
cellular signal-regulated protein kinase (ERK), c-Jun N-terminal kinase (JNK) 
and p38 MAPK [Cowan and Storey, 2003]. A detailed list of the isoforms, 
alternative nomenclature, physiological substrates and function are described 
in Table 4.1. Activation of a cell surface receptor by growth factors and 
cytokines initiates these phosphorylation relay cascades through the step­
wise phosphorylation-induced conformational change and activation of a 
series of at least three MAPKs. Following receptor stimulation, the MAP 
kinase kinase kinases (MAPKKKs) are recruited, and it is at this stage where 
a high degree of cross talk occurs between the three cascades. The Raf 
isoforms for the downstream activation of ERK1/2 are the most commonly 
studied MAPKKKs, which are recruited to the plasma membrane by the 
GTPase, Ras [Daum et al., 1994 and Kolch, 2005]. MAPKKK phosphorylation 
and activation of the downstream MAP kinase kinases (MAPKKs) induces the 
dual phosphorylation and activation of the MAP kinases (MAPK). MAPK 
kinase phosphorylation occurs at a serine or threonine residue and a tyrosine 
residue within the consensus motif [Ser/Thr]-Xaa-Tyr. It is at this level where 
greatest specificity is conferred across the three signalling pathways [Cowan
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and Storey, 2003]. The intermediate amino acid residue (Xaa) within this 
phosphorylation motif controls the specificity of kinase activation, where the 
presence of glutamate confers ERK, proline confers JNK, and glycine confers 
p38 MAPK [Hommes et ai., 2003]. Signalling specificity through ERK is 
achieved by MAPKK1 and MAPKK2, and via JNK through MAPKK4 and 
MAPKK7 [Dong et al., 2002]. p38 MAPK is directly activated through
MAPKK3 and MAPKK6 [Dong et al., 2002]. Cross talk occurs between the 
JNK and p38 MAPK pathways through MAPKK4, which is able to activate 
both downstream MAPKs [Ho et al., 2003]. MAPKs direct the incorporation of 
phosphate groups at specific serine and threonine residues contained within a 
minimal consensus motif, and in some cases the presence of additional 
docking sites are required for target protein specificity [Tanoue et al., 2000, 
Sharrocks et al., 2000, Tanoue and Nishida, 2003 and Biondi and Nebreda, 
2003]. Target proteins for phosphorylation by MAPKs are wide and varied, 
and include further downstream protein kinases within the same cascade and 
other protein kinases participating in alternative pathways [Houslay and Kolch,
2000]. Similarly, signalling enzymes such as PDE4s, scaffold and adaptor 
proteins such as (3-arrestins, and the modulation of gene expression through 
the phosphorylation of transcription factors, are also targets for MAPKs 
[Lefkowitz and Shenoy, 2005].
4,1.2 p38 Mitogen-Activated Protein Kinase
‘k-The p38 MAPK signalling cascade is a key signal transduction pathway 
involved in the control of cellular immune, inflammatory and stress responses 
[Tibbies and Woodgett, 1999, Dong et al., 2002 and Hommes et al., 2003]. 
There are four isoforms of p38 MAPK encoded by four distinct genes, as 
shown in Table 4.1, which show cell type specific patterns of endogenous 
expression [Kyriakis and Avruch, 2001 and Hommes et al., 2003]. The a and 
p isoforms are ubiquitously expressed, with the a isoform predominating in 
immune and inflammatory cells. The y (skeletal muscle) and 5 (lungs, 
kidneys, testis, pancreas, and small intestine) isoforms have a more restricted 
expression pattern, as indicated in parenthesis.
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4.1.2.1 Activation and Inhibition of p38 MAPK
p38 MAPKs are activated by a variety of extra-cellular stimuli such as 
growth factors, ultra-violet light, ionising radiation, oxidative stress, osmotic 
shock, and cytokines, as shown in Figure 4.1 [Cowan and Storey, 2003, Dent 
et al., 2003, Dodeller and Schulze-Koops, 2006 and Xu et al., 2006]. The 
activation of this 38kDa protein kinase occurs through the direct 
phosphorylation by upstream kinases such as MAPKK3, MAPKK4 and 
MAPKK6, the regulation of which is poorly understood. All isoforms are 
activated by MAPKK6 whereas MAPKK3 only activates the a and p isoforms. 
These kinases phosphorylate p38 MAPK at two residues essential for kinase 
activity, namely Thr-180 and Tyr-182, with specificity for p38 MAPK driven by 
Gly-181. Anisomycin, Figure 4.5, is a protein synthesis inhibitor and a 
commonly used agent that can initiate a robust activation of p38 MAPK 
activity in many cells through synergistic stimulation of Rac and Cdc42, as 
shown in Figure 4.1 [Cahill et al., 1996 and Uhlik et al., 2003]. Similarly 
shown in Figure 4.1 is the activation of p38 MAPK by TNFa through the 
recruitment of intra-cellular scaffold signalling proteins to the TNF receptor. 
Plasma membrane recruitment of these proteins, specifically TRAF2, 
facilitates the activation of apoptosis signal-regulating kinase (ASK), of which 
MAPKK6 is a substrate [Ichijo et al., 1997, Nishitoh et al., 1998, and Yuasa et 
ai., 1998]. Selective inhibition of p38 MAPK activity can be achieved with the 
cytokine-suppressive anti-inflammatory drug and specific p38 MAPK inhibitor, 
SB203580, Figure 4.5, which directly competes at the ATP binding site 
[Cuenda et al., 1995, Young et al., 1997, Davies et al., 2000 and Guo et al., 
2003]. SB203580 is specific for p38a and p38p due to the presence of the 
conserved Thr-106, His-107, Leu-108 binding pocket and therefore has no 
effect on the activity of p38y or p385, or the other MAPKS, ERK and JNK 
[Cuenda et al., 1995 and Guo et al., 2003].
4.1.2.2 Downstream Effectors of p38 MAPK
The substrates or downstream effectors of p38 MAPK include other 
protein kinases such as mitogen-activated protein kinase-activated protein
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kinase 2 and 3 (MAPKAPK2 and 3), p38-regulated/activated protein kinase 
(PRAK), MAPK signal-integrating kinases (MNKs), and mitogen- and stress- 
activated protein kinases (MSKs) [Stokoe et al., 1992, McLaughlin et al.,
1996, Fukunaga and Hunter, 1997, New et al., 1998 and Deak et al., 1998]. 
p38 MAPKs can directly, or indirectly via downstream protein kinases, 
phosphorylate cytosolic proteins, such as phospholipase Ag, heat shock 
protein 25/27 (HSP25/27) and 5-lipoxygenase, plus numerous transcription 
factors, including serum response factor, CREB, c-Jun, activating transcription 
factor 2 (ATF2), nuclear factor of activated T-cells (NFAT), nuclear factor-xB 
(NF-kB) and signal transducers and activators of transcription (STAT) [Nahas 
et al., 1996, Guay et al., 1997, Tibbies and Woodgett, 1999, Heidenreich et 
al., 1999, Werz et al., 2000, Delghandi et al., 2005 and Dodeller and Schulze- 
Koops, 2006]. Recent work using fibroblasts derived from p38a knock-out 
mice has indicated that p38 MAPK can actually control the expression level of 
its downstream kinase MAPKAPK2, where knock-in of p38a rescues 
MAPKAPK2 expression [Sudo et al., 2005]. Conversely, in osteoblasts, the 
activation of ERK1/2 drives MAPKAPK2 synthesis [San Miguel et al., 2005].
MAPKAPK2 is a downstream protein kinase of p38 MAPK and is 
composed of an N-terminal regulatory domain and a C-terminal kinase 
domain [Stokoe et al., 1992, Ben-Levy et al., 1995 and Meng et al., 2002]. It 
is encoded by one gene that is subject to 3’ mRNA splicing resulting in the 
differential inclusion of both a nuclear localisation signal (NLS) and a nuclear 
export signal (NES), giving rise to isoforms with marginally different molecular 
weights of 60kDa and 53kDa respectively [Stokoe et al., 1992 and Kervinen et 
al., 2006]. The 53kDa MAPKAPK2 gene product is rare and entirely cytosolic.
Its phosphorylation and activation by p38a/p MAPK allows it to phosphorylate 
cytosolic target proteins (see below). p38a/{3 MAPK can translocate to the 
nucleus, where it activates the 60kDa MAPKAPK2 gene product through 
phosphorylation at critical residues, namely Thr-25, followed co-operatively by 
Thr-222, which is located within the activation loop, Ser-272, and Thr-334,
.which is positioned between the N- and C-terminal domains and relieves an 
auto-inhibitory constraint [Rouse et al., 1994, Freshney et al., 1994, and Ben- 
Levy et al., 1995]. The nuclear phosphorylation and activation of MAPKAPK2
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masks the NLS and exposes the NES resulting in its expulsion from the 
nucleus [Ben-Levy et al., 1998 and Meng et al., 2002]. Down-regulation of 
MAPKAPK2 activity occurs through de-phosphorylation by the 
serine/threonine protein phosphatase 2A (PP2A) [Stokoe et al., 1992].
Prior to its exclusion from the nucleus, MAPKAPK2 can directly 
phosphorylate the transcription factors, SRF and, to a lesser extent CREB 
[Tan et al., 1996 and Heidenreich et al., 1999]. It is now becoming clear that 
a major role for MAPKAPK2 is the control of gene expression at the post- 
transcriptional level [Dodeller and Schulze-Koops, 2006]. MAPKAPK2 
phosphorylation of mRNA binding proteins, such as tristetraprolin (TTP) and 
heterogeneous nuclear ribonucleoprotein AO (hnRNP AO), confers 
stabilisation of the AU-rich elements (ARE) in the 3’ un-translated region of
'mRNA transcripts, thereby stimulating gene expression of cytokines such as 
TNFa, IL-6 and IL-8, and enzymes such as urokinase plasminogen activator 
and cyclo-oxygenase-2 [Winzen et al., 1999, Rousseau et al., 2002 and 
Gaestel, 2006].
i
The p38 MAPK-MAPKAPK2 pathway also has a key role to play in the 
regulation of the cell cycle [Gaestel, 2006]. p53 is a tumour suppressor gene 
that is activated upon cell damage and prevents Gi/S-phase transition and 
initiates the apoptosis mechanism. Phosphorylation and activation of p53 
occurs directly via p38 MAPK. Conversely downstream activation of 
MAPKAPK2 targets p53 for degradation through the phosphorylation-induced 
activation of the ubiquitin ligase, HDM2 [Weber et al., 2005]. MAPKAPK2 
also controls the PP activity of Cdc25B, which is a crucial component of the 
Gg/M cell cycle checkpoint [Gaestel, 2006].
in the cytosol MAPKAPK2 can phosphorylate cytosolic target proteins 
such as HSP25/27, 5-lipoxygenase, and neurite outgrowth inhibitor protein 
(Nogo-B) [Stokoe et al., 1992, Guay et al., 1997, Larsen et al., 1997, Werz et 
al., 2000, Rousseau et al., 2005]. HSP25/27 can function as a chaperone or 
scaffold protein, and is an important regulatory component in F-actin 
accumulation and microfilament structural stabilisation of the cytoskeleton
  ...........
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[Guay et al., 1997]. Furthermore, the phosphorylation of HSP27 by 
MAPKAPK2 appears to play a fundamental role in regulating cell motility, and 
this may indicate a potential role in cancer cell metastasis [Xu et al., 2006]. 
The MAPKAPK2 phosphorylation and activation of 5-lipoxygenase, in the 
presence of arachidonic acid, may underlie a proportion of the pro- 
inflammatory effects of MAPKAPK2 signalling pathway [Werz et al., 2000 and 
Werz et al., 2002]. More recently, MAPKAPK2 phosphorylation of Nogo-B 
was described but the functional significance of this phosphorylation has still 
to be elucidated [Rousseau et al., 2005].
PRAK or MAPKAPK5 is a 50kDa protein kinase with 20-30% homology 
with other MAPKs [New et al., 1998 and Gaestel, 2006]. It is activated by 
p38a/p MAPK phosphorylation at Thr-182. Of note, p380 MAPK can 
phosphorylate at a different site but cannot activate PRAK. RNA transcripts 
for PRAK have been detected in human tissues and many commonly used 
human cell lines, confirming the authenticity of the protein kinase. As with 
MAPKAPK2, PRAK efficiently phosphorylates HSP25/27.
MNKs, of which there are two isoforms, MNK1 and MNK2, are 
serine/threonine protein kinases activated through the MAPK signalling 
pathways and have sequence similarities to the MAPKAPKs [Fukunaga and 
Hunter, 1997 and Waskiewicz et al., 1997]. Phosphorylation of MNK1 by 
ERK1/2 and p38 MAPKs, but not JNKs, induces kinase activation and this 
activation indicates another point of convergence of these two pathways and 
further supports evidence of signalling cross talk. ERK1/2 phosphorylates 
MNK1 at Thr-344, the equivalent residue to Thr-334 in MAPKAPK2. 
Activation of MNK1 also requires Thr-197 and Thr-202 [Waskiewicz et al., 
1997]. Activation of the p38 MAPK pathway by anisomycin and pro- 
inflammatory cytokines such as TNFa and IL-1 also activate MNK1, an effect 
ablated by co-incubation with SB202190, a derivative of SB203580 [Young et 
al., 1997]. However, there are likely to be multiple sites for activation with 
Thr-344 directing specificity for ERK1/2 and a second site directing specificity 
for p38 MAPK. MNK1 phosphorylates the RNA 5’ cap binding protein
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eukaryotic translation initiation factor 4E (elF-4E) at Ser-209 to modulate RNA 
translation [Waskiewicz et al., 1999].
A second group of downstream protein kinases that facilitates the 
convergence of the ERK1/2 and p38 MAPK signalling cascades are the MSKs 
[Deak et at., 1998]. There are two isoforms of MSK, namely MSK1 and 
MSK2, of which MSK1 is the most extensively studied. MSK1 is a nuclear 
protein kinase and accordingly, the major physiological substrate for MSK1, 
but not MSK2, is CREB [Deak et al., 1998 and Delghandi et al., 2005]. MSKs 
can also phosphorylate other transcription factors including ATF1, NK-kB and 
STAT [Dodeller and Schulze-Koops, 2006]. MSKs also target histone H3 for 
phosphorylation, inducing chromatin remodelling and the modulation of gene 
expression [Kyriakis and Avruch, 2001].
4.1.2.3 p38 MAPK in the immune and Inflammatory Response
The activation of p38 MAPK plays a central role in the regulation of the 
immune and inflammatory response. It is involved in the regulation of PBL 
adhesion to the vascular endothelial cells, diapedisis or cell migration through 
the cell-cell junctions of the vascular endothelium, the production of super­
oxide (Og) and ROS via phosphorylation of p47-phox, assembly and 
activation of NADPH oxidase, and release of proteinases such as elastase 
and metalloproteinases that degrade the cell matrix and compromise tissue 
integrity [Herlaar and Brown, 1999].
TNFa and IL-1 are expressed in a variety of immune and inflammatory 
cells including monocytes and macrophages. Specific inhibition of p38 MAPK 
activity with SB203580 attenuates their expression [Lee et al., 1994]. Using 
SB203580 also attenuated the cell type specific expression of IL-6 and IL-10 
(anti-inflammatory cytokine) as well as IL-1 and TNFa, corroborating the early 
studies [Guo et al., 2003]. Therefore, p38 MAPK must play a fundamental 
role in the regulation of the immune and inflammatory response. In support of 
this, MAPKAPK2 '^ '^  ^mice, when exposed to bacterial LPS to induce endotoxic 
shock or sepsis, showed increased survival coupled with near ablation of
187
Chapter 4 MAPKAPK2 phosphorylation of PDB4A5
TNFa expression [Kotlyarov et a!., 1999]. Cytokines can also activate the p38 
MAPK pathway in cells in which they are expressed and thus have the ability 
to regulate their own expression in an autocrine manner, e.g. TNFa and IFNy.
Activation of the T-cell receptor (TOR) and CD28 by antigen-presenting 
cells (APO) elicits the proliferation and differentiation of CD4+ T-cells to either 
T-helper type 1 (Thi) or T-helper type 2 (Th2) cell lineage. Thi cells mediate 
autoimmune disorders whereas Th2 cells mediate allergic inflammation. The 
balance of Thi and Th2 cells is thought to be critical in the pathogenesis 
many disease states where excessive Thi cells may cause chronic 
inflammation, e.g. in rheumatoid arthritis, and where Th2 cells are believed to 
underlie airway hyper-sensitivity in asthma [Bertrand, 2000 and Hart, 2001]. 
Each cell type is characterised by the expression of specific cytokines. 
Cytokines such as IL-12 and IL-18 activate p38 MAPK in Thi cells and 
phosphorylate STAT4 and ATF2 inducing interferon-y (IFNy) gene expression 
[Dodeller and Schulze-Koops, 2006]. Inhibition of IL-12 stimulated p38 MAPK 
activity in these cells attenuates IFNy gene expression and subsequently the 
level of the pro-inflammatory response [Rincon et al., 1998]. Additionally, 
activation of p38 MAPK can occur through IFN signalling indicating further 
autocrine regulation of cytokine expression [Platanias, 2003]. Thi cells 
predominantly express IFNy, which has anti-viral activity, activates phagocytic 
killing and activates natural killer cell cytotoxicity through TNFa production.
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The endogenous expression of IL-4 and IL-5 is also controlled by TCR- 
induced p38 MAPK activity in Th2 cells [Dodeller and Schulze-Koops, 2006].
Th2 cells express IL-4 and IL-5, which induces IgE production from B-cells 
and promotes eosinophil and mast cell immune responses [Hart, 2001].
"I
The activation of p38 MAPK in many cells plays a fundamental role in 
the expression of pro-inflammatory cytokines and subsequent activation of the 
immune and inflammatory response. As such, modulation of p38 MAPK
.activity through specific inhibition of p38 MAPK isoforms, specifically p38a, or 
its downstream protein kinases, such as MAPKAPK2, may be of benefit in the 
treatment of both autoimmune and inflammatory disease [Herlaar and Brown,
1999 and Saklatvala, 2004]. Indeed, p38 MAPK inhibition with SB203580 in
I
PDE4 enzymes are subject to phosphorylation and catalytic activity 
regulation by PKA [Sette et al., 1994, Sette and Conti, 1996, Laliberte et al., 
2002 and MacKenzie et al., 2002], ERK1/2 [Lenhard et al., 1996, Hoffmann et 
al., 1998, Hoffmann et al., 1999, Baillie et al., 2000, MacKenzie et al., 2000
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many animal models of inflammatory disease have shown reduced pro- 
inflammatory cytokine expression and PBL recruitment [Badger et al., 1996]. 
Unfortunately, serious ONS side effects and hepatic toxicity have hampered 
the progress of p38 MAPK inhibitors [Herlaar and Brown, 1999 and 
Saklatvala, 2004].
7
4.1.3 Phosphorylation o f PDE4 Enzymes
and Baillie et al., 2001], and a hitherto unknown protein kinase involved in the 1,PI-3K signalling pathway [MacKenzie et al., 1998]. These phosphorylation 
events are discussed in some detail in Section 1.7.5.
As discussed above, the p38 MAPK plays a fundamental role in the 
immune and inflammatory response. The aim of this chapter was to identify 
whether PDE4 enzymes could be phosphorylated and regulated through 
activation of the p38 MAPK pathway and elucidate the functional significance 
of the integration of cross talk between p38 MAPK and cAMP signalling.
i
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MAPK
Isoform
Alternative
Name Substrates Cell Response
ERK1 p44 MAPK
PDE4B, PDE4C, PDE4D, p47- 
phox, MAPKAPK1 (p90'*''), MNK, 
MSK, Elk1
Cell proliferation 
Cell differentiation 
Cell survival
ERK2 p42 MAPK
PDE4B, PDE4C, PDE4D, p47- 
phox, MAPKAPK1 (p90'^"), MNK, 
MSK, Elk1
ERK30 p63 MAPK
MNK, MSKERK33 Human ERK3ERK4 ERKIb
ERK5
ERK7
JNK1 SAPKy
c-Jun, JunD, ATF2, Elkl, Myc
Cell apoptosis 
Inflammation 
Tumourigenesis
JNK2 SAPKa
JNK3 SAPK3
p38a CSBP, SAPK2a, MPK2, RK, Mxi2 p47-phox, PLAg, MAPKAPK2/3, PRAK, MNK, MSK, c-Jun, ATF2, 
NFAT, MEF2A/C, STAT4, SRF
Cell motility 
Cell apoptosis 
Chromatin 
remodelling 
Cytoskeletal 
reorganisation
p38(3 p38-2, p38p2, SAPK2b
p38y ERK6, SAPK3 ATF2, Sapip385 SAPK4
Table 4.1 -  The MAPK Isoforms, alternative nomenclature, known 
substrates and cell response.
For description of abbreviations the reader is referred to the List of 
Abbreviations. Note that MAPKAPK1 (p90'^ ®‘^ ) is structurally unrelated to 
MAPKAPK2/3.
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Growth Factors 
Trophic Factors 
Ultra-violet Light
Oxidative Stress 
Osmotic Shock 
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Figure 4.1 -  Schematic representation of the p38 MAPK signalling 
pathway.
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4.2 Results
Analysis of the PDE4A5 primary structure revealed two serine residues 
within the UCR1 module that conform to the putative MAPKAPK2 
phosphorylation consensus motif, 0-Xaa-Arg~Xaa-Xaa-Ser-0, where 0  are 
hydrophobic amino acids [Stokoe et al., 1993 and Rousseau et al., 2005].
The putative target residues were Ser-147, within the motif Leu-Tyr-Arg-Ser- 
Asp-Ser-Asp, and Ser-161, within the motif Val-Ser-Arg-Ser-Ser-Ser-Val.
Unpublished work from the Houslay laboratory postulated that a purified MBP 
fusion protein of PDE4A5, generated by expression in E.coli, could be 
phosphorylated in vitro by recombinant MAPKAPK2. In contrast, little 
phosphorylation was evident in comparable studies done on MBP fusions of 
PDE4B1 and PDE4D3 [E.V. Hill and M.D. Houslay, unpublished 
observations]. Also preliminary studies by E.V. Hill have shown that 
incubation of purified PDE4A5 with a lysate from anisomycin-treated cells, to 
activate p38 MAPK, induced a marked phosphorylation of PDE4A5 when 
pP]-ATP was added to the incubation. Lysates from cells treated additionally 
with the specific p38 MAPK inhibitor, SB203580, were ineffective. In these 
experiments a proportion of residual phosphorylation was identified in the no 
treatment control. Furthermore, in pull down assays and co-immuno- 
precipitation experiments MAPKAPK2 was shown to be able to interact 
directly with PDE4A5 [F, McCallum and M.D. Houslay, unpublished 
observations]. In addition, transfection of a Ser-147-Asp mutant of PDE4A5,
designed to mimic the theoretical phosphorylated protein, showed altered
.intra-cellular distribution versus wild type [F. McCallum and M.D. Houslay, 
unpublished observations].
Analysis of the PDE4A5 amino acid sequence using the ScanSite 
consensus motif scanning database (http://scansite.mit.edu.cqi- 'bln/motifscan seq) on high stringency, also identified two putative p38 MAPK 
phosphorylation motifs within the catalytic unit of PDE4A5, namely Thr-437 
and Thr-776. The identified regions of PDE4A5 potentially susceptible to 
phosphorylation by MAPKAPK2 or p38 MAPK are shown in Figure 4.2.
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4.2.1 In Vitro Phosphorylation o f PDE4A5 by MAPKAPK2 and/or p38
In order to determine whether PDE4A5 was able to be phosphorylated 
directly by either p38 MAPK, or its downstream effector kinase MAPKAPK2, it 
was expressed and purified as a N-terminal MBP fusion protein in E.coli, as 
shown in Figure 4.3. Full-length PDE4 enzymes are notoriously difficult to 
express as a soluble protein in E.coli and require the addition of a sizeable 
soluble fusion protein tag, such as MBP. However, I managed to express 
MBP-PDE4A5 as a moderately soluble protein and purified it to a final 
concentration of approximately 0.5mg/ml. In addition to the native enzyme, 
mutant versions were also expressed and purified in E.coli. These were 
generated by site-directed mutagenesis (serine or threonine to alanine) of the 
indicated putative phosphorylation sites for MAPKAPK2 and p38 MAPK.
These mutants could be expressed and purified on a similar scale to the wild 
type enzyme (data not shown).
In an in vitro phosphorylation assay I showed that PDE4A5 was 
phosphorylated by purified recombinant forms of both MAPKAPK2 (Figure 
4.4(a)) and p38 MAPK (Figure 4.4(b)). Mutation of Ser-147 to alanine, the
site identified by former laboratory colleagues, significantly reduced the level
'of phosphorylation to 40% +/- 2%, compared to the phosphorylation of wild 
type, which was set at 100% (p < 0.05). Conversely, mutation of Ser-161 to 
alanine had no effect on the phosphorylation status of PDE4A5, 90% +/- 2% 
compared to the wild type at 100% (p > 0.05).
I
Wild type PDE4A5 was also potentially phosphorylated by p38 MAPK. 
With the level of wild type phosphorylation set at 100%, the level of 
phosphorylation of the Thr-437 to alanine mutant was determined at 121% +/- 
4% (p > 0.05) and was comparable to the level of phosphorylation of the Thr- 
776 to alanine mutant at 90% +/- 17% (p > 0.05). As described, mutation to 
alanine of either of the identified putative threonine target residues showed no 
reduction in phosphorylation efficiency. These data indicated that either these
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sites were not the p38 MAPK phosphorylation targets, or alternatively, these 
could be non-specific in vitro phosphorylation assay events.
4.2.2 In Vivo Phosphorylation of PDE4A5 by p38 MAPK-dependent
pathway
As with all in vitro phosphorylation assays, the data was approached 
with caution because these experiments were undertaken in isolation, 
normally with supra-physiological protein kinase concentrations. Therefore, 
artificial and indiscriminate phosphorylation of target proteins may have 
occurred. From Section 4.2.1, it was concluded that PDE4A5 was a substrate 
for MAPKAPK2, and furthermore the data indicates Ser-147 as the target 
residue for MAPKAPK2 phosphorylation. Whether PDE4A5 is a true 
substrate for p38 MAPK remains to be elucidated as Thr-437-Ala and Thr- 
776-Ala mutants of the potential sites did not attenuate the phosphorylation. 
However, it was pertinent to elucidate whether the MAPKAPK2 
phosphorylation was able to occur in a bone fide cell signalling system, where 
all components were present in their natural environment.
To achieve this, COS1 and HEK293 cells were assessed for p38 
MAPK and MAPKAPK2 activation following treatment with anisomycin, which 
initiates a robust activation of p38 MAPK, and also after treatment with the 
inflammatory cytokine, TNFa. Figure 4.6(a) shows that endogenous p38 
MAPK activity in C0S1 cells was low in the basal state, and that anisomycin 
initiated a robust and time-dependent activation of p38 MAPK, as indicated by 
dual phosphorylation of p38 MAPK at Thr-180 and Tyr-182. The activation of 
p38 MAPK reached a maximum in approximately 20min and was sustained 
for up to 60min. Activation of p38 MAPK caused a concomitant activation of 
MAPKAPK2, as indicated in Figure 4.6(b) by phosphorylation at Thr-334. 
MAPKAPK2 was also activated in a time-dependent manner, was fully 
activated at 30min, and sustained up to at least 60min post-stimulation. 
HEK293 cells had relatively low, but immunologically detectable, basal p38 
MAPK and MAPKAPK2 activity, as shown in Figure 4.7. Although TNFa was
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able to initiate a rapid activation of p38 MAPK activity after 5min, the 
downstream activation of MAPKAPK2 over time-zero was less convincing 
than that observed with the anisomycin treatment of C0S1 cells. On this 
basis, anisomycin activation of the p38 MAPK cell-signalling pathway in C0S1 
cells was selected for the in vivo phosphorylation experiments.
C0S1 cells were grown in phosphate-free growth media and 
transfected to transiently over-express VSV-tagged PDE4A5. The cell media 
was supplemented with [^^P]-orthophosphate and the cells were then either 
retained untreated, treated with anisomycin, or treated with anisomycin plus 
the p38 MAPK inhibitor, SB203580. PDE4A5 was immuno-precipitated and 
assessed for f^P] incorporation as a marker of protein phosphorylation.
VSV-tagged PDE4A5 was exclusively immuno-precipitated with the 
VSV monoclonal antibody conjugated to Protein G agarose, as shown in 
Figure 4.8(a), bottom panel. Therefore, PDE4A5 in Figure 4.8(a), top panel, 
was easily distinguishable from a non-specific protein interaction at a slightly 
higher molecular weight, which was isolated with the Protein G agarose alone 
control immuno-precipitation. In untreated cells, residual phosphorylation of 
PDE4A5 was detected and, for quantification purposes, this control level was 
described as 100%. Figure 4.8(b) shows no detection of basal p38 MAPK or 
MAPKAPK2 activity in unstimulated cells. However, a marked increase in the 
intensity of PDE4A5 pP]-orthophosphate incorporation was measured,
-Figure 4.8(a), on activation of both p38 MAPK and MAPKAPK2 with 
anisomycin. Figure 4.8(b), first and third panels.
When the activation of both p38 MAPK and MAPKAPK2 was prevented 
by SB203580 the increase in phosphorylation of PDE4A5 was attenuated to 
near control state, as shown in Figure 4.8(a). The significant increase in 
PDE4A5 phosphorylation following anisomycin action was quantified at 172%
+/- 8% (p < 0.01), whilst the level of phosphorylation was reduced, but still 
significantly elevated over the control, to 124% +/- 4% (p < 0.01) in the 
presence of SB203580.
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Such p38 MAPK-dependent phosphorylation of PDE4A5 was also seen 
using other stimuli to activate the p38 MAPK pathway, including H2O2 , to 
induce cellular oxidative stress, and NaCI, to induce cellular osmotic stress 
[E.V. Hill and M.D. Houslay, unpublished observations].
In order to gain preliminary insight into the site of PDE4A5 subject to 
phosphorylation following anisomycin treatment of C0S1 cells, two truncates, 
which removed the significant amino acids that comprise the unique N- 
terminal (Met-1 to Thr-134) and the N-terminal plus UCR1 (Met-1 to Val-196), ‘I-of PDE4A5, which have been described previously by others [Beard et al.,
2002], were evaluated. These untagged PDE4A5 constructs were immuno- 
precipitated using a rat PDE4A C-terminal specific anti-serum. Although 
PDE4A5 was clearly immuno-precipitated, Figure 4.9(a) and Figure 4.10(a), 
bottom panels, these truncated forms of PDE4A5 migrated with a non­
specific, phosphorylated protein of similar molecular weight.
The p38 MAPK-dependent phosphorylation of PDE4A5, less the 
unique N-terminal region, occurred as per the full-length enzyme, with an 
increase in phosphorylation to approximately 164% over the no treatment 
control, as shown in Figure 4.9(a). Protection from phosphorylation was 
afforded by SB203580, where the phosphorylation level was quantified at 
approximately 120%. In this experiment the level of basal p38 MAPK activity 
was markedly increased prior to anisomycin stimulation of p38 MAPK and 
may have played a role in preventing complete ablation of activity with 
SB203580. However, Figure 4.10 revealed that removal of both the N- 
terminal and UCR1 domains resulted in the prevention of anisomycin-induced 
PDE4A5 phosphorylation, with the level of phosphorylation determined at 
88% +/- 35% (p > 0.05) with anisomycin and 82% + /-11% (p > 0.05) with prior 
SB203580 treatment, compared to the control level of 100%. Basal p38 :2:'MAPK activity was notably lower than previously measured, i.e. Figure 4.10(b) 
compared to Figure 4.9(b), top panels of each. These data indicates that the 
p38 MAPK-dependent phosphorylation occurred within UCR1, the region with 
the putative phosphorylation sites for MAPKAPK2, and that had previously
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been identified as providing the phosphorylation target in the experiments of 
Figure 4.4(a).
Site-directed mutagenesis of either Ser-147 to alanine or Ser-161 to 
alanine did not impact either expression in C0S1 cells or catalytic activity of 
PDE4A5 (data not shown). Treatment of cells expressing the Ser-147 to 
alanine mutant of PDE4A5 demonstrated no significant increase in the level of 
phosphorylation following anisomycin treatment (109% +/- 9%; p > 0,05) nor 
did the pre-incubation of SB203580 prior to anisomycin addition alter this 
(93% +/- 10%; p > 0.05), as shown in Figure 4.11(a). On the other hand, the 
Ser-161 to alanine mutant of PDE4A5 was phosphorylated in the same 
manner as the wild type, Figure 4.8(a), and N-terminal truncate, Figure 4.9(a), 
with an increase in phosphorylation to 189% +/- 28% (p > 0.05), Figure 
4.12(a), compared to the 100% control level. SB203580 ameliorated, on 
average, any effect induced by anisomycin to 97% +/- 64% (p > 0.05). A re­
producible activation of p38 MAPK was achieved at comparable levels in both 
cases, as shown in Figure 4.11(b) and Figure 4.12(b), top panels.
Taken together, the above data lead to the hypothesis that MAPKAPK2 
and not p38 MAPK caused the phosphorylation of PDE4A5. In order to 
address this I used small interfering RNA (siRNA) to knockdown endogenous 
MAPKAPK2 expression in order to determine whether this prevented the 
phosphorylation of wild type PDE4A5. siRNA specific for MAPKAPK2 was 
transfected into C0S1 cells and MAPKAPK2 expression monitored over a 72h 
period, as shown in Figure 4.13(a). This figure confirmed that MAPKAPK2 
was expressed in C0S1 cells at endogenous levels sufficient for 
immunological detection. The use of non-targeting or control siRNA indicated 
that any knockdown of expression was target protein specific and not a global 
effect of siRNA transfection, as shown in Figure 4.13(a), middle panel. 
MAPKAPK2 siRNA prevented expression of the endogenous kinase, as 
detected by standard Western immuno-blotting in Figure 4.13(c), bottom 
panel, with minimal MAPKAPK2 expression 24h after transfection, and 
complete ablation of expression at 48-72h. Figure 4.13(b), bottom panel, and 
Figure 4.13(c) confirmed that co-transfection of VSV-PDE4A5 and
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MAPKAPK2 siRNA had no effect on either the level of PDE4A5 expression 
and immuno-precipitation, the level of endogenous p38 MAPK expression and 
activation, or the siRNA knockdown efficiency of MAPKAPK2 expression.
The level of phosphorylation of PDE4A5, following anisomycin treatment in 
c o s t  cells, with complete knockdown of MAPKAPK2 expression, showed no 
significant change from the unchallenged control, quantified in Figure 4.13(b), 
graph, at 95% +/- 15% (p > 0.05). These data imply that PDE4A5 was 
phosphorylated by MAPKAPK2, a downstream substrate of p38 MAPK, at 
Ser-147 within its UCR1 regulatory module. Control siRNA allowed the 
MAPKAPK2 phosphorylation of PDE4A5 to progress as per the wild type 
(data not shown).
4.2.3 Functional Effects o f PDE4A5 Phosphorylation
As has been discussed extensively in Section 1.7.5 and Section 3.2.5,
PDE4 enzymes are subject to activity regulation by both PKA and ERK1/2 
phosphorylation [Houslay, 2001]. The common UCR1 domain of all PDE4 
long isoforms contains a single PKA phosphorylation target residue, the 
phosphorylation of which induces up to a 2-fold increase in PDE4 activity 
dependent upon the long isoform target [Sette and Conti, 1996, Hoffman et
■al., 1998, MacKenzie et al., 2002 and Manganiello, 2002]. However, only in 
the case of PDE4D3 can PKA phosphorylation induce a conformational 
change in catalytic unit that leads to an increase in the sensitivity to inhibition 
by rolipram. PDE4A isoforms are not subject to regulation by ERK2 
phosphorylation of the catalytic unit as they lack the phosphorylation 
consensus site, but they do contain the required docking domains [Baillie et
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al., 2000]. In PDE4 isoforms, excluding the PDE4A gene family, ERK2 
phosphorylation exerts an activation of short isoforms and an inhibition of long 
isoforms [Lenhard et al., 1996, Hoffman et al., 1999, MacKenzie et al., 2000 
and Houslay and Adams, 2003]. The inhibitory effect of ERK2 action is
overcome by the PKA activating phosphorylation [Houslay and Kolch, 2000 
and Baillie et al., 2001]. A third activating phosphorylation event on 
PDE4A4B/PDE4A5, where the kinase responsible has not been assigned,
Î
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4.2.3.1 Enzymatic Activity of PDE4A5
occurs through the stimulation of the PI-3K pathway, an effect that is sensitive 
to both wortmannin and rapamycin, indicating the involvement of a PI-3K 
downstream effector protein kinase [MacKenzie et al., 1998 and MacKenzie 
and Houslay, 2000].
Described above are three examples of protein kinase phosphorylation 
of PDE4 isoforms that confers regulation of PDE activity. In C0S7 cells the 
UCR1 regulatory module of PDE4A5 was phosphorylated by active PKA, and I
was detected using an anti-serum specific for the phosphorylated residue, as 
described previously [Bolger et al., 2003]. Similarly in C0S1 cells, the 
activation of PKA was instigated, through ablation of global PDE-mediated 
cAMP degradation, with the non-specific PDE inhibitor, IBMX. Subsequent 
treatment with the adenylyl cyclase activator, forskolin, induced a time- 
dependent increase in PDE4A5 PKA phosphorylation, to a maximum and 
persistent response after 10-20min, as shown in Figure 4.14(a), top panel.
This was quantified, as a function of PDE4A5 expression (Figure 4.14(a), 
bottom panel) in Figure 4.14(b). On the basis of optimal PKA phosphorylation 
being 100%, the time-zero PKA phosphorylation of PDE4A5 was determined 
at 18% +/- 4% of the peak response. Figure 4.14(c) showed that the time 
course of PDE4A5 PKA phosphorylation accurately translated to a robust 
activation of PDE4A5, as expected. In the native state PDE4A5 activity was 
considered to 100%. Mirroring the phosphorylation time course, the activity of 
PDE4A5 increased to a plateau at 10min, where the activity was calculated to 
be some 219% +/- 11%, above the control. The activation was maintained up 
to 20min at a equivalent level of some 223% +/- 6%.
I successfully generated an anti-serum specific to the MAPKAPK2 
phosphorylated Ser-147 of PDE4A5 and this facilitated the resolution of the 
phosphorylation time course, and in addition confirmed the identity of the 
phosphorylation target residue. Indeed, Figure 4.15(a), and the quantification 
of this figure. Figure 4.15(b), showed that PDE4A5 was phosphorylated at 
Ser-147 in a time-dependent manner with anisomycin. The residual
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phosphorylation of PDE4A5, also observed with the in vivo phosphorylation 
experiments, Figure 4.8(a), was mirrored, with immunological detection of 
phosphorylation at time-zero, calculated as being 28% +/- 4% of the peak 
response. The phosphorylation progressed in a near linear fashion to 20min 
before tailing off and reaching saturation at 30-60min post-stimulation. Unlike 
PKA phosphorylation, the time-dependent MAPKAPK2 phosphorylation of 
PDE4A5 had negligible effect on enzymatic activity with the activity 93% +/- 
7%, versus the 100% control activity after 30min. Further confirmation of 
having correctly identified the target residue was achieved when 
phosphorylation of Ser-147 was not detected in cells transfected to express 
the alanine mutant, as shown in Figure 4.15(d). To eliminate the possibility of 
antibody irregularity, a non-specific band of a 37kDa was consistently 
detected with this antibody, irrespective of the PDE4A5 construct expressed 
(data not shown).
PDE4A5 was capable of being phosphorylated by PKA, following 
phosphorylation by MAPKAPK2, as shown in Figure 4.16(a). Quantification of 
the PDE4A5 PKA phosphorylation, succeeding MAPKAPK2 phosphorylation, 
offered a potential modification in the phosphorylation profile. An initial burst 
of PKA phosphorylation is observed at Imin, as shown in Figure 4.16(b),
which is followed by a more restrained linear increase to the 20-minute
,;ÿmaximum response. Comparison with Figure 4.14(b) showed solitary PKA
phosphorylation to have a more incremental increase to the maximal 
response post-stimulation. The overall reduction in phosphorylation efficiency 
translates to a 50% inhibition of PKA-mediated PDE4A5 activation. The 
maximum activation following a 20-minute treatment with the adenylyl cyclase 
activator, forskolin reached 156% +/- 8%, as shown in Figure 4.16(c), 
compared to a PKA alone activation, above the 100% control level, of 223% 
+/- 6%, in Figure 4.14(c).
PKA phosphorylation of long PDE4 isoforms results in stimulation of 
enzyme activity, but substantial disparity exits as to whether this translates to 
an increase in the sensitivity to inhibition by rolipram [Hoffman et al., 1998, 
Laliberte et al., 2002 and MacKenzie et al., 2002]. To elucidate whether the
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showed a small reduction In sensitivity with an IC50 value of 2.1 ijM +/- 0.4plVI. 
4.2.3.2 Intra-ceilular Distribution of PDE4A5
4.2.3.3.1 B-arrestin
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-I
Iphosphorylation of PDE4A5 at Ser-147 had an effect on the conformational 
status of the catalytic unit, concentration response curves to rolipram were 
generated and the IC50 values were determined for both the wild type and the 
Ser-147 to aspartate mutant that I generated as a potential phospho-mimetic, 
as shown in Figure 4.17. Rolipram inhibited both forms of PDE4A5 in 
concentration-dependent fashion. The IC50 value for rolipram inhibition of wild
type PDE4A5 was 1.1 pM +/- 0.3pM, whereas the Ser-147-Asp mutant
The intra-cellular distribution of PDE4A5, following sub-cellular 
fractionation, was found to be completely cytosolic in C0S1 cells with no 
Immunological detection within the particulate fractions, as shown in Figure 
4.18(a). This contradicts the published literature, which shows PDE4A5 to be
:v
of both particulate and cytosolic distribution [Huston et al., 2000]. 
Phosphorylation of PDE4A5, via the anisomycin activation of MAPKAPK2, did
-not alter this cellular localisation profile. Confocal microscopy analysis of 
PDE4A5, Figure 4.18(b), all panels, showed it to be localised at the 
perinuclear region around the nuclear membrane and at distinct regions of the f
plasma membrane, when transiently over-expressed in C0S1 cells.
Furthermore, this intra-cellular distribution of PDE4A5, over-expressed in both 
live and fixed COS1 cells, showed no change in distribution on anisomycin 
treatment using analogous time and concentrations to induce protein 
phosphorylation.
4.2.3.3 PDE4A5 Protein Interactions
In Chapter 3, Figure 3.16, it was concluded that PDE4A4B, the human 
homologue of PDE4A5, was able to interact with the scaffold protein, p- 
arrestin. It is widely appreciated that p-arrestin preferentially interacts with 
PDE4D5, but PDE4A isoforms can interact via a PDE4 common interaction
..|
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site within the catalytic unit [Perry et al., 2002, Bolger et al., 2003 and Bolger 
et al., 2006]. The interaction is discussed extensively in Section 1.7.6.6.
Figure 4.19(a) was in accordance with Figure 3.16, and showed that 
PDE4A5 interacted effectively with p-arrestin, following immuno-precipitation 
and immuno-probing for PDE4A5, when both proteins were co-expressed in 
COS1 cells. Cell lysates expressing PDE4A5 alone showed no interaction 
with the FLAG agarose used to immuno-precipitate p-arrestin, indicating the 
absence of non-specific interactions, as shown in Figure 4.19(c). Cell lysates 
expressing both proteins were then pre-treated with anisomycin to instigate 
MAPKAPK2 phosphorylation, and IBMX plus forskolin to instigate PKA 
phosphorylation, or both for dual phosphorylation of PDE4A5. Figure 4.19(b) 
quantified the level of interaction, and in each case the relative amount of 
PDE4A5 interacting with p-arrestin was 134% following treatment with 
anisomycin alone, 112% following treatment with IBMX and forskolin, and 
127% with anisomycin pre-treatment followed by IBMX and forskolin.
4.2.3.3.2 Immunophilin XAP2
The C-terminal component containing the TPR domains of XAP2 
interacts specifically with human PDE4A4B and rat PDE4A5 through a unique 
interaction sequence located within the N-terminal region of the enzyme 
together with an additional, recognisable TPR binding site within the UCR2 
region, common to all PDE4 isoforms [Bolger et al., 2003]. The interaction is 
discussed fully in Section 1.7.6.3.
PDE4A5 and XAP2 were co-expressed in COS1 cells and the 
interaction in untreated cells was confirmed by co-immuno-precipitation, as 
shown in Figure 4.20(a). Figure 4.20(a) aimed to determine whether this 
interaction was modulated, following PDE4A5 phosphorylation by
MAPKAPK2, PKA or both kinases simultaneously. In each case equal 
immuno-reactive amounts of PDE4A5 and XAP2 were co-expressed, coupled 
with comparable levels of XAP2 immuno-precipitation. Quantification of the 
immuno-reactive level of PDE4A5 co-immuno-precipitated with XAP2
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revealed a 50% +/- 9% (p < 0.001) significant reduction of XAP2 binding to 
PDE4A5 following PDE4A5 phosphorylation by MAPKAPK2, Figure 4.20(b). 
This reduction in interaction was reverted to control, at 99% +/- 7% (p > 0.05) 
upon co-challenge of cells with SB203580.
It was also noted that XAP2 was not phosphorylated in cells via 
activation of the p38 MAPK signalling pathway with anisomycin [E.V. Hill and
M.D. Houslay, unpublished observation]. Conversely, phosphorylation of 
PDE4A5 by PKA had no effect on the efficiency of interaction at 84% +/- 14% 
(p > 0.05) compared to the 100% control.
Simultaneous MAPKAPK2 and PKA phosphorylation of PDE4A5, 
stimulated by pre-treatment with anisomycin followed by IBMX and forskolin, 
showed a similar significant reduction in XAP2 binding to PDE4A5 when 
compared with anisomycin alone, with the interaction some 54% +/- 5% (p < 
0.05) of the control. This further confirmed that PKA phosphorylation of 
PDE4A5 plays no role in modulating the PDE4A5-XAP2 interaction. 
Furthermore, PKA phosphorylation of PDE4A5 does not influence the ability 
of MAPKAPK2 phosphorylation to attenuate the interaction of PDE4A5 and 
XAP2.
Cell lysates expressing PDE4A5 alone showed no interaction with the 
FLAG agarose used to immuno-precipitate XAP2, indicating the absence of 
non-specific interactions, as shown in Figure 4.20(c).
4.2.3.3.3 Action of Caspase-3
PDE4A5 contains a caspase-3 cleavage motif at Asp-69 to Asp-72. 
Cleavage at this site by caspase-3 results in the intra-cellular re-distribution of 
PDE4A5 and loss of the SH3 binding domains required for interaction with 
tyrosyl kinases, such as Lyn [Huston et al., 2000].
The ability of recombinant, active caspase-3 to cleave equal immuno- 
reactive amounts of PDE4A5 wild type and PDE4A5 after being MAPKAPK2
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phosphorylated, and both the Ser-147-Asp and Ser-147-Ala mutants were 
assessed in vitro. In all instances, PDE4A5 was cleaved by caspase-3, as 
indicated by the detection of two immuno-reactive bands, of 110kDa and 
lOOkDa respectively, with the rat C-terminal specific anti-serum. The 
PDE4A5 Ser-147-Asp and Ser-147-Ala mutants were cleaved more efficiently 
by caspase-3, as indicated by the conversion of nearly all available PDE4A5 
to the lower molecular weight product (1 OOkDa).
I
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Figure 4.2 -  Truncation and phosphorylation site mutants of rat PDE4A5.
The schematic shows the two positions at which PDE4A5 N-terminal 
truncations were engineered and also putative MAPKAPK2 and p38 MAPK 
phosphorylation sites on long PDE4A isoforms. Plasmids were generated 
encoding rat PDE4A5 less the entire N-terminal region (A N-terminal region 
truncated at Ser-135) and less the entire N-terminal and UCR1 regions (A N- 
terminal & UCR1 regions truncated at Pro-197). Also shown are the putative 
phosphorylation residues contained within either MAPKAPK2 phosphorylation 
motifs (Ser-147 and Ser-161) within UCR1 or p38 MAPK phosphorylation 
motifs (Thr-437 and Thr-776) located within the catalytic unit. These residues 
were subjected to site directed mutagenesis with nucleotide codons for the 
serine or threonine amino acids altered to code for alanine in all instances 
respectively.
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Figure 4.3 -  E.coli expression and purification of recombinant MBP- 
tagged rat PDE4A5.
209
Coomassie® staining of SDS polyacrylamide gels showing the E.coli 
expression of full-length recombinant rat PDE4A5 as a fusion with maltose 
binding protein (MBP). Briefly, competent E.co//BL21 pLysS (DE3) cells were 
transformed with pMAL plasmids encoding MBP-PDE4A5. Expression of the 
protein was induced with 0.2mM IPTG for 4h at 30 C. The cells were 
collected, re-suspended in lysis buffer and subjected to sonication to produce 
total cell extract (P). The soluble proteins were isolated by centrifugation (S).
The expressed recombinant MBP fusion protein was purified using amylose 
resin and eluted using excess maltose (10mM). The MBP fusion protein 
could be purified to two bands as detectable by Coomassie® staining of the 
SDS-PAGE (Purified). These gels are representative of numerous successful 
expression experiments undertaken to produce PDE4A5 wild type and various 
single serine or threonine to alanine mutants in E.coli.
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Figure 4.4 -  In vitro phosphorylation of wild type PDE4A5 and putative 
phosphorylation site mutants with recombinant MAPKAPK2 or p38 
MAPK.
The phosphorylation of rat PDE4A5 (wild type, Ser-147-Ala and Ser-161-Ala) 
by recombinant MAPKAPK2 and rat PDE4A5 (wild type, Thr-437-Ala and Thr- 
776-Ala) by recombinant p38 MAPK were carried out in vitro. Briefly, purified 
rat MBP-PDE4A5 wild type, or mutants, were incubated with either 
MAPKAPK2 or p38 MAPK and pP]-ATP for lOmin at 30“C. The 
phosphorylated MBP-PDE4A5 proteins were separated by SDS-PAGE and 
transferred to a nitrocellulose membrane. The radioactive nitrocellulose 
membrane was exposed in close proximity to a storage phosphor image 
screen for at least 3 hours and developed using a high-resolution laser 
scanner, (a) (I), top panel, is a scanned storage phosphor screen image 
showing PDE4A5 (wild type, Ser-147-Ala and Ser-161-Ala) phosphorylation 
by recombinant MAPKAPK2. (a) (i), bottom panel, is a Western blot of the
radioactive nitrocellulose membrane, probed using a rat PDE4A C-terminal
specific anti-serum, showing the relative immuno-reactive amounts of 
PDE4A5 in each assay, (a) (ii), displays the quantification of PDE4A5 
phosphorylation as a function of the immuno-reactive PDE4A5 in each assay. 
Similarly, (b) (i), top panel, is a scanned storage phosphor screen image 
showing PDE4A5 (wild type, Thr-437-Ala and Thr-776-Ala) phosphorylation 
by recombinant p38 MAPK. (b) (i), bottom panel, is a Western blot of the
radioactive nitrocellulose membrane, probed using a rat PDE4A C-terminal
specific anti-serum, showing the relative immuno-reactive amounts of 
PDE4A5 in each assay. (b) (ii), shows the quantification of the 
phosphorylation as a function of the immuno-reactive PDE4A5 in each assay. 
All scanned storage phosphor screen images and Western blots are 
representative of in vitro phosphorylation assays done three times. The 
quantification of the phosphorylation experiments are expressed as mean 
values +/- standard deviations of the three separate experiments. Paired t- 
test statistical analysis of the quantified phosphorylation data were 
undertaken, where p < 0.05 indicates statistical significant difference in the 
level of phosphorylation between wild type and mutant forms of PDE4A5.
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Figure 4.5 Chemical structures of anisomycin and SB203580.
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Figure 4.6 -  Anisomycin time course of p38 MAPK and MAPKAPK2
activation in C0S1 cells.
separate experiments.
C0S1 cells were treated with anisomycin (10pg/ml) at the indicated time 
points (0-60min). Total cell extract was produced and the lysates immuno- 
probed with anti-sera specific for the respective kinase activation, (a), top 
panel, is a Western blot probed with anti-sera able to detect endogenous 
levels of the dual phosphorylated (Thr-180 and Tyr-182), and activated, p38 
MAPK. (a), bottom panel, is the same Western blot re-probed with an anti­
serum to detect total endogenous p38 MAPK. (b), top panel, is a Western 
blot of phosphorylated, and activated, MAPKAPK2, as indicated by the
■detection of the mono phosphorylated (Thr-334) form, (b), bottom panel, is 
the same Western blot re-probed for total endogenous MAPKAPK2, using a 
specific anti-serum. All Western blots are representative blots of at least three
I
-I
Î
214
Chapter 4 MAPKAPK2 phosphorylation of PDE4A5
(a)
Time with TNFa (min)
0 2.5 5 10 20 30
mm # # mm mm
Phosphorylated p38 MAPK 
Total p38 MAPK
(b)
Time with TNFa (min)
' 0 2.5 5 10 20 30
^ Phosphorylated MAPKAPK2 
Total MAPKAPK2
215
Chapter 4 MAPKAPK2 phosphorylation of PDE4A5
Figure 4.7 -  Activation of p38 MAPK and MAPKAPK2 with TNFa in 
HEK293 cells.
HEK293 cells were treated with TNFa (10ng/ml) at the indicated time points 
(0-30min). Total cell extract was produced and the lysates immuno-probed 
with anti-sera specific for the respective kinase activation, (a), top panel, is a 
Western blot probed with anti-sera able to detect endogenous levels of the 
dual phosphorylated (Thr-180 and Tyr-182) and activated p38 MAPK. (a), 
bottom panel, is the same Western blot re-probed with an anti-serum to detect 
total endogenous p38 MAPK. (b), top panel, is a Western blot of 
phosphorylated and activated MAPKAPK2, as indicated by the detection of 
the mono phosphorylated (Thr-334) form, (b), bottom panel, is the same 
Western blot re-probed for total endogenous MAPKAPK2, using a specific 
anti-serum. All Western blots are representative blots of at least three 
separate experiments.
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Figure 4.8 -  In vivo phosphorylation of rat PDE4A5 wild type in COS1 
cells stimulated with anisomycin.
C0S1 cells were transfected with a plasmid encoding vsv-PDE4A5 for 
transient over-expression. The cells were grown in phosphate-free cell media 
that was supplemented with [^^P]-orthophosphate overnight. The cells were 
treated with anisomycin (10pg/ml) for 60min, to activate the p38 MAPK 
phosphorylation cascade, or anisomycin plus the p38 MAPK inhibitor 
SB203580 (10pM) for 60min respectively. Total cell lysate was produced. 
PDE4A5-VSV was immuno-precipitated using an anti-vsv antibody conjugated 
to Protein G agarose with un-conjugated Protein G agarose used as a control 
immuno-precipitation. The immuno-precipitated proteins were separated by 
SDS-PAGE and transferred to a nitrocellulose membrane where the 
radioactive proteins were resolved using phosphor image screen technology,
(a), top panel, is a scanned phosphor image screen of the phosphorylated 
PDE4A5 immuno-precipitated following treatment with anisomycin plus or 
minus SB203580. (a), bottom panel, is a Western blot of the same
nitrocellulose membrane probed with the anti-vsv antibody to determine the 
relative immuno-precipitation of PDE4A5 from the three samples, (a), graph, 
quantifies the change in phosphorylation of PDE4A5 following activation of the 
p38 MAPK signalling cascade relative to the no treatment control (100%). 
These data account for the relative immuno-reactive amounts of PDE4A5 
isolated by immuno-precipitation. (b), are Western blots of total cell lysate 
immuno-probed for both p38 MAPK and MAPKAPK2 activation together with 
the corresponding total cellular expression of both kinases. All scanned 
phosphor image screens and Western blots are representative of at least 
three separate transfections and experiments. The quantification data are 
expressed as the mean percentage change in phosphorylation over the 
control +/- standard deviation of at least three separate transfections and 
experiments. Paired t-test statistical analysis of the quantified 
phosphorylation data were undertaken, where p < 0.05 indicates a statistically 
significant difference in the level of wild type PDE4A5 phosphorylation 
between untreated and treated cells, as indicated.
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Figure 4.9 -  In vivo phosphorylation of rat PDE4A5, less the entire N- 
terminal region, in C0S1 cells stimulated with anisomycin.
I
cell media that was supplemented with [^^P]-orthophosphate overnight and
C0S1 cells were transfected to express the truncated rat PDE4A5, amino 
acids Ser-135 to Ala-844 inclusive. The cells were grown in phosphate-free
then treated with anisomycin (lOpg/ml) for 60min or anisomycin plus 
SB203580 (lOpM) for 60min each respectively. Total cell lysate was 
produced. PDE4A5-A N-terminal was immuno-precipitated using an anti­
serum specific to the C-terminal region of rat PDE4A isoforms. This antibody 
was conjugated to Protein G agarose with un-conjugated Protein G agarose 
used as a control immuno-precipitation. The immuno-precipitated proteins 
were separated by SDS-PAGE and transferred to a nitrocellulose membrane
220
where the radioactive proteins were resolved using phosphor image screen 
technology, (a), top panel, is a scanned phosphor image screen of the 
phosphorylated PDE4A5-A N-terminal, immuno-precipitated following
treatment with anisomycin plus or minus SB203580. (a), bottom panel, is a ,:S'Western blot of the same nitrocellulose membrane probed with the specific rat 
PDE4A antibody to determine the relative PDE4A5 immuno-precipitation for 
the three treatment samples, (a), graph, shows the quantification of the ■Ïchange in the phosphorylation state of PDE4A5-A N-terminal protein following 
activation of the p38 MAPK signalling cascade relative to the no treatment 
control (100%). These quantifications take into account the relative immuno- 
reactive amounts of PDE4A5-A N-terminal isolated by immuno-precipitation.
(b), are Western blots of total cell lysate immuno-probed for p38 MAPK 
activation together with the corresponding total cellular expression. All 
scanned phosphor image screens and Western blots are of a preliminary
j,experiment of one transfection. The quantification data are expressed as the 
percentage change in phosphorylation over the control of this one experiment.
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Figure 4.10 -  In vivo phosphorylation of truncated rat PDE4A5, less the 
N-terminal and UCR1 region, in C0S1 cells stimulated with anisomycin.
C0S1 cells were transfected to transiently over-express Pro-197 to Ala-844 of 
PDE4A5. The cells were grown in phosphate-free cell media, which was 
supplemented with pP]-orthophosphate 24h prior to cell treatments. 
Activation of the p38 MAPK signalling pathway was initiated with anisomycin 
(lOpg/ml) for 60min. The cells were also treated with anisomycin plus the p38 
MAPK inhibitor, SB203580 (lOpM) for 60min each respectively. Total cell 
lysate was produced and PDE4A5-A N-terminal and UCR1 was immuno- 
precipitated using an anti-serum specific to the C-terminal region of all rat 
PDE4A isoforms. Again, this antibody was conjugated to Protein G agarose 
with the control immuno-precipitation un-conjugated Protein G agarose. The 
immuno-precipitated proteins were separated by SDS-PAGE and transferred 
to a nitrocellulose membrane where the radioactive proteins were resolved 
using phosphor image screen technology, (a), top panel, is a scanned 
phosphor image screen of the phosphorylated PDE4A5-A N-terminal and 
UGR1, immuno-precipitated following treatment with anisomycin plus or minus 
SB203580. (a), bottom panel, is a Western blot of the same nitrocellulose 
membrane probed with the C-terminal specific rat PDE4A antibody to 
determine the relative PDE4A5 immuno-precipitation in the three treatment 
cell extracts, (a), graph, shows the quantification of the change in the 
phosphorylation state of the PDE4A5-A N-terminal and UCR1 protein 
following activation of the p38 MAPK signalling pathway compared to the no 
treatment control (100%). These quantifications take into account the relative 
immuno-reactive amounts of PDE4A5-A N-terminal and UCR1 isolated by 
immuno-precipitation. (b), are Western blots of total cell lysate immuno- 
probed for both p38 MAPK activation and total p38 MAPK cellular expression. 
All scanned phosphor image screens and Western blots are typical of 
separate transfections and experiments undertaken twice. The quantification 
data, representative of the change in phosphorylation as a function of 
PDE4A5-A N-terminal and UCR1 immuno-precipitated, are mean values +/- 
standard deviation of the two experiments. Paired t-test statistical analysis of 
the quantified phosphorylation data were undertaken, where p < 0.05
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indicates a statistically significant difference in the level of truncated PDE4A5 
phosphorylation between untreated and treated cells, as indicated.
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Figure 4.11 ~ In vivo phosphorylation of rat PDE4A5 Ser-147-Ala in C0S1 
cells stimulated with anisomycin.
à'-ï.
The vsv-tagged rat PDE4A5-Ser-147-Ala protein was transiently expressed in 
C0S1 cells. The cells were grown in phosphate-free cell media that was 
supplemented with pP]-orthophosphate at least 24h prior to cell treatment.
The cells were treated with anisomycin (lOpg/mi for 60min) or anisomycin
plus SB203580 (10pM for 60min). PDE4A5-Ser-147-Ala-vsv was immuno-
precipitated from total cell lysate using an anti-vsv monoclonal antibody
conjugated to Protein G agarose. Un-conjugated Protein G agarose was
used as the control immuno-precipitation. The immuno-precipitated proteins |
were separated by SDS-PAGE and transferred to a nitrocellulose membrane
where the radioactive proteins were resolved using phosphor image screen
technology, (a), top panel, is a laser scanned phosphor image screen of the
phosphorylated PDE4A5-Ser-147-Ala-vsv immuno-precipitated following
treatment with anisomycin plus or minus SB203580. (a), bottom panel, is a
Western blot of the same nitrocellulose membrane probed with the anti-vsv
monoclonal antibody to determine the relative PDE4A5 immuno-precipitation
from the three cell lysates, (a), graph, displays the quantification of the
Ichange in phosphorylation of PDE4A5-Ser-147-Ala-vsv following activation of 
the p38 MAPK signalling cascade against the no treatment control (100%).
These data take into account the relative immuno-reactive amounts of
■5PDE4A5-Ser-147-Ala-vsv isolated by immuno-precipitation. (b), are Western 
blots of total cell lysate immuno-probed for p38 MAPK activation together with 
the corresponding total cellular expression of the kinase. All scanned ■-Îphosphor image screens and Western blots are representative of at least four 
separate transfections and experiments. These quantification data are 
expressed as the mean percentage change in phosphorylation over the no 
treatment control +/- standard deviation of the four separate experiments.
Paired t-test statistical analysis of the quantified phosphorylation data were 
undertaken, where p < 0.05 indicates a statistically significant difference in the 
level of PDE4A5 Ser-147-Ala phosphorylation between untreated and treated 
cells, as indicated. |
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Figure 4.12 -  In vivo phosphorylation of rat PDE4A5 Ser-161 -Ala in COS1 
cells stimulated with anisomycin.
The vsv-tagged PDE4A5-Ser-161-Ala protein was transiently expressed In 
C0S1 cells. The cells were grown in phosphate-free cell media that was 
supplemented with pP]-orthophosphate at least 24h prior to cell treatment. 
The cells were treated with anisomycin (10pg/ml for 60min) or anisomycin 
plus SB203580 (10pM for 60min). PDE4A5-Ser-161-Ala-vsv was immuno- 
precipitated from total cell lysate using an anti-vsv monoclonal antibody 
conjugated to Protein G agarose. Un-conjugated Protein G agarose was 
used as the immuno-precipitation control. The immuno-precipitated proteins 
were separated by SDS-PAGE and transferred to a nitrocellulose membrane 
where the radioactive proteins were resolved using phosphor image screen 
technology, (a), top panel, is a laser scanned phosphor image screen of the 
phosphorylated PDE4A5-Ser-161 -Ala-vsv immuno-precipitated following 
treatment with anisomycin plus or minus SB203580. (a), bottom panel, is a 
Western blot of the same nitrocellulose membrane probed with the anti-vsv 
monoclonal antibody to determine the relative PDE4A5 immuno-precipitation 
from the three cell lysates, (a), graph, displays the quantification of the 
change in the phosphorylation state of PDE4A5-Ser-161-Ala-vsv following 
activation of the p38 MAPK signalling cascade compared to the no treatment 
control (100%). These data take into account the relative immuno-reactive 
amounts of PDE4A5-Ser-161-Ala-vsv isolated by immuno-precipitation. (b), 
are Western blots of total cell lysate immuno-probed for both p38 MAPK 
activation and the corresponding total cellular expression of the kinase. All 
scanned phosphor image screens and Western blots are representative of 
two separate transfections and experiments. These quantification data are 
expressed as the mean percentage change in phosphorylation over the no 
treatment control +/- standard deviation of the two separate experiments. 
Paired t-test statistical analysis of the quantified phosphorylation data were 
undertaken, where p < 0.05 indicates a statistically significant difference in the 
level of PDE4A5 Ser-161-Ala phosphorylation between untreated and treated 
cells, as indicated.
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Figure 4.13 -  In vivo anisomycin-induced phosphorylation of rat PDE4A5 
in COS1 cells with siRNA to eliminate endogenous MAPKAPK2.
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A time course of siRNA knockdown of MAPKAPK2 was undertaken in C0S1 
cells and the total cell lysates were immuno-probed for endogenous 
MAPKAPK2 expression. C0S1 cells were optimally co-transfected with 
MAPKAPK2 siRNA and wild type vsv-PDE4A5. The cells were grown in 
phosphate-free cell media supplemented with pP]-orthophosphate 24h prior 
to anisomycin (10pg/ml for 60min) cell treatment. PDE4A5-vsv was immuno- 
precipitated from cell lysate using an anti-vsv antibody conjugated to Protein 
G agarose. Un-conjugated Protein G agarose was used as the immuno- 
precipitation control. The immuno-precipitated proteins were separated by 
SDS-PAGE, transferred to a nitrocellulose membrane and the radioactive .'Iproteins resolved using phosphor image screen technology, (a), top panel, is 
a Western blot of endogenous MAPKAPK2 expression in C0S1 cells, (a), 
middle panel, shows a Western blot of endogenous MAPKAPK2 expression in 
C0S1 cells transfected with a non-targeting siRNA. (a), bottom panel, is a 
Western blot of endogenous MAPKAPK2 expression in C0S1 cells following 
transfection with MAPKAPK2 specific siRNA. (b), top panel, is a laser 
scanned phosphor image screen of the phosphorylated PDE4A5-vsv immuno- 
precipitated following anisomycin treatment, (b), bottom panel, is a Western 
blot of the same membrane probed with the anti-vsv antibody to determine the 
relative PDE4A5 immuno-precipitation from the cell lysates, (b), graph, 1'displays the quantification of the phosphorylation state of PDE4A5-vsv, in '/Icells with no expression of MAPKAPK2, following p38 MAPK activation.
These data incorporate the relative immuno-reactive amounts of PDE4A5-vsv 
isolated by immuno-precipitation. (c), are Western blots of cell lysate 
immuno-probed for p38 MAPK activation together with total cellular 
expression of p38 MAPK and MAPKAPK2. All scanned phosphor image 
screens and Western blots are representative of three separate transfections 
and experiments. These quantification data are expressed as the mean 
percentage change in phosphorylation of at least three separate transfections 
and experiments over the no treatment control +/- standard deviation. Paired 
t-test statistical analysis of the quantified phosphorylation data were
■s
I
Chapter 4 MAPKAPK2 phosphorylation of PDE4A5 uiundertaken, where p < 0.05 indicates a statistically significant difference in the 
level of PDE4A5 wild type phosphorylation between untreated and treated 
cells, as indicated.
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Figure 4.14 -  Phosphorylation and activation of rat PDE4A5 by PKA.
232
COS1 cells were transfected to transiently express wild type rat PDE4A5.
■The transfected cells were pre-treated for 10min with the non-specific PDE 
inhibitor, IBMX (100pM) before challenge, 0-20min, with the adenyly! cyclase 
activator, forskolin (lOOpM). (a), top panel, is a Western blot probed with the 
phospho-UCR1 specific anti-serum to the PKA phosphorylated serine (S*) 
residue within the RRES*F consensus motif [MacKenzie et al., 2002]. (a), 
bottom panel, shows the same Western blot re-probed with a rat PDE4A C- 
terminal specific anti-serum to provide both loading and PDE4A5 expression 
controls, (b), shows the densitometry of the phospho-UCR1 time course.
corrected for PDE4A5 expression, (c), shows the effect of the PKA %phosphorylation on PDE4A5 enzymatic activity. Assays were done using 1 pM 
cAMP as substrate with C0S1 cell lysates expressing equal immuno-reactive 
amounts of PDE4A5, as determined by the quantification of PDE4A5 
expression. All data shown are either representative Western blots of three 
separate transfections and experiments, or mean data +/- standard deviation 
of the three separate transfections and experiments.
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Figure 4.15 -  Phosphorylation of rat PDE4A5 by MAPKAPK2 and activity 
analysis.
C0S1 cells were transfected to transiently express rat PDE4A5. The 
transfected cells were treated for up to 60min with anisomycin (lOpg/ml). (a), 
top panel, is a Western blot probed with a novel, specific anti-serum to the 
MAPKAPK2 phosphorylated serine (S*) residue in the LYRSDS* consensus 
motif within the UCR1 regulatory module, (a), bottom panel, shows the same 
Western blot re-probed with a rat PDE4A C-terminal specific anti-serum to 
provide both loading and PDE4A5 expression controls, (b), quantifies the 
MAPKAPK2 phosphorylation time course of PDE4A5 by determining the 
densitometry of the immuno-reactive bands detected with both the novel 
phosphorylation anti-serum and the anti-serum for PDE4A5 total cellular 
expression. These were expressed as a percentage of the maximum 
phosphorylation to expression ratio, (c), shows the effect of the MAPKAPK2 
phosphorylation on PDE4A5 wild type catalytic activity. Assays were done 
using 1pM cAMP as substrate with C0S1 cell lysates expressing equal 
immuno-reactive amounts of PDE4A5, as determined by the quantification of 
PDE4A5 expression, (d), top panel, is a Western blot of total C0S1 cell 
lysate transfected with rat PDE4A5-Ser-147-Ala and probed with the novel 
anti-serum specific to the MAPKAPK2 phosphorylated target Ser-147. (d), 
bottom panel, is the associated PDE4A5-Ser-147-Ala loading and expression 
control detected using the rat PDE4A C-terminal specific antibody. All data 
shown are either representative Western blots of three separate transfections 
and experiments, or are mean data +/- standard deviation of the three 
separate transfections and experiments.
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Figure 4.16 -  Dual phosphorylation of PDE4A5 by MAPKAPK2 and PKA.
C0S1 cells were transfected to transiently express PDE4A5. Cells were pre­
treated with anisomycin (10pg/ml) for 30min and then IBMX (lOOpM) for 
lOmin. The cells were then challenged with forskolin (100pM) for 0-20min, as 
indicated, (a), top panel, is a Western blot probed with the phospho-UCRI 
anti-serum to the PKA phosphorylated serine within the RRES*F consensus a
motif of all long PDE4 isoforms [MacKenzie et al., 2002]. (a), bottom panel, is 
the same Western blot re-probed for PDE4A5 expression using an anti-serum 
specific to the unique C-terminal region of rat PDE4A isoforms and also acts 
as loading controls. (b), illustrates the quantification of the PKA 
phosphorylation corrected for the total PDE4A5 expression. This is presented 
as a percentage of the maximum phosphorylation, (c), shows the effect of the 5dual MAPKAPK2 and PKA phosphorylation on PDE4A5 enzymatic activity. itAssays were done using 1pM cAMP as substrate with C0S1 cell lysates
expressing equal immuno-reactive amounts of PDE4A5, as determined by the
quantification of PDE4A5 expression. All data shown are either
representative Western blots of two separate transfections and experiments,
or are mean data +/- standard deviation of the two separate transfections and 
.experiments.
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Figure 4.17 -  Rolipram inhibition of PDE4A5 wild type or PDE4A5 Ser- 
147“Asp.
COS1 cells were transfected to transiently express wild type PDE4A5 or 
PDE4A5 Ser-147-Asp before sub-cellular fractionation into high-speed 
supernatant (82). PDE4 activity assays were done using IpM cAMP as 
substrate against a range of rolipram concentrations, as indicated. The data 
presented here are mean values +/- standard deviation of three separate 
transfections and sub-cellular fractionations. The determinations of the 
respective IC50 values for each inhibitor are shown in Table 4.1.
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Inhibitor PDE4A5 Wild type (S2)
PDE4A5 
Sen 47Asp (S2)
Rolipram 1.10+/- 0.28 2.13+/- 0.36
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Table 4.2 -  Rolipram inhibition of PDE4A5 wild type or PDE4A5 Ser-147-
,Asp.
C0S1 cells were transfected to transiently express each isoform before sub- 
cellular fractionation into high-speed supernatant (S2). Assays were done 
using 1pM cAMP as substrate against a range of inhibitor concentrations as 
indicated in Figure 4.17. These data are given as IC50 values in micro-molar 
(pM) concentrations and are mean values +/- the standard deviation from 
three separate transfections.
.ill-.
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IFigure 4.18 -  Distribution of native PDE4A5 and MAPKAPK2 
phosphorylated PDE4A5 in C0S1 cells.
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(a), top panel, shows a Western blot of the distribution of wild type PDE4A5 
when transiently over-expressed in untreated C0S1 cells, (a), bottom panel, 
shows a Western blot of the distribution of wild type PDE4A5 following 
treatment with anisomycin (lOpg/ml for 60min). C0S1 cells were harvested 
and subjected to sub-cellular fractionation producing the high-speed 
supernatant (S2), the high-speed pellet (P2), and the low-speed pellet (P1) as I
described previously [McPhee et al., 1999]. (b), shows laser-scanning
confocal microscopy analysis of PDE4A5 distribution in C0S1 cells with 
anisomycin treatment (lOpg/ml) at the indicated times. COS1 cells were 
transfected to express PDE4A5 and then visualised immunologically using the 
rat PDE4A C-terminal specific anti-serum to evaluate any change in PDE4A5 
localisation compared to the time zero control. All data are examples of 
experiments done at least three times with different transfections.
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Figure 4.19 -  MAPKAPK2 phosphorylation of PDE4A5 and the 
interaction with the scaffold protein p-arrestin2.
C0S1 cells were co-transfected to transiently express both vsv-tagged 
PDE4A5 and FLAG-tagged ^-arresting. The transfected cells were either 
retained as control cells or treated with anisomycin (10pg/ml for 60 minutes), 
IBMX and forskolin (100pM for iOmin respectively) or both treatments 
together. Total cell lysate was produced and ^-arresting, and its associated 
proteins, was immuno-precipitated using FLAG agarose. The immuno- 
precipitated proteins were separated by SDS-PAGE and immuno-probed for 
possible PDE4A5-p-arrestin2 interaction using a specific anti-serum to the 
unique C-terminal region of rat PDE4A isoforms, (a) (i), is a Western blot 
showing the relative immuno-reactive amounts of PDE4A5 expressed in each 
cell lysate prior to immuno-precipitation and the immuno-reactive amounts 
interacting with j3-arrestin2 following co-immuno-precipitation. (a) (ii), is a 
Western blot showing the relative immuno-reactive amounts of (3-arrestin2 
expressed in each cell lysate and the relative immuno-reactive amounts 
immuno-precipitated using FLAG agarose, (b), presents the quantification of 
the Western blots assessing the effect of the MAPKAPK2 and/or PKA 
phosphorylation of PDE4A5 upon the interaction with (3-arrestin2. 
Quantification of the immuno-precipitation corrects for the expression of both 
proteins in the initial cell extract and for immuno-precipitation efficiency, (c), is 
a Western blot of a control FLAG agarose immuno-precipitation using C0S1 
cell lysate singularly transfected with vsv-tagged PDE4A5. All Western blots 
are representative of transfections and experiments undertaken at least three 
times and quantification data is expressed as mean values +/- standard 
deviation of at least three separate transfections and experiments.
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Figure 4.20 -  MAPKAPK2 phosphorylation of PDE4A5 and the 
interaction with the immuno-phllin XAP2.
C0S1 cells were co-transfected to transiently express both vsv-tagged 
PDE4A5 and FLAG-tagged XAP2. The transfected cells were either retained 
as control cells or treated with anisomycin (10pg/ml for 60min), IBMX and 
forskolin (lOOpM for 10min respectively) or both treatments together. Total 
cell lysate was produced and XAP2, and its associated proteins, were 
immuno-precipitated using FLAG agarose. The immuno-precipitated proteins 
were separated by SDS-PAGE and immuno-probed for possible PDE4A5- 
XAP2 interaction using a specific anti-serum to the unique C-terminal region 
of rat PDE4A isoforms, (a) (i), is a Western blot showing the relative immuno- 
reactive amounts of PDE4A5 expressed in each cell lysate prior to immuno- 
precipitation and the immuno-reactive amounts interacting with XAP2 
following co-immuno-precipitation. (a) (ii), is a Western blot showing the
relative immuno-reactive amounts of XAP2 expressed in each cell lysate and 
the relative immuno-reactive amounts immuno-precipitated using FLAG 
agarose, (b), presents the quantification of the Western blots assessing the 
effect of the MAPKAPK2 and/or PKA phosphorylation of PDE4A5 upon the 
interaction with XAP2. Quantification of the immuno-precipitation corrects for 
the expression of both proteins in the initial cell extract and for immuno- 
precipitation efficiency, (c), is a Western blot of a control FLAG agarose 
immuno-precipitation using C0S1 cell lysate singularly transfected with vsv- 
tagged PDE4A5. All Western blots are representative of transfections and 
experiments undertaken at least three times and quantification data is 
expressed as mean values +/- standard deviation of at least three separate 
transfections and experiments. Paired t-test statistical analysis of the 
quantified co-immuno-precipitation data were undertaken, where p < 0.05 
indicates a statistically significant difference in the level of PDE4A5 co- 
immuno-precipitated with XAP2 between native and treated cells, as 
indicated.
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Chapter 4 MAPKAPK2 phosphorylation of PDE4A5 IFigure 4.21 -  Cleavage of wild type and MAPKAPK2 phosphorylated 
PDE4A5 by recombinant caspase-3.
■
Total cellular lysates from C0S1 cells transiently expressing PDE4A5 (wild 
type; no treatment, wild type; anisomycin treated, Ser-147-Asp mutant or Ser- 
147-Ala mutant) were incubated in the presence of recombinant caspase-3 for 
2h at 37°C. All panels are Western blots of C0S1 cell lysate expressing ;
249
PDE4A5 and probed with a specific anti-serum to the unique C-terminal 
region of rat PDE4A isoforms to detect both full length (-110 kDa) and 
caspase-3 cleaved species (-100 kDa) [Huston et al., 2000]. All Western 
blots are representative of transfections and experiments undertaken at least 
three times.
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4.3 Discussion
s
■|
The p38 MAPK phosphorylation cascade plays a fundamental role in 
regulating the immune and inflammatory response to infection and tissue 
injury [Herlaar and Brown, 1999 and Dong et al., 2002]. p38 MAPK activity 
regulates cell adhesion and migration, cytokine expression, and function of 
many immune and inflammatory cells including monocytes, macrophages, 
mast cells and T-lymphocytes [Guo et al., 2003]. Therefore, it has been 
proposed that inhibition of p38 MAPK activity may be of potential therapeutic 
benefit in disease states characterised by excessive immune or inflammatory 
reactions, such as asthma, COPD, rheumatoid arthritis and psoriasis [Herlaar 
and Brown, 1999 and Saklatvala, 2004].
Early work from the Houslay laboratory has indicated potential 
signalling cross talk between the p38 MAPK signalling cascade and the 
regulation of intra-cellular cAMP concentrations [MacKenzie and Houslay, 
2000]. This work concluded for the first time that IFNy, a pro-inflammatory 
cytokine, could activate monocytic p38 MAPK activity and that the activation 
was attenuated by rolipram inhibition of PDE4 activity. However, in contrast 
to these data, cAMP has been shown to activate p38 MAPK in FRTL-5 rat 
thyroid cells in a PKA- and Rad-dependent manner indicating cell-type 
specific signalling patterns [Pomerance et al., 2000].
These effects are consistent with the plethora of data that implicates 
both PDE4 [Souness et al., 1999, Jin and Conti, 2002, Houslay et al., 2005 
and Zhang et al., 2005] and p38 MAPK inhibition as potential means of 
attenuating pro-inflammatory cytokine production and the overall inflammatory 
response.
%
Scanning the primary amino acid sequence of PDE4A5, utilising the 
ScanSite database (http://scansite.mit.edu/cai-bin/motifscan sea) on medium 
stringency, predicted two putative p38 MAPK phosphorylation sites at Thr-437 
and Thr-776 (Figure 4.2). Scanning the PDE4A5 primary amino acid
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sequence for the MAPKAPK2 phosphorylation consensus sequence, 0-Xaa-
Arg-Xaa-Xaa-Ser*-0 where 0  represents a hydrophobic amino acid, revealed
two potential MAPKAPK2 phosphorylation sites, namely Ser-147 and Ser-161
(Figure 4.2). Ser-161 (Val-Ser-Arg-Ser-Ser-Ser*-Val) is surrounded by i
optimal residues for MAPKAPK2 phosphorylation whereas the Ser-147 (Leu-
Tyr-Arg-Ser-Asp-Ser*-Asp) contains a less favourable N-terminal hydrophobic
leucine residue and a C-terminal aspartic acid residue [Rousseau et al.,
/.i::2005]. Discrepancy exists however for the requirement of the C-terminal
.1hydrophobic residue and therefore both Ser-147 and Ser-161 are possible MAPKAPK2 phosphorylation target sites based on our current knowledge 
[Stokoe et al., 1993], Furthermore, in the case of Nogo-2, a recently identified 
MAPKAPK2 substrate, optimal consensus motifs were not required for
phosphorylation to occur [Rousseau et al., 2005]. Analysis of the consensus 
motifs for MAPKAPK2 phosphorylation on two well-established substrates, 
HSP27 and 5-lipoxygenase, permits the presence of a leucine residue at the 
position n -  5 from the target serine [Werz et al., 2000].
In vitro phosphorylation of a recombinant MBP fusion protein of 
PDE4A5 (Figure 4.3) with recombinant, active MAPKAPK2 or p38 MAPK 
provided initial evidence that PDE4A5 was a potential substrate for both 
kinases (Figure 4.4). These initial experiments alluded to PDE4A5 being 
phosphorylated at Ser-147 by MAPKAPK2. Additional sites may also be
I
available because the level of phosphorylation was not completely ablated 
with the Ser-147-Ala mutant form of PDE4A5. However, as with all in vitro 
protein kinase phosphorylation assays there is a propensity for background or
indiscriminate phosphorylation to occur [Berwick and Ta va ré, 2004]. To
reconcile whether this was the case a time course of in vitro phosphorylation 
coupled with a positive, i.e. HSP27 or 5-lipoxygenase, and a negative control, 
i.e. MBP, needs to be undertaken. Furthermore, it is possible that MBP itself 
is a target for both MAPKAPK2 and p38 MAPK,
Activation of p38 MAPK in most cells can be induced with anisomycin, 
which acts synergistically with growth factors through stimulation of the G- 
proteins, Rac and Cdc42 (Figures 4.1 and 4.6) [Cahill et al., 1996 and Uhlik et
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al., 2003]. The delayed onset of MAPKAPK2 activation with anisomycin was 
noted and this is indicative of its location downstream of p38 MAPK in the 
phosphorylation cascade. The pro-inflammatory cytokine TNFa is a potent 
and rapid activator of p38 MAPK and MAPKAPK2 via the TNF receptor, 
recruitment of TRAF2, and activation of ASK (Figures 4.1 and 4.7) [Ichijo et 
al., 1997 and Nishitoh et al., 1998]. Anisomycin was used to stimulate p38 
MAPK activity in COS1 cells over-expressing PDE4A5, with the aim of 
confirming any physiological effects with TNFa-treated cells expressing 
immuno-logically detectable levels of endogenous PDE4A5.
PDE4A5 was phosphorylated in vivo in a p38 MAPK-dependent 
manner, as indicated following anisomycin treatment and co-incubation with 
the specific p38 MAPK inhibitor, SB203580 (Figure 4.8) [Cuenda et al., 1995, 
Young et al., 1997, Davies et al., 2000 and Guo et al., 2003]. These data 
identified PDE4A5 as a substrate of p38 MAPK or a p38 MAPK-dependent 
protein kinase. Of intrigue was the immuno-precipitation of a phosphorylated 
band of a marginally higher molecular weight to PDE4A5. This protein was 
also immuno-precipitated with Protein G agarose beads alone and was not 
detected following Western immuno-blotting with the VSV monoclonal 
antibody used to assess PDE4A5 immuno-precipitation efficiency. PDE4A5 
(IIOkDa) is subject to cleavage by caspase-3 at Asp-69 within the Asp-Ala- 
Val-Asp motif located within the unique N-terminal region [Huston et al., 
2000]. Cleavage results in the production of a truncated PDE4A5 species of 
approximately lOOkDa. If indeed the doublet was indicative of native and 
cleaved PDE4A5 then an immuno-reactive doublet would have been revealed 
on the Western blot, as PDE4A5 is in fusion with VSV at the C-terminal. 
Furthermore, the unidentified protein in the control immuno-precipitation does 
not appear to be subject to p38 MAPK-dependent phosphorylation.
Utilising N-terminal truncations of PDE4A5 [Beard et al., 2002], it was 
concluded that the UCR1 module was subject to phosphorylation via 
activation of the p38 MAPK signalling pathway (Figures 4.9 and 4.10). 
Relating these data to the initial phosphorylation motif scanning and 
preliminary in vitro phosphorylation data implied that MAPKAPK2 was
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responsible for mediating the p38 MAPK-dependent phosphorylation. Site- 
directed mutagenesis of Ser-147-Ala and Ser-161-Ala within the MAPKAPK2 
consensus motifs identified Ser-147 as the sole target for PDE4A5 
phosphorylation (Figures 4.11 and 4.12). Generation of a phospho-specific 
anti-serum further confirmed Ser-147 as the target phosphorylation residue 
and, as expected, anisomycin induced a time-dependent increase in the level 
of phosphorylation at this site (Figure 4.15). The anti-serum also identified a 
level of basal phosphorylation at Ser-147, which was ablated on alanine î
mutation.
Small interfering RNA (siRNA) is a very powerful tool used to 
elucidate the functional significance of cell signalling enzymes, kinases and 
scaffold proteins. siRNAs are targeted 19-25 nucleotides that specifically 
knockdown endogenous protein expression in mammalian cells [Banan and 
Puri, 2004 and Jones et al., 2004]. They do this by incorporating into RNA- 
induced silencing complexes, which bind to mRNA transcripts through 
complementary base pair interactions. This targets the mRNA for 
degradation, resulting in the ablation of protein expression. MAPKAPK2 
siRNA completely ablated endogenous expression in COS1 cells [San Miguel 
et al., 2005]. Phosphorylation of PDE4A5 was completely ablated in 
MAPKAPK2 deficient C0S1 cells and therefore identified MAPKAPK2 as the 
relevant protein kinase downstream of p38 MAPK.
Proving that proteins are authentic substrates for specific protein 
kinases is extremely difficult given the promiscuous nature of in vitro 
phosphorylation assays, and the complexity and integration of cell signalling 
pathways. To address such concerns certain criteria should be satisfied en- 
route to formally identifying protein kinase substrates [Berwick and Tavaré,
2004]. These criteria include (1) the recombinant in vitro phosphorylation of 
the proposed substrate and reduction of phosphorylation using site-specific 
alanine mutant(s) (Figure 4.4), (2) proving that the phosphorylation can occur 
in intact cells to a stimuli that activates the protein kinase in a stimulus and 
concentration-dependent time course (Figures 4.6, 4.8 and 4.15), (3) 
matching the phosphorylation site in vivo to the phosphorylation site in vitro
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(Figures 4.4, 4.11 and 4.15) and (4) ablating, or at least attenuating, the 
phosphorylation using specific inhibitors or siRNA knockdown of protein 
kinase expression (Figures 4.8 and 4.13) [Berwick and Tavaré, 2004]. As 
PDE4A5 satisfies each of these criteria for MAPKAPK2 phosphorylation, I 
conclude that PDE4A5 is a bone fide substrate of MAPKAPK2 in cells, with 
phosphorylation occurring at a single serine residue (Ser-147).
The phosphorylation of PDE4 enzymes by a cAMP-dependent protein 
kinase, now known to as PKA, was first shown in thyroid FRTL-5 cells on 
stimulation with TSH [Sette et al., 1994]. Further work identified a conserved 
single serine residue (Ser-54 of PDE4D3) within the UCR1 module as the 
phosphorylation target and the enzyme activation it conferred [Sette and 
Conti, 1996, Hoffman et al., 1998 and MacKenzie et al., 2002]. These data 
provided the first evidence that these domains participate in the regulation of 
catalytic activity, and therefore must interact in some way. PKA 
phosphorylation is proposed to relieve an inhibitory constraint conferred upon 
the catalytic machinery by UCR2 via disruption of the intra-molecular 
interactions between the UCR1 and UCR2 regulatory domains [Lim et al.,
1999 and Beard et al., 2000]. The resolution of the crystal structure of the N- 
terminal region and UCR domains of full-length PDE4 isoforms will provide 
much needed insight into the mechanism through which these domains 
regulate the catalytic unit and how PKA phosphorylation impacts on such 
regulation.
As previously described, PDE4A5 enzyme activity is markedly 
enhanced following PKA phosphorylation (Figure 4.14) [MacKenzie et al.,
2002 and Bolger et al., 2003]. However, MAPKAPK2 phosphorylation of 
PDE4A5 exerts no functional effect upon catalytic activity (Figure 4.15).
Because of UCR1 conservation across the PDE4 gene families, one would 
expect MAPKAPK2 to phosphorylate all PDE4 long isoforms. PDE4 isoforms 
differ by virtue of their unique N-terminal regions and their sub-family specific 
LR1, LR2 and C-terminal regions [Houslay, 2001 and Houslay et al., 2005].
Therefore, although PDE4A5 phosphorylation by MAPKAPK2 does not exert 
functional consequences upon catalytic activity, other long isoforms may
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behave differently, by virtue of their unique properties. For example, the 
PDE4D3 long isoform is phosphorylated by PKA, but this is the only isoform 
where it confers both activation of catalytic activity and increased sensitivity to 
rolipram inhibition [Hoffmann et al., 1998]. Phosphorylation of other long 
isoforms across all gene families facilitates a similar activation but displays no 
altered rolipram inhibition profile to the native form [MacKenzie et al., 2002]. 
Utilising a Ser-147-Asp phospho-mimetic shows that MAPKAPK2 
phosphorylation does not alter PDE4A5 sensitivity to rolipram inhibition 
(Figure 4.17).
Adding credence to isoform specific modifications conferred upon 
phosphorylation and/or protein interactions, PDE4A4B is the only isoform 
susceptible to conformational switching, as sensed by altered rolipram 
inhibition, on interaction with the SH3 domain of the tyrosyl kinase Lyn 
[McPhee et al., 1999]. It is also the only isoform to form accretion foci in cells 
following chronic rolipram treatment [Terry et al., 2003]. Thus, long isoforms 
for the PDE4B, PDE4C and PDE4D gene families should be assessed for 
functional attributes conferred upon MAPKAPK2 phosphorylation, including 
enzyme activity and rolipram inhibition.
The phosphorylation site for MAPKAPK2 is located some n + 7 
residues upstream of the target PKA phosphorylation site at Ser-140. It was 
hypothesised that phosphorylation by MAPKAKP2 may not confer a functional 
effect in isolation but may play a role in controlling the PKA activation state of 
PDE4A5. This was indeed the case where MAPKAPK2 phosphorylation 
delayed both the onset and amplitude of PKA activation (Figure 4.16). A 
similar effect was noted upon interaction of PDE4A5 with XAP2 [Bolger et al.,
2003]. This also delayed the onset and amplitude of PKA-mediated PDE4A5 
activation and was attributed to two possible mechanisms; (1) the interaction 
of XAP2 with the unique N-terminal region and UCR2 or (2) the disruptions of 
the UCR1-UCR2 intra-molecular interaction, where both interdict the 
availability of the PKA phosphorylation motif. Therefore, one can infer that 
MAPKAPK2 phosphorylation of PDE4A5 may modulate the PKA-mediated 
activation in a similar vain, as it hinders XAP2 binding (Figure 4.20) and also
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delays the onset and amplitude of PKA phosphorylation. Therefore, in cells 
where the p38 MAPK-MAPKAPK2 signalling pathway is active, activation of 
PKA in a negative feedback system to control local cAMP concentrations will 
be attenuated due to active MAPKAPK2.
IIn T-lymphocytes PDE4A isoforms can interact with AKAP1, AKAP3 
and AKAP8 [Asirvatham et al., 2004]. In bovine spermatozoa PDE4A5 has 
been specifically targeted for interaction with AKAP3 [Bajpai et al., 2006].
Thus, the delayed onset and amplitude of PKA activation of PDE4A5 may be 
mediated by attenuation of AKAP interactions with PDE4A5 following 
MAPKAPK2 phosphorylation. Mapping of potential AKAPs and their binding 
sites on PDE4A5 will give insight into whether such modulation of interaction 
is possible. There is a precedent for such phosphorylation-induced 
modification of PDE4-AKAP interactions, where the PKA phosphorylation 
state of Ser-13 within the N-terminal region of PDE4D3 enhances its affinity 
for binding AKAP6 [Carlisle Michel et al., 2004]. One would advocate
Ï
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experiments in T-lymphocytes, where endogenous levels of PDE4A5 and 
specifically AKAP1 and AKAP8 can be immunologically detected, to assess 
their interaction following activation of the p38 MAPK phosphorylation 
cascade [Asirvatham et al., 2004]. Furthermore, given the comparable intra­
cellular distribution of these AKAPs and PDE4A5, e.g. at the perinuclear 
region, raises the possibility of their co-localisation (Figure 4.18) [McPhee et 
al., 1995, Huston et al., 2000, Beard et al., 2002 and Asirvatham et al., 2004].
■i
The unique N-terminal region of PDE4A5 has also been shown to 
mediate multiple interactions with partner proteins. These include SH3 
domain-containing proteins, such as Lyn tyrosyl kinase, susceptibility for 
binding and cleavage by caspase-3, and interaction with scaffold and adaptor |
proteins such as (3-arrestin and XAP2 [McPhee et al., 1999, Huston et al.,
2000, Beard et al., 2002, Bolger et al., 2003 and Wallace et al., 2005]. Many 
of these interactions are supported at additional sites within the regulatory and 
catalytic domains.
I
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MAPKAPK2 can also bind SH3 domains through its proline-rich N~ 
terminal region [Ben-Levy et al., 1995]. The Abl tyrosyl kinase has been 
identified as a partner protein of MAPKAPK2 and this may imply the 
requirement of SH3 domain-containing proteins to control its intra-cellular :localisation. Additionally, SH3 domain-containing proteins may act as a 
scaffold protein to recruit PDE4A isoforms in vivo and impart specificity to the 
phosphorylation, as only PDE4A isoforms and the unique N-terminal region of 
PDE4D4 can interact with SH3 domain-containing proteins and thus will not 
be able to recruit MAPKAPK2 [McPhee et al., 1999 and Beard et al., 1999].
However, the positive phosphorylation of the N-terminal truncated form of 
PDE4A5 potentially eliminates such a possibility of using the N-terminal SH3 
binding region and given the other proline-rich region located within the C- 
terminal region of PDE4A4B are not conserved to provide additional or 
compensatory binding regions (Figures 3.15 and 4.9) [McPhee et al., 1999].
Furthermore, the Abl tyrosyl kinase interacts poorly with PDE4A4B adding 
power to the argument against SH3-mediated bridging interactions [McPhee 
et al., 1999].
MAPKAPK2 phosphorylation of PDE4A5 does not alter PDE4A5 
susceptibility for caspase-3 cleavage (Figure 4.21). PDE4A5 cleavage by 
caspase-3 disrupts both interactions with SH3 domain-containing proteins and 
its intra-cellular targeting [Beard et al., 1999 and Huston et al., 2000].
Therefore, it is unlikely that MAPKAPK2 phosphorylation will disrupt N- 
terminal SH3 domain Interactions as this would result in alterations to its intra­
cellular targeting in a manner analogous to either progressive N-terminal 
truncation or caspase-3 cleavage (Figure 4.18(b)) [Huston et al., 2000 and 
Beard et al., 2002].
Analysis of PDE4A5 intra-cellular localisation by laser-scanning 
confocal microscopy identified PDE4A5 expression to predominate at a 
distinct perinuclear localisation with a proportion located at the cell margins, 
as previously identified [Beard et al., 2002]. No effect on intra-cellular 
localisation was mediated with anisomycin following sub-cellular fractionation 
or laser-scanning confocal microscopy (Figure 4.18). A note of caution; there
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are limitations to analysing the intra-cellular localisation profile of any protein 
when over-expressed due to the saturation of anchor sites and that different 
anchors are present at different concentrations in different cells. Also, sub- 
cellular fractionation is a crude means of evaluating intra-cellular distribution 
because reversible or weak protein interactions can be released upon cell 
breakage and this is likely to underlie the absence of PDE4A5 in the 
particulate fractions, as described previously [McPhee et al., 1995 and Beard 
et al., 2002]. Assessment of the intra-cellular distribution of MAPKAPK2 will 
also determine whether MAPKAPK2 and PDE4A5 exist in the same sub- 
cellular location in the basal state, or whether activation is required to release 
MAPKAPK2 from the nucleus and direct it towards a PDE4A5-containing sub- 
cellular location. Furthermore, it would be advantageous to confirm that 
PDE4A5 can be co-immuno-precipitated with MAPKAPK2 and identify further 
proteins involved in the complex, such as members of the Src tyrosyl kinases, 
which may be significant in kinase docking [Ben-Levy et al., 1995 and 
McPhee et al., 1999].
Adaptation of the structure of the actin cytoskeleton regulates a variety 
of cellular processes including migration, chemotaxis, adhesion and 
phagocytosis [Ibarra et al., 2005]. Activation of the p38 MAPK-MAPKAPK2 
pathway results in the phosphorylation of HSP27, actin polymerisation and 
accumulation, thereby contributing to the maintenance of the microfilament 
network [Guay et al., 1997]. Wiskott-Aldrich syndrome protein verprolin 
homologous-1 (WAVE-1) is a scaffold protein also involved in the regulation of 
the actin cytoskeleton [Soderling and Scott, 2006]. It recruits the actin-related 
protein 2/3 (Arp2/3) complex, which catalyses the formation of actin polymers 
and branching. Arp2/3 is a target for MAPKAPK2 and may be involved in its 
regulation [Singh et al., 2003]. The N-terminal WAVE homology domain of 
the WAVE-1 scaffold protein supports numerous protein interactions including 
HSPG300, Abi2 (Abl-interacting protein 2), Napi (Nck-associated protein), |
and Sral (specifically Rac-associated protein 1) [Soderling and Scott, 2006].
Active Racl-GTP regulates WAVE-1 through recruitment of Sral. It is also 
able to the recruit the Abl tyrosyl kinase through SH3 domain interactions with 
the proline-rich region of WAVE-1 and this interaction may facilitate the
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recruitment of MAPKAPK2 and the phosphorylation of Arp2/3 complex [Ben- 
Levy et al., 1995, Westphal et al., 2000 and Singh et al., 2003]. Furthermore, 
WAVE-1, but not WAVE-2 or WAVE-3, is able to function as an AKAP, 
binding the Rll sub-units of PKA [Westphal et al., 2000]. Indeed the Rll 
binding site is hypothesised to compete with actin for binding and therefore 
may be subject to regulation by actin concentration [Taskén and Aandahl,
2004]. Therefore, it would be interesting to ascertain whether PDE4A5 was 
part of this complex. If so, the reduction in onset and amplitude of PDE4A5 
PKA phosphorylation and activation, as a result of MAPKAPK2 
phosphorylation (Figure 4.16), could be indicative of enhanced actin binding 
and disruption of PKA interactions with WAVE-1. Given the evidence that 
Rad activity can also be regulated by cAMP and PKA in a variety of cells, 
PDE4 recruitment may participate in the regulation of the actin cytoskeleton 
[Pomerance et al., 2000, Waschke et al., 2004 and Pelletier et al., 2005].
I
iThe interaction of PDE4 enzymes with the scaffold protein (3-arrestin2 occurs at a conserved site within the catalytic unit, with preference for 
PDE4D5 facilitated through a second site located within the unique N-terminal 
region [Perry et al., 2002, Bolger et al., 2003 and Bolger et al., 2006]. In 
Chapter 3, Figure 3.16, it was confirmed that PDE4A4B, the human 
homologue of PDE4A5, and also PDE4A11, could interact with p-arrestin2 
[Wallace et al., 2005]. Consistent with these data is the confirmation that this >1interaction extends to PDE4A5 (Figure 4.19). Furthermore, it was concluded 
that conformational changes conferred upon the catalytic unit following UCR1 
phosphorylation of PDE4A5 by PKA or MAPKAPK2 do not affect its ability to 
interact with (3-arrestin2 (Figure 4.19).
PDE4D5 is the preferential and functionally relevant PDE4 isoform that 
interacts with p-arrestin2 and is responsible for the recruitment of PDE4 
activity to the GRK phosphorylated (32-adrenoceptor, resulting in the 
attenuation of local PKA activity and blockade of Gs to G| switching [Perry et 
al., 2002, Lynch et al., 2005, and Li et al., 2006]. Whether MAPKAPK2 affects 
the ability of the PDE4D5 isoform to interact with p-arrestin2 given the
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additional binding sites within the unique N-terminal region remains to be 
elucidated [Bolger et al., 2003 and Bolger et al., 2006].
Modulation of PDE4 activity upon protein Interaction with the unique N- 
terminal region of PDE4A5 has been observed with XAP2. XAP2 or AlP is an 
immunophilin-like protein that interacts and confers a specific partial, non­
competitive inhibitory effect on PDE4A5 [Bolger et al., 2003]. This interaction 
was attenuated upon MAPKAPK2 phosphorylation of PDE4A5 and restored 
upon co-incubation with SB203580 (Figure 4.20). Furthermore, XAP2 itself 
was not subject to phosphorylation by a p38 MAPK-dependent protein kinase, 
indicating that this effect is dependent upon PDE4A5 phosphorylation [E.V. 
Hill and M.D. Houslay, unpublished observation]. The functional interaction 
site for XAP2 binding on PDE4A5 is predominantly the unique N-terminal 
region with additional binding supported by UCR2 [Bolger et al., 2003]. As 
discussed above, it is likely that the MAPKAPK2 phosphorylation of PDE4A5 
induces structural reorganisation of the intra-molecular interactions between 
the unique N-terminal and regulatory domains, which not only precludes the 
accessibility of the PKA phosphorylation site but also one, or both, of the 
XAP2 interaction sites. Relief of the XAP2 inhibitory constraint upon PDE4A5 
will no doubt contribute to altered cAMP signalling responses in cellular 
locations where these interactions occur. Future experiments should be 
performed to prove PDE4A5 activity modulation can occur following 
MAPKAPK2 phosphorylation and partial release of XAP2-mediated inhibition 
of PDE4A5 catalytic activity.
However, one caveat to this interaction in the intact cell may be the 
requirement for XAP2 release from the nucleus. In undisclosed work, I have 
shown that over-expression of PDE4A5 and XAP2 in C0S7 cells shows 
divergent patterns of localisation, with XAP2 predominantly nuclear and 
PDE4A5 located in the perinuclear regions of the cell. Sequence analysis of 
XAP2 indicates that it contains no NLS and was reliant on secondary 
interacting proteins to confer nuclear localisation [Kashuba et al., 2000].
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XAP2 controls both the stability and cytoplasmic cellular localisation of 
the AhR and therefore negatively regulates AhR-mediated gene expression 
[Meyer and Perdew, 1999, Lees et al., 2003 Ramadoss et al., 2004 and 
Pollenz and Dougherty, 2005]. Activation of the lung AhRs by pollutants, such 
as dioxin (TCDD) and poly-aromatic hydrocarbons present in cigarette smoke,
.increases neutrophil recruitment and the onset of the excessive inflammatory 
response, a characteristic of COPD [Martinez et al., 2002 and Teske et al.,
2005]. Enhanced neutrophil recruitment is likely to be mediated, in part, by 
the generation of IL-8 and LTB4 [Harlaar and Brown, 1999]. Interestingly,
TCDD can also induce the expression of MAPKAPK2 in lung epithelial cells
[Martinez et al., 2002]. Therefore, activation of the AhR may be important in 
the pathogenesis of inflammatory lung disease.
Human airway smooth muscle cells express peroxisome proliferator- 
activated receptor (PPAR) a and y sub-types, which are ligand-activated 
nuclear hormone receptors [Patel et al., 2003]. XAP2 is a critical component 
of the PPARa gene transcription complex, and functions to repress gene 
transcription in hepatocytes [Sumamasekera et al., 2003]. Similarly, PPARa 
activation inhibits pro-inflammatory mediator gene expression in smooth 'muscle cells and this may be due to the repressive action of XAP2 [Staels et 
al., 1998 and Delerive et al., 1999]. This indicates a further role for XAP2 in 
asthma and COPD, as it would function to attenuate both inflammatory 
mediator gene expression and cAMP degradation in smooth muscle cells.
K-
PDE4 inhibition coupled with the elevation of cAMP levels is well 
established to promote anti-inflammatory effects in cells [Souness et al., 2000 
and Houslay et al., 2005]. The exact mechanisms as to how cAMP modulates 
inflammatory cell function are only beginning to be understood. PDE4 
inhibition reduces TNFa pro-inflammatory cytokine production and enhances 
IL-10 anti-inflammatory cytokine production, the expression of which, are 
dependent upon p38 MAPK activity [Guo et al., 2003 and Houslay et al.,
2005]. Similarly, the expression of adhesion molecules, the de-granulation of 
neutrophils and eosinophils and the activation of T-cells can all be inhibited by 
both PDE4 and p38 MAPK inhibition [Teixeira et al., 1997, Herlaar and Brown,
I
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1999, Pryzwansky and Madden, 2003, Ariga et al., 2004, Abrahamsen et al., 
2004 and Jones et al., 2005]. Excessive mucus production is also a 
characteristic of COPD and clearance is controlled by the PKA activation state 
of the CFTR [Houslay et al., 2005]. Additionally, in smokers with and without 
COPD, PDE4A4B and PDE4B2 expression is induced [Barber et al., 2004].
The partial inhibition of PDE4A4B/PDE4A5 activity on interaction with 
XAP2 assigns it as an isoform-specific inhibitor of PDE4A4B/PDE4A5 activity 
[Bolger et al., 2003]. PDE4A11, the major mRNA transcript in immune and 
inflammatory cells, also interacts with XAP2 but whether this interaction 
translates similar functional consequences remains to be elucidated (Figure 
3.17) [Wallace et al., 2005]. Therefore, one would expect XAP2 to adapt 
PDE4A4B/PDE4A5, and possibly PDE4A11, activity in specific compartments 
of the cell in which both proteins are present. Additionally, activation of the 
p38 MAPK-MAPKAPK2 pathway in the inflammatory response would promote 
the expression of pro-inflammatory mediators while simultaneously relieving 
the XAP2 inhibitory constraint placed upon the phosphorylated PDE4A 
isoform. This would allow the degradation of local cAMP concentrations 
potentiating pro-inflammatory cell function.
There is evidence for MAPKAPK2 in the activation of the E3 ubiquitin 
ligase, HDM2, which is responsible for the degradation of the tumour 
suppressor, p53 [Weber et al., 2005]. Is it possible that PDE4 isoforms could 
be targeted for degradation via ubiquitination and the interaction with XAP2 
enhances their cellular stability in an analogous manner to the AhR? [Lees et 
al., 2003]. if this were true, it is then possible that both PDE4A4B/PDE4A5 
and ubiquitin ligase phosphorylation facilitates the reduction of PDE4-XAP2 
binding with a concomitant increase in PDE4 ubiquitin ligase-mediated 
degradation.
As discussed above, XAP2 has also been identified as being an 
important component in the repression of PPARa gene transcription in 
hepatocytes, which regulates fatty acid oxidation, O2' and ROS generation, 
enlargement of the liver through both an increase in cell size and cell
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proliferation [Sumamasekera et al., 2003]. Furthermore, it has been 
established that mutations in XAP2 confers susceptibility to pituitary 
adenomas [Vierimaa et al., 2006]. Taken together these data are consistent 
with the role of XAP2 as a tumour suppressor. Survivin is a member of the 
inhibitor of apoptosis family that functions to regulate cell division and protect 
cells from apoptosis [Kang and Altieri, 2006]. In contrast to the tumour 
suppressor function of XAP2, the XAP2 stabilising interaction preventing 
survivin degradation reveals a role for XAP2 as anti-apoptotic, and will 
function in this instance to promote the survival of cancerous cells.
, :'■4
In certain types of cancer, the up-regulation of PDE4 expression has 
been described [Smith et al., 2005]. This is consistent with notion of cAMP as 
anti-proliferative agent, promoting cell cycle arrest and apoptosis [Schmitt and 
Stork, 2001, Balmanno et al., 2003 and Zambon et al., 2005]. Consistent with 
the role for XAP2 as tumour suppressor is its ability to specifically inhibit 
PDE4A5 activity [Bolger et al., 2003 and Fleming et al., 2004]. Given that p38 
MAPK regulates cell apoptosis and MAPKAPK2 regulates cell motility and 
potentially cancer cell metastasis, therapeutic targeting of the p38 MAPK- 
MAPKAPK2 signalling pathway might be of benefit in some cancers 
[Platanias, 2003 and Xu et al., 2006]. ■
In summary, PDE4A5 is a genuine substrate for MAPKAPK2 
phosphorylation at Ser-147 within the UGR1 regulatory domain. This 
phosphorylation delays the onset and amplitude of PKA-mediated activation 
of PDE4A5 while relieving the propensity for the potential inhibitory interaction 
with XAP2. The endogenous PDE4A5 phosphorylation by MAPKAPK2 using 
a physiologically relevant stimulus remains important to confirm. Similarly, 
whether MAPKAPK2 can phosphorylate other PDE4 isoforms across all gene
families and confer isoform-specific functional attributes remains to be 
elucidated and may reveal important PDE4 modifications. Nevertheless, this 
phosphorylation event provides further evidence of the integration of the 
cAMP and p38 MAPK signalling systems.
■
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Chapters NADPH Oxidase, cAMP signalling and 
PDE4A isoforms
5.1 Introduction
5 .1.1 Super-oxide and Reactive Oxygen Species
The production of reactive oxygen species (ROS), such as hydrogen 
peroxide and hypochlorite from super-oxide (O2") during oxidative stress can 
result in the attack of many key biological molecules such as enzymes, 
membrane lipids and DNA, and can ultimately lead to cell death [Hayes and
McLellan, 1999]. Oxidative stress occurs when the excessive production of 
these highly reactive species outweighs their control by enzymes such as
super-oxide dismutase (SOD), catalase, and the anti-oxidants such as 
ascorbic acid, glutathione and a-tocopherol.
Oxidative stress underlies the pathogenesis of many disease states 
including respiratory and inflammatory diseases such as asthma and COPD 
and neuro-degenerative diseases such as motor neurone disease. Much 
research has focussed upon cardiovascular conditions such as cardiac 
hypertrophy and heart failure [Li et al., 2002 and Murdoch et al., 2006]. 
Indeed, the treatment of cardiac myocytes with anti-oxidants can reduce the 
level of cardiac hypertrophy and O2" production induced by angiotensin II 
[Nakamura, et al., 1998 and Nakagami et al., 2003].
..4
The attenuation or ablation of O2 and ROS production, for example in 
chronic granulomatous disease (CGD), results in a reduced immune response 
coupled with increased bacterial infection [Vignais, 2003]. For that reason, 
the production of O2" and ROS is required in the innate immune response
■where polymorphonuclear blood leukocytes (PBLs) engulf, kill and digest 
invading microorganisms, through a process known as oxidative or respiratory
II
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burst. Respiratory burst is generally coupled with the release of proteases via 
cellular de-granulation of secretory vesicles [Larson et al., 2005].
Aside from their role as microbicidal agents, O2' and ROS are now 
implicated in cellular signalling transduction cascades, through the action of 
protein kinases, protein phosphatases and control of gene transcription 
[Groemping and Rittinger, 2005].
The production of O2" and ROS in immune and inflammatory cells 
occurs through the reduced nicotinamide adenine di-nucleotide phosphate 
(NADPH) oxidase enzyme, which can exist in three states: rest, primed and 
activated [Sheppard et al., 2005]. Tight control of this enzyme state is 
essential in maintaining individual cellular function and whole tissue integrity 
[Babior, 1999]. It is also worth noting here that the production of O2' and ROS 
is not confined to PBLs, and homologues of the core components, known as 
Nox (NADPH oxidase) proteins, have been identified in a wide variety of 
tissues including the heart, thyroid, kidney, lung, pancreas, liver, colon, 
intestine, placenta, testis and uterus [Bokoch and Knaus, 2003]. However, 
these proteins may have a different mechanism of action, as the activation of 
Nox proteins with stimuli that initiates a robust activation of the NADPH 
oxidase enzyme in phagocytic cells is inconsistent in non-phagocytic cells.
5 .12  NADPH Oxidase
5.1.2.1 Membrane Components
The phagocytic NADPH oxidase enzyme is a hetero-heptameric 
enzyme that contains a membrane-bound glycoprotein, flavocytochrome bess 
[Vignais, 2002]. This is composed of a 1:1 stoichiometry of gp91-p/?ox (where 
phox stands for phagocyte oxidase) and p22-phox, together with the RaplA 
G-protein, two haem groups, and a flavin adenine di-nucleotide (FAD).
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The gp91 “p/?ox subunit is composed of an intra-cellular N-terminal tail, 
followed by six trans-membrane a-helices, the extra-cellular loops two and 
three contain the three asparagine residues for N-linked glycosylation, and a 
C-terminal tail responsible for NADPH and FAD binding [Groemping and '
Rittinger, 2005]. The molecular weight of gp91-p5ox from its primary amino 
acid sequence is 65kDa, which rises to 91kDa following post-translational 
glycosylation. NADPH transfers electrons to the FAD, which subsequently 
transfers the electrons to the O2  carrying haem groups, resulting in its 
reduction to O2 . Both the FAD, removal of which ablates the production of 
O2 ', and the haem groups are responsible for the transfer of electrons across 
the plasma membrane [Sheppard et al., 2005]. However, inconsistency exists 
with respect to the role of the haem groups as an electron carrier due to rate 
limiting kinetics of haem reduction [Babior, 1999].
p22-p/?ox is a three trans-membrane a-helical protein of 21kDa with 
sequence homology for core and classical SH3 binding motifs at its intra­
cellular C-terminal tail, which mediate protein-protein interactions, specifically 
with the cytosolic subunit p47-phox [Groemping and Rittinger, 2005].
There is no consensus of opinion regarding the requirement for RaplA 
in NADPH oxidase activation [Sheppard et al., 2005]. RaplA can be co- 
immuno-precipitated with the flavocytochrome bgss in resting cells indicating 
that RaplA is a constitutively membrane-bound protein [Babior, 1999]. 
However, a second mechanism is proposed where RaplA is a cytosolic 
protein that migrates to the plasma membrane on phosphorylation by PKC 
and conversely this migration is inhibited by PKA phosphorylation [Vignais, 
2002]. The GDP/GTP-bound state of RaplA influences the affinity with which 
it interacts with the flavocytochrome bssa, where the GTP-bound RaplA 
interacts with greater affinity than the GDP-bound form. Stimulation of 
neutrophils with platelet-activating factor (PAF) or N-formyl-Met-Leu-Phe 
(fMLP), a tri-peptide secreted by bacterial cells, increases the proportion of 
GTP-bound RaplA at the neutrophil membrane [Zwartkruis and Bos, 1999].
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In resting cells 15% of the flavocytochrome bgss are present at the 
plasma membrane, with the remaining 85% at the membrane of cytosolic 
secretory vesicles or granules [Sheppard et al., 2005]. Enzyme priming and 
activation, through a plethora of stimuli, results in secretory vesicle membrane 
fusion and the delivery of the full cytochrome bssa complement to the plasma 
membrane.
I
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5.1.2.2 Cytosolic Components
In the resting state p47-phox exists auto-inhibited with the intra­
molecular binding of the tandem SH3 domains to a polybasic region at the C- 
terminal [Groemping et al., 2003, Yuzawa et al., 2004 and Durand et al.,
2006]. p47-p/?ox is subject to extensive phosphorylation, in comparison to the 
related p67- and p40-phox cytosolic subunits. These phosphorylation events 
have been assigned to a plethora of protein kinases including PI-3K and 
PKB/Akt, PKC ((3, Ô, and Ç isoforms only), Src tyrosyl kinase, p21-activated 
kinase, and the mitogen-activated protein kinases (MAPKs), p38 and ERK1/2 
[El Benna et al., 1996, Lopes, et al., 1999, Hoyal et al., 2003, Brown et al., 
2004, Chowdhury et al., 2005, Lin et al., 2005, Martyn et al., 2005 and Dang 
et al., 2006]. The treatment of phagocytic cells with PMA initiates a direct 
PKC phosphorylation and robust translocation of p47-p/iox to the plasma 
membrane [Inanami et al., 1998]. Indeed, p47-phox has the potential to be 
sequentially phosphorylated at up to eleven serine residues, namely 303, 304, 
310, 315, 320, 328, 345, 348, 359, 370, and 379 within the SH3 domain- 
containing region [Groemping and Rittinger, 2005]. Preferential 
phosphorylation of p47-phox at Ser-359 and Ser-370 is necessary for 
translocation, although contradicting data exists, before further 
phosphorylation occurs at Ser-303 and Ser-304 to complete the activation 
step [Johnson et al., 1998, Hoyal et al., 2003 and Massenet et al., 2005]. 
What is widely accepted though is the pre-requisite phosphorylation of Ser- 
379 for the translocation of p47-phox and the activation of the NADPH 
oxidase enzyme [Inanami et al., 1998, Babior, 1999, Massenet et al., 2005 
and Mitzuki et al., 2005]. The phosphorylation of p47~phox, by many of the 
aforementioned protein kinases, unmasks the PX domain, the SH3 domains,
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and the polybasic and proline-rich regions. The availability of both SH3 
domains, although preference is observed for domain A situated between 
residues 159 and 214, facilitates the interaction with the core Pro-Xaa~Xaa- 
Pro SH3 interaction motif within the C-terminal tail of p22~phox at the plasma 
membrane [Vignais, 2002]. The N-terminal phox (PX) domain stabilises direct 
membrane association through the binding of phospho-inositides (PI) 
[Wientjes et al., 2001 and Zhan et al., 2004].
p67-phox is a 60kDa protein composed of up to four N-terminal TPR 
domains, required for the competing interaction with either Rac2 or Cdc42, 
where differential binding confers either activation or inhibition on NADPH 
oxidase activity [Lapouge et al., 2000]. The C-terminal of p67-phox is 
composed of two SH3 domains, surrounding a phox and Bemi (PB1) domain, 
which is a site for high affinity (Kd = 7nM) heterodimerisation with the PB1 : 
domain of p40-phox [Groemping and Rittinger, 2005]. The region between 
the TPR and SH3 domains, i.e. amino acids 199-210, is absolutely essential 
for forming the active enzyme at the plasma membrane through gp91-p/îox 
binding, and may also play a role in binding NADPH [Babior, 1999, and 
Bokoch and Knaus, 2003]. Phosphorylation of p67-phox by either p38 MAPK 
or ERK1/2 may also play a fundamental role in membrane translocation, 
implying that a possible p67-phox conformational change is required to relieve 
an inhibitory constraint, similar to that described for p47-phox [Brown et al., 
2004, Groemping and Rittinger, 2005 and Lin et al., 2005]. p67-p/?ox and 
p40“phox exist together in the cytosol of the cell and translocation to the 
plasma membrane occurs in a p47-phox-dependent fashion [Sheppard et al.,
2005].
The final cytosolic phox protein is a 39kDa protein called p4Q-phox, 
which is composed of an N-terminal PX domain for interaction with the plasma 
membrane, an SH3 domain for possible interaction with the proline-rich region 
of p47-phox and a C-terminal PB1 domain [Wientjes et al., 2001, Groemping 
and Rittinger, 2005 and Sheppard et al., 2005]. As mentioned above, p40- 
phox is associated with pQ7-phox in the resting state and this occurs through 
the dimérisation of the PB1 domains. p40~phox is also basally
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phosphorylated by PKC at Thr-154 and Ser-315 [Vignais, 2002]. p40-phox is 
a stimulatory subunit directly enhancing the membrane translocation of p67- 
phox and indirectly enhancing p47-phox translocation via p67-phox 
[Kuribayashi et al., 2002]. Unfortunately, p4Q-phox is the least well studied 
and characterised of the three cytosolic phox proteins so little information
.■••Iexists around its regulation.
Translocation of GTP-bound Rac2 to the flavocytochrome bssg, or 
certainly to the plasma membrane through prénylation, is also a pre-requisite 
for NADPH oxidase activation [Sheppard et al., 2005]. Rac2 associates with 
Rho GDP dissociation inhibitor in the cytosol and translocation to the plasma 
membrane occurs on dissociation of Rho GDP dissociation inhibitor, where it 
interacts with high affinity with p67-phox [Lapouge et al., 2000 and Bokoch 
and Knaus, 2003]. Cdc42 acts as a competitive inhibitor for Rac2 and 
attenuates the production of O2 and ROS by the NADPH oxidase enzyme.
5.1.3 cAMP Signalling
cAMP is known for its anti-inflammatory properties and there is an 
abundance of data to support the notion of PDE4 inhibitors as anti­
inflammatory agents [Souness et al., 1999, Giembycz, 2002, Houslay et al.,
2005 and Zhang et al., 2005]. The generation of O2" and ROS underpins a 
fundamental part of the inflammatory response. Various studies have 
implicated an increase in intra-cellular cAMP concentrations, with the 
concomitant activation of PKA, in attenuating the production of O2" and ROS 
[Bengis-Garber and Gruener, 1996 and Lin et al., 2005]. No functional role for 
the direct PKA phosphorylation of the NADPH oxidase phox proteins has 
been identified [Babior, 1999]. PDE4 inhibitors can attenuate the generation 
of O2" and ROS in immune and inflammatory cells, and also regulate the
%expression of the NADPH oxidase phox proteins [Hatzelmann and Schudt,
2001 and Jacob et al., 2004]. The phox proteins contain SH3 and TPR 
domains, domains through which PDE4A long isoforms can interact [McPhee 
et al., 1999 and Bolger et al., 2003]. There is a precedent for cell signalling
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enzymes to associate with the phox proteins and control NADPH oxidase 
activation [Shmelzer et al., 2003 and Chowdhury et al., 2005].
270
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Taken together these data implies a potential key role for cAMP 
signalling, PKA activation and PDE4 inhibition in the generation of O2" through 
the recruitment and regulation of the phox proteins. The aim of this chapter
.was to elucidate an accepted means for cAMP signalling in O2 generation 
through possible PDE4 interactions with the phox proteins controlling the
direct phosphorylation of the phox proteins by PKA, thereby influencing the 
assembly of the active, membrane-bound NADPH oxidase enzyme complex.
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Figure 5.1 -  Schematic representation of the core components of the 
NADPH oxidase enzyme complex.
i
Î
272
. ............
Chapter 5 NADPH Oxidase, cAMP signalling and PDE4A isoforms
5.2 Results
Analysis of the primary amino acid sequence of proteins using the 
ScanSite protein motif-scanning database (http : //sea nslte. mit, ed u ./eg i- 
bin/motifscan seq) predicts both phosphorylation and secondary structural 
motifs within any given protein. The amino acid sequences of the p47- and 
pQ7-phox proteins were analysed using this database to elucidate potential 
PKA phosphorylation and/or structural motifs that may designate a potential 
role for their interaction with PDE4 enzymes. ScanSite identified p47-phox to 
consist of a PX domain at the N-terminal of the protein, with two tandem SH3 
domains towards the C-terminal. The presence of these SH3 domains 
indicated a potential interaction with PDE4A isoforms and a precedent for 
these interactions are well established [McPhee et al., 1999, Rena et al., 2001 
and Wallace et al., 2005]. Furthermore, a number of putative PKA consensus 
motifs were identified at the extreme C-terminal segment of the protein 
positioned beyond the tandem SH3 domains, namely Ser-304, Ser-320 and 
Ser-328. Similar analyses of p67-p/?ox revealed the presence of up to four N- 
terminal TPR domains, and a PB module sandwiched between two SH3 
domains towards the C-terminal. The presence of further SH3 domains and 
the additional TPR domains add credence to the possibility of PDE4A 
interactions where TPR domain interactions with PDE4A enzymes have also 
been previously described [Bolger et al., 2003]. No putative PKA 
phosphorylation sites were identified.
5.2.1 PKA Phosphorylation o f p47- phox and p67~phox
To determine whether p47-p/?ox and p67-p5ox were phosphorylated by 
PKA in vitro, recombinant GST fusion proteins of both were expressed and
■purified in E.coli, as shown in Figure 5.2. The phox proteins were expressed 
as soluble proteins and the purification on glutathione sepharose resin 
yielded 8.0mg/ml of GST-p47-phox and 4.3mg/ml of GST-p67-p/jox.
Truncations of p47-phox were also available, specifically the PX domain 
(amino acids 5-122) and the C-terminal portion containing the SH3 domains
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(amino acids 155-390) as fusion proteins with GST. These were also 
expressed and purified in E.coli as per the full-length species to 
concentrations of 9.1 mg/ml for the PX domain and 11.2 mg/ml for the C- 
terminal region respectively. Furthermore, single serine to alanine mutants of 
full-length p47-p/?ox (Ser-304, Ser-320 and Ser-328) generated by site- 
directed mutagenesis and showed no impact upon E.coli protein expression, 
solubility, purification or yield.
over-lapping phosphorylated sequences, a result of the peptide array 
synthesising technique where five-residue sequences are removed and added
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The purified recombinant phox proteins were assayed for PKA 
phosphorylation in vitro, together with GST as a negative control.
Recombinant PKA phosphorylated p47-phox but not p67-p/?ox or the GST 
control, as shown in Figure 5.3(a). Moreover in Figure 5.3(a), the truncated ■Iforms of p47-p/?ox were differentially phosphorylated by PKA, indicating that 
the phosphorylation sites were contained at the C-terminal end of the protein.
This region contains the SH3 domains and the previously identified putative 
phosphorylation serine residues within the PKA consensus motifs. In an 
attempt to further define the target residues peptide array technology was 
utilised, in a radioactive phosphorylation assay, with recombinant PKA. The 
incorporation of [^^P]-ATP to the p47-phox peptide array. Figure 5.3(b), 
transpired within the C-terminal region. One such site occurred between Val- 
186 and Pro-230 of the first SH3 domain of p47-phox and Ser-208 was 
identified as the probable residue, within the sequence Iso-Pro-Ala-Ser-Phe, 
as shown in red in Figure 5.3(b), panel (i). The three putative PKA 
phosphorylation sites at Ser-304, Ser-320 and Ser-328 were also identified as
I
in a step-wise manner for the full length of the protein. Figure 5.3(b), panel 
(ii), indicated that Ser-304 was contained within the consensus motif Arg-Arg- 
Ser-Ser-lso, highlighted in red, Ser-320 within the sequence Lys-Arg-Leu-Ser- 
Gin, highlighted in blue, and Ser-328 within a consensus sequence Arg-Arg- 
Asn-Ser-Val, highlighted in green. A further two possible PKA consensus 
sites, not identified using the ScanSite database, were identified using the 
peptide array approach. Figure 5.3(b), panel (iii), suggested that Ser-370 
(Pro-Arg-Pro-Ser-Ala) in red, and Ser-379 (Asn-Arg-Cys-Ser-Glu) in blue, ,4;,i
5.2.2 PDE4 Interaction with p47-phox and p67-phox
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were a target residue for PKA phosphorylation. Single alanine mutants of 
Ser-304, Ser-320 and Ser-328 within full-length p47-phox were evaluated in 
an in-vitro PKA phosphorylation assay, as shown and quantified in Figure 
5.3(c). All mutant proteins exhibited a moderate reduction in PKA 
phosphorylation to 66%, 84% and 69% respectively from the wild type p47- 
phox theoretical control level of 100%.
The full-length GST fusion proteins of p47- and p67-phox were used in 
pull-down assays to determine whether they were able to directly interact with 
PDE4A4B, which can bind proteins containing both SH3 and TPR domains, 
and PDE4A10, known to bind with weaker affinity with SH3 domain containing 
proteins and theoretically unable 4o interact with proteins containing TPR 
domains. Figure 5.4(a) confirmed that PDE4A4B was able to interact directly 
with both p47- and pG7-phox proteins whereas PDE4A10 showed specificity 
for interaction with p47~phox and interacted with p67-phox at a level 
comparable to that of the GST alone control. To further probe the interaction 
of PDE4A long isoforms with p47~phox, the full-length peptide array of 
PDE4A4B was incubated with the recombinant GST fusion protein of p47- 
phox. These data identified a binding site within the UCR2 module and a 
further three interaction sites within the catalytic unit. Pro-216 to Thr-250 
contained the pertinent amino acids responsible for mediating the interaction 
of p47-phox. The three sites within the catalytic unit were mapped to Val-501 
to Leu-525, Thr-656 to Glu-685 and Pro-691 to Glu-725.
5.2.3 Translocation o f NADPH Oxidase in Cardiac Myocytes
Previous work in rat cardiac myocytes has indicated the existence of 
compartmentalised cAMP signalling [Zaccolo and Pozzan, 2002, Mongillo et 
al., 2004 and Zaccolo, 2006]. Rat cardiac myocytes were cultured from 
isolated rat hearts and the production of whole cell lysates facilitated the 
immunological detection of PDE4 isoforms from the PDE4A, PDE4B and
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PDE4D gene families, as shown in Figure 5.5(a). Significantly, Figure 5.5(a),
panel (i), detected the endogenous expression of a long form PDE4A isoform 'of equivalent molecular weight to the isoforms, PDE4A5 or PDE4A8. Panels 
(ii) and (iii) of Figure 5.5(a) also identified the expression of two PDE4B 
isoforms, almost certainly PDE4B2 and PDE4B4, together with significant 
endogenous expression of the PDE4D long isoform, PDE4D3. Likewise, both 
p47- and pG7-phox were also endogenous expressed at appreciable levels 
indicating the presence of two of the core components of the NADPH oxidase 
enzyme, as shown in Figure 5.5(b).
To evaluate the translocation of p47-phox to the plasma membrane the 
cells were treated with angiotensin II, a known agonist of NADPH oxidase 
translocation and activation, leading to the production of O2" and ROS 
[Nakamura, et al., 1998 and Nakagami et al., 2003]. In cultured cardiac 
myocytes angiotensin II elicited translocation of p47-phox to the plasma 
membrane, as indicated by increased p47-phox immuno-reactivity in the P2 
fraction of the cells, as shown in Figure 5.6(a). Figure 5.6(b) quantified the 
magnitude of p47-phox translocation, and the effect of various cell treatments 
to modulate activation of the cAMP signalling system, against the maximum 
response (100%) with angiotensin II. On this basis, basal p47-phox 
expression at the plasma membrane was some 17% +/- 5% (p < 0.05).
Angiotensin II in combination with forskolin, to directly activate adenylyl 
cyclase, or rolipram, to specifically inhibit PDE4 activity, reduced the level of 
translocation to 54% +/- 2% (p > 0.05), and 54% +/-19% (p > 0.05), 
respectively. No effect on the translocation of p47-phox was observed with 
the PDE3 inhibitor, cilostimide in combination with angiotensin II (data not 
shown). Treatment with angiotensin II and the PKA inhibitor H89 reduced the 
level of translocation to 63% +/- 11% (p > 0.05). A corresponding band shift 
accompanied this H89-induced reduction in p47-phox membrane 
translocation. Stimulation of cardiac myocytes with angiotensin II, forskolin 
and rolipram ablated p47-phox translocation to plasma membrane, quantified 
at 13% +/-13% (p > 0.05). The addition of H89 partially rescued this effect to 
49% +/- 28% (p > 0.05).
276
Chapter 5 NADPH Oxidase, cAMP signalling and PDE4A isoforms
(a) Time after induction
(hours) P S Unb Purified
0 2 4
4 ' GST-p47-phox
(b) Time after induction
(hours) P S Unb Purified
0 2 4
4 GST-p67-p/?ox
277
Chapter 5 NADPH Oxidase, cAMP signalling and PDE4A isoforms
Figure 5.2 -  E.coU expression and purification of recombinant p47~phox 
and p67-p/jox.
(a), shows the expression and purification of GST-p47-p/?ox and (b), shows 
the expression and purification of GST-p67-p/?ox in E.coU. Briefly, competent 
E.coli BL21 pLysS (DE3) cells were transformed with pGEX plasmids 
encoding either GST-p47-p/?ox or GST-p67-p/ïox. Protein expression was 
induced with 0.2mM IPTG for 4h at 30°C. The cells were collected, re­
suspended in lysis buffer and subjected to sonication to produce total cellular 
extract (P). The soluble proteins were isolated by centrifugation (S). The 
expressed recombinant GST fusion proteins were purified using glutathione 
sepharose resin and eluted using excess glutathione (10mM). Fractions of 
the GST fusion proteins remained unbound to the glutathione sepharose resin '(Unb) whereas a significant proportion of bound fusion protein could be 
purified to a major band as detectable by Goomassie® staining of the SDS 
polyacrylamide gels (Purified). These gels represent one of many successful 
expression experiments undertaken to express both proteins as full-length 
wild type, full-length single site mutants or truncated species in E.coli.
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(a)
GST
GST-p47 GST-p47- GST-p47- GST-p67 
(5-122) (155-390)1 r 1 r 1 r
PKA phosphorylation
GST
(b) (i)
VEKSESGWWFCQMKAKRGWIPASFL
SGWWFCQMKAKRGWIPASFLEPLDS
CQMKAKRGWIPASFLEPLDSPDETE
KRGWIPASFLEPLDSPDETEDPEPN
PASFLEPLDSPDETEDPEPNYAGEP
p47-phox peptide array 
(Val-186-Pro-230)
SH3 domain 1 
Phosphorylation target Ser-208
(II)
I # ' # # # *
OKSGODVSOAQRQIKRGAPPRRSSI
DVSQAQRQIKRGAPPRRSSIRNAHS
QRQIKRGAPPRRSSIRNAHSIHQRS
RGAPPRRSSIRNAHSIHQRSRKRLS
RRSSIRNAHSIHQRSRKRLSQDAYR
RNAHSIHQRSRKRLSQDAYRRNSVR
IHQRSRKRLSQDAYRRNSyRFLOOR
RKRLSODAYRRNSVRFLOORRROAR
ODAYRRNSVRFLOORRROARPGPOS
RNSVRFLOORRROARPGPOSPGSPL
p47-phox peptide array 
(Gln-281 -  Leu-350) 
C-terminal region 
Phosphorylation targets
Ser-304, Ser-320 & Ser-328
(iii)
EEEROTORSKPOPAVPPRPSADLIL
TORSKPOPAVPPRPSADLILNRCSE
POP AVPPRPSADLILNRCSESTKRK
PPRPSADLILNRCSESTKRKLASAV
p47-phox peptide array 
(Glu-351 -  Val-390) 
C-terminal region 
Phosphorylation targets 
Ser-370 & Ser-379
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Figure 5.3 -  Phosphorylation of the p47-phox by recombinant PKA.
The in vitro PKA phosphorylation of GST-tagged full-length p47-phox, p47- 
phox (amino acids 5-122), p47-phox (amino acids 155-390), and full-length 
p67-phoxwas undertaken. GST was included as a negative control. Purified
■GST-phox proteins were incubated with PKA and pP]-ATP for lOmin at 30°C. |
The phosphorylated proteins were then separated by SDS-PAGE, transferred 
to a nitrocellulose membrane, exposed in close proximity to a storage 
phosphor image screen for 3h, and developed using a high-resolution laser 
scanner, (a), top panels, are scanned storage phosphor screen images of the 
PKA phosphorylation of phox proteins, (a), bottom panels, are Western blots 
of the radioactive nitrocellulose membrane, probed using a GST anti-serum 
showing the relative immuno-reactive amounts of each phox protein present 
in the phosphorylation assays. The scanned storage phosphor screen 
images and Western blots are representative of in vitro phosphorylation
assays of three separate experiments, (b), panels (i)-(iii), is a peptide array of
p47-phox used to map the phosphorylation target Serine residues in putative 
PKA consensus motifs. The entire p47-phox peptide sequence was 
synthesised on a membrane and the membrane incubated with PKA and 
pP]-ATP for 30min at 30°C. The membrane was exposed in close proximity 
to a storage phosphor image screen and developed as described above. The 
p47-phox peptide array PKA phosphorylation data are from an experiment 
done once, (c), top panel, is a scanned storage phosphor screen image 
showing p47-phox (wild type, Ser-304-Ala, Ser-320-Ala and Ser-328-Ala) 
phosphorylation by recombinant PKA. (c), bottom panel, is a Western blot of 
the radioactive nitrocellulose membrane, probed using a p47-p/?ox specific 
anti-serum, showing the relative immuno-reactive amounts present in the 
phosphorylation assays. The scanned storage phosphor screen image and 
Western blot in (c) are from one experiment, (d), shows the quantification of 
the p47-phox phosphorylation as a function of the immuno-reactive p47-phox 
in each assay. The phosphorylation of the mutant forms of p47-phox is 
calculated relative to that of the wild type control. The quantification of the 
phosphorylation of p47-phox wild type and the serine to alanine mutants are 
from one experiment.
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4 PDE4A4B
4 PDE4A10
(b) <i)
PDE4A4B peptide array 
(Leu211 to Ser255) 
Upstream conserved region 2LGGPTPVCKATLSEETCOQLARETL
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TLSEETCQQLARETLEELDWCLEQL
TCQQLARETLEELDWCLEQLETMQT
ARETLEELDWCLEQLETMQTYRSVS
(ii)
PDE4A4B peptide array 
(Glu491 to Lys535) 
Catalytic unitELALMYNDESVLENHHLAVGFKLLQ
YNDESVLENHHLAVGFKLLQEDNCD
VLENHHLAVGFKLLQEDNCDIFQNL
(iii)
IDYIVHPLWETWADLVHPDAQEILD
HPLWETWADLVHPDAQEiLDTLEDN
TWADLVHPDAQEiLDTLEDNRDWYY
VHPDAQEiLDTLEDNRDWYYSAiRQ
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PDE4A4B peptide array 
(lso646 to Pro690) 
Catalytic unit
(iv)
SPSPPPEEESRGPGHPPLPDKFQFE
PEEESRGPGHPPLPDKFQFELTLEE
RGPGHPPLPDKFQFELTLEEEEEEE
PPLPDKFQFELTLEEEEEEEiSMAQ
KFQFELTLEEEEEEEISMAQiPCTA
PDE4A4B peptide array 
(Ser686 to Ala730) 
Catalytic unit
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Figure 5.4 -  Interaction of p47-pAïox with PDE4A long isoforms.
Pull-down assays were used to probe the interaction of the purified GST-p47- 
phox and GST-p67-phox. The phox fusion proteins were immobilised on 
glutathione sepharose resin and incubated with C0S7 cell lysate expressing 
equal immuno-reactive amounts of either PDE4A4B or PDE4A10, determined 
using the C-terminal PDE4A-specific anti-serum, (a), shows the interaction of 
GST-p47-phox and GST-p67-p/70X with PDE4A4B or PDE4A10 respectively. 
As a control, the pull-down of PDE4A4B or PDE4A10 with GST alone was 
compared (an example of PDE4A pull-down with GST alone is shown 
previously in Figure 3.11). (b), panels (i) -  (iv), map the interaction sites of 
GST-p47-phox on full-length PDE4A4B using peptide array technology. 
Briefly, the entire PDE4A4B peptide sequence was synthesised on a 
membrane and the membrane incubated with the purified GST-p47-phox. 
The membrane was probed for p47-phox interaction using a specific p47~phox 
anti-serum. The Western blots and peptide array interaction data are 
representative of the results obtained from three separate experiments.
283
Chapter 5 NADPH Oxidase, cAMP signalling and PDE4A isoforms
(i)
ISOkDa
lOOkDa
75kDa
(ii)
50kDa
(iii)
lOOkDa
75kDa
50kDa
Standards
4A1 4A4B 4A5 4A8 4A10 4A11 I Lysate
<-------  Rat PDE4A
^____  Rat PDE4A
Standards
4B1 4B2 4B3 4B4 I Lysate
lOOkDa
75kDa
Standards
4D1 4D3 4D3/5 I Lysate
PDE4B4
PDE4B2
PDE4D3
60kDa
45kDa
Lysate
p67-p/?ox
p47-phox
284
Chapter 5 NADPH Oxidase, cAMP signalling and PDE4A isoforms
Figure 5.5 -  Expression profile of endogenous PDE4 isoforms and 
endogenous p47- and p67-pfjox proteins in rat cardiac myocytes.
Total cell lysate was generated from separately transfected C0S7 cells 
expressing known PDE4 isoforms, as indicated. These were used as PDE4 
isoform standards to determine the PDE4 isoform profile of the rat cardiac 
myocyte cultured cell line. Total cell lysates produced from cultured rat 
cardiac myocytes were subjected to SDS-PAGE and the endogenous PDE4 
profile determined by Western blotting with either the rat PDE4A specific C- 
terminal anti-serum, (a), panel (i), the PDE4B specific C-terminal anti-serum, 
(a), panel (ii), or the PDE4D specific C-terminal anti-serum, (a), panel (iii). 
Panel (b), shows Western blots of the same rat cardiac myocyte cell lysate 
immuno-probed for endogenous p47-phox and endogenous p67-phox using 
specific anti-sera to both proteins respectively. The Western blots are from 
screening experiments done once.
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Figure 5.6 -  Plasma membrane translocation of cytosolic p47-p/iox in 
response to angiotensin II in rat cardiac myocytes.
ICultured rat cardiac myocytes were either retained untreated, treated with angiotensin II alone (lOOnM for 5 minutes), or pre-treated with combinations 
of forskolin (100pM for 10 minutes), rolipram (lOpM for 10 minutes) and/or 
H89 (lOpM for 10 minutes) prior to angiotensin II. The cells were harvested 
and sub-cellular fractions produced by centrifugation. This method, described 
previously [MoPhee et al., 1995], separates the total cellular matter into the 
soluble, cytosolic cellular components (high-speed supernatant or S2), the 
plasma membrane and internal organelles (high-speed pellet or P2), and 
intact cells and other cellular debris (low-speed pellet or PI), (a), is a 
Western blot of the relative immuno-reactive amounts of p47-phox at the 
plasma membrane, foltowing the indicated treatments, as determined by 
immuno-probing the isolated membrane fractions (P2) with an anti-serum 
specific to the p47-phox protein, (b), quantifies the effect of these treatments 
and any change in p47-phox translocation to the plasma membrane, 
compared against the maximum p47-phox translocation. The Western blot is 
representative of translocation experiments done three times on different 
batches of cultured rat cardiac myocytes and the quantification data are 
expressed as mean values +/- standard deviation from the three separate 
translocation experiments. Paired t-test statistical analysis of the 
quantification data were undertaken, where p < 0.05 indicates a statistically 
significant difference in the relative p47~phox immuno-reactivity within the P2 
sub-cellular fraction between untreated and treated cells, as indicated.
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5.3 Discussion
The production of 0%' and ROS is an important aspect of the innate 
immune response, providing host defence against invading microorganisms. 
However, the uncontrolled generation of such species underlies oxidative 
stress and the onset of a variety of cardiovascular disease states such as 
cardiac hypertrophy and heart failure [Li et al., 2002 and Murdoch et al., 
2006]. Cardiac hypertrophy is characterised by an Increase in the size of the 
heart cells and can be caused by hypertension. Hypertension affects the left 
ventricle due to chronic pumping against increased arterial pressure. Over 
time the integrity of the myocardial cells change prompting a decrease in 
contractile function eventually leading to cardiac failure. In renal hypertension 
there is an increase in renin release, which is converted to angiotensin I by 
angiotensinogen, and then to angiotensin II by angiotensin converting enzyme 
(AGE). Angiotensin II is a potent vasoconstrictor and therefore increases 
blood pressure, which, in turn, increases the load upon the heart. In cardiac 
myocytes, angiotensin II can induce the onset of cardiac hypertrophy and this 
change in cell morphology is mediated, in part, by the production of O2" and 
ROS, and is sensitive to a variety of anti-oxidants [Nakamura, et al., 1998 and 
Nakagami et al., 2003].
■
,
The NADPH oxidase enzyme catalyses the reduction of oxygen (O2 ) to
■Æ-O2 ' and enzyme activity is tightly regulated by the extensive phosphorylation 
of the cytosolic p47-phox protein (Figure 5.1) [Groemping and Rittinger, 2005 
and Sheppard et al., 2005]. These phosphorylation events occur at the 
extreme C-terminal region of p47-p/?ox and function to relieve an inhibitory 
constraint [Groemping et al, 2003]. The p40-p/?ox/p67-phox hetero-dimer is 
also phosphorylated to a lesser degree, but this is essential, together with the 
preceding p47-p/?ox phosphorylation, for its translocation to the plasma 
membrane [Vignais, 2002]. The dissociation of Rac2-GDP from the Rho GDP 
dissociation inhibitor in the cytosol, and the association of Rac2-GTP with the 
TPR domains of p67-phox at the plasma membrane, is also a key event in the 
activation process [Lapouge et al., 2000]. At the plasma membrane, the now
I
288
Chapter 5 NADPH Oxidase, cAMP signalling and PDE4A isoforms
289
accessible SH3 domains of the heavily phosphorylated p47~phox interact with 
the proline-rich region of p22-phox and directly with the membrane through PI 
binding to the PX domain [Zhan et al., 2004 and Groemping and Rittinger,
2005]. The proline-rich region of p47-phox interacts with the SH3 domains of 
both p67- and p40-p/?ox, with p40~p/?ox also utilising its PX domain for 
additional membrane binding [Wientjes et al., 2001]. p67-p/?ox bound to
Rac2-GTP and RaplA interacts directly with both the membrane and the 
membrane-bound flavocytochrome bssg [Babior, 1999, Zwartkruis and Bos, 
1999, Lapouge et al., 2000 and Bokoch and Knaus, 2003]. The membrane- 
bound flavocytochrome bgse, specifically the gp91-phox subunit, binds 
NADPH, FAD and the haem groups [Vignais, 2002].
In non-phagocytic cells, such as cardiac myocytes, homologous 
components of the phagocytic NADPH oxidase enzyme are present including 
gp91-phox, or Nox2 as it is known in non-phagocytic cells [Murdoch et al.,
2006]. In isolated rat cardiac myocytes, the endogenous expression of both 
p47- and p67-phox was immunologically detected together with various 
isoforms from the PDE4A, 4B and 4D gene families (Figure 5.5) [Mongillo et 
al., 2004]. Stimulation of cardiac myocytes with lOOnM angiotensin II initiated 
a robust translocation of p47-phox to the plasma membrane, as indicated by 
increased immunological detection in the membranous sub-cellular fraction 
(Figure 5.6). This is in complete agreement with previous work showing that ;the treatment of cardiac myocytes with the same concentration of angiotensin
■II induced a significant increase in the production of O2' and ROS [Nakamura 
et al., 1998]. The angiotensin II receptor is a GPCR that couples to Gq and 
activates both PKC and ERK1/2, protein kinases implicated in p47~phox 
phosphorylation and translocation [Lopes et al., 1999, Liebmann, 2001, Ahn
et al., 2004 and Dang et al., 2006]. Furthermore, the angiotensin II receptor 
also recruits (3-arrestin and the recruitment of other protein kinases through |3- 
arrestin interactions, which might play a fundamental role in controlling the 
p47-phox phosphorylation state and translocation [Lefkowitz and Shenoy,
2005]. Forskolin or rolipram attenuated the magnitude of this angiotensin II 
response on activation of the cAMP-PKA signalling cascade, through either 
direct activation of adenylyl cyclase or global PDE4 inhibition respectively.
;:i'
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accompanying this was a notable band shift indicating a possible increase in 
the extent of protein phosphorylation. It is possible that this may be a H89 
non-specific effect (10pM for endogenous PKA inhibition is considered an 
excess) inhibiting p47-phox phosphorylation resulting in attenuation of plasma 
membrane translocation [Davies, et al., 2000, Hoyal et al., 2003 and Brown et 
al., 2004]. Indeed, 10pM can markedly attenuate the activity of p38 MAPK
regulation.
Using both forskolin and rolipram together the synergistic activation of PKA 
ablated p47-phox translocation to the membrane, an effect that was partially 
rescued by PKA inhibition. From these data it was concluded that enhanced 
PKA activity might, in part, underlie the mechanism through which PDE4 
inhibitors reduce O2" and ROS production. Angiotensin II plus the PKA 
inhibitor H89 also reduced p47-phox translocation, an unexpected effect, but
i
downstream kinases such as MSK1 and MAPKAPK1, and PKB/Akt, with both 
pathways proposed to be involved in the translocation of p47-phox and the 
activation of NADPH oxidase [Davies, et al., 2000]. However, this simple 
explanation does not reconcile the band shift and further work is required to 
determine whether this effect is of functional significance to p47-phox protein
The current and limited information on the role that PKA activation 
exerts upon the NADPH oxidase enzyme components is conflicting. In 
neutrophils isolated from the bronchoalveolar lavage (BAL) of rats treated with 
LPS, O2' and ROS production was attenuated on treatment with PDE4 
inhibitors [Jacob et al., 2004]. This is consistent with the current knowledge of 
PDE4 inhibition. However, this mechanism was proposed to occur through 
the activation of ERK1/2 and not through an increase in intra-cellular cAMP 
concentrations or the associated activation of PKA phosphorylation or EPAC. 
Although this study contradicts the proposal here that PKA activation is 
directly responsible for mediating an inhibitory effect on O2" and ROS 
production, it does provide evidence of kinase activation that is capable of 
mediating O2" and ROS inhibition, which is also in contrast to the current 
knowledge of NADPH oxidase activation by phosphorylation. The activation 
of neutrophils measured by both O2' production and p2-integrin expression,
using fMLP is inhibited by lysophosphatidylcholine (LPC) through an
290
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accompanying increase in intra-cellular cAMP concentrations and activation of
PKA [Lin et al., 2005]. H89 rescued this inhibitory effect, indicating an
inhibitory role of PKA phosphorylation and not an EPAC-mediated effect. 1
Furthermore, at the level of p47- and p67-p/?ox, their translocations induced
by fMLP were inhibited by LPC and rescued by H89. This study corroborates
.the possibility of a similar mechanism in cardiac myocytes where the direct 
phosphorylation of p47-phox prevents translocation together with p67~phox, 
as it cannot translocate in isolation [Johnson et al., 1998 and Babior, 1999].
328 yielded a reduction but not ablation of PKA phosphorylation in each case 
indicating that further sites are likely to be involved. Thus, mutagenesis of
The p47-phox cytosolic subunit is known to be a substrate for 
numerous protein kinases that elicit its translocation to the plasma membrane.
Utilising recombinant GST fusion proteins of full-length phox proteins In an in 
vitro kinase assay, it was confirmed that p47-phox, but not p67~phox, was a 
target for PKA phosphorylation (Figure 5.3). Predictably, the PKA 
phosphorylation region on p47-phox was mapped, using truncated versions of 
the protein, to the C-terminal, SH3 domain-containing region with no 
detectable phosphorylation of the N-terminal PX domain. In an attempt to 
elucidate putative target phosphorylation residues a similar in vitro kinase 
assay was undertaken using a peptide array of full-length p47-phox. This 
identified six putative phosphorylation sites for PKA, namely Ser-208, Ser- 
304, Ser-320, Ser-328, Ser-370 and Ser-379. The consensus motif for Iphosphorylation by PKA is Arg-Arg-Xaa-Ser-0, where 0  is a hydrophobic 
residue. Of the six possible PKA target serine residues identified, Ser-304 
and Ser-328 conform to perfect PKA consensus motifs. The first residue of 
the consensus motif surrounding Ser-370 is a proline, but the remaining 
residues are of the correct amino acid classification. Ser-320 and Ser-379 
contain the core Arg-Xaa-Ser motif but lack the acceptable extreme residues 
to conform to perfect PKA consensus sites. Perhaps most important, due to 
its positioning within the first SH3 domain or SH3 domain A, is Ser-208, which 
contains the correct amino acid complement surrounding the target serine to 
conform as a PKA target site. A brief attempt to determine the PKA target
/■Isites by site-directed serine to alanine mutagenesis of residues 304, 320 and
291
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amino acids 208, 370 and 379 as single alanine mutants, and combinations 
therein, will allow the delineation of the relative contribution of each putative 
target serine. It is well established that Ser-304, Ser-320, Ser-328, Ser-370 
and Ser-379 are key phosphorylation sites for the relief of the inhibitory 
constraints placed upon p47~phox in the resting state [Groemping and 
Rittinger, 2005]. Phosphorylation of Ser-303, Ser-304 and Ser-328 are the 
major sites for mediating high affinity interactions with p22-phox following 
translocation, with Ser-315 and Ser-320 playing relatively minor roles 
[Groemping et al., 2003]. Thus, one would expect phosphorylation at one, 
some or all of these five sites to promote a conformational change in p47- 
phox to allow translocation to, and interaction with, the p22~phox component 
of the flavocytochrome base at the plasma membrane. Of course in the intact 
cell, lack of phosphorylation at Ser-359 may impact the activation status of
p47-phox by preventing the sequential phosphorylation at the N-terminal“
residues thereby impacting translocation efficiency [Johnson et al., 1998, 
Hoyal et al., 2003 and Massenet et al., 2005]. Alternatively, the preceding 
phosphorylation events at the aforementioned residues may promote access 
to SH3 domain A for further PKA phosphorylation at Ser-208. This 
phosphorylation may attenuate the interaction with the proline-rich region of 
the p22-phox, in a similar manner to PR-39, an anti-microbial peptide, which 
binds to the SH3 domains and prevents the p22-phox interaction [Babior, 
1999 and Groemping and Rittinger, 2005]. Indeed, the exposure of the first
fit
SH3 domain is sufficient to interact with p22-phox, where the second SH3 
domain in isolation cannot associate [Groemping et al., 2003]. However, the 
second SH3 domain must play a co-operative role, forming a so-called 
“superSH3 domain”, in the binding at the plasma membrane, as the affinity is 
greatest when both are present. Phosphorylation at this site may also prevent 
the interaction of the PX domain with the first SH3 domain preventing access 
for lipid-mediated binding at the plasma membrane [Durand et al., 2006]. Of 
course a point of caution with all in vitro phosphorylation assays is the 
propensity for indiscriminate phosphorylation to occur. Direct phosphorylation 
of p47-phox may not be involved in the mechanism and simply the 
phosphorylation of an intermediate substrate in signalling cross talk, e.g. Raf 
isoforms or Rapi, may prevent the translocation of p47-phox and underlie the
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Inhibitory action of PKA [Houslay and Kolch, 2000]. Therefore, whole cell 
phosphorylation experiments should be undertaken to determine whether 
translocation is modified with PKA phosphorylation in vivo. It is possible that 
a co-transfection to transiently over-express p47-phox, and its membrane 
partner protein p22~phox, will be sufficient components for interaction. If so, 
then single and multiple serines to alanine mutants can be employed to 
assess the effect of direct PKA phosphorylation upon p47-phox interaction 
with p22-phox.
Activation of the (3-adrenoceptor in cardiac myocytes controls the 
strength, duration and frequency of myocardial contraction and is also 
involved in the onset of cardiac hypertrophy [Zou et al., 1999 and Zaccolo and 
Pozzan, 2002]. Indeed, in cardiac myocytes cAMP-dependent intra-cellular 
signalling and the endogenous expression of PDE4 isoforms is highly f
compartmentalised [Mongillo et al., 2004 and Zaccolo, 2006]. Supporting 
such compartmentalisation was the identification of PDE4D isoforms as the 
key PDE4 sub-family in controlling (Sg-adrenoceptor signalling in cardiac 
myocytes, where PDE4D knock-out had no effect on pi-adrenoceptor 
signalling, which activates the PKA phosphorylation of L-type Ca^^ channels 
and the ryanodine receptor to control myocardial contraction [Xiang et al.,
2005 and Zaccolo, 2006]. Activation of GgPCRs is also associated with the 
onset of cardiac hypertrophy [Zou et al., 1999]. On the basis of the data 
shown in this chapter, this effect is unlikely to mediated through a PKA driven 
mechanism upon the NADPH oxidase enzyme components as global 
increases in intra-cellular cAMP concentrations prevent p47-phox 
translocation to the plasma membrane (Figure 5.6). A possible mechanism of 
an activating phosphorylation conferring pA7-phox translocation may lie in Gs 
to Gi, or Gq, switching [Zou et al., 1999 and Lawler et al., 2001]. 
Compartmentalised p-adrenoceptor signalling may facilitate the activation of 
ERK1/2 or PKC, by switching to Gi or Gq, thereby activating the NADPH 
oxidase enzyme via extensive phosphorylation of the p47-phox, and p67-p/70X 
in the case of ERK1/2. Thus, cAMP signal compartmentalisation and the sub- 
cellular localisation of specific PDE4 isoforms may underlie the differential
%
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effects of stimuli on the activation of the NADPH oxidase enzyme, the 
production of 0 2 “ and ROS, and the onset of cardiac hypertrophy.
p47-phox and p67-phox both contain SH3 and TPR domains, which 
are known to facilitate interactions with PDE4A isoforms [McPhee et al., 1999 
and Bolger et al., 2003]. On this premise, p47- and p67-phox might also 
interact with PDE4A isoforms to allow the temporal and spatial control of 
cAMP concentrations and subsequent PKA phosphorylation of phox proteins. 
In concert, these interactions could modulate PDE4A activity by inducing a
294
conformational change in the catalytic unit as sensed by increased sensitivity 
to inhibition by rolipram [McPhee et al., 1999 and Bolger et al., 2003]. In pull­
down assays, PDE4A4B was able to interact with both p47- and p67-phox 
whereas, PDE4A10 was only able to interact with p47-phox (Figure 5.4). This 
differential binding indicates isoform specificity of interaction with p67-phox 
and possibly PDE4A gene family specificity for interaction with p47-phox. On 
the basis of the current knowledge of these interactions this is what one would 
predict. PDE4A4B is known for its interaction with both SH3 and TPR 
domain-containing proteins whereas, PDE4A10 can interact with SH3
domain-containing proteins but not those with TPR domains as this 
interaction, in the case of XAP2, was mediated through the unique N-terminal 
region of PDE4A4B and its homologue PDE4A5 [McPhee et al., 1999, Rena 
et al., 2001 and Bolger et al., 2003]. To further probe the interaction sites of 
p47-p/?ox on PDE4A4B, the full-length peptide array was utilised (Figure 5.4).
All interaction sites were core conserved sequences within the PDE4 family 
and thus one would expect all PDE4 isoforms to interact with p47-phox. The 
UCR2 interaction site is analogous to that participating in the XAP2 interaction 
with PDE4A4B/PDE4A5, i.e. Glu-Glu-Leu-Asp [Bolger et al., 2003]. The 
catalytic binding region identified between Iso-646 and Pro-690 also contains 
a similar motif, i.e. Glu-lso-Leu-Asp. This is also the site required for the 
UCR1-UGR2 intra-molecular interaction and may disrupt PDE4 'oligomerisation [Beard et al., 2000, Richter and Conti, 2002 and Richter and 
Conti, 2004]. It is interesting that p47-phox did not interact with the regions 
required for SH3 domain binding, as described for the SH3 domains of the 
tyrosyl kinase Lyn, indicating that the SH3 domains are probably not involved
Chapter 5 NADPH Oxidase, cAMP signalling and PDE4A isoforms
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in this Interaction. Furthermore, the identification of the region responsible for 
mediating the XAP2 interactions may indicate competition for p47- and p67~ 
phox binding on PDE4A4B/PDE4A5. It would be beneficial to map the 
interaction sites for p67-phox on PDE4A4B using the peptide array technique 
to identify whether competition for binding is possible. Alanine scanning will f
elucidate the specific residues involved in mediating these interactions, as has 
been described previously for the interactions of both p-arrestin and RACK1 
with PDE4D5 [Bolger et al., 2006]. The activation state of p47-phox may be 
crucial to its interaction with PDE4 isoforms. Priming or activation of the 
NADPH oxidase enzyme, i.e. a conformational change induced by p47-phox 
phosphorylation, may be required before further phosphorylation and/or 
interaction can occur. Similarly, the activation state could drive the specificity 
of PDE4 interaction. Auto-inhibited p47~phox may be able to interact with all 
PDE4 enzymes, whereas activation and exposure of the SH3 domains may 
be fundamental in conferring specificity to PDE4A. Endogenous co-immuno- 
precipitation of both p47- and p67-phox with PDE4 enzymes, identified either 
through Western immuno-blotting or PDE activity assays will allow the 
identification of interaction specificity in the three NADPH oxidase states; rest, 
primed and activated [Sheppard et al., 2005]. Therefore, distinct PDE4 
isoforms, perhaps from the PDE4A gene family, may be important in the 
control of NADPH oxidase activity through interactions with the NADPH 
oxidase phox proteins. To elucidate such specificity the use of dominant 
negative PDE4 isoforms or sub-family specific siRNA techniques could be 
employed, as described before [Lynch et al., 2005 and McCahill et al., 2005].
Furthermore, with the resolution of the crystal structure of the catalytic unit of 
PDE4 enzymes and the extensive structural information available with respect 
to the activation and assembly of the NADPH oxidase enzyme, it would be of 
interest to model the proposed interaction to determine if an interaction is 
theoretically viable [Xu et al., 2000 and Groemping and Rittinger, 2005].
Other possible mechanisms that have the potential to be involved in 
the regulation of O2 and ROS production through the PKA phosphorylation of 
p47-phox include the requirement for AKAP-mediated interactions. Indeed, 
p47-phox is able to bind moesin, a member of the ERM (ezrin, radixin and
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moesin) family of proteins, through its PX domain and translocation to the 
plasma membrane through association with F-actin components of the 
cytoskeleton [Wientjes et al., 2001 and Zhan et al., 2004]. Thus, the 
activation of ERK1/2 or ERK5 may be inhibitory to p47-p/?ox translocation 
through direct disruption of the cellular cytoskeletal structure [Barros and
'Marshall, 2005]. Although moesin is not considered to be an AKAP, the 
associated family member ezrin has been assigned such functionality and 
may play a role in recruiting PKA [Dransfield et al., 1997 and Sun et al., 2000].
However, WAVE-1 has been assigned AKAP function and it has been shown 
that it participates in the translocation of p47-p/?ox to membrane ruffles in 
endothelial cells [Westphal et al., 2000 and Wu et al., 2003]. AKAPs may also 
play a role in the recruitment of protein phosphatases to p47-phox, as many 
studies have implicated the balance between phosphorylation versus de­
phosphorylation as being extremely important i in controlling p47~phox 
translocation [Bengis-Garber and Gruener, 1996 and Babior, 1999].
in cardiac myocytes and support the necessity for distinct isoforms of PDE4 
enzymes to control functionally distinct cellular processes.
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The activation of EPAC through cAMP is unlikely to be involved, as the 
exchange of GDP for GTP on RaplA will result in the activation of NADPH 
oxidase activity [Jacob et al., 2004]. However, control of the activation state 
of Rac2 may underlie part of the inhibitory translocation mechanism conferred 
upon increases in intra-cellular cAMP levels [Pomerance et al., 2000 and 
Pelletier et al., 2005].
Further exploration of this mechanism is certainly required. If the 
activation of the NADPH oxidase enzyme is indeed controlled through the 
PKA phosphorylation state of p47-phox through interactions with distinct :PDE4 isoforms, following a specific stimulation within a given cell type, then 
this would further substantiate the need for cAMP signal compartmentalisation
«
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PDE4-selective inhibitors promote the immuno-suppressive, anti­
inflammatory and smooth muscle relaxant properties associated with cAMP, 
and are being pursued as novel therapeutics for disease states such as 
asthma, COPD, rheumatoid arthritis and psoriasis [Souness et al., 2000,
Burnouf and Pruniaux, 2002, Houslay et al., 2005 and Zhang et al., 2005].
The beneficial effects of PDE4 Inhibition are also being exploited for the 
treatment of CNS disorders including cognitive enhancement, depression,
Alzheimer’s, Parkinson’s and Schizophrenia, as well as cardiovascular 
diseases such as atherosclerosis, restenosis, pulmonary hypertension and 
stroke [Maurice et al., 2003, O’Donnell and Zhang, 2004, Houslay et al., 2005,
Millar et al., 2005 and Zhang et al., 2005]. cAMP also modulates the
: . 'J jexpression levels of proteins involved in the regulation of the cell cycle,
: .1causing Gi/S-phase cell cycle arrest and apbptosis, indicating the therapeutic 
potential for PDE4 inhibition in cancer [Schmitt and Stork, 2001, Balmanno et 
al., 2003 and Zambon et al., 2005]. PDE4 inhibition prevents chemotaxis and 
cell migration implying a potential role in both inflammatory cell diapedesis 
and cancer cell metastasis [Kohyama et al., 2002 and Fleming et al., 2004].
However, cAMP concentrations are not controlled by global PDE4
;activity but restricted to isoforms, in distinct cAMP micro-domains, expressed 
on a cell-type specific basis and participating in dedicated signalling systems. ',;ï
Unsurprisingly, collective PDE4 inhibition is associated with severe side
■effects, a likely consequence of the vast number of physiological and 
metabolic processes that are regulated by cAMP [Huang et al., 2001 and 
Zhang et al., 2005]. Therefore, complete knowledge of the plethora of PDE4 
isoforms expressed in humans and their regulation is essential, and will allow 
their selective inhibition, specific gene knockout, siRNA ablation or the use of iidominant negative constructs to delineate the physiological requirement for 
such an array of PDE4 isoforms. In the process, this will allow the 
identification of beneficial and adverse effects arising from isoform-specific 
PDE4 inhibition.
. '
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Twenty-one human isoforms of the cAMP-specific PDE4 enzyme family 
have now been characterised and these provide the predominant cAMP- 
hydrolysing activity in many cells [Houslay, 2001 and Conti et al., 2003]. 
PDE4 isoforms are widely expressed and distributed on a cell-type specific 
basis. The unique N-terminal region of each isoform is responsible for its 
intra-cellular targeting to discrete regions of the cell, in concert with protein 
kinases, scaffold, anchoring, and adaptor proteins [Houslay and Adams,
2003]. The protein interactions with the unique N-terminal regions of PDE4 
isoforms are often stabilised by additional contacts within PDE4 conserved 
regions. The many established protein interactions and their functional effects 
upon PDE4 activity are discussed in some detail in Section 1.7.6. PDE4 
activity and some protein interactions are regulated by phosphorylation, and 
these are discussed in Section 1.7.5.
To assess the physiological requirement for multiple PDE4 isoforms it 
is first essential to ascertain the full complement of enzymes that can be 
expressed. Accordingly, the first objective of this thesis was to characterise 
the novel PDE4A11 long isoform, summarising its key distinguishing features 
in relation to our current knowledge of the PDE4A isoforms, and elucidating 
the functional significance of its expression. Chapter 3 described the 
PDE4A11 isoform in detail [Wallace et al., 2005].
;ÿ;
PDE4A11 is an authentic PDE4A long isoform. mRNA transcripts were 
detected in many human tissues (Figure 3.4) and were most striking in liver, 
stomach, testis, thyroid, adrenal gland, PBLs and foetal brain. Of interest 
were the low levels of PDE4A11 transcripts in the adult brain. In contrast, 
PDE4A10 provides abundant transcript levels [Rena et al., 2001 and McPhee 
et al., 2001], indicating isoform specific changes at different stages of brain 
development. PDE4A11 is also widely expressed in immune and 
inflammatory cells, as well as bronchial smooth muscle cells, providing the 
principal PDE4A transcript [Wallace et al., 2005]. Of course, the presence of 
PDE4A11 transcripts does not necessarily translate to protein expression. 
Specific changes in PDE4A isoform expression have already been 
established during monocyte to macrophage differentiation (up-regulation of
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PDE4A10), in monocytes and macrophages in smokers and people 
diagnosed with COPD (up-regulation of PDE4A4B) and in human pulmonary 
arterial smooth muscle cells in response to hypoxia (up-regulation of 
PDE4A10 and PDE4A11) [Shepherd et al., 2004, Barber et al., 2004 and 
Millen et al., 2006]. Therefore, the identification of endogenous PDE4A11 
expression at various tissue developmental stages and during disease 
progression will develop our understanding of its physiological significance.
To facilitate these experiments a specific anti-sera to the unique N-terminal 
region of PDE4A11 was generated (Figure 3.5).
PDE4A11 is characterised by a unique 81 amino acid N-terminal region
rthat is likely to confer its distinct intra-cellular targeting to membrane ruffles 
(Figure 3.5). The identification of a putative PIP3 binding PH domain within 
the unique N-terminal region of PDE4A11 may facilitate its appropriate 
positioning to participate in cAMP-mediated cell signalling events at ruffled 
membranes, such as cell motility. This implies a potential role for PDE4A11 in 
the regulation of inflammatory cell migration or cancer cell metastasis.
Furthermore, the activation of PKA attenuates PI-3K activation, as indicated
Agi
by reduced phosphorylation of PKB/Akt [Leemhuis et al., 2004]. PDE4A11 
recruitment may control the cAMP regulation of PI-3K activity and 
consequently physiologic and metabolic processes such as glucose uptake.
No re-distribution of PDE4A11 expression was observed upon 
stimulation of PI-3K enzyme activity (Figures 3.6 and 3.7). However, the 
over-expression of recombinant proteins in cells is potentially misleading 
because of the likely saturation of anchor sites and the fact that different 
anchors are present in different cells. Moreover, the endogenous expression
of PDE4A isoforms is relatively low compared to the PDE4B and PDE4D 
enzymes. Therefore, gross over-expression of PDE4A isoforms is in no way
representative of the endogenous state. To assess the effect of the putative 
PIP3 binding PH domain and its potential role in the intra-cellular targeting of 
PDE4A11, cells with immunologically detectable levels of endogenous 
enzyme should be evaluated. Alternatively, the use of a low expression
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construct, plus mutation of the putative PIP3 binding PH domain, will ascertain 
whether this domain does indeed participate in PDE4A11 intra-cellular 
targeting in transfected cells.
PDE4 enzymes can form distinct conformers as sensed by different 
sensitivities to inhibition by rolipram. As a general rule, in the absence of 
phosphorylation or specific interacting proteins, PDE4 enzymes exist in a low 
affinity rolipram binding state (LARBS). The interactions of PDE4A4B with the 
SH3 domains of Src tyrosyl kinases [McPhee et al., 1999] and PDE4A5 with 
the immunophilin XAP2 [Bolger et al., 2003] are interactions that are capable 
of increasing enzyme sensitivity for inhibition by rolipram, thus forming a high 
affinity rolipram binding state (HARBS). An analogous effect is not induced by 
PKA phosphorylation of either PDE4A4B or PDE4A5 [MacKenzie et al., 2002]. 
PDE4D3 is the only isoform to date where PKA phosphorylation confers both 
activation and the formation of HARBS, and these are proposed to occur via
distinct mechanisms [Hoffmann et al., 1998]. Furthermore, chronic rolipram
treatment of PDE4A4B induces the formation of accretion foci and it is 
currently proposed that this is caused by conformational switching to HARBS 
induced by rolipram and in the absence of cAMP [Terry et al., 2003]. 
Additionally, cytosolic and particulate forms of the same isoform display 
distinct thermal inactivation kinetics, providing further evidence for existence 
of altered catalytic conformations of the same protein [Rena et al., 2001 and 
Wallace et al., 2006].
:
It was hypothesised that the emetic side effects of PDE4 inhibition 
were a result of HARBS inhibition in the brain and that generating LARBS- 
specific inhibitors could overcome these effects; LARBS predominates in 
inflammatory cells [Richter and Conti, 2004 and Houslay et al., 2005].
Although this theory is now considered obsolete the mechanisms that underlie 
such conformational switching are still being pursued and resolution of the 
full-length PDE4 crystal structure will greatly advance our understanding of 
this phenomenon.
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The specific interaction of PDE4A5 with XAP2 also results in an 
increase in the sensitivity with which rolipram inhibits PDE4A5 [Bolger et al.,
The particulate targeting of PDE4A4B, but not PDE4A10, is sufficient to 
induce enhanced sensitivity to inhibition by rolipram (Table 3.2) [Huston et al., 
1996 and Rena et al., 2001]. PDE4A11 was also detected in the particulate 
fraction and although some alteration of conformation was indicated from 
thermal stability analysis (Figure 3.10) no conformational change in the 
catalytic unit was measured in response to rolipram (Figure 3.9 and Table 
3.2). PDE4A10 and PDE4A11 both interact with the SH3 domain of Lyn, but 
to a lesser degree than that observed for PDE4A4B (Figure 3.15) [McPhee et 
al., 1999, Rena et al., 2001 and Wallace et al., 2005]. It was perceived that 
the lack of PDE4A10 and PDE4A11 N-terminal SH3 binding domains, given 
that this is the only point of primary sequence divergence, was responsible for 
the reduced interaction [Rena et al., 2001 and Wallace et al., 2005]. This 
theory does not explain the absence of conformational switching from LARBS 
to HARBS, as this effect is clearly mediated through the PDE4A conserved 
LR2 [McPhee et al., 1999]. However, analysis of the SH3 domain interactions 
using the peptide array approach has mapped N-terminal SH3 binding 
domains to both PDE4A10 and PDE4A11, but displayed limited interaction 
with the N-terminal of PDE4A4B (Figure 3.15). Therefore, it is my belief that 
the conformational switching occurs in PDE4A4B through preferential SH3 
domain interactions with LR2, and conversely the N-terminal regions of 
PDE4A10 and PDE4A11 provide the preferential SH3 domain interaction sites
within these isoforms. The properties of the unique N-terminal regions must 
confer a masking effect on the LR2 binding site and/or have higher affinity N- 
terminal SH3 binding, thus preventing the formation of high affinity 
conformers. Higher affinity for the N-terminal binding site over LR2 is unlikely 
given the reduced interaction in fusion protein pull-down assays (Figure 3.15) 
[Rena et al., 2001 and Wallace et al., 2005].
In agreement, long-term challenge of cells transfected with PDE4A4B 
causes the formation of accretion foci, an effect not observed with PDE4A10 
or PDE4A11 [Terry et al., 2003 and Wallace et al., 2005].
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Finally, I have concluded that the PDE4A4B/PDE4A5 and PDE4A11 
isoforms can interact directly with p-arrestin (Figures 3.16 and 4.20), an effect 
that is likely to be mediated through the conserved catalytic binding domains 
[Bolger et al., 2003 and Bolger et al., 2006]. As such, PDE4A isoforms have 
the potential to form complexes with the P-arrestin scaffold proteins and 
therefore, participate in critical events such a p2 -adrenoceptor Gs to Gj 
switching, desensitisation and internalisation, and the activation of the T-cell 
receptor [Perry et al., 2002, Baillie et al., 2003 and Abrahamsen et al., 2004].
'^"1
2003]. However, data here shows that PDE4A11 is also capable of 
interacting with XAP2, with equal magnitude to PDE4A4B (Figure 3.17). One 
would advocate characterisation of this interaction to assess whether it 
confers similar inhibitory effects on PDE4A11 catalytic activity and alters the 
rolipram inhibition profile.
One potential mechanism for conformational switching that has not 
been addressed here is the suggestion that PDE4 enzymes form homo­
dimers through inter-molecular UCR1-UCR2 interactions [Richter and Conti,
2004]. Dimérisation appears to be essential for PDE4 function and serves to
stabilise PDE4 enzymes in HARBS. The use of alternatively tagged 
constructs of PDE4A11 would allow one to elucidate whether PDE4A11 is 
able to form dimers and whether this is essential for the modulation of both 
catalytic activity and inhibitor sensitivity.
The PKA phosphorylation of PDE4A11 at Ser-119 within the UCR1 
regulatory module confers the expected activation of catalytic activity and 
enhanced degradation of localised cAMP concentrations (Figure 3.11) 
[Wallace et al., 2005]. The current consensus of opinion is that only PKA 
phosphorylation of PDE4D3 is able to activate and induce conformation 
switching [Sette and Conti, 1996, Hoffmann et al., 1998 and MacKenzie et al., 
2002]. This effect is a likely consequence of the unique properties of the 
PDE4D3 N-terminal region. Therefore, although all long form PDE4A 
isoforms to date have not shown altered rolipram inhibition following PKA 
phosphorylation, it would be remiss to discount PDE4A11 at this stage.
i
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Our current knowledge of the other PDE4A isoforms indicates that 
PDE4A11, over PDE4A4B and PDE4A10, may represent an attractive target 
for therapeutic intervention for disease states characterised by excessive 
immune and inflammatory responses, such as asthma, COPD and 
rheumatoid arthritis. From these data, the promotion of PDE4A11 for 
selective inhibition stems from its low transcript levels in the adult brain, 
reduced interaction with SH3 domain-containing proteins, and prevention of 
accretion foci formation upon chronic rolipram treatment, underlying its 
inability to form HARBS. PDE4A11 can also interact with p-arrestin indicating 
a potential role in P2 -adrenoceptor function and full T-cell receptor activation. 
Furthermore, its specific recruitment to membrane ruffles, perhaps utilising a 
PIP3 binding PH domain, may indicate a potential role in cell migration. Only 
in cells where endogenous expression of PDE4A11 is detected and available 
for siRNA knockdown can we truly define the physiological significance of 
PDE4A11 expression.
The expression and action of inflammatory cytokines is fundamental in 
the onset of the immune and inflammatory response against infection and 
tissue injury. The activation of the p38 MAPK cascade initiates pro-
inflammatory cytokine expression, including TNFa, IFNy and lL-1, and
A point of convergence of cAMP and p38 MAPK signalling pathways 
has been established in monocytes, where IFNy activation of p38 MAPK was 
attenuated by PDE4 Inhibition by rolipram [MacKenzie and Houslay, 2000]. 
This indicates intra-cellular cAMP is involved in controlling the activation state 
of p38 MAPK, although the authors do not address the mechanism of such 
regulation. IFNy activation of p38 MAPK occurs through activation of the IFN
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appropriately, inhibition prevents such gene transcription [Lee et a!., 1994]. 
p38 MAPK is widely appreciated to play a key role in the regulation of various 
stages of the inflammatory response, including cell adhesion, diapedisis, O2 ' 
and ROS production, and release of elastase and metalloproteinase enzymes 
[Herlaar and Brown, 1999]. p38 MAPK inhibitors and inhibitors of their
downstream substrates, specifically MAPKAPK2, are also being pursued as 
potential drugs for inflammatory disease states [Saklatvala, 2004].
I
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Type I receptor signalling cascade involving GEF activation, stimulation of 
Rac GDP/GTP exchange, and activation of the MAPK signalling cascade, as 
indicated in Figure 4.1 [Platanias, 2003].
The aim of the fourth chapter of this thesis was to probe a point of 
cross talk between these signalling cascades, by firstly exploring the 
possibility that p38 MAPK-dependent protein kinases could phosphorylate 
PDE4 isoforms, and secondly, identifying any functional effects this may 
bestow. Chapter 4 described the MAPKAPK2 phosphorylation of PDE4A5.
Cell over-expression of PDE4A5 and activation of the p38 MAPK 
phosphorylation cascade facilitated its phosphorylation by MAPKAPK2 
(Figures 4.8 -  4.13). Phosphorylation occurring in the whole cell, in the 
presence of other p38 MAPK integrated signalling systems, indicates that 
PDE4A5 is an authentic substrate for MAPKAPK2. Functionally, MAPKAPK2 
phosphorylation of PDE4A5 attenuates its ability to be activated by PKA 
phosphorylation and reduces its ability to interact with XAP2.
PDE4A5 is activated by PKA (Figure 4.14) [MacKenzie et al., 2002 and 
Bolger et al., 2003]. Phosphorylation of PDE4A5 by MAPKAPK2 exerts
negligible effect upon catalytic activity (Figure 4.15), but activity changes
:consequent upon MAPKAPK2 phosphorylation of PDE4 long isoforms from 
the other gene families, in view of the fact that UCR1 is conserved, should not 
be discounted. However, if phosphorylation by MAPKAPK2 is allowed to 
occur before PKA phosphorylation is induced, then the onset and amplitude of 
PKA activation is attenuated (Figure 4.15). Indeed, if all long isoforms can be 
phosphorylated by MAPKAPK2 then it may attenuate the PKA-induced 
conformational switching of PDE4D3 to HARBS. Therefore, in cells where 
these signalling pathways are present, the timing of pathway activation will be 
crucial in the regulation of intra-cellular cAMP concentrations. But how does 
phosphorylation at Ser-147 confer such an effect? A similar effect has been 
observed with XAP2 and the authors proposed that XAP2 binding could either 
hamper the ability of the active catalytic units of PKA to access the UCR1 site, 
or that it disrupts the conformation of the intra-molecular interactions between
I
Î
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UCR1 and UCR2 [Bolger et al., 2003]. The true mechanism of both PKA 
activation and such attenuation of activation will only be explicitly understood 
on resolution of the crystal structure of a full-length PDE4 isoform.
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One should consider the effect of potential AKAP interactions with 
PDE4A5. Recent studies have shown that AKAP1, AKAP3 (specific for 
PDE4A5 in spermatozoa [Bajpai et al., 2005]) and AKAP8 can interact with 
PDE4A isoforms in T-lymphocytes [Asirvatham et al., 2004]. The dissociation 
of an AKAP interaction from PDE4A5 upon MAPKAPK2 phosphorylation may 
spatially re-locate PKA to a distant compartment of the cell and attenuate 
PKA-mediated activation.
WAVE-1 has been assigned AKAP function and is involved in the 
regulation of the actin cytoskeleton [Westphal et al., 2000]. It is found in a 
complex with both WRP and R ad, where WRP, a GAP protein, negatively Iregulates Rad function [Soderling and Scott, 2006]. WAVE-1 binds Arp2/3, a 
substrate for MAPKAPK2 [Singh et al., 2003], which catalyses the formation
of actin resulting in cell cytoskeletal rearrangements. Such modifications will 
alter cell motility and cell migration. Evidence also exists for the regulation of 
Rad function by intra-cellular cAMP in many cells, including OHO cells, 
myocardial endothelial cells, and vascular smooth muscle [Pomerance et al.,
2000, Waschke et al., 2005 and Pelletier et al., 2005]. However, there is no 
clear consensus across cell types whether cAMP positively or negatively 
regulates Rad function. WAVE-1 can also bind the Abl tyrosyl kinase, known 
to interact with MAPKAPK2 but poorly with PDE4A isoforms through SH3 
domain interactions [Ben-Levy et al., 1995 and McPhee et al., 1999].
Therefore, given the multitude of proteins involved in this complex, it would be 
fascinating to explore the possibility that a PDE4A isoform could also be 
recruited and participate in the function and regulation of the actin
- icytoskeleton. This may then have functional consequences for cell migration 
and underlie some mechanism through which cAMP inhibits Rad function 
and attenuates actin modifications that enhance cell motility. Furthermore, 
the formation of PIP3 is key in the regulation of Rad function, and therefore 
PDE4A11, given its intra-cellular localisation in membrane ruffles (Figure 3.5),
_ _
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may be appropriately positioned to control the activation state of R ad and 
influence cell motility.
Furthermore, the PDE4A1, PDE4A5 and PDE4A10 isoforms are 
endogenously expressed in similar brain regions to WAVE-1 [McPhee et al.,
2001 and Taskén and Aandahl, 2004]. Targeted knock out of WAVE-1 in
■
mice, the central molecule in this complex, or the associated Abi2 or WRP 
proteins, gives rise to mice with reduced motor function and a cognitive 
deficient phenotype [Soderling and Scott, 2006]. The PDE4 inhibitor rolipram 
has shown clinical benefit in a variety of CNS defects including depression,
Parkinson's, Alzheimer’s and cognitive enhancement [O’Donnell and Zhang,
2004 and Houslay et al., 2005]. Therefore, PDE4 inhibition and the disruption 
of cAMP signalling through the WAVE-1 signalling cassette may underlie 
some of the beneficial CNS effects.
XAP2 induces conformational switching upon interaction with PDE4A5, 
as indicated by differential rolipram inhibition [Bolger et al., 2003]. Utilising 
the Ser-147-Asp phospho-mimetic conferred no alteration in rolipram 
inhibition (Figure 4.17). Foci formation is hypothesised to be indicative of
■:} i.PDE4A4B conformational changes and is dependent upon protein synthesis 
[Terry et al., 2003]. Anisomycin has been shown to reduce foci formation but 
this effect should be confirmed on reversal with a p38 MAPK inhibitor, such as ■ ■'
SB203580, because anisomycin can also act as a protein synthesis inhibitor 
as well as a p38 MAPK activator [S. Vadrevu and M.D. Houslay, unpublished 
observation]. Taken together, the above data suggests that the 
phosphorylation of PDE4A5 by MAPKAPK2 has a role to play in the 
stabilisation of PDE4A5 conformation.
Moreover, PDE4 enzymes have the ability to form homo-dimers 
through inter-molecular interactions spanning the C-terminal of UCR1 and the 
N-terminal of UCR2 [Richter and Conti, 2002]. Dimérisation is not affected by 
PDE4 phosphorylation by PKA, but is in fact a pre-requisite for activation to
occur. Furthermore, disruption of dimérisation shifts affinity of PDE4D3 to 
LARBS and the authors postulated that dimérisation stabilised PDE4D3 in
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LARBS is proposed to underlie the beneficial effects of PDE4 inhibition with
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HARBS. It would be interesting to elucidate if PDE4A5 can form homo-dimers 
and if the interaction was subject to modification upon MAPKAPK2 
phosphorylation. If phosphorylation of PDE4A5 by MAPKAPK2 served to 
disrupt dimérisation, and it is appropriately positioned to do so given its 
location at the dimérisation interface, then this would provide yet further 
evidence for PDE4 conformation stabilisation. Indeed, MAPKAPK2 
phosphorylation of HSP27 serves to disrupt HSP27 oligomers [Gaestel,
2006].
The outcome of these experiments may provide a compelling argument 
that the functional effect of MAPKAPK2 phosphorylation of PDE4 isoforms is 
to protect them from conformational change, which results in an increase in 
sensitivity to inhibition by rolipram. Subsequently, this would provide the first
'evidence, to my knowledge, of a PDE4 modification that stabilises the enzyme 
in LARBS. This would be of therapeutic benefit given that the formation of
the formation of HARBS associated with the undesirable side effects.
Further experiments should be undertaken in T-cells to assess the 
physiological significance of MAPKAPK2 activation and PDE4A5 
phosphorylation. T-cells are known contain all the relevant components to 
assess potential endogenous signalling cassettes, with which 
PDE4A4B/PDE4A5 may participate including Src tyrosyl kinases, AKAPs and 
p-arrestin [Abrahamsen et al., 2004 and Asirvatham et al., 2004]. PDE4 
inhibition is known to regulate the function of the T-cell receptor in a PKA- 
dependent manner [Abrahamsen et al., 2004]. Activation of the TCR-CD3 
induces an increase in intra-cellular cAMP concentrations and stimulation of 
PKA. Active PKA targets the Src tyrosyl kinase Csk, which negatively 
regulates Lck tyrosyl kinase activity, and attenuates T-cell activation. This is 
controlled by CD28-dependent recruitment of PDE4 through p-arrestin, which V'functions to lower cAMP and activate Lck tyrosyl kinase activity for full T-cell 
activation. One can then appreciate how PDE4 inhibition serves to down- 
regulate T-cell activation through enhancing the inhibitory Csk 
phosphorylation of Lck.
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Furthermore, inhibition of PDE4 in T-cells has also been shown to 
suppress TNFa, IFNy, IL-2, IL-4 and IL-5 expression, which are responsible 
for p38 MAPK activation and Th1-Th2 cell differentiation [Houslay et al.,
2005]. Significant mRNA transcripts are detected for all PDE4A long isoforms 
with transcript levels in Th2 cells predominating over the corresponding Th1 
cell transcripts [Wallace et al., 2005]. Potentially, this suggests that PDE4A 
expression may have a role in T-cell function, regulating the immune and 
inflammatory response [Bertrand, 2000 and Hart, 2001]. Therefore, this 
would be an intriguing system to assess any physiological role of MAPKAPK2 
phosphorylation upon T-cell function. MAPKAPK2 phosphorylation does not 
affect the PDE4A5 interaction with p-arrestin (Figure 4.19) but whether this is 
consistent with PDE4D5 remains to be ascertained.
XAP2 is known to confer a partial, non-competitive, inhibitory effect 
upon PDE4A5, with maximal inhibition of approximately 60% and an IC50 of 
120nM [Bolger et al., 2003]. Phosphorylation of PDE4A5 reduces the 
interaction by approximately 50% (Figure 4.20), and therefore one is tempted 
to suggest that inhibition of PDE4A5 would be relieved and returned to some 
70% of its native activity.
In the context of the inflammation, where p38 MAPK is active and 
controlling several stages of the response, relief of PDE4A5 inhibition by 
XAP2 and the concomitant lowering of cAMP levels will function to exacerbate 
the inflammatory reaction.
The AhR and PPARa are both ligand-activated intra-cellular receptors 
that directly bind to DNA and influence gene transcription. The endogenous 
expression of both receptors occurs in lung epithelial cells [Patel et al., 2003 
and Teske et al., 2005]. The major risk factor in the development of COPD, 
defined as an irreversible and progressive restriction of airflow coupled with 
an abnormal lung inflammatory response, is exposure to noxious gases and 
particles, and in particular, cigarette smoke [Anderson and Bozinovski, 2003]. 
Lung AhRs are activated by dioxin and poly-aromatic hydrocarbons and 
results in increased neutrophil recruitment and the onset of an excessive
308
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inflammatory response [Martinez et al., 2002 and Teske et al., 2005]. 
Activation of PPARa attenuates inflammatory mediator release, e.g. GM-CSF, 
IL-6, and adhesion molecule expression, and PPARa^ '^ "^  mice develop an 
excessive inflammatory reaction phenotype [Staels et al., 1998 and Delerive 
et al., 1999]. XAP2 is an important component of both receptors and serves 
to confer both cytoplasmic stability and repression of gene transcription 
[Meyer and Perdew, 1999 and Sumamasekera et al., 2003]. Therefore, one 
can appreciate the beneficial role of such effects in the onset of the 
inflammatory response in COPD. Given the established ability of cAMP to 
attenuate the inflammatory response by a variety of mechanisms the partial 
inhibitory effect of XAP2 upon PDE4A5 activity further promotes the beneficial 
effects of XAP2 expression [Bolger et al., 2003]. Furthermore, PDE4A4B 
expression is up-regulated in smokers irrespective of their COPD status 
[Barber et al., 2004]. XAP2 inhibition of PDE4A4B may provide some 
protective or compensatory mechanism to the increased expression.
In the context of cancer cell proliferation there is a growing body of 
evidence to suggest that XAP2 is an important tumour suppressor protein. 
Very recently the role of XAP2 as a tumour suppressor has been identified in 
a study population from Finland, where mutations in XAP2 conferred 
susceptibility to pituitary adenomas [Vierimaa et al., 2006]. PPARa activation 
causes hypertrophy of the liver and hepatocyte proliferation, but interaction 
with XAP2 represses PPARa-mediated gene transcription [Sumamasekera et 
al„ 2003].
MAPKAPK2 participates in the control of cell cycle regulation at both 
Gi/S phase and Gg/M phase [Gaestel, 2006]. At Gi/S phase, ubiquitin- 
mediated degradation of the p53 tumour suppressor occurs via MAPKAPK2 
activation of HDM2 E3 ubiquitin ligase [Weber et al., 2006]. Phosphorylation 
and activation of the Cdc25B phosphatase, which is a critical checkpoint for 
G2/M phase, is also mediated by MAPKAPK2. In prostate cancer, activation 
of MAPKAPK2, the phosphorylation of HSP27 and activation of matrix 
metalloproteinase 2 are necessary for cell invasion and metastasis [Xu et al..
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Consistent with these observations of XAP2 as a tumour suppressor, 
the activation of MAPKAPK2 in the control of the cell cycle and the 
maintenance intra-cellular cAMP inducing cell cycle arrest and apoptosis, is 
the inhibitory effect of XAP2 on PDE4A5 activity [Houslay et aL, 2005].
PDE4A5 is phosphorylated by MAPKAPK2 and here I have proposed 
that the integration of the cAMP and p38 MAPK signalling pathways has 
potential physiological significance in the control of PDE4 activity. Of interest 
for follow-up experiments is the hypotheses that (1) phosphorylation may 
confer stability of PDE4 conformation in LARBS, (2) experiments in T-cells 
may provide novel insight into the physiological significance of PDE4A5 
phosphorylation and the interaction with AKAPs and (3) that PDE4 isoforms 
may be part of the WAVE-1 AKAP complex, where this scaffold protein 
controls the recruitment of PDE4A5 to MAPKAPK2 and the rearrangement of 
the actin cytoskeleton.
The production of O2" and ROS is a key factor in the innate immune 
response, and when this response is impaired, e.g. CGD, the host has 
increased susceptibility to infection [Vignais, 2000]. The characterisation of 
the oxidative or respiratory burst process has focussed upon phagocytic cells, 
where these cells engulf and subsequently destroy, through ROS production 
and protease release, invading micro-organisms, and also scavenge
damaged and senescent cells. However, it is now widely appreciated that 
similar systems for the production of ROS are present in non-phagocytic cells, 
including the lung and the heart [Bokoch and Knaus, 2003]. The generation 
of O2" and ROS is generally a controlled process, but when this control is 
compromised excessive O2 ' and ROS can underlie the pathogenesis of a 
variety of disease states, including COPD and cardiac hypertrophy [Anderson 
and Bovinovski, 2003 and Murdoch et al., 2006].
Cardiac myocyte hypertrophy is an adaptive response of the heart to 
excessive exertion in an attempt to maintain optimal function. However, 
coupled with this response is the increased likelihood of arrhythmia and 
congestive heart failure. In cardiac myocytes, angiotensin II treatment
3 3
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increases the production of O2" and induces the onset of cardiac hypertrophy 
[Nakamura, et al., 1998 and Nakagami et al., 2003]. These effects are 
dependent upon O2' production and can be diminished with anti-oxidant
(Figure 6.3), and that p47-p/?ox expression at the membrane of cardiac 
myocytes was increased with angiotensin II, ablated with co-incubation of 
forskolin and rolipram, and partially rescued with the PKA inhibitor, H89 
(Figure 5.6). Furthermore, the direct interaction of p47-phox with both
311
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PDE4 inhibition attenuates the production of O2" in many phagocytic 
cells, but how this is achieved and whether it translates to non-phagocytic 
cells is poorly understood [Hatzelmann and Schudt, 2001, Bokoch and Knaus, 
2003 and Jacob et al., 2004]. What is appreciated though is that part of the 
inhibitory mechanism in phagocytic cells is PKA-dependent [Bengis-Garber 
and Gruener, 1996 and Lin et al., 2004].
The membrane translocation of p47-p/?ox is a pre-requisite for NADPH 
oxidase activation and represents the rate-limiting step in enzyme assembly. 
In CGD, where p47-p/?ox is deficient, the remaining cytosolic components are 
unable to translocate to the membrane [Sheppard et al., 2005]. p47-p/70X 
exists in an auto-inhibited state at rest and the inhibitory constraint is relieved 
upon multiple, preferential and sequential phosphorylation by an extensive 
array of protein kinases [Johnson et al., 1998, Inanami et al., 1998, Babior, 
1999, Hoyal et al., 2003, Massenet et al., 2005 and Mitzuki et al., 2005]. The 
p47-phox structural rearrangement conferred following phosphorylation 
exposes the appropriate domains for p40-p/?ox and p67-pbox/Rac2-GTP 
recruitment and membrane association [Groemping and Rittinger, 2005].
The work presented in Chapter 5 proposed that a possible mechanism 
exists in cardiac myocytes, where increasing intra-cellular cAMP
concentrations may serve to attenuate the production of O2 and ROS via a 
PKA-dependent mechanism. This hypothesis is based upon the observations 
that p47-phox was directly phosphorylated by PKA within the C-terminal SH3 
domain-containing regions responsible for promoting p47-phox translocation
i
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PDE4A4B and PDE4A10, and p67~phox specifically with PDE4A4B, indicated 
that PDE4 could play a critical role in controlling the PKA phosphorylation 
state of phox proteins (Figure 5.4).
From this preliminary work to address how PDE4 inhibition attenuates 
O2" and ROS production in cardiac myocytes, there are fundamental 
experiments required to elucidate the precise mechanism.
Site-directed mutagenesis of the putative PKA phosphorylation sites 
identified from the peptide array experiments should be generated and used 
to confirm the target site(s) in vitro. However, given the promiscuous nature 
of in vitro phosphorylation assays, the phosphorylation, and subsequent 
attenuation of phosphorylation, should also be confirmed in vivo, in a similar 
manner to the MAPKAPK2 phosphorylation of PDE4A5.
Future experiments should also confirm the PDE4 specificity of the 
p47-phox interaction by co-immuno-precipitation. Experiments should also 
extend the use of peptide array technology utilising the alanine scanning 
technique to identify the critical residues involved in each protein [Bolger et 
al., 2006]. Although from these initial experiments the use of SH3 domain 
interactions is excluded, it will be intriguing to determine whether p47-phox 
competes with other proteins for interaction with PDE4 isoforms, e.g. XAP2 or 
PDE4 dimérisation, and whether the interactions confer any functional effect 
upon PDE4 catalytic activity.
Initial experiments indicated that p67-p/?ox showed interaction 
specificity with PDE4A4B, perhaps through TPR-mediated interactions, and 
the relevance of this interaction should not be overlooked. If the interaction 
between p67-phox and PDE4A4B was mediated through TPR domains, in an 
analogous manner to XAP2, then one could hypothesise p67-phox to confer 
inhibition of PDE4 activity, maintaining intra-cellular cAMP concentrations and 
preventing phox protein translocation. On activation of p38 MAPK- 
MAPKAPK2 signalling, a known activator of NADPH oxidase, MAPKAPK2 
phosphorylation of PDE4A4B may promote the dissociation of p67-phox and
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up-regulation of PDE4A4B activity to attenuate PKA activation, preventing 
inhibition of NADPH oxidase complex formation at the plasma membrane.
Given the attenuation of p47~phox translocation upon PDE4 inhibition.
siRNA knockdown of endogenous PDE4 expression will facilitate the 
identification of the functionally relevant PDE4 isoform [Lynch et al., 2005].
IFinally, experiments are certainly required to confirm the attenuation of 
p47-phox translocation following increases in intra-cellular cAMP 
concentrations does Indeed translate to a reduction in O2 and ROS 
generation, perhaps using 2’, 7'-dichlorofluorescein diacetate [Nakamura et 
al., 1998 and Nakagami et al., 2003]. As an indicator of cardiac hypertrophy, 
the measurement of cardiac myocyte surface area or incorporation of [^H]- 
leucine experiments could be undertaken.
The work in this thesis forms three distinct chapters, (1) the 
characterisation of the novel PDE4A11 isoform, (2) the phosphorylation of 
PDE4A5 by MAPKAPK2, and (3) the participation of the cAMP-PKA-PDE4 
signalling module in the control of NADPH oxidase function. However, it is 
entirely possible that PDE4A11, possibly the most abundantly expressed 
PDE4A isoform, is also a target for MAPKAPK2 phosphorylation and that the %activation of p38 MAPK signalling may connect, regulate and allow interplay 
between these signalling pathways.
t
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